<SEC-DOCUMENT>0001213900-26-056595.txt : 20260514
<SEC-HEADER>0001213900-26-056595.hdr.sgml : 20260514
<ACCEPTANCE-DATETIME>20260514160536
ACCESSION NUMBER:		0001213900-26-056595
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260514
DATE AS OF CHANGE:		20260514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Jasper Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001788028
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				842984849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39138
		FILM NUMBER:		26978754

	BUSINESS ADDRESS:	
		STREET 1:		2200 BRIDGE PKWY SUITE #102
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		6505491400

	MAIL ADDRESS:	
		STREET 1:		2200 BRIDGE PKWY SUITE #102
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Amplitude Healthcare Acquisition Corp
		DATE OF NAME CHANGE:	20190912
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ea0289477-10q_jasper.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:jspr="http://jaspertx.com/20260331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>jspr-20260331</title>
    <meta http-equiv="Content-Type" content="text/html"/>
  </head>
  <body style="font: 10pt Times New Roman, Times, Serif">
    <div style="display:none">
      <ix:header>
        <ix:hidden>
          <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="cref_1378370445" id="fc_541668956" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_2072460258" id="fc_2072460258" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_762749261" id="fc_167423569" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_2072460258" id="fc_1035803401" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1291783619" id="fc_640081597" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_347088362" id="fc_347088362" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_249853930" id="fc_881676001" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_347088362" id="fc_1099697568" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1075311384" id="fc_1883212435" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="cref_1378370445" id="fc_54230030" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="cref_784925054" id="fc_534795495" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="cref_784925054" id="fc_1525497196" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="cref_784925054" id="fc_1714580687" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_111159347" id="fc_111159347" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_1894122814" id="fc_1894122814" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_1072361442" id="fc_1072361442" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_1361797107" id="fc_804810147" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_1196049397" id="fc_1196049397" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_1867564296" id="fc_1867564296" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_414108446" id="fc_1620055900" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_1072361442" id="fc_1092525917" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_1276276239" id="fc_1276276239" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_707032855" id="fc_707032855" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_1289593603" id="fc_1289593603" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_894353261" id="fc_1353737602" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_166082834" id="fc_166082834" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_1176672139" id="fc_1176672139" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_1483965117" id="fc_1449616030" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_1289593603" id="fc_978200156" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_937223270" id="fc_554114115" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="cref_784925054" id="fc_1783648313" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="cref_438560971" id="fc_357656926" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_1844764249" id="fc_1844764249" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="cref_736074492" id="fc_1765267982" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="cref_736074492" id="fc_1111002203" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="cref_438560971" id="fc_2072766674" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="cref_736074492" id="fc_2048509785" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="cref_1054403778" id="fc_1054403778" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="cref_1086398820" id="fc_1454690266" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="cref_1086398820" id="fc_1900409824" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="cref_477447857" id="fc_1792648283" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="cref_477447857" id="fc_1994038587" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="cref_1840882305" id="fc_838649266" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="cref_1086398820" id="fc_1603413953" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="cref_1206044327" id="fc_1799126299" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="cref_477447857" id="fc_723560973" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="cref_784925054" id="fc_577259707" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="cref_1378370445" id="fc_729631792" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="jspr:PerformanceBasedStockOptionActivity" contextRef="cref_784925054" id="fc_597754003" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_2065545269" id="fc_1423726112" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_1768916711" id="fc_1768916711" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_1479140823" id="fc_1479140823" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_1505739634" id="fc_1505739634" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="cref_784925054" id="fc_1666881356" unitRef="uref_1666881356" scale="0" decimals="0">1</ix:nonFraction>
          <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="cref_784925054" id="fc_975557945" unitRef="uref_1666881356" scale="0" decimals="0">1</ix:nonFraction>
          <ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_1357899928" id="fc_1357899928" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_1112529675" id="fc_1112529675" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonNumeric name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="cref_784925054" id="fc_743175501">http://fasb.org/srt/2026#ChiefExecutiveOfficerMember</ix:nonNumeric>
          <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="cref_438560971" id="fc_371358555" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="cref_268000114" id="fc_960120892" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="cref_438560971" id="fc_549550349" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="cref_438560971" id="fc_1556204817" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="cref_268000114" id="fc_1282959221" unitRef="uref_668202531" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="cref_438560971" id="fc_1568976284" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="cref_268000114" id="fc_1557480139" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="cref_438560971" id="fc_137921896" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="cref_268000114" id="fc_1463662633" unitRef="uref_469718384" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="cref_502686246" id="fc_1964576807" unitRef="uref_1055712422" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="cref_402018995" id="fc_402018995" unitRef="uref_1055712422" xsi:nil="true"></ix:nonFraction>
          <ix:nonNumeric name="dei:AmendmentFlag" contextRef="cref_784925054" id="ixv-6813">false</ix:nonNumeric>
          <ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="cref_784925054" id="ixv-6814">Q1</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="cref_784925054" id="ixv-6815">0001788028</ix:nonNumeric>
          <ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="cref_784925054" id="ixv-6816">--12-31</ix:nonNumeric>
        </ix:hidden>
        <ix:references>
          <link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="jspr-20260331.xsd" xlink:type="simple"/>
        </ix:references>
        <ix:resources>
          <xbrli:context id="cref_784925054">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_668202531">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-31</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_486425029">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-03-31</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1417501004">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1378370445">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_358966682">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:MDSAMLMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_543821224">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:SCIDMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1187366974">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CIndUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1533989264">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CIndUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_217583461">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:AsthmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2109719354">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:AsthmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_158858565">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_768267355">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_199674710">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CMOMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_920960091">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CMOMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_585224753">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:BriquilimabPlatformMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1773614604">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:BriquilimabPlatformMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_268000114">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_438560971">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1722756702">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1720545267">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1107233758">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_34643640">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_565409357">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_442461320">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_887924682">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1055712422">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1143859271">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1518267216">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2040753095">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_502686246">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_279398949">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1680691002">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1571420461">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_155304082">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1083033443">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                  <us-gaap:QName.domain>ResearchanddevelopmentMember</us-gaap:QName.domain>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1852720650">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                  <us-gaap:QName.domain>ResearchanddevelopmentMember</us-gaap:QName.domain>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2045662903">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                  <us-gaap:QName.domain>GeneralandadministrativeMember</us-gaap:QName.domain>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1364903650">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                  <us-gaap:QName.domain>GeneralandadministrativeMember</us-gaap:QName.domain>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_784622662">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1154412494">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_664802157">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_155106258">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroTwoFourESPPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2065545269">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_714368909">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-06-01</xbrli:startDate>
              <xbrli:endDate>2024-06-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1835780786">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-06-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2127221751">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1227972248">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_384482861">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_477447857">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_853288868">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-31</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1206044327">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1511983395">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1086398820">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1367888496">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-31</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1840882305">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_436942179">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroTwoFourESPPMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1757947245">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroTwoTwoInducementPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_517605843">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroTwoFourESPPMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1436491688">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroOneNinePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1643317952">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoThousandTwentyFourPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_343598538">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">jspr:UnderwrittenOfferingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2042008173">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">jspr:UnderwrittenOfferingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-09-18</xbrli:startDate>
              <xbrli:endDate>2025-09-18</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1187790031">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_648885515">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-03-26</xbrli:startDate>
              <xbrli:endDate>2025-03-26</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_415871009">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_238056073">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1422418476">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1088620590">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1516512986">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1623292660">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_671366674">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1068906306">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEquityIncentivePlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_835672883">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEquityIncentivePlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_467908750">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPreFundedWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_653971143">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPreFundedWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_749757817">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfCommonStockWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_695848034">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfCommonStockWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1665866085">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1365582304">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1329622523">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_166765776">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedRestrictedStockUnitsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1634329083">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedRestrictedStockUnitsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1455265214">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_841215262">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_736074492">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_601785078">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:VotingCommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1989808306">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-12-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_107187006">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-03-01</xbrli:startDate>
              <xbrli:endDate>2021-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1406915345">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2133957400">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-03-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_739243793">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:CommonWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_143115946">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:CommonWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_937223270">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PreFundedWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_400739651">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PreFundedWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1893484374">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:CommonWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-09-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_859966735">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PreFundedWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-09-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_26166482">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:September2025OfferingMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-09-01</xbrli:startDate>
              <xbrli:endDate>2025-09-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1282057323">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyFourStanfordLicenseAgreementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1140767225">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyFourStanfordLicenseAgreementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_549257824">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyOneStanfordLicenseAgreementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_145174291">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyOneStanfordLicenseAgreementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_862585213">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyOneStanfordLicenseAgreementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1284574516">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1842275578">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-11-01</xbrli:startDate>
              <xbrli:endDate>2020-11-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_753159246">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1539753648">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_671786867">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1979065684">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1742280107">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_176880314">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_445054501">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_982217023">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2051178283">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1331265187">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1403457930">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_823902052">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_940893104">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1240913286">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_634664125">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1826855759">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_566781871">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_611083158">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1378325364">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1785879477">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_894353261">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_243881147">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_739502903">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1483965117">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1288544829">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1849531206">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1966633800">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1361797107">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_13823206">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_15337254">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_414108446">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_505402133">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_10449924">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1935535027">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1788895550">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1234679342">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1080624732">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_249853930">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1075311384">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1511423065">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_218143529">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1220156236">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1995654471">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1859494511">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1426826830">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_762749261">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1291783619">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1415246794">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1740623832">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1982379788">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_382561751">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-05-11</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2142854251">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1847374087">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:VotingCommonStockParValue00001PerShareMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2072460258">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_347088362">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_111159347">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1894122814">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1072361442">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1196049397">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1867564296">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1276276239">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_707032855">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1289593603">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_166082834">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1176672139">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1844764249">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1054403778">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1768916711">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1479140823">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1505739634">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1357899928">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:SCIDMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1112529675">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:MDSAMLMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-01</xbrli:startDate>
              <xbrli:endDate>2026-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_402018995">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:unit id="uref_668202531">
            <xbrli:measure>iso4217:USD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_469718384">
            <xbrli:measure>xbrli:shares</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_1987543344">
            <xbrli:divide>
              <xbrli:unitNumerator>
                <xbrli:measure>iso4217:USD</xbrli:measure>
              </xbrli:unitNumerator>
              <xbrli:unitDenominator>
                <xbrli:measure>xbrli:shares</xbrli:measure>
              </xbrli:unitDenominator>
            </xbrli:divide>
          </xbrli:unit>
          <xbrli:unit id="uref_1055712422">
            <xbrli:measure>xbrli:pure</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_1104703976">
            <xbrli:measure>utr:sqft</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_1666881356">
            <xbrli:measure>jspr:Segment</xbrli:measure>
          </xbrli:unit>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fref_296657012" fromRefs="fc_1365582304 fc_1665866085"/>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fref_1477796849" fromRefs="fc_1840909275"/>
        </ix:resources>
      </ix:header>
    </div>
<p style="margin: 0"></p><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">UNITED STATES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Washington, D.C. 20549</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;">FORM&#160;<ix:nonNumeric name="dei:DocumentType" contextRef="cref_784925054" id="ixv-8181">10-Q</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">(Mark One)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="cref_784925054" format="ixt:fixed-true" id="ixv-8182">&#9746;</ix:nonNumeric>&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> For the quarterly period ended&#160;<ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="cref_784925054" format="ixt:date-monthname-day-year-en" id="ixv-8183">March 31, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="cref_784925054" format="ixt:num-dot-decimal" id="ixv-8184">2026</ix:nonNumeric></ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">OR</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="cref_784925054" format="ixt:fixed-false" id="ixv-8185">&#9744;</ix:nonNumeric>&#160;<span style="font-weight: bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from ______________
to ______________</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Commission File Number:&#160;<ix:nonNumeric name="dei:EntityFileNumber" contextRef="cref_784925054" id="ixv-8186">001-39138</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="cref_784925054" id="ixv-8187">JASPER THERAPEUTICS, INC.</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="cref_784925054" format="ixt-sec:stateprovnameen" id="ixv-8188">Delaware</ix:nonNumeric></span></span></td><td style="width: 2%; text-align: center">&#160;</td><td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="cref_784925054" id="ixv-8189">84-2984849</ix:nonNumeric></span></span></td> </tr>
<tr style="vertical-align: top">
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction
    of<br/>
    incorporation or organization)</span></td>
<td style="text-align: center">&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/>
    Identification No.)</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr> <td style="vertical-align: top; width: 49%; border-bottom: black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="cref_784925054" id="ixv-8190">2200 Bridge Pkwy</ix:nonNumeric>&#160;<ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="cref_784925054" id="ixv-8191">Suite #102</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="cref_784925054" id="ixv-8192">Redwood City</ix:nonNumeric>,&#160;<ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="cref_784925054" id="ixv-8193">CA</ix:nonNumeric></span></p></td><td style="vertical-align: top; width: 2%; text-align: center">&#160;</td><td style="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="cref_784925054" id="ixv-8194">94065</ix:nonNumeric></span></span></td> </tr>
<tr style="vertical-align: top">
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive
    offices)</span></td>
<td style="text-align: center">&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top"> <td style="width: 100%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;"><ix:nonNumeric name="dei:CityAreaCode" contextRef="cref_784925054" id="ixv-8195">(650)</ix:nonNumeric>&#160;<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="cref_784925054" id="ixv-8196">549-1400</ix:nonNumeric></span></span></td> </tr>
<tr style="vertical-align: top">
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s telephone
    number, including area code)</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom">
<td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Title
    of each class</span></span></td>
<td style="width: 2%; text-align: center">&#160;</td>
<td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Trading
    Symbol(s)</span></span></td>
<td style="width: 2%; text-align: center">&#160;</td>
<td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Name
    of each exchange on which registered</span></span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="cref_1847374087" id="ixv-8197">Voting Common Stock, par     value $0.0001 per share</ix:nonNumeric></span></td><td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="cref_1847374087" id="ixv-8198">JSPR</ix:nonNumeric></span></td><td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="cref_1847374087" format="ixt-sec:exchnameen" id="ixv-8199">The&#160;Nasdaq&#160;Stock     Market LLC</ix:nonNumeric></span></td> </tr>
<tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="cref_2142854251" id="ixv-8200">Redeemable Warrants, each     ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00</ix:nonNumeric></span></td><td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="cref_2142854251" id="ixv-8201">JSPRW</ix:nonNumeric></span></td><td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="cref_2142854251" format="ixt-sec:exchnameen" id="ixv-8202">The&#160;Nasdaq&#160;Stock     Market LLC</ix:nonNumeric></span></td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="cref_784925054" id="ixv-8203">Yes</ix:nonNumeric>&#160; &#9746; &#160;No&#160; &#9744; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="cref_784925054" id="ixv-8204">Yes</ix:nonNumeric>&#160; &#9746; &#160;No&#160; &#9744; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom">
<td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&#160;accelerated&#160;filer</span></td>
<td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
<td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td>
<td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
<tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="cref_784925054" format="ixt-sec:entityfilercategoryen" id="ixv-8205">Non-accelerated&#160;filer</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="cref_784925054" format="ixt:fixed-true" id="ixv-8206">&#9746;</ix:nonNumeric></span></td> </tr>
<tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="cref_784925054" format="ixt:fixed-false" id="ixv-8207">&#9744;</ix:nonNumeric></span></td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes&#160;&#9744;&#160;No&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="cref_784925054" format="ixt:fixed-false" id="ixv-8208">&#9746;</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of May 11, 2026, the number of shares of the registrant&#8217;s common stock outstanding was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="cref_382561751" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8209">27,996,819</ix:nonFraction> shares of voting common stock, $0.0001 par value per share, and no shares of non-voting common stock, $0.0001 par value per share. </p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><!-- Field: Page; Sequence: 1; Options: NewSection --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">JASPER THERAPEUTICS, INC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">FORM 10-Q FOR THE QUARTERLY PERIOD ENDED</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">MARCH 31, 2026</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">TABLE OF CONTENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
<td style="vertical-align: top; width: 8%">&#160;</td>
<td style="vertical-align: top; width: 83%; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">PAGE</span></span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PART I. FINANCIAL INFORMATION</a></span></td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Financial Statements (Unaudited)</a></span></td>
<td style="vertical-align: bottom; text-align: center">1</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025</a></span></td>
<td style="vertical-align: bottom; text-align: center">1</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2026 and 2025</a></span></td>
<td style="vertical-align: bottom; text-align: center">2</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three months ended March 31, 2026 and 2025</a></span></td>
<td style="vertical-align: bottom; text-align: center">3</td></tr>
<tr>
<td style="vertical-align: top; text-align: justify">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; text-align: justify">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025</a></span></td>
<td style="vertical-align: bottom; text-align: center">4</td></tr>
<tr>
<td style="vertical-align: top; text-align: justify">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; text-align: justify">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Notes to Condensed Consolidated Financial Statements</a></span></td>
<td style="vertical-align: bottom; text-align: center">5</td></tr>
<tr>
<td style="vertical-align: top; text-align: justify">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
<td style="vertical-align: bottom; text-align: center">22</td></tr>
<tr>
<td style="vertical-align: top; text-align: justify">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
<td style="vertical-align: bottom; text-align: center">36</td></tr>
<tr>
<td style="vertical-align: top; text-align: center">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Controls and Procedures</a></span></td>
<td style="vertical-align: bottom; text-align: center">36</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">PART II. OTHER INFORMATION</a></span></td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Legal Proceedings</a></span></td>
<td style="vertical-align: bottom; text-align: center">37</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Risk Factors</a></span></td>
<td style="vertical-align: bottom; text-align: center">37</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
<td style="vertical-align: bottom; text-align: center">44</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Defaults Upon Senior Securities</a></span></td>
<td style="vertical-align: bottom; text-align: center">44</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Mine Safety Disclosures</a></span></td>
<td style="vertical-align: bottom; text-align: center">44</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Other Information</a></span></td>
<td style="vertical-align: bottom; text-align: center">44</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">Exhibits</a></span></td>
<td style="vertical-align: bottom; text-align: center">45</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
<td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
<td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">SIGNATURES</a></span></td>
<td style="vertical-align: bottom; text-align: center">46</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><span id="a_001" style="display: inline-block;"></span>PART&#160;I. FINANCIAL INFORMATION</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_002" style="display: inline-block;"></span><span style="font-weight: bold;">Item 1. Financial Statements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><span id="a_003" style="display: inline-block;"></span>JASPER THERAPEUTICS, INC.</span><br/><span style="font-weight: bold;">
CONDENSED CONSOLIDATED BALANCE SHEETS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><i>(in thousands, except share and per share
data)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><i>(unaudited)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold">Assets</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>Current assets:</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8210">14,144</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8211">28,692</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8212">6,148</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8213">5,953</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Total current assets</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8214">20,292</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8215">34,645</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Property and equipment, net</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8216">81</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8217">102</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating lease right-of-use assets</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8218">317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8219">502</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Restricted cash</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8220">417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8221">417</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8222">77</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8223">113</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8224">21,184</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8225">35,779</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Current liabilities:</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8226">2,439</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8227">6,220</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating lease liabilities</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8228">757</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8229">1,235</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8230">5,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8231">5,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Total current liabilities</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8232">8,996</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8233">13,200</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Warrant liability</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8234">6,524</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8235">16,164</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8236">2,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8237">2,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8238">17,784</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8239">31,628</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and contingencies (Note 8)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_371358555">&#160;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_960120892">&#160;</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stockholders&#8217; equity</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Preferred stock: $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="cref_438560971" unitRef="uref_1987543344" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-8240"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="cref_268000114" unitRef="uref_1987543344" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-8241">0.0001</ix:nonFraction></ix:nonFraction> par value &#8212; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="cref_438560971" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8242"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="cref_268000114" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8243">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March     31, 2026 and December 31, 2025; <span style="-sec-ix-hidden:fc_1568976284"><span style="-sec-ix-hidden:fc_1557480139"><span style="-sec-ix-hidden:fc_137921896"><span style="-sec-ix-hidden:fc_1463662633">none</span></span></span></span> issued and outstanding at March 31, 2026 and December 31, 2025</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1556204817">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1282959221">&#8212;</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Common stock: $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="cref_438560971" unitRef="uref_1987543344" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-8244"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="cref_268000114" unitRef="uref_1987543344" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-8245">0.0001</ix:nonFraction></ix:nonFraction> par value &#8212; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="cref_438560971" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8246"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="cref_268000114" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8247">492,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March     31, 2026 and December 31, 2025; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="cref_438560971" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8248"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="cref_268000114" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8249"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="cref_438560971" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8250"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="cref_268000114" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8251">27,996,819</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2026 and December 31, 2025</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8252">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8253">3</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8254">321,241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8255">320,818</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8256">317,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8257">316,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8258">3,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8259">4,151</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total liabilities and stockholders&#8217;     equity</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8260">21,184</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8261">35,779</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><span id="a_004" style="display: inline-block;"></span>JASPER THERAPEUTICS, INC.</span><br/><span style="font-weight: bold;">
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><i>(in thousands, except share and per share
data)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><i>(unaudited)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/>
    March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>Operating expenses</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 9pt">Research and development</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8262">5,814</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8263">16,157</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8264">5,138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8265">5,645</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8266">10,952</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8267">21,802</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss from operations</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8268">10,952</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8269">21,802</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8270">164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8271">624</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Change in fair value of warrant liability</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8272">9,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_541668956">&#8212;</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8273">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8274">63</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8275">9,778</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8276">561</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8277">1,174</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8278">21,241</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Net loss per share attributable to common stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="cref_784925054" unitRef="uref_1987543344" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-8279"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="cref_784925054" unitRef="uref_1987543344" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-8280">0.04</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="cref_1378370445" unitRef="uref_1987543344" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-8281"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="cref_1378370445" unitRef="uref_1987543344" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-8282">1.41</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted-average shares used in computing     net loss per share attributable to common stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="cref_784925054" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8283"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="cref_784925054" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8284">28,671,819</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="cref_1378370445" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8285"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="cref_1378370445" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8286">15,022,122</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><!-- Field: Page; Sequence: 4; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><span id="a_005" style="display: inline-block;"></span>JASPER THERAPEUTICS, INC.</span><br/><span style="font-weight: bold;">
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><i>(in thousands, except share data)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><i>(unaudited)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Three Months Ended March 31, 2026</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="6" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Additional<br/> Paid-In</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Total<br/> Stockholders&#8217;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance as of December 31, 2025</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="cref_1982379788" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8287">27,996,819</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1982379788" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8288">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1740623832" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8289">320,818</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1415246794" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8290">316,670</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8291">4,151</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Stock-based compensation expense</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2072460258">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1291783619" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8292">423</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_167423569">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8293">423</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1035803401">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_640081597">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_762749261" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8294">1,174</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8295">1,174</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance as of March 31, 2026</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="cref_1426826830" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8296">27,996,819</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1426826830" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8297">3</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1859494511" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8298">321,241</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1995654471" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8299">317,844</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8300">3,400</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Three Months Ended March 31, 2025</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="6" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Additional<br/> Paid-In</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Total<br/> Stockholders&#8217;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance as of December 31, 2024</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="cref_1220156236" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8301">15,022,122</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1220156236" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8302">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_218143529" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8303">302,541</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1511423065" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8304">240,869</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1935535027" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8305">61,674</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Stock-based compensation expense</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_347088362">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1075311384" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8306">1,811</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_881676001">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8307">1,811</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1099697568">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1883212435">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_249853930" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8308">21,241</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8309">21,241</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance as of March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="cref_1080624732" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8310">15,022,122</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1080624732" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8311">2</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1234679342" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8312">304,352</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1788895550" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8313">262,110</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1406915345" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8314">42,244</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><!-- Field: Page; Sequence: 5; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><span id="a_006" style="display: inline-block;"></span>JASPER THERAPEUTICS, INC.</span><br/><span style="font-weight: bold;">
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><i>(in thousands)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><i>(unaudited)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold">Cash flows used in operating activities</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8315">1,174</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8316">21,241</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating
    activities</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Depreciation and amortization expense</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8317">21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8318">279</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Non-cash lease expense</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8319">185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8320">193</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Stock-based compensation expense</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8321">423</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8322">1,811</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in fair value of warrant liability</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8323">9,640</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_54230030">&#8212;</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Changes in operating assets and liabilities:</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Prepaid expenses and other current assets</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8324">195</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8325">201</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Other non-current assets</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8326">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8327">288</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Accounts payable</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8328">3,781</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8329">1,039</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Accrued expenses and other current liabilities</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8330">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8331">2,617</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8332">478</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8333">315</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.5in">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8334">14,548</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8335">22,842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows provided by investing activities</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Proceeds from sales of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_534795495">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8336">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.5in">Net cash provided by investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1525497196">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8337">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net decrease in cash, cash equivalents and restricted cash</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8338">14,548</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8339">22,838</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents and restricted cash     at beginning of the period</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8340">29,109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_1935535027" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8341">72,054</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents     and restricted cash at end of the period</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8342">14,561</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_1406915345" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8343">49,216</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental and non-cash items reconciliations</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Right-of-use asset obtained in exchange for     lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1714580687">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8344">1,092</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><!-- Field: Page; Sequence: 6; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><span id="a_007" style="display: inline-block;"></span>JASPER THERAPEUTICS, INC.<br/>
NOTES TO UNAUDITED INTERIM CONDENSED<br/>
CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p>
 <ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="cref_784925054" escape="true" id="ixv-1460"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Description of Business </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Jasper Therapeutics, Inc. and its consolidated subsidiary, Jasper Tx Corp. (collectively, &#8220;Jasper&#8221; or the &#8220;Company&#8221;), is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases, such as chronic spontaneous urticaria, chronic inducible urticaria and asthma. Briquilimab has been evaluated in clinical studies in chronic spontaneous urticaria, chronic inducible urticaria and allergic asthma. The Company&#8217;s clinical development activities are currently focused on chronic urticarias, and while the clinical data generated in allergic asthma supports further development in the broader asthma population, advancing any future clinical studies in asthma would be based on an evaluation of the competitive landscape, the potential for strategic partnerships and capital availability. The Company has also historically explored diseases where targeting diseased hematopoietic stem cells can provide benefits, such as stem cell transplant conditioning regimens, but is currently focused on development of briquilimab in mast cell driven diseases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is headquartered in Redwood City, California. The Company is a Delaware corporation and was incorporated in March 2018. In September 2021, the Company completed a merger with Amplitude Healthcare Acquisition Corporation and became a public company.&#160;</p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>
 <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="cref_784925054" escape="true" id="ixv-1474"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="cref_784925054" escape="true" id="ixv-1478"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Basis of Presentation</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) for financial reporting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The accompanying condensed financial statements are consolidated and include the accounts of Jasper Therapeutics, Inc. and its wholly-owned subsidiary, Jasper Tx Corp, which had no operations during the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2025 included in the Company&#8217;s Annual Report on the Form 10-K filed with the SEC on March 30, 2026. There were no changes to the Company&#8217;s significant accounting policies as described in the Annual Report on Form 10-K. The information as of December 31, 2025, included in the condensed consolidated balance sheets was derived from the Company&#8217;s audited financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company&#8217;s consolidated financial statements. The results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026 or for any other interim period or for any other future year.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="jspr:GoingConcernPolicyTextBlock" contextRef="cref_784925054" escape="true" id="ixv-1489"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Going Concern</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, <i>Going Concern</i>, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of the Company&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating effect of the Company&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. In performing this analysis, the Company excluded certain elements of its operating plan that cannot be considered probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 7; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company has incurred significant losses and negative cash flows from operations since its inception. During the three months ended March 31, 2026 and 2025, the Company incurred net losses of $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_784925054" unitRef="uref_668202531" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal" id="ixv-8345">1.2</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1378370445" unitRef="uref_668202531" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal" id="ixv-8346">21.2</ix:nonFraction> million, respectively. During the three months ended March 31, 2026 and 2025, the Company had negative cash flows from operations of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="cref_784925054" unitRef="uref_668202531" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal" id="ixv-8347">14.5</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="cref_1378370445" unitRef="uref_668202531" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal" id="ixv-8348">22.8</ix:nonFraction> million, respectively. As of March 31, 2026, the Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="cref_438560971" unitRef="uref_668202531" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal" id="ixv-8349">317.8</ix:nonFraction> million. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support the Company&#8217;s cost structure. As of March 31, 2026, the Company had cash and cash equivalents of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="cref_438560971" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8350">14.1</ix:nonFraction> million. The Company&#8217;s management expects that the existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management expects to finance the Company&#8217;s future cash needs through equity or debt financings, collaborations or a combination of these approaches, and given the imminent need for additional funding to continue to fund operations in the near-term, the Company is actively seeking additional capital to extend the cash runway. However, due to several factors, including those outside management&#8217;s control, there can be no assurance that the Company will be able to complete additional financings. The Company&#8217;s ability to raise additional funds may be adversely impacted by negative global economic conditions and any disruptions to and volatility in the credit and financial markets in the United States and worldwide or other factors. There can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms favorable or acceptable to the Company. The Company routinely evaluates cost reduction measures to proactively manage cash burn, but if the Company is unable to obtain adequate financing when needed or on terms favorable or acceptable to it, the Company may be forced to take broader actions such as to delay, reduce the scope of or eliminate one or more of its research and development programs. The Company concluded the likelihood that its plan to successfully obtain sufficient funding or adequately delay or reduce expenditures, while reasonably possible, is less than probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The accompanying unaudited interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. These unaudited interim condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="cref_784925054" escape="true" id="ixv-1512"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Use of Estimates</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the condensed consolidated financial statements include, but are not limited to, the determination of the accrued research and development expenses, the measurement of stock-based compensation expense and the valuation of warrant liability. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 8; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p></ix:exclude><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="cref_784925054" escape="true" id="ixv-1526"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Cash, Cash Equivalents, and Restricted Cash</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" contextRef="cref_784925054" escape="true" id="ixv-1531"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total amount shown in the condensed consolidated statements of cash flows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Cash and cash equivalents</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8351">14,144</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8352">28,692</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8353">417</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8354">417</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total cash, cash equivalents and restricted cash</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8355">14,561</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8356">29,109</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cash and cash equivalents consist of cash held in operating accounts and investments in money market funds. Restricted cash relates to the letter of credit secured in conjunction with the operating lease (Note 8).</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="cref_784925054" escape="true" id="ixv-1585"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Concentrations of Credit Risk and Other Risks and Uncertainties</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company&#8217;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America. Cash balances are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced any losses on its cash, cash equivalents and marketable securities&#8217; balances and periodically evaluates the creditworthiness of its financial institutions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is subject to risks common to companies in the development stage, including, but not limited to, development and regulatory approval of new product candidates, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product plans. To achieve profitable operations, the Company must successfully develop and obtain requisite regulatory approvals for, manufacture, and market its product candidates. There can be no assurance that any such product candidate can be developed and approved or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product will be successfully marketed. These factors could have a material adverse effect on the Company&#8217;s future financial results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Products developed by the Company require approval from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#8217;s future products will receive the necessary clearances. If the Company were denied such clearances or such clearances were delayed, it could have a materially adverse impact on the Company.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="cref_784925054" escape="true" id="ixv-1596"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Recent Accounting Pronouncements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Accounting Pronouncements Not Yet Adopted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;In November 2024, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date (&#8220;ASU 2025-01&#8221;). The amendments do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 9; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In September 2025, the FASB issued ASU No. 2025-06, Intangibles - Goodwill and Other - Internal - Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (&#8220;ASU 2025-06&#8221;). The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages. This ASU requires entities to begin capitalizing software costs when management authorizes and commits to funding the software project, and it is probable that the project will be completed, and the software will be used for its intended purpose. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2025, the FASB issued ASU No. 2025-10, Accounting for Government Grants Received by Business Entities (Topic 832). This ASU provides recognition, measurement, presentation, and disclosure requirements for government grants, including guidance for grants related to an asset and grants related to income. ASU No. 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting: Narrow-Scope Improvements (Topic 270). This ASU improves clarity for interim financial reporting requirements under the existing guidance within ASC Topic 270, by creating a comprehensive list of interim disclosure requirements, clarifying scope and applicability, along with adding a principle to disclose all material events that have occurred since the most recently filed Annual Report on Form 10-K. ASU No. 2025-11 is effective for interim reporting for fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.</p></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>
 <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="cref_784925054" escape="true" id="ixv-1621"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 3. FAIR VALUE MEASUREMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"><td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 &#8211; Inputs are unadjusted, quoted prices     in active markets for identical assets or liabilities at the measurement date;</span></td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"><td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 &#8211; Inputs are observable, unadjusted quoted     prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities     in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially     the full term of the related assets or liabilities; and</span></td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"><td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 &#8211; Unobservable inputs that are significant     to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value and is a Level 1 financial instrument under the fair value hierarchy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 10; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. The Company had no financial instruments classified at Level 2 as of March 31, 2026 and December 31, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques and at least one significant model assumption or input is unobservable. As of March 31, 2026 and December 31, 2025, the Company&#8217;s Level 3 liabilities consisted of the warrant liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There were no transfers within the hierarchy during the three months ended March 31, 2026 and 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="cref_784925054" escape="true" id="ixv-1673"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>Financial assets</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Money market funds</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_10449924" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8357">13,144</ix:nonFraction></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_111159347">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1894122814">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_505402133" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8358">13,144</ix:nonFraction></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Total fair value of assets</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_414108446" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8359">13,144</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1072361442">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_804810147">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_1966633800" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8360">13,144</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Financial liabilities</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Warrant liability</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1196049397">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1867564296">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_15337254" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8361">6,524</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_13823206" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8362">6,524</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt">Total fair value of financial liabilities</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1620055900">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1092525917">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_1361797107" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8363">6,524</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_1966633800" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8364">6,524</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>Financial assets</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Money market funds</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_1849531206" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8365">27,692</ix:nonFraction></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1276276239">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_707032855">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_1288544829" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8366">27,692</ix:nonFraction></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Total fair value of assets</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_1483965117" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8367">27,692</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1289593603">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1353737602">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="cref_1785879477" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8368">27,692</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Financial liabilities</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Warrant liability</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_166082834">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1176672139">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_739502903" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8369">16,164</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_243881147" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8370">16,164</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt">Total fair value of financial liabilities</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1449616030">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_978200156">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_894353261" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8371">16,164</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_1785879477" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8372">16,164</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="cref_784925054" escape="true" id="ixv-1980"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the three months ended March 31, 2026, the changes in the Company&#8217;s warrant liability were as follows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant<br/> Liability</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; font-weight: bold">Fair Value as of December 31, 2025</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_1378325364" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8373">16,164</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in the fair value</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="cref_611083158" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8374">9,640</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; padding-bottom: 4pt">Fair Value as of March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="cref_566781871" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8375">6,524</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company uses the Black-Scholes pricing model to determine the fair value of its warrant liability using Level 3 inputs. Inputs used to determine estimated fair value of the warrant liability include the fair value of the underlying stock at the valuation date, the term of the warrants, and the expected volatility of the underlying stock. The significant unobservable input used in the fair value measurement of the warrant liability is the expected volatility of the warrants. The estimates of fair value are uncertain and&#160;changes in&#160;any of the estimated inputs used as of the date of this report could have resulted in significant adjustments to the fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 11; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:exclude><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2019"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The key inputs into valuation models used to estimate the fair value of the warrant liability as of March 31,2026 and December 31, 2025 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%">Common stock price</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_1826855759" unitRef="uref_1055712422" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8376">.88</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_634664125" unitRef="uref_1055712422" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8377">1.83</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Expected term (in years)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_1240913286" unitRef="uref_1055712422" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8378">3.98</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_940893104" unitRef="uref_1055712422" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8379">4.22</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Expected volatility</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_823902052" unitRef="uref_1055712422" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8380">115.68</ix:nonFraction></td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_1403457930" unitRef="uref_1055712422" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8381">113.30</ix:nonFraction></td> <td style="text-align: left">%</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_1331265187" unitRef="uref_1055712422" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8382">3.86</ix:nonFraction></td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_2051178283" unitRef="uref_1055712422" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8383">3.66</ix:nonFraction></td> <td style="text-align: left">%</td> </tr></tbody></table></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>
 <ix:nonNumeric name="srt:CondensedFinancialStatementsTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2081"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 4. CONDENSED CONSOLIDATED BALANCE SHEET COMPONENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Prepaid expenses and other current assets</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2091"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the details of prepaid expenses and other current assets as of the dates set forth below (in thousands):&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Research and development prepaid expenses</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="jspr:ResearchAndDevelopmentPrepaidExpenses" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8384">4,847</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="jspr:ResearchAndDevelopmentPrepaidExpenses" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8385">4,320</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Prepaid insurance</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8386">653</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8387">866</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Prepaid travel expenses</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="jspr:PrepaidTravelExpenses" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8388">243</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="jspr:PrepaidTravelExpenses" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8389">103</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and current assets</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8390">405</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8391">664</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 4pt">Total</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8392">6,148</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8393">5,953</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Property and equipment, net</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2167"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the details of property and equipment, net as of the dates set forth below (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Leasehold improvements</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_982217023" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8394">2,711</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_445054501" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8395">2,711</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Lab equipment</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_176880314" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8396">1,513</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_1742280107" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8397">1,513</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Office furniture &amp; fixtures</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_1979065684" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8398">522</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_671786867" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8399">522</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Computer equipment</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_1539753648" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8400">170</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_753159246" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8401">170</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-left: 9pt">Property and equipment, gross</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8402">4,916</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8403">4,916</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8404">4,835</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8405">4,814</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Property and equipment, net</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8406">81</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8407">102</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Depreciation and amortization expense was $<ix:nonFraction name="us-gaap:Depreciation" contextRef="cref_784925054" unitRef="uref_668202531" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8408">21,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="cref_1378370445" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8409">0.3</ix:nonFraction> million for the three months ended March 31, 2026 and 2025, respectively. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 12; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Accrued expenses and other current liabilities</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2272"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the details of accrued expenses and other current liabilities as of the dates set forth below (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Research and development accrued expenses</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="jspr:ResearchAndDevelopmentAccruedExpensesCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8410">3,422</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="jspr:ResearchAndDevelopmentAccruedExpensesCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8411">3,775</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Accrued employee and related compensation expenses</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8412">1,889</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8413">1,589</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Accrued legal and professional expenses</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8414">321</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8415">261</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 1.5pt">Other</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8416">168</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8417">120</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 4pt">Total</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8418">5,800</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8419">5,745</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><i>&#160;</i></span></p>
 <ix:nonNumeric name="jspr:CirmGrantDisclosureTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2346"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 5. CIRM GRANT</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In November 2020, California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) awarded the Company $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="cref_1842275578" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8420">2.3</ix:nonFraction> million in support of the research project related to a monoclonal antibody that depletes blood stem cells and enables chemotherapy-free transplants. The Company has received an aggregate of $<ix:nonFraction name="jspr:ReceivedAggregateFromCIRM" contextRef="cref_784925054" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8421">2.3</ix:nonFraction> million from CIRM through March 31, 2026. &#160;&#160;There are no further amounts available for future distribution to the Company under the grant. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the terms of the grant, both CIRM and the Company agreed to co-fund the research project and the amount of the Company&#8217;s co-funding requirement was predetermined as a part of the award. Under the terms of the CIRM grant, the Company is obligated to pay royalties and licensing fees based on <ix:nonFraction name="jspr:PercentageOfLicensingFees" contextRef="cref_784925054" unitRef="uref_1055712422" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-8422">0.1</ix:nonFraction>% of net sales of CIRM-funded inventions per $<ix:nonFraction name="jspr:NetSales" contextRef="cref_1284574516" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8423">1.0</ix:nonFraction> million of CIRM grant. As an alternative to revenue sharing, the Company has the option to convert the award to a loan. In the event the Company exercises its right to convert the award to a loan, it would be obligated to repay the loan within ten business days of making such election. Repayment amounts vary dependent on when the award is converted to a loan, ranging from <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="cref_784925054" unitRef="uref_1055712422" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-8424">60</ix:nonFraction>% of the award granted to amounts received plus interest at the rate of the three-month LIBOR rate plus <ix:nonFraction name="us-gaap:InvestmentInterestRate" contextRef="cref_438560971" unitRef="uref_1055712422" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-8425">25</ix:nonFraction>% per annum. Since the Company may be required to repay some or all of the amounts awarded by CIRM, the Company accounted for this award as a liability. Given the uncertainty in amounts due upon repayment, the Company has recorded amounts received without any discount or interest recorded, and upon determination of amounts that would become due, the Company will adjust accordingly. In the absence of explicit U.S. GAAP guidance on contributions received by business entities from government entities, the Company has applied to the CIRM grant the recognition and measurement guidance in ASC Topic 958-605 Not-for-Profit Entities: Revenue Recognition&#8212;Contributions by analogy. As of each of March 31, 2026 and December 31, 2025, the amount of CIRM grant received of $<ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8426"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8427">2.3</ix:nonFraction></ix:nonFraction> million is included in other non-current liabilities in the condensed consolidated balance sheets. </p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
 <ix:nonNumeric name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2354"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 6. SIGNIFICANT AGREEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Stanford License Agreements</i></span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March 2021, the Company entered into an exclusive license agreement with Stanford (the &#8220;2021 Stanford License Agreement&#8221;). In July 2023, the Company entered into an amendment to the 2021 Stanford License Agreement to modify certain milestones set forth thereunder. The Company received a worldwide, exclusive license, with a right to sublicense, for briquilimab in the field of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated. Stanford transferred to the Company certain know-how and patents related to briquilimab (together, the &#8220;Licensed Technology&#8221;). Under the terms of this agreement, the Company is required to use commercially reasonable efforts to develop, manufacture and sell licensed product and to develop markets for a licensed product. In addition, the Company is required to use commercially reasonable efforts to meet the milestones as specified in the agreement over the six years from execution of the 2021 Stanford License Agreement and must notify Stanford in writing as each milestone is met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company is obligated to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $<ix:nonFraction name="jspr:MilestonePaymentsObligationToBePaidFirstAndSecondYear" contextRef="cref_862585213" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8428">25,000</ix:nonFraction> for each first and second year, $<ix:nonFraction name="jspr:MilestonePaymentsObligationToBePaidThirdAndFourthYear" contextRef="cref_862585213" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8429">35,000</ix:nonFraction> for each third and fourth year and $<ix:nonFraction name="jspr:MilestonePaymentsObligationToBePaidThereafter" contextRef="cref_862585213" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8430">50,000</ix:nonFraction> at each anniversary thereafter ending upon the first commercial sale. The Company is also obligated to pay late-stage clinical development milestone payments and first commercial sales milestone payments of up to $<ix:nonFraction name="jspr:SalesMilestonePayments" contextRef="cref_145174291" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8431">9.0</ix:nonFraction> million in total. The Company will also pay low single-digit royalties on net sales of licensed products, if approved. As of March 31, 2026, the Company recorded $<ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="cref_862585213" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8432">50,000</ix:nonFraction> in accrued expenses and other current liabilities in the condensed consolidated balance sheets related to annual license maintenance fees, with corresponding recognition of such amount as research and development expense in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026. The Company recognized $<ix:nonFraction name="us-gaap:CostMaintenance" contextRef="cref_145174291" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8433"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="cref_549257824" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8434">35,000</ix:nonFraction></ix:nonFraction> in annual license maintenance fees as research and development expense in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2025.&#160;&#160; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 13; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The 2021 Stanford License Agreement expires on a country-by-country basis on the last-to-expire valid claim of a licensed patent in such country. The Company may terminate the agreement by giving Stanford written notice at least 12 months in advance of the effective date of termination. The Company may also terminate the agreement solely with respect to any particular patent application or patent by giving Stanford written notice at least 60 days in advance of the effective date of termination. Stanford may terminate the agreement after 90 days from a written notice by Stanford, specifying a problem, including a delinquency on any report required pursuant to the agreement or any payment, missing a milestone or a material breach, unless the Company remediates the problem in that 90-day period.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In December 2024, the Company entered into a co-exclusive license agreement with Stanford (the &#8220;2024 Stanford License Agreement&#8221;). The Company received a co-exclusive license in the United States, with a right to sublicense, for a certain patent to be used in the field of the treatment and prevention of human diseases, including the use of anti-CD117 antibodies (other than JSP191) for the purpose of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated (the &#8220;Co-Exclusive Licensed Field of Use&#8221;) and an exclusive license in the United States for the use of the same patent in the field provided in the 2021 Stanford License Agreement (the &#8220;Exclusive Licensed Field of Use&#8221;). Stanford will have at most one other commercial license for the licensed patent in the Co-Exclusive Licensed Field of Use. Under the terms of this agreement, the Company is required to use commercially reasonable efforts to develop, manufacture and sell a licensed product and to develop markets for a licensed product. In addition, the Company is required to use commercially reasonable efforts to meet the milestones as specified in the agreement over approximately <ix:nonNumeric name="jspr:ApproximatelyAgreement" contextRef="cref_1282057323" format="ixt-sec:duryear" id="ixv-8435">4.5</ix:nonNumeric> years from the execution of the agreement and must notify Stanford in writing when, and if, each milestone is met. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company paid a license issue fee of $<ix:nonFraction name="jspr:LicenseMaintenanceFee" contextRef="cref_1282057323" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8436">75,000</ix:nonFraction>, following the execution of the agreement, in January 2025. The Company is also obligated to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement, as follows: $<ix:nonFraction name="jspr:MilestonePaymentsObligationToBePaidFirstThroughThirdYear" contextRef="cref_1140767225" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8437">25,000</ix:nonFraction> for each of the first through third years, $<ix:nonFraction name="jspr:MilestonePaymentsObligationToBePaidFourthThroughSixthYear" contextRef="cref_1140767225" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8438">50,000</ix:nonFraction> for each of the fourth through sixth years and $<ix:nonFraction name="jspr:MilestonePaymentsObligationToBePaidThereafter" contextRef="cref_1140767225" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8439">65,000</ix:nonFraction> at each anniversary thereafter. The Company is also obligated to pay clinical development milestone payments of up to $<ix:nonFraction name="jspr:SalesMilestonePayments" contextRef="cref_1282057323" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8440">1.3</ix:nonFraction> million and sales milestone payments of up to $<ix:nonFraction name="jspr:ClinicalDevelopmentMilestonePayments" contextRef="cref_1282057323" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8441">7.0</ix:nonFraction> million in total. The Company will pay low single-digit royalties on net sales of licensed products, if approved. The Company will pay Stanford a portion of sublicensee consideration if a sublicense is granted. As of March 31, 2026 and December 31, 2025, there was $<ix:nonFraction name="us-gaap:CostMaintenance" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8442">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:CostMaintenance" contextRef="cref_1417501004" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8443">25,000</ix:nonFraction>, respectively, of accounts payable recorded in the condensed consolidated balance sheets related to the annual license maintenance fee.  </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company may terminate the agreement by giving Stanford written notice at least 30 days in advance of the effective date of termination. Stanford may terminate the agreement by giving the Company 90 days written notice for a problem, including a delinquency on any report required pursuant to the agreement, missing a milestone or a material breach, and by giving the Company 30 days written notice for a payment default, unless the Company remediates the problem in that 90-day or 30-day period.&#160;</p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
 <ix:nonNumeric name="jspr:WarrantsTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2383"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 7. WARRANTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In September 2025, in connection and together with the issuance of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="cref_26166482" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8444">11,670,707</ix:nonFraction> shares of the Company&#8217;s voting common stock through the underwritten offering (the &#8220;September 2025 Offering&#8221;), the Company issued pre-funded warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_859966735" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8445">675,000</ix:nonFraction> shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) and common stock warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1893484374" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8446">12,345,707</ix:nonFraction>&#160;shares of common stock (the &#8220;Common Warrants&#8221;). See Note 9 for additional details about the September 2025 Offering. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 14; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Pre-Funded Warrants</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The exercise price of each Pre-Funded Warrant is $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_937223270" unitRef="uref_1987543344" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-8447">0.0001</ix:nonFraction> per share. The Pre-Funded Warrants are exercisable at the option of each holder in whole or in part at any time after their original issuance and have no expiration date. The Pre-Funded Warrants may be exercised by means of cash or the cashless settlement of the net number of shares of common stock determined according to a formula set forth in the Pre-Funded Warrants. However, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder (together with its affiliates) to exceed <ix:nonFraction name="jspr:PreFundedWarrantPercentage" contextRef="cref_784925054" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8448">4.99</ix:nonFraction>% (or, at the election of the holder, <ix:nonFraction name="jspr:PercentageOfElectionHolderWarrants" contextRef="cref_1187790031" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8449">9.99</ix:nonFraction>% or <ix:nonFraction name="jspr:PercentageOfElectionHolderWarrants" contextRef="cref_400739651" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8450">19.99</ix:nonFraction>%) of the number of issued and outstanding shares of common stock following such exercise. However, any holder of a Pre-Funded Warrant may increase or decrease such percentage to any other percentage not in excess of <ix:nonFraction name="jspr:PercentagePreFundedWarrants" contextRef="cref_784925054" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8451">19.99</ix:nonFraction>%, provided that the holder shall provide at least 61 days&#8217; prior written notice to the Company prior to the date such increase shall be effective. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the terms of the Pre-Funded Warrant, upon the consummation of a Fundamental Transaction, as defined in the Pre-Funded Warrants, the holders of the Pre-Funded Warrants are entitled to receive, upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or other property that such holders would have received had they exercised the Pre-Funded Warrants immediately prior to such Fundamental Transaction, without regard to any limitations on exercise contained in the Pre-Funded Warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company concluded that the Pre-Funded Warrants met the equity indexation criteria and the Pre-Funded Warrants are therefore accounted for in stockholders&#8217; equity. The Company recorded $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="cref_937223270" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8452">0.3</ix:nonFraction>&#160;million to additional paid-in capital upon issuance of the Pre-Funded Warrants. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026,&#160;<span style="-sec-ix-hidden:fc_554114115">none</span>&#160;of the Pre-Funded Warrants have been exercised. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Common Warrants</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The exercise price of each Common Warrant is $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_143115946" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8453">2.92</ix:nonFraction> per share. Each Common Warrant is exercisable commencing on the six month anniversary of the date of issuance and thereafter for a period of four years. The Common Warrants may be exercised by means of cash or the cashless settlement of the net number of shares of common stock determined according to a formula set forth in the Common Warrants. However, a holder will not be entitled to exercise any portion of any Common Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder (together with its affiliates) to exceed <ix:nonFraction name="jspr:PreFundedWarrantPercentage" contextRef="cref_739243793" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8454">4.99</ix:nonFraction>% (or, at the election of the holder, <ix:nonFraction name="jspr:PercentageOfElectionHolderWarrants" contextRef="cref_739243793" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8455">9.99</ix:nonFraction>% or <ix:nonFraction name="jspr:PercentageOfElectionHolderWarrants" contextRef="cref_784925054" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8456">19.99</ix:nonFraction>%) of the number of issued and outstanding shares of common stock following such exercise. However, any holder of a Common Warrant may increase or decrease such percentage to any other percentage not in excess of <ix:nonFraction name="jspr:PercentageOfCommonWarrants" contextRef="cref_784925054" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8457">19.99</ix:nonFraction>%, provided that the holder shall provide at least 61 days&#8217; prior written notice to the Company prior to the date such increase shall be effective.&#160; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the terms of the Common Warrant, upon the consummation of a Fundamental Transaction, as defined in the Common Warrants, the holders of the Common Warrants are entitled to receive, upon exercise of the Common Warrant, the kind and amount of securities, cash or other property that such holders would have received had they exercised the Common Warrants immediately prior to such Fundamental Transaction, without regard to any limitations on exercise contained in the Common Warrants or the holder may require the Company or the successor entity to repurchase the unexercised portion of the Common Warrant for its Black Scholes Value, as defined in the Common Warrant; provided, however, if the holder shall only be entitled to receive from the Company or any successor entity the same type or form of consideration (and in the same proportion) at the Black Scholes Value of the unexercised portion of the Common Warrant, that is being offered and paid to the holders of common stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, shares or any combination thereof, or whether the holders of common stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of common stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of common stock will be deemed to have received common stock of the successor entity (which successor entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 15; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company concluded that the Common Warrants did not meet the equity indexation criteria due to the certain inputs to estimate the number of shares issuable in a Fundamental Transaction and the Common Warrants are therefore accounted for as liabilities. The Company recorded $<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="cref_143115946" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8458">24.7</ix:nonFraction>&#160;million to warrant liability upon issuance of the Common Warrants. The Company estimated fair value of the Common Warrants at the issuance date using the Black-Scholes valuation model and will remeasure the liability at each reporting date. The Company recorded a change in fair value of warrant liability of $<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="cref_739243793" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8459">9.6</ix:nonFraction>&#160;million in its condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2026. Refer to Note 3 for assumptions used to estimate the Common Warrants fair value. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2026,&#160;none&#160;of the Common Warrants have been exercised.</p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
 <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2428"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 8. COMMITMENTS AND CONTINGENCIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Operating Leases</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026, the Company leased approximately&#160;<ix:nonFraction name="us-gaap:AreaOfLand" contextRef="cref_438560971" unitRef="uref_1104703976" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8460">25,900</ix:nonFraction>&#160;square feet of laboratory and office space in Redwood City, California, under an operating lease that expires in August 2026. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In conjunction with signing the lease, the Company secured a letter of credit in favor of the lessor in the amount of $<ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8461">0.4</ix:nonFraction> million. The funds related to this letter of credit are presented as restricted cash on the Company&#8217;s condensed consolidated balance sheets. The lease agreement includes an escalation clause for increased base rent and a renewal provision allowing the Company to extend this lease for an additional <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="cref_438560971" format="ixt-sec:durmonth" id="ixv-8462">60</ix:nonNumeric> months at the prevailing rental rate, which the Company is not reasonably certain to exercise. In addition to base rent, the Company pays its share of operating expenses and taxes. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In March 2025, the Company extended its existing short-term lease for <ix:nonFraction name="us-gaap:AreaOfLand" contextRef="cref_1406915345" unitRef="uref_1104703976" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8463">12,500</ix:nonFraction> square feet of laboratory and office space in Redwood City, California, through August 2026. As a result, the Company recorded a right-of-use asset and lease liability of $<ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="cref_2133957400" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8464">1.1</ix:nonFraction> million in March 2025. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In December 2025, in connection with the cessation of the Company&#8217;s vivarium operations and consolidation of personnel office space, the Company ceased use of a portion of its leased headquarters space. As a result, the right-of-use asset associated with that lease was impaired by $<ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="cref_1417501004" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8465">0.4</ix:nonFraction> million. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company also pays variable costs related to its share of operating expenses and taxes. These variable costs are recorded as lease expense as incurred and presented as operating expenses in the condensed consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="cref_784925054" continuedAt="continuation_2145637355" escape="true" id="ixv-2448"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease costs, which were included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss, are as follows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="font-weight: bold">Lease cost</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Operating lease cost</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8466">203</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8467">232</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Short-term lease cost</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1783648313">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8468">169</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Variable lease cost</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8469">178</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8470">118</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: 9.05pt">Total lease cost</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8471">381</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8472">519</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 16; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude><ix:continuation id="continuation_2145637355"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental information related to the Company&#8217;s operating leases is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8473">496</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8474">356</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Weighted average remaining lease term (years)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="cref_438560971" format="ixt-sec:duryear" id="ixv-8475">0.39</ix:nonNumeric></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="cref_1406915345" format="ixt-sec:duryear" id="ixv-8476">1.4</ix:nonNumeric></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Weighted average discount rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="cref_438560971" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8477">8.00</ix:nonFraction></td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="cref_1406915345" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8478">8.00</ix:nonFraction></td> <td style="text-align: left">%</td> </tr></tbody></table></ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2582"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments as of March 31, 2026 (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="font-weight: bold; border-bottom: Black 1.5pt solid">Year Ending December 31,</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: left; padding-bottom: 1.5pt">2026 (remainder of the year)</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8479">764</ix:nonFraction></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-left: 9pt">Total undiscounted lease payments</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8480">764</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8481">7</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-left: 9pt">Total discounted lease payments</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8482">757</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Less current portion of lease liability</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8483">757</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Noncurrent portion of lease liability</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_357656926">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>License Agreements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In March 2021, the Company entered into the 2021 Stanford License Agreement (Note 6), which was amended in July 2023, pursuant to which the Company is required to pay annual license maintenance fees, clinical development and commercial sales milestone payments of up to an aggregate of $<ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="cref_107187006" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8484">9.0</ix:nonFraction> million, and low single-digit royalties on net sales of licensed products. All products were in development as of March 31, 2026, and no royalties were due as of such date. The Company recognized $<ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8485">50,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8486">35,000</ix:nonFraction> in annual license maintenance fees as research and development expense in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026 and 2025, respectively. As of each of March 31, 2026 and December 31, 2025, no milestones were probable to be achieved and payable. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In December 2024, the Company entered into the 2024 Stanford License Agreement (Note 6), pursuant to which the Company is required to pay a license issue and annual license maintenance fees, clinical development and commercial sales milestone payments of up to an aggregate of $<ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="cref_1989808306" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8487">8.3</ix:nonFraction> million and low single-digit royalties on net sales of licensed products. All products were in development as of March 31, 2026, and no royalties were due as of such date. As of March 31, 2026, no milestones were probable to be achieved and payable. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Legal Proceedings</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company, from time to time, may be party to litigation arising in the ordinary course of business. On September 19, 2025, a shareholder class action complaint captioned&#160;<i>Grant v. Jasper Therapeutics, Inc., et al.</i>&#160;(Case No. 25-cv-08010) was filed in the United States District Court for the Northern District of California against the Company and certain of the Company&#8217;s current and former officers. The complaint alleges that certain material misstatements or omissions related to the ongoing clinical trials of briquilimab were made in violation of federal securities laws. The plaintiffs are seeking unspecified monetary&#160;damages&#160;and an award of costs and expenses, including reasonable attorneys&#8217; fees, expert fees and other costs. On December 3, 2025, a stipulated order was entered appointing co-lead plaintiffs and approving their selection of co-lead counsel, and on December 16, 2025, a stipulated order was entered setting a schedule for the filing and responses to an amended complaint. Per the terms of the December 16, 2025 stipulated order, an amended complaint captioned <i>Allard, et al. v. Jasper Therapeutics, Inc., et al.</i> (Case No. 25-cv-08010) was filed, and defendants&#8217; motion to dismiss was filed on April 20, 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, on November 5, 2025, a shareholder derivative complaint captioned <i>Bardauskas v. Martell, et al</i>. (Case No. 25-cv-09561) was filed in the United States District Court for the Northern District of California, and on December 22, 2025, another shareholder derivative complaint was filed in the same court and captioned <i>Walsh v. Martell, et al.</i> (Case No. 25-cv-10899).&#160;The derivative complaints name as defendants certain of the Company&#8217;s current and former officers and directors, and allege claims related to the allegations raised in the shareholder class action complaint. On January 21, 2026, a stipulated order was entered, among other things, consolidating and staying the derivative actions.&#160;The Company believes the claims raised in these lawsuits are without merit, and intends to defend these matters vigorously.&#160;However, there can be no assurance that the Company will prevail.&#160;The Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore, no amount of loss has been accrued in the Company&#8217;s condensed consolidated financial statements as of and for the three months ended March 31, 2026. Regardless of outcome, litigation can have an adverse impact on the Company due to costs involved, diversion of management resources, negative publicity, reputational harm, and other factors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company believes that it is not currently a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations&#160; or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 17; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Guarantees and Indemnifications </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of each of March 31, 2026 and December 31, 2025, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.</p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
 <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2672"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 9. COMMON STOCK</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="cref_601785078" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8488">490,000,000</ix:nonFraction>&#160;shares of voting common stock, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="cref_736074492" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8489">2,000,000</ix:nonFraction>&#160;shares of non-voting&#160;common stock, and <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="cref_438560971" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8490">10,000,000</ix:nonFraction>&#160;shares of undesignated preferred stock. There were&#160;<ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="cref_438560971" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8491">27,996,819</ix:nonFraction> shares of voting common stock, <span style="-sec-ix-hidden:fc_1765267982"><span style="-sec-ix-hidden:fc_1111002203">no</span></span> shares of non-voting common stock&#160;and <span style="-sec-ix-hidden:fc_2072766674"><span style="-sec-ix-hidden:fc_549550349">no</span></span> shares of preferred stock issued and outstanding as of March 31, 2026. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Holders of the voting common stock and the non-voting&#160;common stock have similar rights, except that non-voting stockholders are not entitled to vote, including for the election of directors. Holders of voting common stock do not have conversion rights, while holders of non-voting&#160;common stock have the right to convert each share of non-voting&#160;common stock held by such holder into <ix:nonFraction name="jspr:NumberOfSharePurchase" contextRef="cref_438560971" unitRef="uref_469718384" scale="0" decimals="0" format="ixt-sec:numwordsen" id="ixv-8492">one</ix:nonFraction> share of voting common stock at such holder&#8217;s election by providing written notice to the Company, provided that as a result of such conversion, such holder, together with its affiliates, would not beneficially own in excess of <ix:nonFraction name="jspr:VotingCommonStockPercent" contextRef="cref_438560971" unitRef="uref_1055712422" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-8493">9.9</ix:nonFraction>% of the Company&#8217;s voting common stock following such conversion. There were <span style="-sec-ix-hidden:fc_2048509785"><span style="-sec-ix-hidden:fc_1054403778">no</span></span> outstanding shares of non-voting common stock as of March 31, 2026 and December 31, 2025. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2686"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;As of March 31, 2026 and December 31, 2025, the Company had common stock reserved for future issuance as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Outstanding and issued common stock options</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_841215262" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8494">2,671,358</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_1455265214" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8495">2,246,206</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Outstanding and issued restricted stock units</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_1634329083" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8496">170,100</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_166765776" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8497">198,900</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Outstanding and issued performance-based restricted stock units</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1844764249">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_1329622523" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8498">20,000</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Shares issuable upon exercise of Public Warrants (1)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="fc_1365582304" contextRef="cref_1365582304" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal">499,986</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="fc_1665866085" contextRef="cref_1665866085" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal">499,986</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Shares issuable upon exercise of Common Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_695848034" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8501">12,345,707</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_749757817" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8502">12,345,707</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Shares issuable upon exercise of Pre-Funded Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_653971143" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8503">675,000</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_467908750" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8504">675,000</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Shares available for grant under Equity Incentive Plans</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_835672883" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8505">418,817</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_1068906306" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8506">843,360</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Shares available for grant under Employee Stock Purchase Plan</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_671366674" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8507">920,827</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_1623292660" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8508">920,827</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Shares available for grant under 2022 Inducement Equity Incentive Plan</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_1516512986" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8509">180,960</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_1088620590" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8510">132,769</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Total shares of common stock reserved</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_438560971" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8511">17,882,755</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_268000114" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8512">17,882,755</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><sup>&#160;</sup></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"><td style="width: 0in"/> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="fref_296657012" xml:lang="en-US">The                                             Company has <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1422418476" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8514">4,999,863</ix:nonFraction> outstanding warrants to purchase an aggregate of&#160;<ix:nonFraction name="jspr:PurchaseAnAggregateShares" contextRef="cref_238056073" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8515">499,986</ix:nonFraction>&#160;shares                                             of its common stock (the &#8220;Public Warrants&#8221;). A holder may purchase&#160;one&#160;share                                             of the Company&#8217;s common stock for every&#160;ten&#160;Public Warrants at an exercise                                             price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="fc_415871009" contextRef="cref_415871009" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal">115.00</ix:nonFraction>&#160;per share. The Public Warrants are publicly traded and exercisable                                             during the exercise period, which commenced on October 24, 2021 and ends on September 24,                                             2026, for cash or, in certain circumstances, on a cashless basis. The Public Warrants were                                             reclassified to equity in January 2023.</ix:footnote></span></td> </tr></tbody> </table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><!-- Field: Page; Sequence: 18; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Shelf Registration Statement</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 19, 2025, the Company filed a new shelf registration statement on Form S-3 (the &#8220;S-3&#8221;) with the SEC, which was declared effective on March 26, 2025. As of March 31, 2026, the Company can sell from time to time up to $<ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="cref_438560971" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8517">263.5</ix:nonFraction> million of common stock, preferred stock, debt securities, warrants, rights, units and depositary shares comprised of any combination of these securities, for the Company&#8217;s own account in one or more offerings under the S-3. The terms of any offering under the S-3 will be established at the time of such offering and will be described in a prospectus supplement to the S-3 filed with the SEC prior to the completion of any such offering. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>ATM Offerings</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 19, 2025, the Company entered into an Open Market Sale Agreement<sup>SM</sup>&#160;with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which the Company may offer and sell through or to Jefferies, as sales agent or principal, shares of common stock from time to time (the &#8220;ATM Offering&#8221;). On March 26, 2025, the Company filed with the SEC a prospectus under the S-3 in connection with the ATM Offering (the &#8220;ATM Prospectus&#8221;), pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to $<ix:nonFraction name="jspr:AggregateOfferingPrice" contextRef="cref_648885515" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8518">100.0</ix:nonFraction> million. As of March 31, 2026, the Company issued and sold an aggregate of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="cref_1187790031" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8519">1,231,447</ix:nonFraction> shares of common stock for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="fc_931614726" contextRef="cref_784925054" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction> million pursuant to the ATM Prospectus. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026, $<ix:nonFraction name="jspr:UnderwrittenOfferingRemainedAvailable" contextRef="cref_784925054" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8521">93.5</ix:nonFraction> million remained available under the ATM Prospectus. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Underwritten Offering</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On September 18, 2025, the Company entered into an underwriting agreement with TD Securities (USA) LLC as the representative of the several underwriters, relating to an underwritten public offering under the S-3 of an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="fc_1996495367" contextRef="cref_2042008173" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,670,707</ix:nonFraction> shares of common stock, Pre-Funded Warrants to purchase <ix:nonFraction name="jspr:PreFundedWarrantsToPurchase" contextRef="cref_2042008173" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8523">675,000</ix:nonFraction> shares of common stock and Common Warrants to purchase <ix:nonFraction name="jspr:CommonWarrantsToPurchaseShares" contextRef="cref_2042008173" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8524">12,345,707</ix:nonFraction> shares of common stock. The Company received net proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" id="fc_2042008173" contextRef="cref_2042008173" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.5</ix:nonFraction>&#160;million. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026, $<ix:nonFraction name="jspr:AvailableOfferingAmount" contextRef="cref_343598538" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8526">170.0</ix:nonFraction> million remained available and unallocated under the S-3. </p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
 <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="cref_784925054" escape="true" id="ixv-2852"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 10. STOCK-BASED COMPENSATION</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_1643317952" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8527">2,750,719</ix:nonFraction> shares were reserved for issuance under the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), of which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="cref_1643317952" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8528">418,817</ix:nonFraction> shares were available for future grant and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="cref_1643317952" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8529">2,331,902</ix:nonFraction> shares were subject to outstanding options and restricted stock units (&#8220;RSUs&#8221;), including <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="cref_1643317952" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8530">30,894</ix:nonFraction> shares subject to performance-based awards. As of March 31, 2026, options to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="cref_1436491688" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8531">140,516</ix:nonFraction> shares of common stock remained outstanding and unexercised, and continue to be governed by the 2019 Equity Incentive Plan (the &#8220;2019 EIP&#8221;). As of March 31, 2026, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_436942179" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8532">1,000,000</ix:nonFraction> shares were reserved under the 2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), of which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="cref_436942179" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8533">920,827</ix:nonFraction> shares were available for future issuance and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" id="fc_517605843" contextRef="cref_517605843" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal">79,173</ix:nonFraction> shares had been issued. As of March 31, 2026, <ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" contextRef="cref_1757947245" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8535">550,000</ix:nonFraction> shares were reserved for issuance under the 2022 Inducement Equity Incentive Plan (the &#8220;2022 Inducement Plan&#8221;), of which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="cref_1757947245" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8536">180,960</ix:nonFraction> shares were available for future grant and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="cref_436942179" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8537">369,040</ix:nonFraction> shares were subject to outstanding stock options. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Stock Option Activity</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="cref_784925054" continuedAt="continuation_314766131" escape="true" id="ixv-2862"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the stock option activities, including performance-based stock options, under the 2024 Plan, the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), the 2022 Inducement Plan and the 2019 EIP for the three months ended March 31, 2026:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Outstanding</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise     Price</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average<br/> Remaining<br/>     Contractual<br/> Life&#160;(Years)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic Value <br/>     (in thousands)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%">Balance, December 31, 2025</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="cref_1840882305" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8538">2,246,206</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="cref_1840882305" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8539">13.72</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="cref_1367888496" format="ixt-sec:duryear" id="ixv-8540">4.81</ix:nonNumeric></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_838649266">&#8212;</span></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Options granted</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="cref_1511983395" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8541">1,262,300</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="fc_982109083" contextRef="cref_1511983395" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Options cancelled/forfeited</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="cref_1511983395" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8543">837,148</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="cref_1511983395" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8544">7.08</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Balance, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="cref_1086398820" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8545">2,671,358</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="cref_1086398820" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8546">10.10</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="cref_1511983395" format="ixt-sec:duryear" id="ixv-8547">7.43</ix:nonNumeric></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1603413953">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="cref_1086398820" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8548">2,671,358</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="cref_1086398820" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8549">10.10</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="cref_1511983395" format="ixt-sec:duryear" id="ixv-8550">7.43</ix:nonNumeric></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1454690266">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Exercisable, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="cref_1086398820" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8551">1,018,023</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="fc_1086398820" contextRef="cref_1086398820" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal">18.93</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="cref_1511983395" format="ixt-sec:duryear" id="ixv-8553">4.33</ix:nonNumeric></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1900409824">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 19; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. <span style="-sec-ix-hidden:fc_577259707"><span style="-sec-ix-hidden:fc_729631792">No</span></span> options were exercised during the three months ended March 31, 2026 and 2025. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The total fair value of options that vested during the three months ended March 31, 2026 and 2025 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="cref_784925054" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8554">0.9</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="cref_1378370445" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8555">2.7</ix:nonFraction> million, respectively. The weighted-average grant date fair value of options granted during the three months ended March 31, 2026 and 2025 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="cref_784925054" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8556">1.33</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="cref_1378370445" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8557">4.92</ix:nonFraction> per share, respectively. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Unamortized stock-based compensation expense as of March 31, 2026 was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="cref_438560971" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8558">5.6</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="cref_784925054" format="ixt-sec:duryear" id="ixv-8559">3.0</ix:nonNumeric> years. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Performance-Based Stock Options&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:continuation id="continuation_314766131"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> There was <span style="-sec-ix-hidden:fc_597754003">no</span> performance-based stock option activity under the 2024 Plan or the 2021 Plan during the three months ended March 31, 2026. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Outstanding</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise&#160;Price</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/>     Contractual<br/> Life&#160;(Years)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value     &#160;(in thousands)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%; padding-bottom: 1.5pt">Balance, December 31, 2025</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="cref_1206044327" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8560">30,894</ix:nonFraction></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td> <td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="cref_1206044327" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8561">7.33</ix:nonFraction></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="cref_853288868" format="ixt-sec:duryear" id="ixv-8562">4.43</ix:nonNumeric></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td> <td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden:fc_1799126299">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Balance, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="cref_477447857" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8563">30,894</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="cref_477447857" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8564">7.33</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="cref_1680691002" format="ixt-sec:duryear" id="ixv-8565">4.18</ix:nonNumeric></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_723560973">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="cref_477447857" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8566">30,894</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="cref_477447857" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8567">7.33</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="cref_1680691002" format="ixt-sec:duryear" id="ixv-8568">4.18</ix:nonNumeric></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1792648283">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Exercisable, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="cref_477447857" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8569">30,894</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="cref_477447857" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8570">7.33</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="cref_1680691002" format="ixt-sec:duryear" id="ixv-8571">4.18</ix:nonNumeric></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1994038587">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Restricted Stock Units (RSUs)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="cref_784925054" escape="true" id="ixv-3131"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides a summary of RSU activity under the 2024 Plan during the three months ended March 31, 2026:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Share</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Grant Date     <br/> Fair Value</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Unvested restricted stock units at December 31, 2025</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="cref_384482861" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8572">198,900</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="cref_384482861" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8573">6.00</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 1.5pt">Forfeited</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="cref_1227972248" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8574">28,800</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td> <td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="cref_1227972248" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8575">6.00</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Unvested restricted stock units at March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="cref_2127221751" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8576">170,100</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="cref_2127221751" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8577">6.00</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Performance Restricted Stock Units (PSUs) </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &#160;In June 2024, the Company granted PSUs for <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="cref_714368909" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8578">20,000</ix:nonFraction> shares that would vest in full if the closing price of the Company&#8217;s common stock on the Nasdaq Capital Market reached or exceeded $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" contextRef="cref_714368909" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8579">35.00</ix:nonFraction> per share (subject to adjustment for recapitalizations, stock splits and similar transactions) for thirty consecutive calendar days within two years from the grant date. If the vesting condition was not met within two years from the grant date, the PSUs would be forfeited. The Company concluded that issued PSUs were equity-based awards and include a market based vesting condition. The Company used a Monte Carlo simulation model to estimate the fair value of the PSUs with the following assumptions: common stock fair value of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="cref_1835780786" unitRef="uref_1987543344" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-8580">23.95</ix:nonFraction>, which was the closing market price of the Company&#8217;s common stock at the grant date, volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="cref_714368909" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8581">133.00</ix:nonFraction>%, risk free rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="cref_714368909" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8582">4.87</ix:nonFraction>%, and vesting term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="cref_2065545269" format="ixt-sec:duryear" id="ixv-8583">2.0</ix:nonNumeric> years. Total estimated fair value of $<ix:nonFraction name="jspr:TotalEstimatedFairValue" contextRef="cref_784925054" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8584">0.4</ix:nonFraction> million was recognized as stock-based compensation expense over <ix:nonNumeric name="jspr:RecognizedCompensationExpensePeriod" contextRef="cref_784925054" format="ixt-sec:duryear" id="ixv-8585">0.4</ix:nonNumeric> years, the derived requisite service period from the grant date. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 20; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In January 2026, the employee holding the PSUs was terminated and the award was forfeited. <span style="-sec-ix-hidden:fc_1423726112">No</span> stock-based compensation expense was reversed upon forfeiture, as the award included only a market-based vesting condition and the derived requisite service period had been completed.  </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Employee Stock Purchase Plan</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company did not issue any shares of common stock under the ESPP during the three months ended March 31, 2026 and 2025, and recognized less than $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="cref_155106258" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8586">0.1</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="cref_664802157" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8587">0.1</ix:nonFraction> million compensation expense related to the ESPP during the three months ended March 31, 2026 and 2025, respectively. There was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="cref_784622662" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8588">0.2</ix:nonFraction> million unamortized stock-based compensation for shares issuable under the ESPP as of March 31, 2026, which is expected to be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="cref_1154412494" format="ixt-sec:duryear" id="ixv-8589">1.7</ix:nonNumeric> years. The Company recorded $<ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="cref_784622662" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8590">0.1</ix:nonFraction> million in accrued expenses and other current liabilities related to contributions withheld as of March 31, 2026.&#160; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Stock-Based Compensation Expense</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="cref_784925054" escape="true" id="ixv-3207"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table presents stock-based compensation expenses related to options, PSUs and RSUs granted to employees and non-employees, employee stock purchase plan awards and restricted common stock shares issued to founders (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">General and administrative</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_1364903650" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8591">202</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_2045662903" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8592">1,240</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Research and development</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_1852720650" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8593">221</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_1083033443" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8594">571</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 4pt; padding-left: 9pt">Total</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_155304082" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8595">423</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_1571420461" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8596">1,811</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company recognized $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_1680691002" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8597">0.1</ix:nonFraction>&#160;million and <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_279398949" unitRef="uref_668202531" scale="0" decimals="0" format="ixt-sec:numwordsen" id="ixv-8598">zero</ix:nonFraction> stock-based compensation expense related to performance-based options, PSUs and RSUs during the three months ended March 31, 2026 and 2025, respectively. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Valuation of Stock Options</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="cref_784925054" escape="true" id="ixv-3263"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 70%; text-align: left">Expected term (in years)</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 12%; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="cref_502686246" format="ixt-sec:duryear" id="ixv-8599">6.08</ix:nonNumeric></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 12%; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="cref_1143859271" format="ixt-sec:duryear" id="ixv-8600">6.01</ix:nonNumeric> &#8211; <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="cref_1055712422" format="ixt-sec:duryear" id="ixv-8601">6.08</ix:nonNumeric></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Expected volatility</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="cref_2040753095" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8602">99.87</ix:nonFraction>% &#8211; <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="cref_1518267216" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8603">100.05</ix:nonFraction></td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="cref_1143859271" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8604">97.37</ix:nonFraction>% &#8211; <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="cref_1055712422" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8605">97.93</ix:nonFraction></td> <td style="text-align: left">%</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="cref_2040753095" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8606">3.85</ix:nonFraction>% &#160;&#8211; <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="cref_1518267216" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8607">3.88</ix:nonFraction></td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="cref_1143859271" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8608">3.93</ix:nonFraction>% &#8211; <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="cref_1055712422" unitRef="uref_1055712422" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-8609">4.35</ix:nonFraction></td> <td style="text-align: left">%</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Expected dividend yield</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1964576807">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_402018995">&#8212;</span></td> <td style="text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 21; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
 <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="cref_784925054" escape="true" id="ixv-3331"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 11. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="cref_784925054" escape="true" id="ixv-3335"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>Numerator:</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left; padding-bottom: 4pt">Net loss attributable to common stockholders</td> <td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8610">1,174</ix:nonFraction></td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td> <td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8611">21,241</ix:nonFraction></td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Denominator:</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Weighted average common shares and pre-funded warrant shares outstanding</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" id="fc_1840909275" contextRef="cref_784925054" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal">28,671,819</ix:nonFraction></td> <td style="text-align: left">(a)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="cref_1378370445" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8613">15,022,122</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt">Weighted average shares used to compute basic and diluted net loss per share</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="cref_784925054" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8614"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="cref_784925054" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8615">28,671,819</ix:nonFraction></ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="cref_1378370445" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8616"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="cref_1378370445" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8617">15,022,122</ix:nonFraction></ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Net loss per share attributable to common stockholders &#8211; basic and diluted</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="cref_784925054" unitRef="uref_1987543344" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-8618"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="cref_784925054" unitRef="uref_1987543344" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-8619">0.04</ix:nonFraction></ix:nonFraction></td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="cref_1378370445" unitRef="uref_1987543344" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-8620"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="cref_1378370445" unitRef="uref_1987543344" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-8621">1.41</ix:nonFraction></ix:nonFraction></td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"><td style="width: 0in"/> <td style="width: 0.25in; text-align: left">(a)</td> <td style="text-align: justify"><ix:footnote id="fref_1477796849" xml:lang="en-US">Includes <ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" contextRef="cref_784925054" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8623">675,000</ix:nonFraction> weighted-average shares underlying pre-funded warrants outstanding during the period, as such warrants are exercisable at any time for nominal consideration ($<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="cref_438560971" unitRef="uref_1987543344" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-8624">0.0001</ix:nonFraction> per share).</ix:footnote></td> </tr></tbody> </table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="cref_784925054" escape="true" id="ixv-3420"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Outstanding and issued common stock options</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_887924682" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8625">2,671,358</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_442461320" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8626">2,186,226</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Outstanding and issued restricted stock units</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_565409357" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8627">170,100</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1768916711">&#8212;</span></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Shares issuable upon exercise of Public Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_34643640" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8628">499,986</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_1107233758" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8629">499,986</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Shares issuable upon exercise of Common Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_1720545267" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8630">12,345,707</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1479140823">&#8212;</span></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Unvested performance-based restricted stock units</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1505739634">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_1722756702" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8631">20,000</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="font-weight: bold; padding-bottom: 4pt">Total</td> <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_784925054" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8632">15,687,151</ix:nonFraction></td> <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td> <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_1378370445" unitRef="uref_469718384" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-8633">2,706,212</ix:nonFraction></td> <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td> </tr></tbody></table></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
 <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="cref_784925054" escape="true" id="ixv-3502"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 12. RELATED PARTIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In the first quarter of 2024, a senior executive of the Company joined the board of directors of an information technology service provider that the Company has utilized to support a broad array of the Company&#8217;s systems infrastructure as well as for general information technology support services. For the three months ended March 31, 2026 and 2025, the Company incurred $<ix:nonFraction name="us-gaap:InterestCostsIncurred" contextRef="cref_784925054" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8634">0.3</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:InterestCostsIncurred" contextRef="cref_1378370445" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8635">0.2</ix:nonFraction>&#160;million, respectively, for various information technology support services performed by this service provider. There was $<ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="cref_438560971" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8636"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="cref_268000114" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8637">0.1</ix:nonFraction></ix:nonFraction> million of accounts payable recognized in the condensed consolidated balance sheets as of each of March 31, 2026 and December 31, 2025. </p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 22; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
 <ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="cref_784925054" escape="true" id="ixv-3514"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 13. SEGMENT INFORMATION</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company has determined it operates as a <span style="-sec-ix-hidden:fc_1666881356"><span style="-sec-ix-hidden:fc_975557945">single</span></span> operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.<ix:nonNumeric name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription" contextRef="cref_784925054" id="ixv-3522"> The Company&#8217;s chief operating decision maker, its <span style="-sec-ix-hidden:fc_743175501">Chief Executive Officer</span> (the &#8220;CEO&#8221;), manages the Company&#8217;s operations on a consolidated basis. The CEO assesses the segment&#8217;s performance and allocates resources based on review of various development, manufacturing and clinical programs expenses, along with the segment&#8217;s personnel and general and overhead costs.</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="cref_784925054" escape="true" id="ixv-3525"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the significant expense categories included within net loss presented in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise total operating expenses (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Personnel-related costs</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="jspr:PersonnelCosts" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8638">4,038</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction name="jspr:PersonnelCosts" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8639">8,431</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">General and overhead costs</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="jspr:FacilitiesAndOverheadCosts" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8640">3,291</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="jspr:FacilitiesAndOverheadCosts" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8641">3,611</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Program costs</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-left: 9pt">Briquilimab platform</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_1773614604" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8642">266</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_585224753" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8643">1,957</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-left: 9pt">CMO</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_920960091" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8644">882</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_199674710" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8645">2,138</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 9pt">CSU</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_768267355" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8646">2,378</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_158858565" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8647">2,746</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-left: 9pt">Asthma</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_2109719354" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8648">327</ix:nonFraction></td> <td style="text-align: left">)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_217583461" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8649">1,393</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 9pt">CIndU</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_1533989264" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8650">424</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_1187366974" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8651">885</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-left: 9pt">SCID</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1357899928">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_543821224" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8652">523</ix:nonFraction></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 1.5pt; padding-left: 9pt">MDS/AML</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1112529675">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_358966682" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8653">118</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total program costs</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8654">3,623</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8655">9,760</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expense</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8656">10,952</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8657">21,802</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Other income, net</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8658">9,778</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-8659">561</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Net loss</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_784925054" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8660">1,174</ix:nonFraction></td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1378370445" unitRef="uref_668202531" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-8661">21,241</ix:nonFraction></td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> </tr></tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All long-lived assets are located in the United States.&#160;&#160;</p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
 <ix:nonNumeric name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" contextRef="cref_784925054" escape="true" id="ixv-3699"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 14. RESTRUCTURING</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Starting in July 2025, the Company implemented a corporate reorganization and other cost reduction measures to extend its cash runway. These actions included a workforce reduction, refinement of the Company&#8217;s operating plan to focus on briquilimab clinical development programs in chronic urticaria, halting enrollment in its Phase 1b asthma study, discontinuation of other clinical and preclinical programs and cessation of vivarium operations. In 2025, the Company incurred restructuring charges related to workforce reduction of approximately $<ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="cref_1417501004" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8662">2.3</ix:nonFraction> million, primarily related to severance payments, and recognized impairment charges of $<ix:nonFraction name="us-gaap:OtherAssetImpairmentCharges" contextRef="cref_1417501004" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8663">1.1</ix:nonFraction> million related to the abandonment of certain fixed assets and a right-of-use asset associated with vivarium operations. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026 and December 31, 2025, the Company had $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="cref_486425029" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8664">0.3</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="cref_668202531" unitRef="uref_668202531" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-8665">0.4</ix:nonFraction> million, respectively, of accrued severance costs related to the termination of one employee in connection with the restructuring, which are included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. The related severance payments are expected to be made over a period of approximately <ix:nonNumeric name="jspr:SeveranceCostsPeriod" contextRef="cref_784925054" format="ixt-sec:durmonth" id="ixv-8666">12</ix:nonNumeric> months, through January 2027.&#160;&#160; </p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><!-- Field: Page; Sequence: 23; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><span id="a_008" style="display: inline-block;"></span>Item 2. Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations<i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>You should read the following discussion and
analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related
notes included&#160;</i>in&#160;<i>Part I, Item 1 of this Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) and with
the audited consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2025 filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 30, 2026.&#160;Certain of the information
contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to plans
and strategy for our business, includes forward-looking&#160;statements that involve risks and uncertainties. As a result of many factors,
including those factors set forth in the section entitled &#8220;Risk Factors&#8221;, in Part I - Item 1A of our Annual Report on Form
10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, as updated by the factors described under the heading
&#8220;Risk Factors&#8221; in Part II - Item 1A of this Quarterly Report, our actual results could differ materially from the results
described in or implied by the forward-looking&#160;statements contained in the following discussion and analysis. You should carefully
read the section entitled &#8220;Risk Factors&#8221; to gain an understanding of the important factors that could cause actual results
to differ materially from our forward-looking&#160;statements. Please also see &#8220;Cautionary Note&#160;Regarding Forward-Looking&#160;Statements&#8221;
below. The events and circumstances reflected in our forward-looking statements may not be achieved or may not occur, and actual results
could differ materially from those described in or implied by the forward-looking statements contained in the following discussion and
analysis. As a result of these risks, you should not place undue reliance on these forward-looking statements. We assume no obligation
to revise or update any forward-looking statements for any reason, except as required by law.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Throughout this Quarterly Report, unless the
context otherwise requires, the terms &#8220;Jasper,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this Quarterly
Report refer to Jasper Therapeutics, Inc. and its consolidated subsidiary.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain statements contained in this Quarterly
Report may constitute &#8220;forward-looking&#160;statements&#8221; for purposes of federal securities laws. Such statements can be identified
by the fact that they do not relate strictly to historical or current facts. In addition, any statements that refer to projections, forecasts
or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking&#160;statements.
The words &#8220;<i>anticipate</i>,&#8221; &#8220;<i>believe</i>,&#8221; &#8220;<i>contemplate</i>,&#8221; &#8220;<i>continue</i>,&#8221;
&#8220;<i>could</i>,&#8221; &#8220;<i>estimate</i>,&#8221; &#8220;<i>expect</i>,&#8221; &#8220;<i>intends</i>,&#8221; &#8220;<i>may</i>,&#8221;
&#8220;<i>might</i>,&#8221; &#8220;<i>plan</i>,&#8221; &#8220;<i>possible</i>,&#8221; &#8220;<i>potential</i>,&#8221; &#8220;<i>predict</i>,&#8221;
&#8220;<i>project</i>,&#8221; &#8220;<i>should</i>,&#8221; &#8220;<i>will</i>,&#8221; &#8220;<i>would</i>&#8221; and similar expressions
(including the negative of any of the foregoing) may identify forward-looking&#160;statements, but the absence of these words does not
mean that a statement is not forward-looking.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Forward&#160;-looking&#160;statements in this
Quarterly Report may include, for example, but are not limited to, statements about:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our or our management team&#8217;s
    expectations, hopes, beliefs, intentions or strategies regarding the future;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to research,
    discover and develop additional product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success, cost and timing
    of our product development activities and clinical trials;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential attributes
    and benefits and safety and efficacy of our product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and
    maintain regulatory approval for our product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain additional
    funding for our operations in future offerings;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our projected financial
    information, anticipated growth rate and market opportunity;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain
    the listing of our public securities on the Nasdaq Capital Market LLC (&#8220;Nasdaq&#8221;);</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our public securities&#8217;
    potential liquidity and trading;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our success in retaining
    or recruiting, or changes required in, officers, key employees or directors;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to grow and
    manage growth profitably;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the implementation, market acceptance and success of
    our business model, developments and projections relating to our competitors and industry;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and
    maintain intellectual property protection and not infringe on the rights of others;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to identify,
    in-license or acquire additional technology; </span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain
    our existing license agreements and manufacturing arrangements; </span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding the anticipated benefits
    of our corporate reorganization, including the reduction in force, and our ability to implement and achieve the expected cost savings
    in connection therewith;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to continue as a going concern; and </span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the volatility of the trading price of our common stock.
    </span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 24; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These forward-looking&#160;statements are based
on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future
developments affecting us will be those that we have anticipated. These forward-looking&#160;statements involve a number of risks, uncertainties
(some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from
those expressed or implied by these forward-looking&#160;statements. These risks and uncertainties include, but are not limited to, those
factors described under the heading &#8220;Risk Factors&#8221; in Part I - Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2025, filed with the SEC on March 30, 2026, as updated by the factors described under the heading &#8220;Risk Factors&#8221;
in Part II&#160;<i>-</i>&#160;Item 1A of this Quarterly Report. Should one or more of these risks or uncertainties materialize, or should
any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking&#160;statements.
Some of these risks and uncertainties may in the future be amplified, and there may be additional risks that we consider immaterial or
which are unknown. It is not possible to predict or identify all such risks. Readers are cautioned not to place undue reliance on forward-looking&#160;statements
because of the risks and uncertainties related to them and to the risk factors. We do not undertake any obligation to update or revise
any forward-looking&#160;statements, whether as a result of new information, future events or otherwise, except as may be required under
applicable securities laws.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Overview</span>&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a clinical-stage biotechnology company
focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (&#8220;CSU&#8221;), Chronic
Inducible Urticaria (&#8220;CIndU&#8221;) and asthma. We may also consider additional indications in mast cell driven diseases for potential
future development. We have also historically explored development programs in diseases where targeting diseased hemopoietic stem cells
can provide benefits, such as stem cell transplant conditioning regimens, but those programs have been discontinued and we are exclusively
focused on mast cell driven diseases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our lead product candidate, briquilimab, is a
monoclonal antibody designed to block stem cell factor (&#8220;SCF&#8221;) from binding to and signaling through the CD117 (&#8220;KIT&#8221;)
receptor on mast and stem cells. The SCF/KIT pathway is a survival signal for mast cells and we believe that blocking this pathway may
lead to depletion of these cells throughout the body, including in the lungs and in the skin, which could lead to significant clinical
benefit for patients with mast-cell driven diseases such as asthma and chronic urticarias. To that end, we are focusing on advancing
a portfolio of clinical programs in mast cell driven diseases, highlights of which were as follows:&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We commenced the Phase 1b/2a BEACON study in CSU in
    late 2023 and in January 2025, we presented positive preliminary data from the first 8 dosing cohorts in the study (10mg, 40mg, 80mg
    Q8W, 120mg Q8W, 120mg Q12W, 180mg Q8W, 180mg Q12W, and 240mg single-dose). Average patient duration on study as of the cutoff date
    for the data presented was approximately 28 weeks. Highlights of the data were as follows:</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Briquilimab demonstrated a rapid onset of clinical
    efficacy with clinical responses seen as early as 1 week post-dose and complete responses observed as early as week 2 post-dose.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Briquilimab drove deep and meaningful clinical responses
    with 100% complete responses through 8 weeks demonstrated at the 240mg dose level.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Briquilimab was well-tolerated and demonstrated a favorable
    safety profile:</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 96px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KIT-related adverse events (&#8220;AEs&#8221;) were
    generally transient, low-grade events;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 96px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The majority of AEs observed were resolved while on
    study prior to subsequent doses; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 96px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No dose delays, missed doses or discontinuations were
    reported due to AEs possibly related to KIT blockade.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt"></p><!-- Field: Page; Sequence: 25; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2025, we reported updated data from the Phase
    1b/2a BEACON study in CSU with updates on the 240mg and 360mg single dose cohorts as well as the 240mg Q8W and the 240mg/180mg Q8W
    cohorts. Highlights of the data update were as follows:</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Briquilimab administration continued to demonstrate
    deep and rapid disease control in the 240mg and 360mg single-dose cohorts with 8 of 9 (89%) of participants enrolled across both
    cohorts achieving a complete response, and with 7 of 9 (78%) achieving a clinical response by week 2.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results from the 240mg Q8W and the 240mg/180mg Q8W
    dose cohorts demonstrated an atypical absence of UAS7 reduction in 11 of the 13 patients enrolled, and as a result, we launched an
    investigation into those two cohorts. Factors examined included clinical site conduct, site dosing procedures, patient selection
    criteria, as well as potential product lot variability in one lot of drug product first introduced into the BEACON study in those
    two cohorts. We also provided new clinical drug supply from a different lot for ongoing dosing of existing patients and subsequently
    enrolled an additional 10 patients in aggregate across those two cohorts.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2025, we reported the completion of the
    investigation into the confounded efficacy results reported in July 2025 from the 240mg Q8W and the 240mg/180mg Q8W cohorts of the
    BEACON study in CSU. Based on the work conducted, we concluded the anomalous efficacy results in these two cohorts was not the result
    of any issues with the investigational product used, or from drug substance (&#8220;DS&#8221;) or drug product (&#8220;DP&#8221;)
    manufacturing or distribution processes, but rather appeared to be an issue resulting from patient selection process/criteria at
    certain clinical sites participating in the study. This conclusion reflects, among other factors:</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a comprehensive review of manufacturing and distribution
    records;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">robust testing of multiple lots across the manufacturing
    and clinical supply chain;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">independent, blinded testing of returned drug product
    samples from trial sites;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review of stability samples from the lots used in the
    two cohorts compared against other lots;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review of patient selection and enrollment processes;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review of investigational product handling and administration
    at the site level;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review of drug delivery methods (for example, injection
    site, needle and injection media); and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review of additional patient- and site-level data.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The conclusions reached as a result of the investigation
were supported by expert panels comprised of key opinion leaders in clinical development and antibody manufacturing experts that reviewed
the findings and provided clinical operations and development recommendations on patient enrollment processes that are being integrated
into the planned Phase 2b/3 CSU study to increase the likelihood that CSU patients enrolled in the study would be more likely to have
mast cell driven disease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.25in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 26; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2026, we reported updated data from the
    Phase 1b/2a BEACON study in CSU with updates on an additional 8 patients enrolled in the 240mg/180mg Q8W cohort (6 on briquilimab
    and 2 on placebo). Highlights of the data update were as follows:</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Briquilimab demonstrated a rapid onset of clinical
    efficacy with clinical responses achieved by 5 of 6 participants (83%) by week 3;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Briquilimab drove deep and meaningful clinical responses
    with UAS7 reductions of as much as 29 points noted, and 4 of 6 participants (67%) reporting a complete response at 12 weeks.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Briquilimab continued to be well-tolerated and demonstrated
    a favorable safety profile:</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 96px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KIT-related adverse events (&#8220;AEs&#8221;) were
    generally transient, low-grade events;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 96px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The majority of AEs observed were resolved while on
    study prior to subsequent doses; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 96px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No dose delays, missed doses or discontinuations were
    reported due to AEs possibly related to KIT blockade.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In early 2024, we commenced the Phase 1b/2a SPOTLIGHT
    study in CIndU. In October 2024, we presented positive preliminary data on the 40mg and 120mg cohorts from the study showing the
    following for the 6-week preliminary analysis period following dosing, as follows:</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across the 40mg and 120mg dosing cohorts in the study,
    14 of the 15 participants (93%) achieved a clinical response;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the 120mg dose cohort, 10 of 12 participants (83%)
    experienced a complete response, and 1 participant experienced a partial response; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Briquilimab was well-tolerated in the study, with KIT-related
    AEs being low-grade events, and no grade 3 or higher AEs possibly related to KIT blockade reported in any of the dose cohorts.&#160;&#160;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In late 2024, we added a 180mg single dose cohort to
    the SPOTLIGHT study in CIndU. In June 2025, we reported positive preliminary data from the 180mg single dose cohort, the highlights
    of which were as follows:</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Briquilimab treatment resulted in deep disease control
    at 180mg, with 12 of 12 participants (100%) enrolled in the cohort achieving a clinical response within the 8-week preliminary analysis
    period;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The efficacy observed was rapid and durable, with 8
    of 12 participants (66%) achieving clinical response by week 2, and 7 of 12 participants (58%) maintaining clinical response through
    week 8; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Briquilimab continued to be well tolerated in the study,
    with no SAEs and no grade 3 or higher AEs reported in the 180mg cohort.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also commenced an Open Label Extension study (the
    &#8220;OLE&#8221;) in which patients in the BEACON study in CSU and the SPOTLIGHT study in CIndU are eligible to roll over to once
    they have completed their initial safety follow up period or experienced return of disease during the safety follow up period. All
    patients rolling over to the OLE study are treated with a 180mg Q8W dosing regimen. In January 2026, we reported preliminary data
    from the OLE study in both CSU and CIndU patients.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Highlights of the clinical efficacy observed in CSU and
CIndU participants for the OLE study released in January 2026 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In CSU participants, briquilimab treatment resulted
    in deep and durable disease control in the OLE study with 27 of 36 participants (75%) achieving complete response or well controlled
    disease at the week 12 assessment; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In CIndU participants, briquilimab treatment resulted
    in deep and durable disease control as well, with 11 of 17 participants (65%) achieving complete response or partial response at
    the week 16 assessment, which was 8 weeks following administration of the second dose.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49pt"></p><!-- Field: Page; Sequence: 27; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Across both CSU and CIndU participants in the OLE study,
briquilimab continued to demonstrate a favorable safety profile:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KIT-related AEs were generally transient, low-grade
    events;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The majority of AEs observed were resolved while on
    study prior to subsequent doses;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One patient discontinued therapy due to taste disturbance
    potentially related to briquilimab; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 72px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No other dose delays, missed doses or discontinuations
    were reported due to AEs possibly related to KIT blockade.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In late 2024, we commenced a Phase 1b study in asthma,
    the &#8220;ETESIAN&#8221; study, which is a single dose double-blind, placebo-controlled challenge study seeking to demonstrate proof-of-concept
    in asthma utilizing a potential therapeutic dose to inform future trials in the broader asthma population. The study was conducted
    utilizing a single 180mg dose of subcutaneous briquilimab and key assessments included measuring improvements in Forced Expiratory
    Volume in 1 second (&#8220;FEV<sub>1</sub>&#8221;) in both Early Asthmatic Response (&#8220;EAR&#8221;) measured at 6 weeks, and
    Late Asthmatic Response (&#8220;LAR&#8221;) measured at 12 weeks, changes in airway hyperresponsiveness, mast cell depletion and
    recovery, and safety. </span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2025, we reported preliminary results from
    the ETESIAN study in 14 participants (7 receiving a single dose of 180mg briquilimab and 7 receiving placebo) who completed at least
    7 weeks of allergen challenge testing following dosing with investigational product. Highlights of the clinical response observed
    in ETESIAN participants reported in December 2025 were as follows:</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 67px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compared to baseline, briquilimab reduced the allergen
    induced LAR (measured by the mean maximum percentage fall in FEV<sub>1</sub>&#160;(%Max FEV<sub>1</sub>) and fall in area under the
    FEV<sub>1&#160;</sub>time response curve (&#8220;AUC&#8221;)) at both 6 and 12 weeks. Patients who received briquilimab showed an
    improvement in the LAR %Max FEV<sub>1</sub>&#160;of 10.4% at 6 weeks and 8.7% at 12 weeks compared to baseline, as well as demonstrating
    an improvement in the LAR AUC of 25.4% at 6 weeks and 23.3% at 12 weeks.&#160;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 67px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sputum eosinophils, a potential marker of inflammatory
    response, were also measured at various timepoints in conjunction with observing the EAR and LAR. Participants receiving briquilimab
    demonstrated notably lower eosinophil levels as compared to those receiving placebo, indicating a reduction in the inflammatory response
    to their allergen.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The positive proof of concept
data generated in the ETESIAN study supports further development in the broader asthma population, however, advancing any future clinical
studies in asthma would be based on an evaluation of the competitive landscape, the potential for strategic partnerships and capital
availability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Historically, we have also evaluated briquilimab
as a one-time conditioning therapy for severe combined immunodeficiency (&#8220;SCID&#8221;) patients undergoing a second stem cell transplant
for which we conducted a Phase 1/2 clinical trial as well as via Investigator Sponsored Trials (&#8220;ISTs&#8221;) in several other
stem cell transplant indications. In July 2025, the SCID program and any remaining ISTs were discontinued to focus resources exclusively
on our mast cell disease development portfolio.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to become a fully integrated discovery,
development and commercial company in the field of mast cell therapeutics. We are developing our product candidates to be used individually
or, in some cases, in combination with other therapeutics. Our goal is to advance our product candidates through regulatory approval
and bring them to the commercial market based on the data from our clinical trials and communications with regulatory agencies and payor
communities. We expect to continue to broaden our pipeline with additional mast cell indications and next-generation products by leveraging
our research organization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 28; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have an exclusive license agreement with Amgen
Inc. (&#8220;Amgen&#8221;) for the development and commercialization of the briquilimab monoclonal antibody in all indications and territories
worldwide. We also have an exclusive license agreement with Stanford University for the right to use briquilimab in the clearance of
diseased stem cells prior to the transplantation of hematopoietic stem cells.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have incurred significant losses and negative
cash flows from operations since our inception. During the three months ended March 31, 2026 and 2025 we incurred net losses of $1.2
million and $21.2&#160;million, respectively. We generated negative operating cash flows of $14.5 million and $22.8 million for the three
months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, we had an accumulated deficit of $317.8&#160;million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We had cash and cash equivalents of $14.1 million
as of March 31, 2026. We expect to continue to incur substantial losses for the foreseeable future, and our transition to profitability
will depend upon successful development, approval and commercialization of our product candidates and upon achievement of sufficient
revenues to support our cost structure. We do not expect to generate any revenue from commercial product sales unless and until we successfully
complete development and obtain regulatory approval for one or more of our product candidates. We may never achieve profitability, and
unless we do and until then, we will need to continue to raise additional capital. Accordingly, based on our current operating plan,
and along with our history of operating losses, our current cash and cash equivalents will not be sufficient to fund our ongoing operations
for a period of at least twelve months from the date the condensed consolidated financial statements included in this Quarterly Report
on Form 10-Q are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management plans to monitor expenses and raise
additional capital through a combination of public and private equity, debt financings, strategic alliances or licensing arrangements.
Our ability to access capital when needed is not assured and, if capital is not available to us when, and in the amounts, needed, we
may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization
of any product candidate, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which
could materially harm our business, financial condition and results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect our expenses will increase substantially
in connection with our ongoing and planned activities, as we:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance product candidates through preclinical studies
    and clinical trials;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">procure the manufacture of supplies for our preclinical
    studies and clinical trials;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire, validate, and develop additional product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract, hire and retain additional personnel;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operate as a public company;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implement operational, financial and management systems;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursue regulatory approval for any product candidates
    that successfully complete clinical trials;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing, and distribution infrastructure
    to commercialize any product candidate for which we may obtain marketing approval and related commercial manufacturing build-out;
    and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain, maintain, expand, and protect our portfolio
    of intellectual property rights.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 29; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not currently own or operate any manufacturing
facility. We rely on contract manufacturing organizations (&#8220;CMOs&#8221;) to produce our drug candidates in accordance with the
FDA&#8217;s current good manufacturing practices (&#8220;cGMP&#8221;) regulations for use in our clinical trials. The manufacture of
pharmaceuticals is subject to extensive cGMP regulations, which impose various procedural and documentation requirements and govern all
areas of record keeping, production processes and controls, personnel and quality control. Under our license agreement with Amgen, we
have received a substantial amount of drug product to support initiation of our planned clinical trials of briquilimab. In November&#160;2019,
we entered into development and manufacturing agreements with Lonza Sales AG (&#8220;Lonza&#8221;) relating to the manufacturing of briquilimab
and product quality testing. The facility of Lonza in Slough, United Kingdom is responsible for production and testing of drug substance.
The facility of Lonza in Stein, Switzerland is responsible for production and testing of drug product. Labelling, packaging and storage
of finished drug product is provided by PCI Pharma Services, in San Diego, California. Our agreement with Lonza includes certain limitations
on our ability to enter into supply arrangements with any other supplier without Lonza&#8217;s consent. In addition, Lonza has the right
to increase the prices it charges us for certain supplies depending on a number of factors, some of which are outside of our control.
In addition, given drug substance and drug product manufacturing and testing with Lonza currently occurs outside the United States, drug
product imported into the United States for clinical or commercial use could be subject to significant tariffs in the current political
environment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not currently have sales and marketing infrastructure
to support commercial launch of our product candidates, if approved. We may build such capabilities in North America prior to potential
launch of briquilimab. Outside of North America, we may rely on licensing, co-sale and co-promotion agreements with strategic partners
for the commercialization of our product candidates. If we build a commercial infrastructure to support marketing in North America, such
commercial infrastructure could be expected to include a targeted sales force supported by sales management, internal sales support,
an internal marketing group and distribution support. To develop the appropriate commercial infrastructure internally, we would have
to invest financial and management resources, some of which would have to be deployed prior to any confirmation that briquilimab will
be approved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because of the numerous risks and uncertainties
associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able
to achieve or maintain profitability. Even if we are able to generate revenue from the sale of our product candidates, we may not become
profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue
our operations at planned levels and may be forced to reduce our operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Components of Results of Operations</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Operating Expenses</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Research and Development</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The largest component of our total operating expenses
since our inception has been research and development activities, including the preclinical and clinical development of our product candidates.
Research and development expenses consist primarily of compensation and benefits for research and development employees, including stock-based&#160;compensation;
expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) and investigative sites that conduct preclinical
studies and clinical trials; the costs of acquiring and manufacturing clinical trial materials and other supplies; payments under licensing
and research and development agreements; other outside services and consulting costs; and facilities, information technology and overhead
expenses. Research and development costs are expensed as&#160;incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 30; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development costs include:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">program costs, including costs incurred under agreements
    with third-party&#160;CROs, CMOs and other third parties;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related&#160;costs, including salaries, benefits
    and stock-based&#160;compensation expense for our research and development personnel; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other expenses and allocated
    overheads incurred in connection with our research and development programs.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect our research and development expenses
to increase substantially for the foreseeable future as we advance our product candidates into and through preclinical studies and clinical
trials, pursue regulatory approval of our product candidates and expand our pipeline of product candidates. The process of conducting
the necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of
success for our product candidates may be affected by a variety of factors, including the safety and efficacy of our product candidates,
early clinical data, investment in our clinical programs, competition, manufacturing capability and commercial viability. We may never
succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are
unable to determine the duration and completion costs of our research and development projects or if, when and to what extent we will
generate revenue from the commercialization and sale of our product candidates, if approved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our future research and development costs may
vary significantly based on factors, such as:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, rate of progress,
    expense and results of our discovery and preclinical development activities;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of our chemistry, manufacturing
    and controls activities, including fulfilling cGMP-related&#160;standards and compliance, and identifying and qualifying suppliers;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per patient clinical trial
    costs;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of trials required
    for approval;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of sites included
    in our clinical trials;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the countries in which
    the trials are conducted;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in adding a sufficient number of trial sites
    and recruiting suitable patients to participate in our clinical trials;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of patients
    that participate in the trials;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of doses that
    patients receive;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient drop-out&#160;or
    discontinuation rates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential additional safety
    monitoring requested by regulatory agencies;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the duration of patient
    participation in the trials and follow up;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost and timing of
    manufacturing our product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the phase of development
    of our product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the efficacy and safety
    profile of our product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, receipt, and terms of any approvals from
    applicable regulatory authorities, including the FDA and non-U.S.&#160;regulators;</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining a continued acceptable safety profile of
    our product candidates following approval, if any, of our product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant and changing
    government regulation and regulatory guidance;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></p><!-- Field: Page; Sequence: 31; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the standard of care on which a clinical
    development plan was based, which may require new or additional trials;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which we
    establish additional strategic collaborations or other arrangements; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of any business interruptions to our operations
    or to those of the third parties with whom we work, particularly in light of geopolitical and macroeconomic trends.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General and Administrative</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses consist primarily
of personnel costs and expenses, including salaries, employee benefits, and stock-based&#160;compensation for our executive and other
administrative personnel; legal services, including relating to intellectual property and corporate matters; accounting, auditing, consulting
and tax services; insurance; and facility and other allocated costs not otherwise included in research and development expenses. We expect
our general and administrative expenses to increase substantially for the foreseeable future as we anticipate an increase in our personnel
headcount to support expansion of research and development activities, as well as to support our operations generally. We also expect
to continue to incur significant expenses associated with being a public company, including costs related to accounting, audit, legal,
regulatory, and tax-related&#160;services associated with maintaining compliance with applicable Nasdaq and SEC requirements; additional
director and officer insurance costs; and investor and public relations costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Total Other Income, Net</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Total other income, net includes foreign currency
transactions gains and losses, interest income and changes in the fair value of warrant liability. Warrant liability was classified as
a liability in our condensed consolidated financial statements and was re-measured&#160;at each reporting period end.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Results of Operations</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Comparison of the Three Months Ended March 31, 2026 and 2025
</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes our results of
operations for the three months ended March 31, 2026 and 2025 (in thousands, except percentages):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="6" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>Operating expenses</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%; text-align: left; padding-left: 9pt">Research and development</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,814</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,157</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(10,343</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(64</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,645</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(507</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,952</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,802</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,850</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(50</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Loss from operations</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(10,952</td><td style="text-align: left">)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(21,802</td><td style="text-align: left">)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">10,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(50</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(460</td><td style="text-align: left">)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(74</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt">Change in fair value of warrant liability</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">9,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">9,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(63</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(59</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,778</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">561</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,217</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NM</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,174</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(21,241</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,067</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">(94</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NM = Not meaningful</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 32; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Research and Development Expenses</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes our research and
development expenses for the periods indicated (in thousands, except percentages):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="6" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%; text-align: left; padding-left: 9pt">Personnel-related costs</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,320</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,821</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,501</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(73</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-left: 9pt">General and overhead costs</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">871</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">1,576</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(705</td><td style="text-align: left">)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(45</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Program costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,623</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,137</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(63</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 4pt">Total research and development expenses</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,814</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,157</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(10,343</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">(64</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NM = Not meaningful</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses decreased by
$10.4 million, from $16.2 million for the three months ended March 31, 2025 to $5.8 million for the three months ended March 31, 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Personnel-related costs, including employee payroll
and related expenses, decreased by $3.5 million, from $4.8 million for the three months ended March 31, 2025 to $1.3 million for the
three months ended March 31, 2026, primarily due to the workforce reduction as part of the corporate reorganization in 2025. Stock-based
compensation expenses, included in personnel-related costs, decreased by $0.4 million, from $0.6 million for the three months ended March
31, 2025 to $0.2 million for the three months ended March 31, 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and overhead costs, which include common
facilities, human resources and information technology related expenses allocated to research and development, decreased by $0.7 million,
from $1.6 million for the three months ended March 31, 2025 to $0.9 million for the three months ended March 31, 2026, primarily due
to decreased allocated overheads to research and development costs following our corporate reorganization in 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Program costs decreased by $6.2 million, from
$9.8 million for the three months ended March 31, 2025 to $3.6 million for the three months ended March 31, 2026. Clinical program expenses
primarily consisted of expenses incurred under agreements with CROs, CMOs, consultants, other professional services, in vivo study costs
and lab supplies. Clinical program expenses decreased primarily due to a decrease in CRO expenses of $2.0 million from $4.0 million for
the three months ended March 31, 2025 to $2.0 million for the three months ended March 31, 2026, a decrease in CMO expenses of $1.2 million
from $2.1 million for the three months ended March 31, 2025 to $0.9 million for the three months ended March 31, 2026, a decrease in
external consulting and other professional services costs of $1.2 million from $1.8 million for the three months ended March 31, 2025
to $0.6 million for the three months ended March 31, 2026, and a decrease in the preclinical in vivo study costs of $0.8 million with
no such costs incurred during the three months ended March 31, 2026, as we halted the related preclinical programs in 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our program costs for the three months ended March
31, 2026 and 2025 were as follows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="6" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
<td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%; text-align: left">Briquilimab platform</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,957</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,691</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(86</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>CMO</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">882</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">2,138</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(1,256</td><td style="text-align: left">)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(59</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>CSU</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">2,378</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">2,746</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(368</td><td style="text-align: left">)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(13</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>Asthma</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(327</td><td style="text-align: left">)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">1,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(1,720</td><td style="text-align: left">)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(123</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>CIndU</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(461</td><td style="text-align: left">)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(52</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>SCID</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(523</td><td style="text-align: left">)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 1.5pt">MDS/AML</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 4pt">Total program costs</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,623</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,760</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,137</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">(63</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the program level, the decrease in clinical
program expenses was primarily driven by decreased costs related to the asthma program, briquilimab platform and CMO product development
and manufacturing expenses not allocated to specific programs. Enrollment in the ETESIAN study for the asthma program, which began in
late 2024, was halted in July 2025. The decrease in asthma program expenses during the three months ended March 31, 2026 was further
impacted by reductions in previously accrued CRO investigator grant costs following the reconciliation and close-out of the study. We
substantially discontinued the SCID program in 2025 and MDS/AML program in late 2024 and do not expect to incur significant costs related
to these programs in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 33; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>General and Administrative Expenses</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses decreased
by $0.5 million, from $5.6&#160;million for the three months ended March 31, 2025 to $5.1&#160;million for the three months ended March
31, 2026. Employee payroll and related expenses decreased by $0.7 million, from $3.3&#160;million for the three months ended March 31,
2025 to $2.6&#160;million for the three months ended March 31, 2026, primarily due to a decrease in stock-based compensation expenses.
Stock-based compensation expenses, included in employee payroll and related expenses, were $0.1 million and $1.0 million
for the three months ended March 31, 2026 and 2025, respectively.&#160;Expenses related to professional consulting services decreased
by $0.1 million, from $2.0&#160;million for the three months ended March 31, 2025 to $1.9&#160;million for the three months ended March
31, 2026. Rent expenses decreased by $0.1 million for the three months ended March 31, 2026 as compared to the three months ended March
31, 2025. Other expenses increased by $0.4&#160;million for the three months ended March 31, 2026 as compared to the three months ended
March 31, 2025, primarily related to an increase in allocation of overhead costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Total Other Income, Net</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Total other income, net increased by $9.2 million,
from $0.6 million for the three months ended March 31, 2025 to $9.8 million for the three months ended March 31, 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Interest income decreased by $0.4 million, from
$0.6 million for the three months ended March 31, 2025 to $0.2 million for the three months ended March 31, 2026, primarily due to lower
cash balances invested in money market funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The change in fair value of warrant liability
of $9.6 million for three months ended March 31, 2026 represents a decrease in the fair value of common stock warrants issued in connection
with our underwritten public offering in September 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Liquidity and Capital Resources</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2026, we had $14.1 million of
cash and cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to assist in funding our future operations,
including our planned clinical trials, on March 19, 2025, we filed a new universal shelf registration statement on Form S-3 (the &#8220;Shelf
Registration Statement&#8221;) with the SEC, which was declared effective on March 26, 2025 and superseded our prior universal shelf
registration statement. As of March 31, 2026, we can sell from time to time up to $263.5 million of common stock, preferred stock, debt
securities, warrants, rights, units and depositary shares comprised of any combination of these securities, for our own account in one
or more offerings under the Shelf Registration Statement. The terms of any offering under the Shelf Registration Statement will be established
at the time of such offering and will be described in a prospectus supplement to the Shelf Registration Statement filed with the SEC
prior to the completion of any such offering. However, as of March 31, 2026, the aggregate market value of our common stock held by non-affiliates
(&#8220;public float&#8221;) is less than $75.0 million, so the amount we can raise through primary public offerings of securities, including
through the ATM offering, in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of our
public float. On March 19, 2025, we entered into an Open Market Sale Agreement<sup>SM</sup>&#160;with Jefferies LLC (&#8220;Jefferies&#8221;),
pursuant to which we may offer and sell through or to Jefferies, as sales agent or principal, shares of common stock from time to time
(the &#8220;ATM Offering&#8221;). On March 26, 2025, we filed with the SEC a prospectus under the S-3 in connection with the ATM Offering
(the &#8220;ATM Prospectus&#8221;), pursuant to which we may offer and sell shares of common stock having an aggregate offering price
of up to $100.0 million. As of March 31, 2026, we issued and sold an aggregate of 1,231,447 shares of common stock for net proceeds of
approximately $6.5 million pursuant to the ATM Prospectus.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 18, 2025, we entered into an underwriting
agreement with TD Securities (USA) LLC as the representative of the several underwriters named therein, relating to an underwritten public
offering under the Shelf Registration Statement. On September 22, 2025, we closed the offering and issued an aggregate of 11,670,707
shares of common stock, pre-funded warrants to purchase 675,000 shares of common stock and common stock warrants to purchase 12,345,707
shares of common stock, for net proceeds of approximately $27.5&#160;million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2026, $93.5 million remains allocated
and available under the ATM Prospectus and $170.0 million remains available and unallocated under the Shelf Registration Statement.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 34; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Future Funding Requirements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our primary uses of cash are to fund our operations,
which consist primarily of research and development expenditures related to our programs and, to a lesser extent, general and administrative
expenditures. We anticipate that we will continue to incur significant expenses for the foreseeable future as we continue to advance
our product candidates, expand our corporate infrastructure, operate as a public company, further our research and development initiatives
for our product candidates, scale our laboratory and manufacturing operations, and incur marketing costs associated with potential commercialization.
We are subject to all the risks typically related to the development of new drug candidates, and we may encounter unforeseen expenses,
difficulties, complications, delays and other unknown factors that may adversely affect our business. We anticipate that we will need
substantial additional funding in connection with our continuing operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have incurred significant losses and negative
cash flows from operations since our inception. As of March 31, 2026, we had an accumulated deficit of $317.8 million. Given our recurring
losses from operations and negative cash flows, and based on our current operating plan, we have concluded that there is substantial doubt
about our ability to continue as a going concern within one year from the date of filing of this Quarterly Report. We expect to finance
our future cash needs through equity or debt financings, collaborations or a combination of these approaches, and given the imminent need
for additional funding to continue to fund operations in the near-term, we are actively seeking additional capital to extend our cash
runway. The sale of equity or convertible debt securities may result in dilution to our stockholders, and, in the case of preferred equity
securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock.
Debt financings may subject us to covenant limitations or restrictions on our ability to take specific actions, such as incurring additional
debt or making capital expenditures. Our ability to raise additional funds may be adversely impacted by negative global economic conditions
and any disruptions to and volatility in the credit and financial markets in the United States and worldwide or other factors. There can
be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable
or acceptable to us. While we routinely evaluate cost reduction measures to proactively manage cash burn, if we are unable to obtain adequate
financing when needed or on terms favorable or acceptable to us, we may be forced to take broader actions such as to delay, reduce the
scope of or eliminate one or more of our research and development programs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our future financing requirements will depend
on many factors, including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, scope, progress, results and costs of research
    and development, preclinical and non-clinical&#160;studies and clinical trials for our current and future product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number, scope and duration of clinical trials required
    for regulatory approval of our current and future product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the outcome, timing and costs of seeking and obtaining
    regulatory approvals from the FDA and comparable foreign regulatory authorities for our product candidates, including any requirement
    to conduct additional studies or generate additional data beyond that which we currently expect would be required to support a marketing
    application;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of manufacturing
    clinical and commercial supplies of our current and future product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of future commercialization activities,
    including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing
    approval;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any product liability or
    other lawsuits related to our product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></p><!-- Field: Page; Sequence: 35; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the revenue, if any, received from commercial sales
    of any product candidates for which we may receive marketing approval;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish a commercially viable pricing
    structure and obtain approval for coverage and adequate reimbursement from third-party&#160;and government payers;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs to establish, maintain, expand, enforce and
    defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make,
    or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing our patents or other
    intellectual property rights;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred to attract,
    hire and retain skilled personnel; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of operating
    as a public company.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A change in the outcome of any of these or other
variables could significantly change the costs and timing associated with the development of our product candidates. Furthermore, our
operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated
with such change.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Contractual Obligations and Commitments</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We enter into contracts in the normal course of
business with CROs&#160;for clinical trials, with CMOs for&#160;clinical supplies manufacturing and with other vendors for preclinical
studies, supplies and other services and products for operating purposes. These contracts generally provide for termination on&#160;notice
or may have a potential termination fee if a purchase order is cancelled within a specified time, and therefore are cancelable contracts.
We do not expect any such contract terminations and did not have any non-cancellable obligations under these agreements as of March 31,
2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Leases</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2026, we leased approximately
25,900 square feet of space for our headquarters in Redwood City, California. The lease expires in August 2026. We have an option to
extend the term for an additional five years to August 2031. In addition to base rent, we pay our share of operating expenses and taxes.
As of March 31, 2026, our rent commitments under the lease agreement were $0.8 million within the next 12 months from March 31, 2026.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stanford License Agreements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March 2021, we entered into an exclusive license
agreement with Stanford (the &#8220;2021 Stanford License Agreement&#160;&#8221;). In July 2023, we entered into an amendment to the
2021 Stanford License Agreement to modify certain milestones set forth thereunder. Pursuant to the 2021 Stanford License Agreement we
are required to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending
upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and
second year, $35,000 for each third and fourth year, and $50,000 at each anniversary thereafter ending upon the first commercial sale.
We are also obligated to pay late-stage clinical development milestone payments and first commercial sales milestone payments of up to
$9.0 million in total. We will also pay low single-digit royalties on net sales of licensed products. All products were in development
as of March 31, 2026, and no such royalties were due as of such date and no milestones were achieved.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2024, we entered into a co-exclusive
license agreement with Stanford (the &#8220;2024 Stanford License Agreement&#160;&#8221;). Pursuant to the 2024 Stanford License Agreement,
we are required to pay a license issuance fee of $75,000, which was paid in January 2025, and annual license maintenance fees, beginning
on the first anniversary of the effective date of the agreement: $25,000 for each of the first through third years, $50,000 for each
of the fourth through sixth years and $65,000 at each anniversary thereafter. We are also obligated to pay clinical development milestone
payments of up to $1.3 million and sales milestone payments of up to $7.0 million in total. We will also pay low single-digit royalties
on net sales of licensed products. All products are in development as of March 31, 2026, and no such royalties were due as of such date
and no milestones were achieved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 36; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Cash Flows</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes our sources and
uses of cash for the periods presented (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months ended <br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(14,548</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(22,842</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 4pt">Net decrease in cash and cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14,548</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(22,838</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash Flows from Operating Activities</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in operating activities was $14.5
million and $22.8&#160;million for the three months ended March 31, 2026 and 2025, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cash used in operating activities in the three
months ended March 31, 2026 was primarily due to our net loss for the period of $1.2 million, net change of non-cash items totaling $9.0
million and net change of $4.3 million in our net operating assets and liabilities. The non-cash items consisted of change in fair value
of warrant liability of $9.6 million, partially offset by $0.4 million related to stock-based compensation expense and $0.2 million of
non-cash lease expense. The changes in our net operating assets and liabilities were primarily due to a decrease of $3.8 million in accounts
payable, a decrease of $0.5 million in the operating lease liability and an increase of $0.2 million in prepaid expenses and other current
assets, partially offset by an increase of $0.1 million in accrued expenses and other current liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cash used in operating activities in the
three months ended March 31, 2025 was primarily due to our net loss for the period of $21.2 million and a net change of $3.9 million
in our net operating assets and liabilities, partially offset by non-cash items totaling $2.3 million. The non-cash amounts
consisted of $1.8 million related to stock-based compensation expense, $0.3 million related to depreciation and amortization expense
and $0.2 million of non-cash lease expense. The changes in our net operating assets and liabilities were primarily due to a decrease
of $2.6 million in accrued expenses and other current liabilities, a decrease of $1.0 million in accounts payable, a decrease of
$0.3 million in operating lease liability, and an increase of $0.2 million in prepaid expenses and other current assets, offset by a
decrease of $0.3 million in other non-current assets.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash Flows from Investing Activities</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There were no cash flows from investing activities
for the three months ended March 31, 2026. Cash used in investing activities was less than $0.1 million for the three months ended March
31, 2025, consisting of sales of property and equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash Flows from Financing Activities</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There were no cash flows from financing activities
for each of the three months ended March 31, 2026 and 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Critical Accounting Policies and Significant Judgments and Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our critical accounting policies are disclosed
in Note 2 to the condensed consolidated financial statements included in Part I - Item 1 of this Quarterly Report and Note 2 to the condensed
consolidated financial statements included in Part II - Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2025,
filed with the SEC on March 30, 2026. There have been no material changes to our significant accounting policies since the date of issuance
of our consolidated financial statements for the year ended December 31, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 37; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Recently Issued Accounting Pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See Note 2 to the condensed consolidated financial
statements included in Part I - Item 1 of this Quarterly Report for more information regarding recently issued accounting pronouncements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Smaller Reporting Company Status</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a &#8220;smaller reporting company,&#8221;
as defined in&#160;Item 10(f)(1) of&#160;Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure
obligations, including, among other things, providing only two years of audited financial statements. We will remain a&#160;smaller reporting
company&#160;until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250
million as of the last business day of our second fiscal quarter, or (ii) our annual revenue exceeded $100 million during such completed
fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the last business day of our second
fiscal quarter.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><span id="a_009" style="display: inline-block;"></span>Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There have been no material changes to our market
risk during the three months ended March 31, 2026. For a discussion of our exposure to market risk, refer to the section titled &#8220;Quantitative
and Qualitative Disclosures About Market Risk&#8221; included in Part II - Item 7A of the Annual Report on Form 10-K for the year ended
December 31, 2025, filed with the SEC on March 30, 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><span id="a_010" style="display: inline-block;"></span>Item 4. Controls and Procedures</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Evaluation of Disclosure Controls and Procedures</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We maintain disclosure controls and procedures
that are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Our disclosure controls
and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us
in the reports we file under the Exchange Act is accumulated and communicated to our management, including our principal executive officer
and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In designing and evaluating the disclosure controls
and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving the desired control objectives. As required by Rule 13a-15(b) or Rule 15d-15(b) promulgated by the SEC under the
Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our principal
executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures
as of the end of the period covered by this Quarterly Report. Based on the foregoing, our principal executive officer and principal financial
officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report
at the reasonable assurance level.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Changes in Internal Controls</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There have been no changes in our internal control
over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2026
that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 38; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><span id="a_011" style="display: inline-block;"></span>PART II. OTHER INFORMATION</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_012" style="display: inline-block;"></span><span style="font-weight: bold;">Item 1. Legal Proceedings</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We, from time to time, may be party to litigation
arising in the ordinary course of business. On September 19, 2025, a shareholder class action complaint captioned&#160;<i>Grant v. Jasper
Therapeutics, Inc., et al.</i>&#160;(Case No. 25-cv-08010) was filed in the United States District Court for the Northern District of
California against us and certain of our current and former officers. The complaint alleges that certain material misstatements or omissions
related to the ongoing clinical trials of briquilimab were made in violation of federal securities laws. The plaintiffs are seeking unspecified
monetary&#160;damages&#160;and an award of costs and expenses, including reasonable attorneys&#8217; fees, expert fees and other costs.
On December 3, 2025, a stipulated order was entered appointing co-lead plaintiffs and approving their selection of co-lead counsel, and
on December 16, 2025, a stipulated order was entered setting a schedule for the filing and responses to an amended complaint. Per the
terms of the December 16, 2025 stipulated order, an amended complaint captioned <i>Allard, et al. v. Jasper Therapeutics, Inc., et al.</i>
(Case No. 25-cv-08010) was filed, and defendants&#8217; motion to dismiss was filed on April 20, 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, on November 5, 2025, a shareholder
derivative complaint captioned <i>Bardauskas v. Martell, et al</i>. (Case No. 25-cv-09561) was filed in the United States District Court
for the Northern District of California, and on December 22, 2025, another shareholder derivative complaint was filed in the same court
and captioned <i>Walsh v. Martell, et al.</i> (Case No. 25-cv-10899).&#160; The derivative complaints name as defendants certain of our
current and former officers and directors, and allege claims related to the allegations raised in the shareholder class action complaint.
On January 21, 2026, a stipulated order was entered, among other things, consolidating and staying the derivative actions.&#160;We believe
the claims raised in these lawsuits are without merit, and intend to defend these matters vigorously. However, there can be no assurance
that we will prevail. We are unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore,
no amount of loss has been accrued in our financial statements as of and for the three months ended March 31, 2026. Regardless of outcome,
litigation can have an adverse impact on us due to costs involved, diversion of management resources, negative publicity, reputational
harm, and other factors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that we are not currently a party to
any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on our consolidated financial
position, results of operations or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><span id="a_013" style="display: inline-block;"></span>Item 1A. Risk Factors</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Our Annual Report on Form 10-K for the year
ended December 31, 2025, filed with the SEC on March 30, 2026, in Part I &#8211;Item 1A, Risk Factors, describes important risk factors
that could cause our business, financial condition, results of operations and growth prospects to differ materially from those indicated
or suggested by forward-looking statements made in this Quarterly Report or presented elsewhere by management from time to time. Except
as set forth below, there have been no material changes in the risk factors that appear in Part I - Item 1A of our Annual Report on Form
10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026. Additional risks and uncertainties not currently known
to us or that we currently deem to be immaterial may also materially and adversely affect our business. </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 39; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Risks Related to Our Financial Position and Need for Additional
Capital</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>We have incurred significant net losses and negative operating
cash flows since our inception which raises substantial doubt about our ability to continue as a going concern. We expect to incur net
losses for the foreseeable future and may never achieve or maintain profitability.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a clinical-stage biotechnology company
dedicated to enabling cures through therapeutics targeting mast and hematopoietic stem cells and have a limited operating history. Investment
in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant
risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval
and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales
to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. As a result,
we are not profitable and have incurred losses and negative operating cash flows in each period since our inception, which raises substantial
doubt about our ability to continue as a going concern beyond one year from the date of filing of this Quarterly Report on Form 10-Q.
See below risk factor, &#8220;As a result of our history of losses and negative cash flows from operations, our management has performed
an analysis and concluded that substantial doubt exists about our ability to continue as a going concern, and we will need to raise additional
financing to continue our products&#8217; development.&#8221; for additional details. For the&#160;three months ended March&#160;31,
2026 and 2025, we reported net losses of $1.2 million and $21.2 million, respectively. For the&#160;three months ended March&#160;31,
2026 and 2025, we reported negative operating cash flows of $14.5 million and $22.8 million, respectively. As of March 31, 2026, we had
an accumulated deficit of $317.8 million. We have devoted all of our efforts to organizing and staffing our company, business and scientific
planning, raising capital, acquiring and developing technology, identifying potential product candidates, undertaking research and preclinical
studies of potential product candidates, developing manufacturing capabilities and evaluating a clinical path for our pipeline programs.
We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, and we expect these losses
to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The net losses we incur may fluctuate significantly
from quarter to quarter. We anticipate that our expenses will increase substantially if and as we:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue the clinical development
    of briquilimab in chronic diseases such as CSU and Chronic Inducible Urticaria (&#8220;CIndU&#8221;);</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">elect to continue development of briquilimab in allergic
    asthma; </span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue our current research programs and development
    of other potential product candidates from our current research programs;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to identify additional product candidates and
    research programs;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate preclinical testing and clinical trials for
    any other product candidates we identify and develop;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, expand, enforce, defend and protect our intellectual
    property portfolio, and provide reimbursement of third-party&#160;expenses related to our patent portfolio;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek marketing approvals for any product candidates
    that successfully complete clinical trials;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ultimately establish a sales, marketing and distribution
    infrastructure to commercialize any product candidates for which we may obtain marketing approval;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adapt our regulatory compliance efforts to incorporate
    requirements applicable to any approved product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire additional research and development and clinical
    personnel;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire commercial personnel and advance market access
    and reimbursement strategies;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add operational, financial and management information
    systems and personnel, including personnel to support our product development;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire or in-license&#160;product candidates, intellectual
    property and technologies;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop or in-license&#160;manufacturing and distribution
    technologies;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">should we decide to do so and receive approval for
    any of our product candidates, build and maintain, or purchase and validate, commercial-scale&#160;manufacturing facilities designed
    to comply with current Good Manufacturing Practices (&#8220;cGMP&#8221;) requirements; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur additional legal, accounting and other expenses
    in operating as a public company.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 40; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a company, we have not completed clinical development
of any product candidate and expect that it will be several&#160;years, if ever, before we have a product candidate ready for commercialization.
To become and remain profitable, we must develop and, either directly or through collaborators, eventually commercialize a product or
products with significant market potential. This will require us to be successful in a range of challenging activities, including identifying
product candidates, completing preclinical testing and clinical trials of product candidates, obtaining marketing approval for these
product candidates, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any
post-marketing requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may never succeed in these activities and,
even if we do, may never generate revenues that are significant or large enough to achieve profitability. Our product candidates and
research programs are currently only in the early stages of development. Because of the numerous risks and uncertainties associated with
developing product candidates, we are unable to predict the extent of any future losses or when we will become profitable, if at all.
If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to
become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research
and development efforts, expand our business or continue our operations. A&#160;decline in the value of our company could also cause
you to lose all or part of your investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>We will need substantial additional funding, which may not be
available on acceptable terms, or at all. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate
our research and product development programs or future commercialization efforts.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect to spend substantial amounts of cash
to conduct further research and development and preclinical testing and clinical trials of our product candidates, to seek regulatory
approvals for our product candidates and to launch and commercialize any product candidates for which we receive regulatory approval.
Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial
additional funding in order to maintain our continuing operations. If we are unable to raise capital when needed or on attractive terms,
we would be forced to delay, reduce or eliminate our research and product development programs or future commercialization efforts. For
example, advancing any future clinical studies in asthma would be based on an evaluation of the competitive landscape, the potential
for strategic partnerships and capital availability. As of March 31, 2026, our cash and cash equivalents were $14.1 million and we had
an accumulated deficit of $317.8 million. We will need to raise additional financing to continue our products&#8217; development for
the foreseeable future, and will continue to need to do so until we become profitable. Our future financing requirements will depend
on many factors, including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the initiation, progress, timing, costs and results
    of preclinical studies and clinical trials for our product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of continuing to build our technology platform
    for use in developing our product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of developing, acquiring or in-licensing&#160;additional
    targeted therapies to use in combination with briquilimab and other product candidates we may develop;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of preparing, filing and prosecuting patent
    applications, maintaining and enforcing our intellectual property and proprietary rights and defending intellectual property-related&#160;claims
    in the United&#160;States and internationally;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and characteristics of product candidates
    that we develop or may in-license;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and maintain collaborations
    on favorable terms, if at all;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 41; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the achievement of milestones or occurrence of other
    developments that trigger payments under any collaboration agreements we enter into;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the outcome, timing and cost of meeting regulatory
    requirements established by the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;), the European Medicines Agency (the
    &#8220;EMA&#8221;) and other comparable foreign regulatory authorities;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost and timing of completion of commercial-scale&#160;outsourced
    manufacturing activities;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of establishing sales, marketing and distribution
    capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize
    our products on our own; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of operating as a public company.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Conducting preclinical testing and clinical trials
is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and we may never generate the necessary data
or results required to obtain marketing approval and achieve product sales. In addition, even if we successfully develop product candidates
and those are approved, we may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products
that we do not expect to be commercially available for several&#160;years, if at all. Accordingly, we&#160;will need to continue to rely
on additional financing to achieve our business objectives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently have an effective universal shelf
registration statement on Form S-3, which we filed with the SEC on March 19, 2025, and which was declared effective on March 26, 2025
and will expire on March 26, 2028 (the &#8220;Shelf Registration Statement&#8221;). Pursuant to the Shelf Registration Statement, we
may offer from time to time up to an aggregate of $300.0 million of securities, including any combination of common stock, preferred
stock, debt securities, warrants, rights, units and depositary shares. On March 19, 2025, we entered into an Open Market Sale Agreement<sup>SM</sup>
with Jefferies LLC (the &#8220;Agent&#8221;), pursuant to which we may offer and sell through or to the Agent, as sales agent or principal,
shares of common stock from time to time (the &#8220;ATM Offering&#8221;). On March 26, 2025, we filed with the SEC a prospectus under
the Shelf Registration Statement in connection with the ATM Offering (the &#8220;ATM Prospectus&#8221;), pursuant to which we may offer
and sell shares of our common stock having an aggregate offering price of up to $100.0 million. As of March 31, 2026, we have issued
and sold an aggregate of 1,231,447 shares of our common stock for net proceeds of approximately $6.5 million pursuant to the ATM Prospectus.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 22, 2025, we completed an underwritten
public offering of our common stock (the &#8220;September Offering&#8221;) pursuant to the Shelf Registration Statement. In the September
Offering, we sold (i) an aggregate of 11,670,707 shares of common stock and accompanying warrants (the &#8220;Common Warrants&#8221;)
to purchase up to an aggregate of 11,670,707 shares of common stock and (ii) pre-funded warrants to purchase up to an aggregate of 675,000
shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) and accompanying Common Warrants to purchase up to an aggregate of 675,000
shares of common stock. Upon the closing of the September Offering, we received net proceeds of $27.5 million, after deducting underwriting
discounts, commissions and other offering expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2026, $93.5 million remains allocated
and available under the ATM Prospectus and approximately $170.0 million remains available and unallocated under the Shelf Registration
Statement. However, as of March 31, 2026, the aggregate market value of our common stock held by non-affiliates (&#8220;public float&#8221;)
is less than $75.0 million, so the amount we can raise through primary public offerings of securities, including through the ATM offering,
in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of our public float. Although
we still maintain the ability to raise funds through other means, such as through the filing of a registration statement on Form S-1
or in private placements, the rules and regulations of the SEC or any other regulatory agencies may restrict our ability to conduct certain
types of financing activities, or may affect the timing of and amounts we can raise by undertaking such activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 42; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we raise additional capital by issuing equity
securities, the percentage ownership of our existing stockholders may be reduced, and accordingly these stockholders may experience substantial
dilution. We may also issue equity securities that provide for rights, preferences and privileges senior to those of our common stock.
Given our need for cash and that equity issuances are the most common type of fundraising for similarly situated companies, the risk
of dilution is particularly significant for our stockholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any additional fundraising efforts may divert
our management from our&#160;day-to-day activities, which may adversely affect our ability to develop and commercialize product candidates.
We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional
capital and, if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly
delay, scale back or discontinue the development or commercialization of product candidates or other research and development initiatives.
Our license agreements and any future collaboration agreements may also be terminated if we are unable to meet the payment or other obligations
under the agreements. We could be required to seek collaborators for product candidates at an earlier stage than otherwise would be desirable
or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to product
candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-weight: bold;"><i>As a result of our history of losses
and negative cash flows from operations, our management has performed an analysis and concluded that substantial doubt exists about our
ability to continue as a going concern, and we will need to raise additional financing to continue our products&#8217; development.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in; background-color: white">Our history of operating losses and negative cash flows from operations combined with our anticipated use of cash to fund operations raises
substantial doubt about our ability to continue as a going concern beyond one year from the date of filing of this Quarterly Report on
Form 10-Q. Our financial statements as of March 31, 2026 do not include any adjustments that might result from the outcome of this uncertainty.
Based on our current operating plan, we will need to raise additional financing to continue our products&#8217; development for the foreseeable
future, and until we become profitable. Our future viability as an ongoing business is dependent on our ability to generate cash from
our operating activities or to raise additional capital to finance our operations. We expect to finance our future cash needs through
equity or debt financings, collaborations or a combination of these approaches, and given the imminent need for additional funding to
continue to fund operations in the near-term, we are actively seeking additional capital to extend the cash runway. The sale of equity
or convertible debt securities may result in dilution to our stockholders, and, in the case of preferred equity securities or convertible
debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. Debt financings may subject
us to covenant limitations or restrictions on our ability to take specific actions, such as incurring additional debt or making capital
expenditures. Our ability to raise additional funds may be adversely impacted by negative global economic conditions and any disruptions
to and volatility in the credit and financial markets in the United States and worldwide or other factors. There can be no assurance that
we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable or acceptable
to us. While we routinely evaluate cost reduction measures to proactively manage cash burn, if we are unable to obtain adequate financing
when needed or on terms favorable or acceptable to us, we may be forced to take broader actions such as to delay, reduce the scope of
or eliminate one or more of our research and development programs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The perception that we
might be unable to continue as a going concern may also make it more difficult to obtain financing for the continuation of our operations
on terms that are favorable to us, or at all, and could result in the loss of confidence by investors and employees. Our consolidated
financial statements do not include any adjustments that might result from the outcome of this uncertainty. If we are unable to continue
as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our
consolidated financial statements, and it is likely that our investors will lose all or a part of their investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><!-- Field: Page; Sequence: 43; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Risks Related to Ownership of Our Common Stock and Warrants</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>If our operations and performance do not meet the expectations
of investors or securities analysts or for other reasons, the market price of our securities may decline, and the market price of our
common stock may continue to be volatile.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of the factors listed below could have a negative
impact on your investment in our securities, and our securities may trade at prices significantly below the price you paid for them.
In such circumstances, the trading price of our securities may not recover and may experience a further decline.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Factors affecting the trading price of our securities
may include:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse regulatory decisions;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any delay in our regulatory filings for our product
    candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s
    review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request
    for additional information;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the war in Iran and other conflicts and instability
    in the Middle East, the ongoing conflict between Ukraine and Russia,&#160;instability in Venezuela and other geopolitical conflicts
    and the global impact of restrictions and sanctions imposed on Russia and the impact thereof on the markets generally, including
    any adverse effects on macroeconomic conditions such as inflation;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the commencement, enrollment or results of any future
    clinical trials we may conduct, or changes in the development status of our product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse results from, delays in or termination of clinical
    trials;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated serious safety concerns related to the
    use of our product candidates;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lower than expected market acceptance of our product
    candidates following approval for commercialization;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in financial estimates by us or by any securities
    analysts who might cover our stock;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market valuations of similar companies;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock market price and volume fluctuations of comparable
    companies and, in particular, those that operate in the biopharmaceutical industry;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication of research reports about us or our industry
    or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or our competitors of significant
    acquisitions, strategic partnerships or divestitures;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of investigations or regulatory scrutiny
    of our operations or lawsuits filed against us;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors&#8217; general perception of our business
    or management;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruitment or departure of key personnel;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall performance of the equity markets;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes or other developments relating to intellectual
    property rights, including patents, litigation matters and our ability to obtain, maintain, defend, protect and enforce patent and
    other intellectual property rights for our technologies;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant lawsuits, including patent or stockholder
    litigation;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proposed changes to healthcare laws in the U.S.&#160;or
    foreign jurisdictions, or speculation regarding such changes;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general political and economic conditions; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors, many of which are beyond our
    control.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 44; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the stock market in general, Nasdaq
and pharmaceutical companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of these companies. The trading price of our common stock is, and is likely to continue to be, volatile.
For example, from January 2, 2025 to December 31, 2025, our closing stock price ranged from $1.58 to $21.09 per share. From January 2,
2026 to May 11, 2026, our closing stock price ranged from $0.67 to $2.05 per share. Broad market and industry factors may negatively
affect the market price of our securities, regardless of our actual operating performance. As a result of this volatility, our stockholders
may not be able to sell their common stock at or above the prices at which they purchased their shares. Moreover, in the past, stockholders
have initiated class&#160;action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market
prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert
management&#8217;s attention and resources from our business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Insiders have substantial control over us, which could limit
your ability to affect the outcome of key transactions, including a change of control.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2026, our directors and executive
officers and their affiliates beneficially owned approximately 15.6% of the outstanding shares of our common stock. As a result, these
stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval,
including the election of directors and approval of significant corporate transactions, such as a merger or other sale of our company
or our assets. This concentration of ownership may have the effect of delaying or preventing a change in control of our company or discouraging
a potential acquirer from making a tender offer or otherwise attempting to obtain control, even if that change in control would benefit
our other stockholders. This significant concentration of ownership may also adversely affect the trading price for our common stock
because investors often perceive disadvantages in owning stock in companies with controlling stockholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;&#160;&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Future sales, or the perception of future sales, by us or our
stockholders in the public market, the issuance of rights to purchase our common stock, including pursuant to the 2024 Plan and the 2024
ESPP, and future exercises of registration rights could result in the additional dilution of the percentage ownership of our stockholders
and cause the market price for our common stock to decline.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The sale of shares of our common stock, convertible
securities or other equity securities in the public market, or the perception that such sales could occur, could harm the prevailing
market price of shares of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult
for us to sell equity securities in the future at a time and at a price that we deem appropriate. In addition, if we sell shares of our
common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales
may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences, and privileges senior
to the holders of our common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Jasper Therapeutics, Inc. 2024
Equity Incentive Plan (the &#8220;2024 Plan&#8221;), which became effective on June 6, 2024, we are authorized to grant equity awards
to our employees, directors and consultants. In addition, pursuant to the Jasper Therapeutics, Inc. 2024 Employee Stock Purchase Plan
(the &#8220;2024 ESPP&#8221;), which became effective on June 6, 2024, we are authorized to sell shares to our employees. As of March
31, 2026, 418,817 shares and 920,827 shares of our common stock are reserved for future issuance under the 2024 Plan and the 2024 ESPP,
respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 45; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 14, 2022, the Compensation Committee
of our Board of Directors (the &#8220;Compensation Committee&#8221;) adopted the 2022 Inducement Equity Incentive Plan (the &#8220;2022
Inducement Plan&#8221;). On June 2, 2023, the Compensation Committee approved an amendment and restatement of our 2022 Inducement Plan
to increase the maximum number of shares of our voting common stock available for grant by 250,000 shares of common stock to an aggregate
of 550,000 shares of common stock. As of March 31, 2026, 180,960 shares of our common stock are available for future issuance under the
2022 Inducement Plan. The 2022 Inducement Plan has not been and will not be approved by our stockholders. Under the 2022 Inducement Plan,
we can grant nonstatutory stock options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards
and other awards, but only to an individual, as a material inducement to such individual to enter into employment with us or an affiliate
of ours, who (i) has not previously been an employee or director of ours or (ii) is rehired following a bona fide period of non-employment
with us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2026, options to purchase an aggregate
of 2,671,358 shares of our common stock were outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, as of March 31, 2026, we had outstanding
Pre-Funded Warrants to purchase up to an aggregate of 675,000 shares of common stock and Common Warrants to purchase up to an aggregate
of 12,345,707 shares of common stock, which, if exercised, would further increase the number of shares of our common stock outstanding
and the number of shares eligible for resale in the public market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the future, we may also issue our securities
in connection with investments or acquisitions. The amount of shares of our common stock issued in connection with an investment or acquisition
could constitute a material portion of our then-outstanding shares of our common stock. Any issuance of additional securities in connection
with investments or acquisitions may result in additional dilution to our stockholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><span id="a_014" style="display: inline-block;"></span>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_015" style="display: inline-block;"></span><span style="font-weight: bold;">Item 3. Defaults Upon Senior Securities</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_016" style="display: inline-block;"></span><span style="font-weight: bold;">Item 4. Mine Safety Disclosures</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_017" style="display: inline-block;"></span><span style="font-weight: bold;">Item 5. Other Information</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> During the fiscal quarter ended March 31, 2026, none of our directors or officers (as defined in Section 16 of the Exchange Act) <ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" contextRef="cref_784925054" format="ixt:fixed-false" id="ixv-8667"><ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" contextRef="cref_784925054" format="ixt:fixed-false" id="ixv-8668">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" contextRef="cref_784925054" format="ixt:fixed-false" id="ixv-8669"><ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" contextRef="cref_784925054" format="ixt:fixed-false" id="ixv-8670">terminated</ix:nonNumeric></ix:nonNumeric> any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Item 408(a) of Regulation S-K. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 46; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><span id="a_018" style="display: inline-block;"></span>Item 6. Exhibits</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom">
<td style="width: 9%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Exhibit<br/>
    Number</span></span></td>
<td style="width: 1%">&#160;</td>
<td style="width: 54%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Description</span></span></td>
<td style="width: 1%">&#160;</td>
<td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Registrant&#8217;s
    Form</span></span></td>
<td style="width: 1%">&#160;</td>
<td style="border-bottom: black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Date&#160;Filed<br/>
    with&#160;the<br/>
    SEC</span></span></td>
<td style="width: 1%">&#160;</td>
<td style="border-bottom: black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Exhibit
    Number</span></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/ea147929ex3-1_jasper.htm">Second Amended and Restated Certificate of Incorporation of the Registrant, dated September 24, 2021.</a></span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/29/2021</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390023047446/ea179979ex3-1_jasper.htm">Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation, dated&#160;June 8, 2023.</a></span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/8/2023</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390024000980/ea191024ex3-1_jasper.htm">Certificate of Second Amendment to the Second Amended and Restated Certificate of Incorporation of Jasper Therapeutics, Inc. January 3, 2024.</a></span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/3/2024</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390023012596/ea173877ex3-1_jasper.htm">Third Amended and Restated Bylaws of the Registrant.</a></span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/17/2023</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390019024606/f8k1119ex4-1_amplitude.htm">Form of Warrant Agreement, dated November&#160;19, 2019, by and between the Registrant and Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent.</a></span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/25/2019</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390019022224/fs12019a1ex4-3_amplitude.htm">Specimen Warrant Certificate.</a></span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/6/2019</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390025089584/ea025802601ex4-1_jasper.htm">Form of Pre-Funded Warrant to Purchase Common Stock.</a></span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/19/2025</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390025089584/ea025802601ex4-2_jasper.htm">Form of Common Warrant.</a></span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/19/2025</span></td>
<td>&#160;</td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028947701ex31-1.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028947701ex31-2.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028947701ex32-1.htm">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
<td style="width: 1%">&#160;</td>
<td style="width: 54%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td>
<td style="width: 1%">&#160;</td>
<td style="text-align: center; width: 11%">&#160;</td>
<td style="width: 1%">&#160;</td>
<td style="width: 12%; text-align: center">&#160;</td>
<td style="width: 1%">&#160;</td>
<td style="width: 10%; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</span></td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
</tbody></table><p style="margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
herewith.</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
herewith.</span></td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 47; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><span id="a_019" style="display: inline-block;"></span>SIGNATURES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
<td style="vertical-align: top">&#160;</td>
<td colspan="2" style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">JASPER
    THERAPEUTICS, INC.</span></span></td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 14,
    2026</span></td>
<td style="vertical-align: bottom; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
<td style="vertical-align: bottom; width: 36%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Jeet Mahal</span></td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeet Mahal</span></td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief
    Executive Officer</span></td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal Executive
    Officer)</i></span></td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 14, 2026</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
<td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Herb Cross&#160;</span></td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Herb Cross&#160;</span></td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal Accounting
    and Financial Officer)</i></span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">46</p><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ea028947701ex31-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-14(a) adopted pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Jeet Mahal, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of Jasper Therapeutics, Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeet Mahal</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; border-top: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeet Mahal</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>President, Chief Executive Officer, and Director</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: May 14, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ea028947701ex31-2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-14(a) adopted pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Herb Cross, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of Jasper Therapeutics, Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Herb Cross</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; border-top: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Herb Cross</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Financial Officer and Corporate Secretary</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: May 14, 2026</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ea028947701ex32-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with the Quarterly Report on Form
10-Q of Jasper Therapeutics, Inc. (the &ldquo;Company&rdquo;) for the period ended March 31, 2026 as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to their knowledge that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 36%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeet Mahal</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 20%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 37%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Herb Cross</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeet Mahal</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Herb Cross</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
and Chief Executive Officer</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Corporate Secretary</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Financial Officer)</I></FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 14, 2026</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 14, 2026</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A signed original of this written statement required
by Section&nbsp;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This certification accompanies the Report, is
not deemed filed for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Report), irrespective of any general incorporation
language contained in such filing.</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>jspr-20260331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><xs:schema targetNamespace="http://jaspertx.com/20260331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:jspr="http://jaspertx.com/20260331" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2026">
  <xs:import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd" />
  <xs:import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd" />
  <xs:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2026" schemaLocation="https://xbrl.sec.gov/ecd/2026/ecd-sub-2026.xsd" />
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jspr-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jspr-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label link" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jspr-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jspr-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple" />
      <link:roleType roleURI="http://jaspertx.com/20260331/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>995300 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited" id="CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals" id="CondensedConsolidatedBalanceSheetsUnauditedParentheticals">
        <link:definition>995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
        <link:definition>995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>995304 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" id="CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/OrganizationandDescriptionofBusiness" id="OrganizationandDescriptionofBusiness">
        <link:definition>995306 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPolicies" id="SummaryofSignificantAccountingPolicies">
        <link:definition>995307 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995308 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponents" id="CondensedConsolidatedBalanceSheetComponents">
        <link:definition>995309 - Disclosure - Condensed Consolidated Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CirmGrant" id="CirmGrant">
        <link:definition>995310 - Disclosure - Cirm Grant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/SignificantAgreements" id="SignificantAgreements">
        <link:definition>995311 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/Warrants" id="Warrants">
        <link:definition>995312 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingencies" id="CommitmentsandContingencies">
        <link:definition>995313 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CommonStock" id="CommonStock">
        <link:definition>995314 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>995315 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholders" id="NetLossPerShareAttributabletoCommonStockholders">
        <link:definition>995316 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/RelatedParties" id="RelatedParties">
        <link:definition>995317 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/SegmentInformation" id="SegmentInformation">
        <link:definition>995318 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/Restructuring" id="Restructuring">
        <link:definition>995319 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/AccountingPoliciesbyPolicyPolicies" id="AccountingPoliciesbyPolicyPolicies">
        <link:definition>996320 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesTables" id="SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996321 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>996322 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/ConsolidatedBalanceSheetComponentsTables" id="ConsolidatedBalanceSheetComponentsTables">
        <link:definition>996323 - Disclosure - Consolidated Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingenciesTables" id="CommitmentsandContingenciesTables">
        <link:definition>996324 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CommonStockTables" id="CommonStockTables">
        <link:definition>996325 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>996326 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersTables" id="NetLossPerShareAttributabletoCommonStockholdersTables">
        <link:definition>996327 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/SegmentInformationTables" id="SegmentInformationTables">
        <link:definition>996328 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesDetails" id="SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996329 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails" id="SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails">
        <link:definition>996330 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" id="FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>996331 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails" id="FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails">
        <link:definition>996332 - Disclosure - Fair Value Measurements - Schedule of Changes in the Company&#8217;s Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails" id="FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails">
        <link:definition>996333 - Disclosure - Fair Value Measurements - Schedule of Estimate the Fair Value of the Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsDetails" id="CondensedConsolidatedBalanceSheetComponentsDetails">
        <link:definition>996334 - Disclosure - Condensed Consolidated Balance Sheet Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" id="CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>996335 - Disclosure - Condensed Consolidated Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" id="CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
        <link:definition>996336 - Disclosure - Condensed Consolidated Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" id="CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>996337 - Disclosure - Condensed Consolidated Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CirmGrantDetails" id="CirmGrantDetails">
        <link:definition>996338 - Disclosure - Cirm Grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/SignificantAgreementsDetails" id="SignificantAgreementsDetails">
        <link:definition>996339 - Disclosure - Significant Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/WarrantsDetails" id="WarrantsDetails">
        <link:definition>996340 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails" id="CommitmentsandContingenciesDetails">
        <link:definition>996341 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails" id="CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails">
        <link:definition>996342 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails" id="CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails">
        <link:definition>996343 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CommonStockDetails" id="CommonStockDetails">
        <link:definition>996344 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails" id="CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails">
        <link:definition>996345 - Disclosure - Common Stock - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationDetails" id="StockBasedCompensationDetails">
        <link:definition>996346 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails" id="StockBasedCompensationScheduleofStockOptionActivitiesDetails">
        <link:definition>996347 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails" id="StockBasedCompensationScheduleofRSUActivityDetails">
        <link:definition>996348 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" id="StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>996349 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails" id="StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails">
        <link:definition>996350 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersDetails" id="NetLossPerShareAttributabletoCommonStockholdersDetails">
        <link:definition>996351 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" id="NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails">
        <link:definition>996352 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" id="NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails">
        <link:definition>996353 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/RelatedPartiesDetails" id="RelatedPartiesDetails">
        <link:definition>996354 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/SegmentInformationDetails" id="SegmentInformationDetails">
        <link:definition>996355 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails" id="SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails">
        <link:definition>996356 - Disclosure - Segment Information - Schedule of Significant Expense Categories Included Within Net Loss Presented on the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/RestructuringDetails" id="RestructuringDetails">
        <link:definition>996357 - Disclosure - Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails1" id="StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails1">
        <link:definition>996300 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) 1</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jspr_ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract" name="ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_WarrantLiabilityMember" name="WarrantLiabilityMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract" name="ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract" name="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable" name="FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear" name="MilestonePaymentsObligationToBePaidThirdAndFourthYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear" name="MilestonePaymentsObligationToBePaidFirstAndSecondYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_SalesMilestonePayments" name="SalesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_SignificantAgreementsDetailsTable" name="SignificantAgreementsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_TwentyTwentyFourStanfordLicenseAgreementMember" name="TwentyTwentyFourStanfordLicenseAgreementMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_TwentyTwentyOneStanfordLicenseAgreementMember" name="TwentyTwentyOneStanfordLicenseAgreementMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_CommitmentsandContingenciesDetailsTable" name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_CommonWarrantsMember" name="CommonWarrantsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_TwoZeroOneNinePlanMember" name="TwoZeroOneNinePlanMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_TwoZeroTwoFourESPPMember" name="TwoZeroTwoFourESPPMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_TwoZeroTwoTwoInducementPlanMember" name="TwoZeroTwoTwoInducementPlanMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember" name="SharesAvailableForGrantUnderEquityIncentivePlansMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_UnderwrittenOfferingRemainedAvailable" name="UnderwrittenOfferingRemainedAvailable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_UnderwrittenOfferingsMember" name="UnderwrittenOfferingsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_VotingCommonStockMember" name="VotingCommonStockMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_VotingCommonStockPercent" name="VotingCommonStockPercent" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember" name="OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_OutstandingAndIssuedRestrictedStockUnitsMember" name="OutstandingAndIssuedRestrictedStockUnitsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_ScheduleOfCommonStockReservedForFutureIssuanceAbstract" name="ScheduleOfCommonStockReservedForFutureIssuanceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember" name="SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember" name="SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember" name="SharesIssuableUponExerciseOfCommonStockWarrantsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember" name="SharesIssuableUponExerciseOfPreFundedWarrantsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember" name="SharesIssuableUponExerciseOfPublicWarrantsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_ScheduleOfStockBasedCompensationExpenseAbstract" name="ScheduleOfStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_AggregateOfferingPrice" name="AggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_AvailableOfferingAmount" name="AvailableOfferingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_CommonStockDetailsTable" name="CommonStockDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_CommonWarrantsToPurchaseShares" name="CommonWarrantsToPurchaseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_NumberOfSharePurchase" name="NumberOfSharePurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="jspr_PreFundedWarrantsToPurchase" name="PreFundedWarrantsToPurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable" name="StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_PublicWarrantsMember" name="PublicWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_PurchaseAnAggregateShares" name="PurchaseAnAggregateShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_PerformanceShareUnitsPSUsMember" name="PerformanceShareUnitsPSUsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract" name="ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable" name="StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_VotingCommonStockParValue00001PerShareMember" name="VotingCommonStockParValue00001PerShareMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_WarrantsTextBlock" name="WarrantsTextBlock" type="dtr:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_CIndUMember" name="CIndUMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_MDSAMLMember" name="MDSAMLMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_PersonnelCosts" name="PersonnelCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="jspr_SCIDMember" name="SCIDMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_CirmGrantDisclosureTextBlock" name="CirmGrantDisclosureTextBlock" type="dtr:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member" name="RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_SeveranceCostsPeriod" name="SeveranceCostsPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" type="dtr:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_CirmGrantDisclosureAbstract" name="CirmGrantDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_PrepaidTravelExpenses" name="PrepaidTravelExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="jspr_ResearchAndDevelopmentPrepaidExpenses" name="ResearchAndDevelopmentPrepaidExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="jspr_ScheduleOfPropertyAndEquipmentNetAbstract" name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_ResearchAndDevelopmentAccruedExpensesCurrent" name="ResearchAndDevelopmentAccruedExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_CaliforniaInstituteForRegenerativeMedicineMember" name="CaliforniaInstituteForRegenerativeMedicineMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_CirmGrantDetailsTable" name="CirmGrantDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_CirmGrantLineItems" name="CirmGrantLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_NetSales" name="NetSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_PercentageOfCommonWarrants" name="PercentageOfCommonWarrants" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_PercentageOfElectionHolderWarrants" name="PercentageOfElectionHolderWarrants" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_PercentagePreFundedWarrants" name="PercentagePreFundedWarrants" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_PreFundedWarrantPercentage" name="PreFundedWarrantPercentage" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_September2025OfferingMember" name="September2025OfferingMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_WarrantsDetailsTable" name="WarrantsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear" name="MilestonePaymentsObligationToBePaidFirstThroughThirdYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear" name="MilestonePaymentsObligationToBePaidFourthThroughSixthYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_MilestonePaymentsObligationToBePaidThereafter" name="MilestonePaymentsObligationToBePaidThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_PercentageOfLicensingFees" name="PercentageOfLicensingFees" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_ReceivedAggregateFromCIRM" name="ReceivedAggregateFromCIRM" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_ApproximatelyAgreement" name="ApproximatelyAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_ClinicalDevelopmentMilestonePayments" name="ClinicalDevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_LicenseMaintenanceFee" name="LicenseMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_PerformanceBasedStockOptionsMember" name="PerformanceBasedStockOptionsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_ScheduleOfStockOptionActivitiesAbstract" name="ScheduleOfStockOptionActivitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_ScheduleOfComponentsOfLeaseCostsAbstract" name="ScheduleOfComponentsOfLeaseCostsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable" name="CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_OutstandingAndIssuedCommonStockOptionsMember" name="OutstandingAndIssuedCommonStockOptionsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_ValuationOfStockOptionsMember" name="ValuationOfStockOptionsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_PerformanceBasedStockOptionActivity" name="PerformanceBasedStockOptionActivity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_PerformanceRestrictedStockUnitsMember" name="PerformanceRestrictedStockUnitsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_RecognizedCompensationExpensePeriod" name="RecognizedCompensationExpensePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="jspr_StockBasedCompensationDetailsTable" name="StockBasedCompensationDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_TotalEstimatedFairValue" name="TotalEstimatedFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="jspr_TwoThousandTwentyFourPlanMember" name="TwoThousandTwentyFourPlanMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_ScheduleOfRsuActivityAbstract" name="ScheduleOfRsuActivityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable" name="StockBasedCompensationScheduleofRSUActivityDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_BriquilimabPlatformMember" name="BriquilimabPlatformMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_CMOMember" name="CMOMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_CSUMember" name="CSUMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_FacilitiesAndOverheadCosts" name="FacilitiesAndOverheadCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="jspr_ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" name="ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract" name="ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="jspr_AsthmaMember" name="AsthmaMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>jspr-20260331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails" roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails" roleURI="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails" roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails" />
  <link:calculationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" />
    <link:calculationArc xlink:type="arc" order="5.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_WarrantsAndRightsOutstanding" />
    <link:calculationArc xlink:type="arc" order="5.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" order="5.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ResearchAndDevelopmentPrepaidExpenses" xlink:label="jspr_ResearchAndDevelopmentPrepaidExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PrepaidTravelExpenses" xlink:label="jspr_PrepaidTravelExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="jspr_ResearchAndDevelopmentPrepaidExpenses" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="jspr_PrepaidTravelExpenses" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ResearchAndDevelopmentAccruedExpensesCurrent" xlink:label="jspr_ResearchAndDevelopmentAccruedExpensesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="jspr_ResearchAndDevelopmentAccruedExpensesCurrent" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>jspr-20260331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails" xlink:href="jspr-20260331.xsd#FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:href="jspr-20260331.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/SignificantAgreementsDetails" xlink:href="jspr-20260331.xsd#SignificantAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/WarrantsDetails" xlink:href="jspr-20260331.xsd#WarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationDetails" xlink:href="jspr-20260331.xsd#StockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:href="jspr-20260331.xsd#CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/CommonStockDetails" xlink:href="jspr-20260331.xsd#CommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:href="jspr-20260331.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/DocumentAndEntityInformation" xlink:href="jspr-20260331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails" xlink:href="jspr-20260331.xsd#SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:href="jspr-20260331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/CirmGrantDetails" xlink:href="jspr-20260331.xsd#CirmGrantDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails" xlink:href="jspr-20260331.xsd#FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails" xlink:href="jspr-20260331.xsd#StockBasedCompensationScheduleofStockOptionActivitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails" xlink:href="jspr-20260331.xsd#StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails" xlink:href="jspr-20260331.xsd#StockBasedCompensationScheduleofRSUActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:href="jspr-20260331.xsd#NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="simple" />
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1281" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1275" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_1278" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_1279" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_1280" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_1277" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1276" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1979" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1282" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1979_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1281" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1275" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain_1979" xlink:to="us-gaap_MeasurementInputExpectedTermMember_1278" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain_1979" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_1279" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain_1979" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_1280" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain_1979" xlink:to="us-gaap_MeasurementInputSharePriceMember_1277" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1275" xlink:to="us-gaap_MeasurementInputTypeAxis_1276" />
    <link:definitionArc xlink:type="arc" order="93.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis_1276" xlink:to="us-gaap_MeasurementInputTypeDomain_1979" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1281" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1282" />
    <link:definitionArc xlink:type="arc" order="93.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis_1276" xlink:to="us-gaap_MeasurementInputTypeDomain_1979_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_1269" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_1271" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1265" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1268" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1978" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1266" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_WarrantLiabilityMember" xlink:label="jspr_WarrantLiabilityMember_1267" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1978_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1268" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_1269" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1268" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_1271" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1268" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1265" />
    <link:definitionArc xlink:type="arc" order="92.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1266" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1978" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1265" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1266" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1978" xlink:to="jspr_WarrantLiabilityMember_1267" />
    <link:definitionArc xlink:type="arc" order="92.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1266" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1978_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1250" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_1251" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_1262" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_1261" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_1248" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1977" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_1257" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_1256" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_1255" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1247" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1253" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1258" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1249" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_1259" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_1260" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_WarrantLiabilityMember" xlink:label="jspr_WarrantLiabilityMember_1252" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable" xlink:label="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_1246" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1250_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1977_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1249" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1250" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1250" xlink:to="us-gaap_MoneyMarketFundsMember_1251" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract_1261" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_1262" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1258" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_1261" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_1977" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_1248" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1253" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254" />
    <link:definitionArc xlink:type="arc" order="91.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1247" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1977" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254" xlink:to="us-gaap_FairValueInputsLevel3Member_1257" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254" xlink:to="us-gaap_FairValueInputsLevel2Member_1256" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254" xlink:to="us-gaap_FairValueInputsLevel1Member_1255" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_1246" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_1247" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_1246" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_1253" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_1246" xlink:to="us-gaap_CashAndCashEquivalentsAxis_1249" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1258" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_1259" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_1259" xlink:to="us-gaap_AssetsFairValueDisclosure_1260" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1250" xlink:to="jspr_WarrantLiabilityMember_1252" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1258" xlink:to="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_1246" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="true" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1249" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1250_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="true" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1253" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254_default" />
    <link:definitionArc xlink:type="arc" order="91.00" priority="1" xbrldt:closed="true" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1247" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1977_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/SignificantAgreementsDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear_1583" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear_1582" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SalesMilestonePayments" xlink:label="jspr_SalesMilestonePayments_1585" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SignificantAgreementsDetailsTable" xlink:label="jspr_SignificantAgreementsDetailsTable_1576" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwentyTwentyFourStanfordLicenseAgreementMember" xlink:label="jspr_TwentyTwentyFourStanfordLicenseAgreementMember_1580" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwentyTwentyOneStanfordLicenseAgreementMember" xlink:label="jspr_TwentyTwentyOneStanfordLicenseAgreementMember_1579" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1578" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance_1586" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_1958" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1577" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear_1589" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear_1590" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidThereafter" xlink:label="jspr_MilestonePaymentsObligationToBePaidThereafter_1584" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ApproximatelyAgreement" xlink:label="jspr_ApproximatelyAgreement_1587" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ClinicalDevelopmentMilestonePayments" xlink:label="jspr_ClinicalDevelopmentMilestonePayments_1591" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_LicenseMaintenanceFee" xlink:label="jspr_LicenseMaintenanceFee_1588" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1578_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear_1583" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear_1582" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_SalesMilestonePayments_1585" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_SignificantAgreementsDetailsTable_1576" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1578" xlink:to="jspr_TwentyTwentyFourStanfordLicenseAgreementMember_1580" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1578" xlink:to="jspr_TwentyTwentyOneStanfordLicenseAgreementMember_1579" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis_1577" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1578" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="us-gaap_CostMaintenance_1586" />
    <link:definitionArc xlink:type="arc" order="81.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_1958" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_SignificantAgreementsDetailsTable_1576" xlink:to="us-gaap_TypeOfArrangementAxis_1577" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear_1589" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear_1590" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_MilestonePaymentsObligationToBePaidThereafter_1584" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_ApproximatelyAgreement_1587" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_ClinicalDevelopmentMilestonePayments_1591" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_LicenseMaintenanceFee_1588" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis_1577" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1578_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/WarrantsDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1599" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1606" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_1612" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonWarrantsMember" xlink:label="jspr_CommonWarrantsMember_1601" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_1605" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1597" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_1613" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_1610" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1596" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1598" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_1603" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1595" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1604" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentageOfCommonWarrants" xlink:label="jspr_PercentageOfCommonWarrants_1611" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentageOfElectionHolderWarrants" xlink:label="jspr_PercentageOfElectionHolderWarrants_1608" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentagePreFundedWarrants" xlink:label="jspr_PercentagePreFundedWarrants_1609" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PreFundedWarrantPercentage" xlink:label="jspr_PreFundedWarrantPercentage_1607" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PreFundedWarrantsMember" xlink:label="jspr_PreFundedWarrantsMember_1602" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_September2025OfferingMember" xlink:label="jspr_September2025OfferingMember_1600" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_WarrantsDetailsTable" xlink:label="jspr_WarrantsDetailsTable_1594" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1599_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1596_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1598" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1599" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1606" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_WarrantsAndRightsOutstanding_1612" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1599" xlink:to="jspr_CommonWarrantsMember_1601" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_1605" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1596" xlink:to="us-gaap_CommonStockMember_1597" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_1613" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_AdditionalPaidInCapital_1610" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1595" xlink:to="us-gaap_ClassOfStockDomain_1596" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_WarrantsDetailsTable_1594" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1598" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_WarrantsDetailsTable_1594" xlink:to="us-gaap_StatementClassOfStockAxis_1595" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1604" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="jspr_PercentageOfCommonWarrants_1611" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="jspr_PercentageOfElectionHolderWarrants_1608" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="jspr_PercentagePreFundedWarrants_1609" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="jspr_PreFundedWarrantPercentage_1607" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1599" xlink:to="jspr_PreFundedWarrantsMember_1602" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1599" xlink:to="jspr_September2025OfferingMember_1600" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="jspr_WarrantsDetailsTable_1594" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="true" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1598" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1599_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="true" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1595" xlink:to="us-gaap_ClassOfStockDomain_1596_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoZeroOneNinePlanMember" xlink:label="jspr_TwoZeroOneNinePlanMember_1675" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoZeroTwoFourESPPMember" xlink:label="jspr_TwoZeroTwoFourESPPMember_1677" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoZeroTwoTwoInducementPlanMember" xlink:label="jspr_TwoZeroTwoTwoInducementPlanMember_1673" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1712" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1702" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1701" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1671" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1672" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1695" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_1704" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1705" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1708" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1706" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1707" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_EmployeeStockPurchasePlanMember" xlink:label="jspr_EmployeeStockPurchasePlanMember_1685" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_1713" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1681" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1692" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_1697" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_1679" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_1678" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1693" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1698" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1694" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1699" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1700" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1710" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1711" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_1680" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceBasedStockOptionActivity" xlink:label="jspr_PerformanceBasedStockOptionActivity_1972" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceBasedStockOptionsMember" xlink:label="jspr_PerformanceBasedStockOptionsMember_1684" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceRestrictedStockUnitsMember" xlink:label="jspr_PerformanceRestrictedStockUnitsMember_1686" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_RecognizedCompensationExpensePeriod" xlink:label="jspr_RecognizedCompensationExpensePeriod_1996" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationDetailsTable" xlink:label="jspr_StockBasedCompensationDetailsTable_1670" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TotalEstimatedFairValue" xlink:label="jspr_TotalEstimatedFairValue_1995" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoThousandTwentyFourPlanMember" xlink:label="jspr_TwoThousandTwentyFourPlanMember_1674" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1672_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_1679_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682_default" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1672" xlink:to="jspr_TwoZeroOneNinePlanMember_1675" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1672" xlink:to="jspr_TwoZeroTwoFourESPPMember_1677" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1672" xlink:to="jspr_TwoZeroTwoTwoInducementPlanMember_1673" />
    <link:definitionArc xlink:type="arc" order="34.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1712" />
    <link:definitionArc xlink:type="arc" order="24.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1702" />
    <link:definitionArc xlink:type="arc" order="23.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1701" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_StockBasedCompensationDetailsTable_1670" xlink:to="us-gaap_PlanNameAxis_1671" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis_1671" xlink:to="us-gaap_PlanNameDomain_1672" />
    <link:definitionArc xlink:type="arc" order="25.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1703" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1695" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_1704" />
    <link:definitionArc xlink:type="arc" order="27.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1705" />
    <link:definitionArc xlink:type="arc" order="30.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1708" />
    <link:definitionArc xlink:type="arc" order="28.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1706" />
    <link:definitionArc xlink:type="arc" order="29.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1707" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682" xlink:to="jspr_EmployeeStockPurchasePlanMember_1685" />
    <link:definitionArc xlink:type="arc" order="35.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_1713" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_StockBasedCompensationDetailsTable_1670" xlink:to="us-gaap_AwardTypeAxis_1681" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1692" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_1697" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_1678" xlink:to="us-gaap_DerivativeContractTypeDomain_1679" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_StockBasedCompensationDetailsTable_1670" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_1678" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1693" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1698" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1694" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1699" />
    <link:definitionArc xlink:type="arc" order="22.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1700" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis_1681" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682" />
    <link:definitionArc xlink:type="arc" order="32.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1710" />
    <link:definitionArc xlink:type="arc" order="33.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1711" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain_1679" xlink:to="us-gaap_StockOptionMember_1680" />
    <link:definitionArc xlink:type="arc" order="87.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="jspr_PerformanceBasedStockOptionActivity_1972" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682" xlink:to="jspr_PerformanceBasedStockOptionsMember_1684" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682" xlink:to="jspr_PerformanceRestrictedStockUnitsMember_1686" />
    <link:definitionArc xlink:type="arc" order="105.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="jspr_RecognizedCompensationExpensePeriod_1996" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="jspr_StockBasedCompensationDetailsTable_1670" />
    <link:definitionArc xlink:type="arc" order="104.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="jspr_TotalEstimatedFairValue_1995" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1672" xlink:to="jspr_TwoThousandTwentyFourPlanMember_1674" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis_1671" xlink:to="us-gaap_PlanNameDomain_1672_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_1678" xlink:to="us-gaap_DerivativeContractTypeDomain_1679_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis_1681" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/CommonStockDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_1650" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1964" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_1962" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_UnderwrittenOfferingRemainedAvailable" xlink:label="jspr_UnderwrittenOfferingRemainedAvailable_1660" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_UnderwrittenOfferingsMember" xlink:label="jspr_UnderwrittenOfferingsMember_1632" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_VotingCommonStockMember" xlink:label="jspr_VotingCommonStockMember_1635" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_VotingCommonStockPercent" xlink:label="jspr_VotingCommonStockPercent_1652" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1634" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_1644" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1641" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1642" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1961" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_1653" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1637" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_1645" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_1647" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_1648" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_AggregateOfferingPrice" xlink:label="jspr_AggregateOfferingPrice_1657" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_AvailableOfferingAmount" xlink:label="jspr_AvailableOfferingAmount_1667" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonStockDetailsTable" xlink:label="jspr_CommonStockDetailsTable_1629" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonWarrantsToPurchaseShares" xlink:label="jspr_CommonWarrantsToPurchaseShares_1665" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_NumberOfSharePurchase" xlink:label="jspr_NumberOfSharePurchase_1651" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PreFundedWarrantsToPurchase" xlink:label="jspr_PreFundedWarrantsToPurchase_1664" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PublicWarrantsMember" xlink:label="jspr_PublicWarrantsMember_1963" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PurchaseAnAggregateShares" xlink:label="jspr_PurchaseAnAggregateShares_1654" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi_1656" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember_1636" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_1646" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_1649" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1631" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1658" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1633" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_1663" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1630" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_1643" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1634_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1642_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1631_default" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_PreferredStockSharesOutstanding_1650" />
    <link:definitionArc xlink:type="arc" order="33.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1964" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_1962" />
    <link:definitionArc xlink:type="arc" order="25.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_UnderwrittenOfferingRemainedAvailable_1660" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1631" xlink:to="jspr_UnderwrittenOfferingsMember_1632" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1634" xlink:to="jspr_VotingCommonStockMember_1635" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_VotingCommonStockPercent_1652" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1633" xlink:to="us-gaap_ClassOfStockDomain_1634" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_CommonStockDetailsTable_1629" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1641" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1641" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1642" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1961" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_1653" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1634" xlink:to="us-gaap_CommonStockMember_1637" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_CommonStockSharesAuthorized_1645" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_CommonStockSharesIssued_1647" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_CommonStockSharesOutstanding_1648" />
    <link:definitionArc xlink:type="arc" order="23.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_AggregateOfferingPrice_1657" />
    <link:definitionArc xlink:type="arc" order="32.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_AvailableOfferingAmount_1667" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_CommonStockDetailsTable_1629" />
    <link:definitionArc xlink:type="arc" order="31.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_CommonWarrantsToPurchaseShares_1665" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_NumberOfSharePurchase_1651" />
    <link:definitionArc xlink:type="arc" order="30.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_PreFundedWarrantsToPurchase_1664" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1642" xlink:to="jspr_PublicWarrantsMember_1963" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_PurchaseAnAggregateShares_1654" />
    <link:definitionArc xlink:type="arc" order="22.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_EquitySecuritiesFvNi_1656" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1634" xlink:to="us-gaap_NonvotingCommonStockMember_1636" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_PreferredStockSharesAuthorized_1646" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_PreferredStockSharesIssued_1649" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1630" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1631" />
    <link:definitionArc xlink:type="arc" order="24.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1658" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_CommonStockDetailsTable_1629" xlink:to="us-gaap_StatementClassOfStockAxis_1633" />
    <link:definitionArc xlink:type="arc" order="29.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_1663" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_CommonStockDetailsTable_1629" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1630" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1642" xlink:to="us-gaap_WarrantMember_1643" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1633" xlink:to="us-gaap_ClassOfStockDomain_1634_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1641" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1642_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1630" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1631_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember" xlink:label="jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember_1340" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember" xlink:label="jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember_1336" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_OutstandingAndIssuedRestrictedStockUnitsMember" xlink:label="jspr_OutstandingAndIssuedRestrictedStockUnitsMember_1335" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember" xlink:label="jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember_1342" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember" xlink:label="jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember_1341" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember" xlink:label="jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember_1338" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember" xlink:label="jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember_1339" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesIssuableUponExerciseOfPublicWarrantsMember" xlink:label="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember_1337" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_1343" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1344" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1332" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1333" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:label="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable_1331" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_OutstandingAndIssuedCommonStockOptionsMember" xlink:label="jspr_OutstandingAndIssuedCommonStockOptionsMember_1334" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1333_default" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember_1340" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember_1336" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_OutstandingAndIssuedRestrictedStockUnitsMember_1335" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember_1342" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember_1341" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember_1338" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember_1339" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember_1337" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1343" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1344" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable_1331" xlink:to="us-gaap_PlanNameAxis_1332" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis_1332" xlink:to="us-gaap_PlanNameDomain_1333" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems_1343" xlink:to="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable_1331" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_OutstandingAndIssuedCommonStockOptionsMember_1334" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis_1332" xlink:to="us-gaap_PlanNameDomain_1333_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_1394" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1387" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1393" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceShareUnitsPSUsMember" xlink:label="jspr_PerformanceShareUnitsPSUsMember_1388" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1393" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_1394" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" xlink:to="us-gaap_AwardTypeAxis_1387" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1393" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" />
    <link:definitionArc xlink:type="arc" order="95.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis_1387" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981" xlink:to="jspr_PerformanceShareUnitsPSUsMember_1388" />
    <link:definitionArc xlink:type="arc" order="95.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis_1387" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1348" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1363" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable" xlink:label="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable_1347" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1360" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1361" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1967" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1976" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1354" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1359" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceBasedStockOptionsMember" xlink:label="jspr_PerformanceBasedStockOptionsMember_1350" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1362" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1366" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1364" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1971" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1356" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1357" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1358" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1980" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1367" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1365" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_1349" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1980_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable_1347" xlink:to="us-gaap_AwardTypeAxis_1348" />
    <link:definitionArc xlink:type="arc" order="30.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1363" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable_1347" />
    <link:definitionArc xlink:type="arc" order="27.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1360" />
    <link:definitionArc xlink:type="arc" order="28.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1361" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1967" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1976" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1354" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1359" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1980" xlink:to="jspr_PerformanceBasedStockOptionsMember_1350" />
    <link:definitionArc xlink:type="arc" order="29.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1362" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1366" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1364" />
    <link:definitionArc xlink:type="arc" order="22.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1971" />
    <link:definitionArc xlink:type="arc" order="23.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1356" />
    <link:definitionArc xlink:type="arc" order="24.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1357" />
    <link:definitionArc xlink:type="arc" order="25.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1358" />
    <link:definitionArc xlink:type="arc" order="94.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis_1348" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1980" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1367" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1365" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1980" xlink:to="us-gaap_StockOptionMember_1349" />
    <link:definitionArc xlink:type="arc" order="94.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis_1348" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1980_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable" xlink:label="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable_1397" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1406" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1407" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1408" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1982" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1409" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ValuationOfStockOptionsMember" xlink:label="jspr_ValuationOfStockOptionsMember_1399" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_1404" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_1403" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1401" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1402" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1398" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1982_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1402_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" xlink:to="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable_1397" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1406" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1407" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1408" />
    <link:definitionArc xlink:type="arc" order="96.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis_1398" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1982" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1409" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1982" xlink:to="jspr_ValuationOfStockOptionsMember_1399" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_1402" xlink:to="srt_MaximumMember_1404" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_1402" xlink:to="srt_MinimumMember_1403" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable_1397" xlink:to="srt_RangeAxis_1401" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis_1401" xlink:to="srt_RangeMember_1402" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable_1397" xlink:to="us-gaap_AwardTypeAxis_1398" />
    <link:definitionArc xlink:type="arc" order="96.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis_1398" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1982_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis_1401" xlink:to="srt_RangeMember_1402_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/DocumentAndEntityInformation" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_1930" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_1955" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1762" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1763" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_VotingCommonStockParValue00001PerShareMember" xlink:label="jspr_VotingCommonStockParValue00001PerShareMember_1764" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_1948" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_1947" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_1931" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_1761" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_1766" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_1932" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member" xlink:label="jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member_1765" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_1938" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_1934" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_1937" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_1936" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_1945" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_1943" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_1941" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_1939" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_1952" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_1940" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_1935" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_1950" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_1949" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_1928" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_1929" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType_1927" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_1986" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_1957" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_1933" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_1942" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_1944" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_1953" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_1954" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_1956" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1763_default" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_AmendmentFlag_1930" />
    <link:definitionArc xlink:type="arc" order="38.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_TradingSymbol_1955" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable_1761" xlink:to="us-gaap_StatementClassOfStockAxis_1762" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1762" xlink:to="us-gaap_ClassOfStockDomain_1763" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1763" xlink:to="jspr_VotingCommonStockParValue00001PerShareMember_1764" />
    <link:definitionArc xlink:type="arc" order="25.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityAddressAddressLine2_1948" />
    <link:definitionArc xlink:type="arc" order="24.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityAddressAddressLine1_1947" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentPeriodEndDate_1931" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentInformationTable_1761" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentFiscalYearFocus_1932" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1763" xlink:to="jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member_1765" />
    <link:definitionArc xlink:type="arc" order="23.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityTaxIdentificationNumber_1938" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityRegistrantName_1934" />
    <link:definitionArc xlink:type="arc" order="22.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityIncorporationStateCountryCode_1937" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityFileNumber_1936" />
    <link:definitionArc xlink:type="arc" order="35.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityEmergingGrowthCompany_1945" />
    <link:definitionArc xlink:type="arc" order="33.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityFilerCategory_1943" />
    <link:definitionArc xlink:type="arc" order="32.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityInteractiveDataCurrent_1941" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_CurrentFiscalYearEndDate_1939" />
    <link:definitionArc xlink:type="arc" order="29.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_CityAreaCode_1952" />
    <link:definitionArc xlink:type="arc" order="31.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityCurrentReportingStatus_1940" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityCentralIndexKey_1935" />
    <link:definitionArc xlink:type="arc" order="27.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityAddressStateOrProvince_1950" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityAddressCityOrTown_1949" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentQuarterlyReport_1928" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentTransitionReport_1929" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentType_1927" />
    <link:definitionArc xlink:type="arc" order="28.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityAddressPostalZipCode_1986" />
    <link:definitionArc xlink:type="arc" order="40.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityCommonStockSharesOutstanding_1957" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentFiscalPeriodFocus_1933" />
    <link:definitionArc xlink:type="arc" order="36.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityShellCompany_1942" />
    <link:definitionArc xlink:type="arc" order="34.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntitySmallBusiness_1944" />
    <link:definitionArc xlink:type="arc" order="30.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_LocalPhoneNumber_1953" />
    <link:definitionArc xlink:type="arc" order="37.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_Security12bTitle_1954" />
    <link:definitionArc xlink:type="arc" order="39.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_SecurityExchangeName_1956" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1762" xlink:to="us-gaap_ClassOfStockDomain_1763_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CIndUMember" xlink:label="jspr_CIndUMember_1498" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MDSAMLMember" xlink:label="jspr_MDSAMLMember_1500" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PersonnelCosts" xlink:label="jspr_PersonnelCosts_1502" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SCIDMember" xlink:label="jspr_SCIDMember_1499" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1492" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_1506" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1507" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1493" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1491" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_1504" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_BriquilimabPlatformMember" xlink:label="jspr_BriquilimabPlatformMember_1494" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CMOMember" xlink:label="jspr_CMOMember_1495" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CSUMember" xlink:label="jspr_CSUMember_1496" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_FacilitiesAndOverheadCosts" xlink:label="jspr_FacilitiesAndOverheadCosts_1503" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_1505" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_AsthmaMember" xlink:label="jspr_AsthmaMember_1497" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_1501" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1493_default" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_CIndUMember_1498" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_MDSAMLMember_1500" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="jspr_PersonnelCosts_1502" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_SCIDMember_1499" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1491" xlink:to="srt_ProductOrServiceAxis_1492" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="us-gaap_NonoperatingIncomeExpense_1506" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="us-gaap_NetIncomeLoss_1507" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis_1492" xlink:to="srt_ProductsAndServicesDomain_1493" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1491" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="us-gaap_CostOfRevenue_1504" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_BriquilimabPlatformMember_1494" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_CMOMember_1495" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_CSUMember_1496" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="jspr_FacilitiesAndOverheadCosts_1503" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="us-gaap_OperatingExpenses_1505" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_AsthmaMember_1497" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis_1492" xlink:to="srt_ProductsAndServicesDomain_1493_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1082" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1057" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1065" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1058" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1063" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_1060" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1080" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1062" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1081" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_1061" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1059" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1062_default" />
    <link:definitionArc xlink:type="arc" order="28.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1063" xlink:to="us-gaap_StockholdersEquity_1082" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems_1063" xlink:to="us-gaap_StatementTable_1057" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1063" xlink:to="us-gaap_SharesOutstanding_1065" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1057" xlink:to="us-gaap_StatementEquityComponentsAxis_1058" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1062" xlink:to="us-gaap_AdditionalPaidInCapitalMember_1060" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1063" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1080" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis_1058" xlink:to="us-gaap_EquityComponentDomain_1062" />
    <link:definitionArc xlink:type="arc" order="27.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1063" xlink:to="us-gaap_NetIncomeLoss_1081" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1062" xlink:to="us-gaap_RetainedEarningsMember_1061" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1062" xlink:to="us-gaap_CommonStockMember_1059" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis_1058" xlink:to="us-gaap_EquityComponentDomain_1062_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1302" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_1298" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_1296" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_1297" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_1295" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1293" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_1301" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_1300" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1292" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_1300" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1302" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" xlink:to="us-gaap_ComputerEquipmentMember_1298" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" xlink:to="us-gaap_EquipmentMember_1296" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" xlink:to="us-gaap_FurnitureAndFixturesMember_1297" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" xlink:to="us-gaap_LeaseholdImprovementsMember_1295" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1292" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1293" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_1300" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_1301" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_1300" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_1303" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1293" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_1300" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1292" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="true" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1293" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/CirmGrantDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="jspr_CaliforniaInstituteForRegenerativeMedicineMember_1565" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CirmGrantDetailsTable" xlink:label="jspr_CirmGrantDetailsTable_1562" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CirmGrantLineItems" xlink:label="jspr_CirmGrantLineItems_1566" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_NetSales" xlink:label="jspr_NetSales_1569" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentageOfLicensingFees" xlink:label="jspr_PercentageOfLicensingFees_1568" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ReceivedAggregateFromCIRM" xlink:label="jspr_ReceivedAggregateFromCIRM_1572" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1563" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1564" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_1570" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate_1571" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_1573" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1567" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1564_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain_1564" xlink:to="jspr_CaliforniaInstituteForRegenerativeMedicineMember_1565" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="jspr_CirmGrantDetailsTable_1562" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="jspr_NetSales_1569" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="jspr_PercentageOfLicensingFees_1568" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="jspr_ReceivedAggregateFromCIRM_1572" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_CirmGrantDetailsTable_1562" xlink:to="srt_ProductOrServiceAxis_1563" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis_1563" xlink:to="srt_ProductsAndServicesDomain_1564" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_1570" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="us-gaap_InvestmentInterestRate_1571" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_1573" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1567" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis_1563" xlink:to="srt_ProductsAndServicesDomain_1564_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1381" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1383" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1966" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable" xlink:label="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable_1370" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1371" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_1965" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1382" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1380" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1966_default" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1381" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1383" />
    <link:definitionArc xlink:type="arc" order="86.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis_1371" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1966" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" xlink:to="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable_1370" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable_1370" xlink:to="us-gaap_AwardTypeAxis_1371" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1966" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_1965" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1382" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1380" />
    <link:definitionArc xlink:type="arc" order="86.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis_1371" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1966_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesIssuableUponExerciseOfPublicWarrantsMember" xlink:label="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember_1428" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1432" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1424" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1431" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1425" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_1430" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_1427" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1423" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_1426" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_1429" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1425_default" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_1425" xlink:to="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember_1428" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1431" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1432" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1423" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1424" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1424" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1425" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_1425" xlink:to="us-gaap_PerformanceSharesMember_1430" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_1425" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_1427" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1431" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1423" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_1425" xlink:to="us-gaap_StockOptionMember_1426" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_1425" xlink:to="us-gaap_WarrantMember_1429" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1424" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1425_default" />
  </link:definitionLink>
  <link:roleRef roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails1" xlink:href="jspr-20260331.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails1" xlink:type="simple" />
  <link:definitionLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails1" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_1394" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1387" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1393" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:label="us-gaap_StatementOfIncomeLocationBalanceAxis_1983" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceShareUnitsPSUsMember" xlink:label="jspr_PerformanceShareUnitsPSUsMember_1388" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1393" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_1394" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" xlink:to="us-gaap_AwardTypeAxis_1387" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1393" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" />
    <link:definitionArc xlink:type="arc" order="95.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis_1387" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" xlink:to="us-gaap_StatementOfIncomeLocationBalanceAxis_1983" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981" xlink:to="jspr_PerformanceShareUnitsPSUsMember_1388" />
    <link:definitionArc xlink:type="arc" order="95.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis_1387" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981_default" />
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd#eedm1" xlink:type="simple" />
  <link:definitionLink xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" order="0" priority="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>jspr-20260331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract" xlink:label="jspr_ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_WarrantLiabilityMember" xlink:label="jspr_WarrantLiabilityMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract" xlink:label="jspr_ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract" xlink:label="jspr_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable" xlink:label="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SalesMilestonePayments" xlink:label="jspr_SalesMilestonePayments" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SignificantAgreementsDetailsTable" xlink:label="jspr_SignificantAgreementsDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwentyTwentyFourStanfordLicenseAgreementMember" xlink:label="jspr_TwentyTwentyFourStanfordLicenseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwentyTwentyOneStanfordLicenseAgreementMember" xlink:label="jspr_TwentyTwentyOneStanfordLicenseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommitmentsandContingenciesDetailsTable" xlink:label="jspr_CommitmentsandContingenciesDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollateralizedAgreementsAbstract" xlink:label="us-gaap_CollateralizedAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonWarrantsMember" xlink:label="jspr_CommonWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoZeroOneNinePlanMember" xlink:label="jspr_TwoZeroOneNinePlanMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoZeroTwoFourESPPMember" xlink:label="jspr_TwoZeroTwoFourESPPMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoZeroTwoTwoInducementPlanMember" xlink:label="jspr_TwoZeroTwoTwoInducementPlanMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember" xlink:label="jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_UnderwrittenOfferingRemainedAvailable" xlink:label="jspr_UnderwrittenOfferingRemainedAvailable" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_UnderwrittenOfferingsMember" xlink:label="jspr_UnderwrittenOfferingsMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_VotingCommonStockMember" xlink:label="jspr_VotingCommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_VotingCommonStockPercent" xlink:label="jspr_VotingCommonStockPercent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember" xlink:label="jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_OutstandingAndIssuedRestrictedStockUnitsMember" xlink:label="jspr_OutstandingAndIssuedRestrictedStockUnitsMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:label="jspr_ScheduleOfCommonStockReservedForFutureIssuanceAbstract" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember" xlink:label="jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember" xlink:label="jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember" xlink:label="jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember" xlink:label="jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesIssuableUponExerciseOfPublicWarrantsMember" xlink:label="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_EmployeeStockPurchasePlanMember" xlink:label="jspr_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:label="jspr_ScheduleOfStockBasedCompensationExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:label="us-gaap_StatementOfIncomeLocationBalanceAxis" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_AggregateOfferingPrice" xlink:label="jspr_AggregateOfferingPrice" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_AvailableOfferingAmount" xlink:label="jspr_AvailableOfferingAmount" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonStockDetailsTable" xlink:label="jspr_CommonStockDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonWarrantsToPurchaseShares" xlink:label="jspr_CommonWarrantsToPurchaseShares" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_NumberOfSharePurchase" xlink:label="jspr_NumberOfSharePurchase" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PreFundedWarrantsToPurchase" xlink:label="jspr_PreFundedWarrantsToPurchase" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable" xlink:label="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PublicWarrantsMember" xlink:label="jspr_PublicWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PurchaseAnAggregateShares" xlink:label="jspr_PurchaseAnAggregateShares" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceShareUnitsPSUsMember" xlink:label="jspr_PerformanceShareUnitsPSUsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract" xlink:label="jspr_ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable" xlink:label="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_DocumentAndEntityInformationAbstract" xlink:label="jspr_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_VotingCommonStockParValue00001PerShareMember" xlink:label="jspr_VotingCommonStockParValue00001PerShareMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_WarrantsTextBlock" xlink:label="jspr_WarrantsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CIndUMember" xlink:label="jspr_CIndUMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MDSAMLMember" xlink:label="jspr_MDSAMLMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PersonnelCosts" xlink:label="jspr_PersonnelCosts" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SCIDMember" xlink:label="jspr_SCIDMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CirmGrantDisclosureTextBlock" xlink:label="jspr_CirmGrantDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member" xlink:label="jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SeveranceCostsPeriod" xlink:label="jspr_SeveranceCostsPeriod" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringCostsAbstract" xlink:label="us-gaap_RestructuringCostsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_GoingConcernPolicyTextBlock" xlink:label="jspr_GoingConcernPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CirmGrantDisclosureAbstract" xlink:label="jspr_CirmGrantDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PrepaidTravelExpenses" xlink:label="jspr_PrepaidTravelExpenses" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ResearchAndDevelopmentPrepaidExpenses" xlink:label="jspr_ResearchAndDevelopmentPrepaidExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:label="jspr_ScheduleOfPropertyAndEquipmentNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ResearchAndDevelopmentAccruedExpensesCurrent" xlink:label="jspr_ResearchAndDevelopmentAccruedExpensesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="jspr_CaliforniaInstituteForRegenerativeMedicineMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CirmGrantDetailsTable" xlink:label="jspr_CirmGrantDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CirmGrantLineItems" xlink:label="jspr_CirmGrantLineItems" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_NetSales" xlink:label="jspr_NetSales" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentageOfCommonWarrants" xlink:label="jspr_PercentageOfCommonWarrants" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentageOfElectionHolderWarrants" xlink:label="jspr_PercentageOfElectionHolderWarrants" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentagePreFundedWarrants" xlink:label="jspr_PercentagePreFundedWarrants" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PreFundedWarrantPercentage" xlink:label="jspr_PreFundedWarrantPercentage" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PreFundedWarrantsMember" xlink:label="jspr_PreFundedWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_September2025OfferingMember" xlink:label="jspr_September2025OfferingMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_WarrantsDetailsTable" xlink:label="jspr_WarrantsDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidThereafter" xlink:label="jspr_MilestonePaymentsObligationToBePaidThereafter" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentageOfLicensingFees" xlink:label="jspr_PercentageOfLicensingFees" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ReceivedAggregateFromCIRM" xlink:label="jspr_ReceivedAggregateFromCIRM" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ApproximatelyAgreement" xlink:label="jspr_ApproximatelyAgreement" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ClinicalDevelopmentMilestonePayments" xlink:label="jspr_ClinicalDevelopmentMilestonePayments" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_LicenseMaintenanceFee" xlink:label="jspr_LicenseMaintenanceFee" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceBasedStockOptionsMember" xlink:label="jspr_PerformanceBasedStockOptionsMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfStockOptionActivitiesAbstract" xlink:label="jspr_ScheduleOfStockOptionActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfComponentsOfLeaseCostsAbstract" xlink:label="jspr_ScheduleOfComponentsOfLeaseCostsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:label="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_OutstandingAndIssuedCommonStockOptionsMember" xlink:label="jspr_OutstandingAndIssuedCommonStockOptionsMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ValuationOfStockOptionsMember" xlink:label="jspr_ValuationOfStockOptionsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceBasedStockOptionActivity" xlink:label="jspr_PerformanceBasedStockOptionActivity" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceRestrictedStockUnitsMember" xlink:label="jspr_PerformanceRestrictedStockUnitsMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_RecognizedCompensationExpensePeriod" xlink:label="jspr_RecognizedCompensationExpensePeriod" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationDetailsTable" xlink:label="jspr_StockBasedCompensationDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TotalEstimatedFairValue" xlink:label="jspr_TotalEstimatedFairValue" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoThousandTwentyFourPlanMember" xlink:label="jspr_TwoThousandTwentyFourPlanMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfRsuActivityAbstract" xlink:label="jspr_ScheduleOfRsuActivityAbstract" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable" xlink:label="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_BriquilimabPlatformMember" xlink:label="jspr_BriquilimabPlatformMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CMOMember" xlink:label="jspr_CMOMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CSUMember" xlink:label="jspr_CSUMember" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_FacilitiesAndOverheadCosts" xlink:label="jspr_FacilitiesAndOverheadCosts" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:label="jspr_ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract" xlink:label="jspr_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CondensedFinancialStatementsTextBlock" xlink:label="srt_CondensedFinancialStatementsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_AsthmaMember" xlink:label="jspr_AsthmaMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract" xlink:to="jspr_ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_WarrantLiabilityMember" xlink:to="jspr_WarrantLiabilityMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract" xlink:to="jspr_ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract" xlink:to="jspr_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable" xlink:to="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear" xlink:to="jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear" xlink:to="jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_SalesMilestonePayments" xlink:to="jspr_SalesMilestonePayments_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_SignificantAgreementsDetailsTable" xlink:to="jspr_SignificantAgreementsDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_TwentyTwentyFourStanfordLicenseAgreementMember" xlink:to="jspr_TwentyTwentyFourStanfordLicenseAgreementMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_TwentyTwentyOneStanfordLicenseAgreementMember" xlink:to="jspr_TwentyTwentyOneStanfordLicenseAgreementMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CommitmentsandContingenciesDetailsTable" xlink:to="jspr_CommitmentsandContingenciesDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralizedAgreementsAbstract" xlink:to="us-gaap_CollateralizedAgreementsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CommonWarrantsMember" xlink:to="jspr_CommonWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_TwoZeroOneNinePlanMember" xlink:to="jspr_TwoZeroOneNinePlanMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_TwoZeroTwoFourESPPMember" xlink:to="jspr_TwoZeroTwoFourESPPMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_TwoZeroTwoTwoInducementPlanMember" xlink:to="jspr_TwoZeroTwoTwoInducementPlanMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember" xlink:to="jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_UnderwrittenOfferingRemainedAvailable" xlink:to="jspr_UnderwrittenOfferingRemainedAvailable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_UnderwrittenOfferingsMember" xlink:to="jspr_UnderwrittenOfferingsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_VotingCommonStockMember" xlink:to="jspr_VotingCommonStockMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_VotingCommonStockPercent" xlink:to="jspr_VotingCommonStockPercent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember" xlink:to="jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_OutstandingAndIssuedRestrictedStockUnitsMember" xlink:to="jspr_OutstandingAndIssuedRestrictedStockUnitsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:to="jspr_ScheduleOfCommonStockReservedForFutureIssuanceAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember" xlink:to="jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember" xlink:to="jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember" xlink:to="jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember" xlink:to="jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember" xlink:to="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_EmployeeStockPurchasePlanMember" xlink:to="jspr_EmployeeStockPurchasePlanMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="jspr_ScheduleOfStockBasedCompensationExpenseAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:to="us-gaap_StatementOfIncomeLocationBalanceAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_AggregateOfferingPrice" xlink:to="jspr_AggregateOfferingPrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_AvailableOfferingAmount" xlink:to="jspr_AvailableOfferingAmount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CommonStockDetailsTable" xlink:to="jspr_CommonStockDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CommonWarrantsToPurchaseShares" xlink:to="jspr_CommonWarrantsToPurchaseShares_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_NumberOfSharePurchase" xlink:to="jspr_NumberOfSharePurchase_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PreFundedWarrantsToPurchase" xlink:to="jspr_PreFundedWarrantsToPurchase_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable" xlink:to="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PublicWarrantsMember" xlink:to="jspr_PublicWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PurchaseAnAggregateShares" xlink:to="jspr_PurchaseAnAggregateShares_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PerformanceShareUnitsPSUsMember" xlink:to="jspr_PerformanceShareUnitsPSUsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract" xlink:to="jspr_ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable" xlink:to="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_DocumentAndEntityInformationAbstract" xlink:to="jspr_DocumentAndEntityInformationAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_VotingCommonStockParValue00001PerShareMember" xlink:to="jspr_VotingCommonStockParValue00001PerShareMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_WarrantsTextBlock" xlink:to="jspr_WarrantsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CIndUMember" xlink:to="jspr_CIndUMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_MDSAMLMember" xlink:to="jspr_MDSAMLMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PersonnelCosts" xlink:to="jspr_PersonnelCosts_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_SCIDMember" xlink:to="jspr_SCIDMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CirmGrantDisclosureTextBlock" xlink:to="jspr_CirmGrantDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member" xlink:to="jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_SeveranceCostsPeriod" xlink:to="jspr_SeveranceCostsPeriod_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostsAbstract" xlink:to="us-gaap_RestructuringCostsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_GoingConcernPolicyTextBlock" xlink:to="jspr_GoingConcernPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CirmGrantDisclosureAbstract" xlink:to="jspr_CirmGrantDisclosureAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PrepaidTravelExpenses" xlink:to="jspr_PrepaidTravelExpenses_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ResearchAndDevelopmentPrepaidExpenses" xlink:to="jspr_ResearchAndDevelopmentPrepaidExpenses_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="jspr_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ResearchAndDevelopmentAccruedExpensesCurrent" xlink:to="jspr_ResearchAndDevelopmentAccruedExpensesCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CaliforniaInstituteForRegenerativeMedicineMember" xlink:to="jspr_CaliforniaInstituteForRegenerativeMedicineMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CirmGrantDetailsTable" xlink:to="jspr_CirmGrantDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CirmGrantLineItems" xlink:to="jspr_CirmGrantLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_NetSales" xlink:to="jspr_NetSales_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PercentageOfCommonWarrants" xlink:to="jspr_PercentageOfCommonWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PercentageOfElectionHolderWarrants" xlink:to="jspr_PercentageOfElectionHolderWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PercentagePreFundedWarrants" xlink:to="jspr_PercentagePreFundedWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PreFundedWarrantPercentage" xlink:to="jspr_PreFundedWarrantPercentage_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PreFundedWarrantsMember" xlink:to="jspr_PreFundedWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_September2025OfferingMember" xlink:to="jspr_September2025OfferingMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_WarrantsDetailsTable" xlink:to="jspr_WarrantsDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear" xlink:to="jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear" xlink:to="jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_MilestonePaymentsObligationToBePaidThereafter" xlink:to="jspr_MilestonePaymentsObligationToBePaidThereafter_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PercentageOfLicensingFees" xlink:to="jspr_PercentageOfLicensingFees_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ReceivedAggregateFromCIRM" xlink:to="jspr_ReceivedAggregateFromCIRM_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ApproximatelyAgreement" xlink:to="jspr_ApproximatelyAgreement_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ClinicalDevelopmentMilestonePayments" xlink:to="jspr_ClinicalDevelopmentMilestonePayments_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_LicenseMaintenanceFee" xlink:to="jspr_LicenseMaintenanceFee_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PerformanceBasedStockOptionsMember" xlink:to="jspr_PerformanceBasedStockOptionsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfStockOptionActivitiesAbstract" xlink:to="jspr_ScheduleOfStockOptionActivitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfComponentsOfLeaseCostsAbstract" xlink:to="jspr_ScheduleOfComponentsOfLeaseCostsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvotingCommonStockMember" xlink:to="us-gaap_NonvotingCommonStockMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_OutstandingAndIssuedCommonStockOptionsMember" xlink:to="jspr_OutstandingAndIssuedCommonStockOptionsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ValuationOfStockOptionsMember" xlink:to="jspr_ValuationOfStockOptionsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PerformanceBasedStockOptionActivity" xlink:to="jspr_PerformanceBasedStockOptionActivity_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_PerformanceRestrictedStockUnitsMember" xlink:to="jspr_PerformanceRestrictedStockUnitsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_RecognizedCompensationExpensePeriod" xlink:to="jspr_RecognizedCompensationExpensePeriod_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_StockBasedCompensationDetailsTable" xlink:to="jspr_StockBasedCompensationDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_TotalEstimatedFairValue" xlink:to="jspr_TotalEstimatedFairValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_TwoThousandTwentyFourPlanMember" xlink:to="jspr_TwoThousandTwentyFourPlanMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfRsuActivityAbstract" xlink:to="jspr_ScheduleOfRsuActivityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable" xlink:to="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_BriquilimabPlatformMember" xlink:to="jspr_BriquilimabPlatformMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CMOMember" xlink:to="jspr_CMOMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_CSUMember" xlink:to="jspr_CSUMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_FacilitiesAndOverheadCosts" xlink:to="jspr_FacilitiesAndOverheadCosts_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="jspr_ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract" xlink:to="jspr_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_InterestCostsIncurred_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsTextBlock" xlink:to="srt_CondensedFinancialStatementsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jspr_AsthmaMember" xlink:to="jspr_AsthmaMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of RSU Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Option Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-Based Compensation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Loss Per Share Attributable to Common Stockholders [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimate The Fair Value Of The Warrant Liability Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value, as of beginning</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value, as of ending</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of financial liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Changes in the Company&#8217;s Warrant Liability [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_WarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_WarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Changes In The Company SWarrant Liability Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Asset (Liability) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Financial Assets and Liabilities Measured on a Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Financial Assets And Liabilities Measured On ARecurring Basis Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of the period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of the period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments obligation to be paid third and fourth year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Obligation To Be Paid Third And Fourth Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments obligation to be paid third and fourth year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price per shares (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments obligation to be paid first and second year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Obligation To Be Paid First And Second Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments obligation to be paid first and second year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of sales milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SignificantAgreementsDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Agreements (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwentyTwentyFourStanfordLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Stanford License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwentyTwentyFourStanfordLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty Four Stanford License Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwentyTwentyOneStanfordLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Stanford License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwentyTwentyOneStanfordLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty One Stanford License Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant liability (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CommitmentsandContingenciesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory and office space area of land (in Square Feet)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Land</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollateralizedAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostMaintenance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostMaintenance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost, Maintenance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Warrants Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Fair value of warrant liability (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional paid-in capital (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwoZeroOneNinePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwoZeroOneNinePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero One Nine Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwoZeroTwoFourESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2024 ESPP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwoZeroTwoFourESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero Two Four ESPPMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwoZeroTwoTwoInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Inducement Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwoZeroTwoTwoInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero Two Two Inducement Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for grant under Equity Incentive Plans [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Grant Under Equity Incentive Plans Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_UnderwrittenOfferingRemainedAvailable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remained available</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_UnderwrittenOfferingRemainedAvailable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Offering Remained Available</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_UnderwrittenOfferingRemainedAvailable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of underwritten offering remained available.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_UnderwrittenOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_UnderwrittenOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Offerings Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_VotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_VotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting Common Stock Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_VotingCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting common stock percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_VotingCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting Common Stock Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_VotingCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of voting common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Common Stock Reserved for Future Issuance [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Voting common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares subject to performance-based awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions common stock fair value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Volatility rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk free rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-Based Compensation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock Option Activities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding and issued performance-based restricted stock units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding And Issued Performancebased Restricted Stock Units Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_OutstandingAndIssuedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding and issued restricted stock units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_OutstandingAndIssuedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding And Issued Restricted Stock Units Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfCommonStockReservedForFutureIssuanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for grant under 2022 Inducement Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Grant Under2022 Inducement Equity Incentive Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for grant under Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Grant Under Employee Stock Purchase Plans Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issuable upon exercise of Common Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issuable Upon Exercise Of Common Stock Warrants Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issuable upon exercise of Pre-Funded Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issuable Upon Exercise Of Pre Funded Warrants Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issuable upon exercise of Public Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issuable Upon Exercise Of Public Warrants Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares of common stock reserved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfStockBasedCompensationExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock Based Compensation Expense Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock-Based Compensation Expense [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeLocationBalanceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Location, Statement of Income, Balance [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_AggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_AggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Offering Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_AggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate offering price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_AvailableOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available offering amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_AvailableOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available Offering Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_AvailableOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of available offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CommonStockDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CommonWarrantsToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common warrants to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CommonWarrantsToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Warrants To Purchase Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CommonWarrantsToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common warrants to purchase shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_NumberOfSharePurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of share of voting common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_NumberOfSharePurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Share Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_NumberOfSharePurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The share purchased.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PreFundedWarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre funded warrants to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PreFundedWarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants To Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PreFundedWarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of pre funded warrants to purchase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-Based Compensation - Schedule of Stock Option Activities (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserved share issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Contract [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PurchaseAnAggregateShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase an aggregate shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PurchaseAnAggregateShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase An Aggregate Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PurchaseAnAggregateShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of purchase an aggregate shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PerformanceShareUnitsPSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PSUs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PerformanceShareUnitsPSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Share Units PSUs Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock remained outstanding and unexercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life (Years), Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Of Stock Options Was Estimated Using ABlack Scholes Option Pricing Model Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-Based Compensation - Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label"></link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_VotingCommonStockParValue00001PerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting Common Stock, par value $0.0001 per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_VotingCommonStockParValue00001PerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting Common Stock Par Value00001 Per Share Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization and Description of Business [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SIGNIFICANT AGREEMENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_WarrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WARRANTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_WarrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_WarrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entity disclosure of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CIndUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIndU [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CIndUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CInd UMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MDSAMLMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MDS/AML [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MDSAMLMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MDSAMLMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel-related costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of personnel costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SCIDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SCID [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SCIDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SCIDMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CirmGrantDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIRM GRANT</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CirmGrantDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cirm Grant Disclosure Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CirmGrantDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure about Cirm Grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows provided by investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset obtained in exchange for lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use asset and lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental and non-cash items reconciliations:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Parties [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Warrants Each Whole Warrant Exercisable For One Share Of Voting Common Stock At An Exercise Price Of1150 Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in the Company&#8217;s Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders &#8211; basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders &#8211; diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, diluted (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common shares and pre-funded warrant shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring charges related to workforce reduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued severance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Asset Impairment Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SeveranceCostsPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance costs period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SeveranceCostsPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_SeveranceCostsPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance costs period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total program costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FAIR VALUE MEASUREMENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern Policy Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for going concern.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CirmGrantDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cirm Grant [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEGMENT INFORMATION</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PrepaidTravelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid travel expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PrepaidTravelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Travel Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PrepaidTravelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of prepaid travel expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ResearchAndDevelopmentPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ResearchAndDevelopmentPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Prepaid Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ResearchAndDevelopmentPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of research and development prepaid expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other prepaid expenses and current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Prepaid Expenses and Other Current Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property And Equipment Net Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office furniture &amp; fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Property and Equipment, Net [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ResearchAndDevelopmentAccruedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ResearchAndDevelopmentAccruedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Accrued Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ResearchAndDevelopmentAccruedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of research and development accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Expenses and Other Current Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal and professional expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued employee and related compensation expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIRM [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Institute For Regenerative Medicine Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CirmGrantDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cirm Grant (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CirmGrantLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cirm Grant [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_NetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_NetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_NetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent of net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentageOfCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentageOfCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentageOfCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentageOfElectionHolderWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of election holder warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentageOfElectionHolderWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Election Holder Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentageOfElectionHolderWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of election holder warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentagePreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentagePreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Pre Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentagePreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage pre-funded warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PreFundedWarrantPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre funded warrant percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PreFundedWarrantPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrant Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PreFundedWarrantPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre funded warrant percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_September2025OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 2025 Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_September2025OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September2025 Offering Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_WarrantsDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)	[Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Option Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Share Price [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimate the fair value of the warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Consolidated Balance Sheet Components [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments obligation to be paid first through third year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Obligation To Be Paid First Through Third Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of milestone payments obligation to be paid first through the third year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments obligation to be paid fourth through sixth year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Obligation To Be Paid Fourth Through Sixth Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments obligation to be paid fourth through sixth year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments obligation to be paid thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Obligation To Be Paid Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_MilestonePaymentsObligationToBePaidThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments obligation to be paid thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentageOfLicensingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of licensing fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentageOfLicensingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Licensing Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PercentageOfLicensingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The 25% rule can be used as a starting point for valuing and setting fair royalty rates for intellectual property assets including copyrights, trademarks and patents in licensing deals. It is an example of an income-based approach licensing fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ReceivedAggregateFromCIRM_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Received aggregate from CIRM</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ReceivedAggregateFromCIRM_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Received Aggregate From CIRM</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ReceivedAggregateFromCIRM_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of revenue and income classified as other.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of converted loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Received from interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">CIRM grant received in other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ApproximatelyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Approximately agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ApproximatelyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Approximately Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ApproximatelyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Approximately agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ClinicalDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical development milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ClinicalDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ClinicalDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of clinical development milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_LicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_LicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_LicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of license maintenance fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of the options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value option vested amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average grant date fair value price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding and issued common stock options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-Based Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Stock Options Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfStockOptionActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock Option Activities Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Grant Date Fair Value, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Grant Date Fair Value, Unvested restricted stock units, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Grant Date Fair Value, Unvested restricted stock units, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life (Years), Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Outstanding, Options cancelled/forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured letter of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Other Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfComponentsOfLeaseCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Lease Costs [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026 (remainder of the year)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total discounted lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less current portion of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Noncurrent portion of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sell from time to time</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Voting Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvoting Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issuable upon exercise of Common Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock - Schedule of Common Stock Reserved for Future Issuance (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_OutstandingAndIssuedCommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding and issued common stock options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_OutstandingAndIssuedCommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding And Issued Common Stock Options Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ValuationOfStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation of Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ValuationOfStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Of Stock Options Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PerformanceBasedStockOptionActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based stock option activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PerformanceBasedStockOptionActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PerformanceBasedStockOptionActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares performance based stock option activity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PerformanceRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Performance Restricted Stock Units (PSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_PerformanceRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Restricted Stock Units Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_RecognizedCompensationExpensePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized compensation expense period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_RecognizedCompensationExpensePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognized Compensation Expense Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_RecognizedCompensationExpensePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognized compensation expense period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_StockBasedCompensationDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-Based Compensation (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TotalEstimatedFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TotalEstimatedFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TotalEstimatedFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwoThousandTwentyFourPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_TwoThousandTwentyFourPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life (Years), Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options cancelled/forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfRsuActivityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Rsu Activity Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-Based Compensation - Schedule of RSU Activity (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of RSU Activity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding and issued restricted stock units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Share, Unvested restricted stock units, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Share, Unvested restricted stock units, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Share, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief operating decision segment manages description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_BriquilimabPlatformMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Briquilimab platform [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_BriquilimabPlatformMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Briquilimab Platform Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CMOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CMO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CMOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CMOMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CSU [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_CSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CSUMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_FacilitiesAndOverheadCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and overhead costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_FacilitiesAndOverheadCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Facilities And Overhead Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_FacilitiesAndOverheadCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of facilities and overhead costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Significant Expense Categories Included Within Net Loss Presented On The Company SCondensed Consolidated Statements Of Operations And Comprehensive Loss Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Diluted Net Loss Per Share Attributable To Common Stockholders Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Antidilutive net loss per share attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested performance-based restricted stock units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Costs Incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of reportable segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COMMON STOCK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCK-BASED COMPENSATION</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RESTRUCTURING</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock: $0.0001 par value &#8212; 492,000,000 shares authorized at March 31, 2026 and December 31, 2025; 27,996,819 shares issued and outstanding at March 31, 2026 and December 31, 2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 8)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedFinancialStatementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONDENSED CONSOLIDATED BALANCE SHEET COMPONENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedFinancialStatementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Statements [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RELATED PARTIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares used to compute diluted net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares used to compute basic net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_AsthmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asthma [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="jspr_AsthmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asthma Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Significant Expense Categories Included Within Net Loss Presented on the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock: $0.0001 par value &#8212; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; none issued and outstanding at March 31, 2026 and December 31, 2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimate the Fair Value of the Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares, Contingently Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Liabilities Measured on a Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Lease Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>jspr-20260331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#DocumentAndEntityInformation" roleURI="http://jaspertx.com/20260331/role/DocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParentheticals" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#OrganizationandDescriptionofBusiness" roleURI="http://jaspertx.com/20260331/role/OrganizationandDescriptionofBusiness" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#SummaryofSignificantAccountingPolicies" roleURI="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#FairValueMeasurements" roleURI="http://jaspertx.com/20260331/role/FairValueMeasurements" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetComponents" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponents" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CirmGrant" roleURI="http://jaspertx.com/20260331/role/CirmGrant" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#SignificantAgreements" roleURI="http://jaspertx.com/20260331/role/SignificantAgreements" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#Warrants" roleURI="http://jaspertx.com/20260331/role/Warrants" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CommitmentsandContingencies" roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingencies" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CommonStock" roleURI="http://jaspertx.com/20260331/role/CommonStock" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#StockBasedCompensation" roleURI="http://jaspertx.com/20260331/role/StockBasedCompensation" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#NetLossPerShareAttributabletoCommonStockholders" roleURI="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholders" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#RelatedParties" roleURI="http://jaspertx.com/20260331/role/RelatedParties" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#SegmentInformation" roleURI="http://jaspertx.com/20260331/role/SegmentInformation" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#Restructuring" roleURI="http://jaspertx.com/20260331/role/Restructuring" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#AccountingPoliciesbyPolicyPolicies" roleURI="http://jaspertx.com/20260331/role/AccountingPoliciesbyPolicyPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#SummaryofSignificantAccountingPoliciesTables" roleURI="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#FairValueMeasurementsTables" roleURI="http://jaspertx.com/20260331/role/FairValueMeasurementsTables" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#ConsolidatedBalanceSheetComponentsTables" roleURI="http://jaspertx.com/20260331/role/ConsolidatedBalanceSheetComponentsTables" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CommitmentsandContingenciesTables" roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingenciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CommonStockTables" roleURI="http://jaspertx.com/20260331/role/CommonStockTables" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#StockBasedCompensationTables" roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationTables" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#NetLossPerShareAttributabletoCommonStockholdersTables" roleURI="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersTables" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#SegmentInformationTables" roleURI="http://jaspertx.com/20260331/role/SegmentInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails" roleURI="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails" roleURI="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails" roleURI="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsDetails" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CirmGrantDetails" roleURI="http://jaspertx.com/20260331/role/CirmGrantDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#SignificantAgreementsDetails" roleURI="http://jaspertx.com/20260331/role/SignificantAgreementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#WarrantsDetails" roleURI="http://jaspertx.com/20260331/role/WarrantsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CommitmentsandContingenciesDetails" roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails" roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails" roleURI="http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CommonStockDetails" roleURI="http://jaspertx.com/20260331/role/CommonStockDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails" roleURI="http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#StockBasedCompensationDetails" roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#StockBasedCompensationScheduleofStockOptionActivitiesDetails" roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#StockBasedCompensationScheduleofRSUActivityDetails" roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails" roleURI="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#NetLossPerShareAttributabletoCommonStockholdersDetails" roleURI="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" roleURI="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" roleURI="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#RelatedPartiesDetails" roleURI="http://jaspertx.com/20260331/role/RelatedPartiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#SegmentInformationDetails" roleURI="http://jaspertx.com/20260331/role/SegmentInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails" roleURI="http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails" />
  <link:roleRef xlink:type="simple" xlink:href="jspr-20260331.xsd#RestructuringDetails" roleURI="http://jaspertx.com/20260331/role/RestructuringDetails" />
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CommonStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1215" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_1216" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1215" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_1216" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1221" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1220" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1219" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1222" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1218" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1218" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1221" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1218" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1220" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1218" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1219" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1218" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1222" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1224" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1226" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1225" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1224" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1226" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1224" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1225" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/SegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1235" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1234" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1234" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1235" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1281" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract" xlink:label="jspr_ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract_1274" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1275" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_1278" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_1279" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_1280" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_1277" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1276" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1979" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1282" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1275" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1281" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract_1274" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1275" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_1979" xlink:to="us-gaap_MeasurementInputExpectedTermMember_1278" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_1979" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_1279" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_1979" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_1280" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_1979" xlink:to="us-gaap_MeasurementInputSharePriceMember_1277" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1275" xlink:to="us-gaap_MeasurementInputTypeAxis_1276" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="93.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_1276" xlink:to="us-gaap_MeasurementInputTypeDomain_1979" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1281" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1282" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_1269" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_1272" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_1271" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1265" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1268" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1978" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1266" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_WarrantLiabilityMember" xlink:label="jspr_WarrantLiabilityMember_1267" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract" xlink:label="jspr_ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract_1264" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1268" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_1269" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1268" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_1272" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1268" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_1271" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract_1264" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1265" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1265" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1268" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="92.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1266" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1978" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1265" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1266" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1978" xlink:to="jspr_WarrantLiabilityMember_1267" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1250" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_1251" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_1262" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_1261" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_1248" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1977" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_1257" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_1256" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_1255" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1247" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1253" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1258" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1249" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_1259" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_1260" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_WarrantLiabilityMember" xlink:label="jspr_WarrantLiabilityMember_1252" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract" xlink:label="jspr_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract_1245" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable" xlink:label="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_1246" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1249" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1250" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1250" xlink:to="us-gaap_MoneyMarketFundsMember_1251" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract_1261" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_1262" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1258" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_1261" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_1977" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_1248" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1253" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="91.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1247" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1977" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254" xlink:to="us-gaap_FairValueInputsLevel3Member_1257" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254" xlink:to="us-gaap_FairValueInputsLevel2Member_1256" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1254" xlink:to="us-gaap_FairValueInputsLevel1Member_1255" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_1246" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_1247" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_1246" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_1253" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_1246" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1258" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_1246" xlink:to="us-gaap_CashAndCashEquivalentsAxis_1249" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1258" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_1259" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_1259" xlink:to="us-gaap_AssetsFairValueDisclosure_1260" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1250" xlink:to="jspr_WarrantLiabilityMember_1252" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract_1245" xlink:to="jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable_1246" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_1242" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_1240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1243" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_1241" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract_1240" xlink:to="us-gaap_RestrictedCashNoncurrent_1242" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract_1240" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1243" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract_1240" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_1241" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_1539" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1537" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_1538" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_1540" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1530" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1530" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_1539" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1530" xlink:to="us-gaap_NetIncomeLoss_1537" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1530" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_1538" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1530" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_1540" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/SignificantAgreementsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear_1583" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear_1582" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SalesMilestonePayments" xlink:label="jspr_SalesMilestonePayments_1585" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SignificantAgreementsDetailsTable" xlink:label="jspr_SignificantAgreementsDetailsTable_1576" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwentyTwentyFourStanfordLicenseAgreementMember" xlink:label="jspr_TwentyTwentyFourStanfordLicenseAgreementMember_1580" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwentyTwentyOneStanfordLicenseAgreementMember" xlink:label="jspr_TwentyTwentyOneStanfordLicenseAgreementMember_1579" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1578" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollateralizedAgreementsAbstract" xlink:label="us-gaap_CollateralizedAgreementsAbstract_1575" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance_1586" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_1958" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1577" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear_1589" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear" xlink:label="jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear_1590" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MilestonePaymentsObligationToBePaidThereafter" xlink:label="jspr_MilestonePaymentsObligationToBePaidThereafter_1584" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ApproximatelyAgreement" xlink:label="jspr_ApproximatelyAgreement_1587" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ClinicalDevelopmentMilestonePayments" xlink:label="jspr_ClinicalDevelopmentMilestonePayments_1591" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_LicenseMaintenanceFee" xlink:label="jspr_LicenseMaintenanceFee_1588" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear_1583" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear_1582" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_SalesMilestonePayments_1585" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralizedAgreementsAbstract_1575" xlink:to="jspr_SignificantAgreementsDetailsTable_1576" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1578" xlink:to="jspr_TwentyTwentyFourStanfordLicenseAgreementMember_1580" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1578" xlink:to="jspr_TwentyTwentyOneStanfordLicenseAgreementMember_1579" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_1577" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1578" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="us-gaap_CostMaintenance_1586" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="81.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_1958" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_SignificantAgreementsDetailsTable_1576" xlink:to="us-gaap_TypeOfArrangementAxis_1577" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_SignificantAgreementsDetailsTable_1576" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear_1589" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear_1590" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_MilestonePaymentsObligationToBePaidThereafter_1584" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_ApproximatelyAgreement_1587" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_ClinicalDevelopmentMilestonePayments_1591" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1581" xlink:to="jspr_LicenseMaintenanceFee_1588" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/WarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1599" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1606" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1593" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_1612" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonWarrantsMember" xlink:label="jspr_CommonWarrantsMember_1601" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_1605" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1597" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_1613" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_1610" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1596" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1598" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_1603" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1595" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1604" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentageOfCommonWarrants" xlink:label="jspr_PercentageOfCommonWarrants_1611" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentageOfElectionHolderWarrants" xlink:label="jspr_PercentageOfElectionHolderWarrants_1608" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentagePreFundedWarrants" xlink:label="jspr_PercentagePreFundedWarrants_1609" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PreFundedWarrantPercentage" xlink:label="jspr_PreFundedWarrantPercentage_1607" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PreFundedWarrantsMember" xlink:label="jspr_PreFundedWarrantsMember_1602" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_September2025OfferingMember" xlink:label="jspr_September2025OfferingMember_1600" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_WarrantsDetailsTable" xlink:label="jspr_WarrantsDetailsTable_1594" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1598" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1599" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1606" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_WarrantsAndRightsOutstanding_1612" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1599" xlink:to="jspr_CommonWarrantsMember_1601" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_1605" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1596" xlink:to="us-gaap_CommonStockMember_1597" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_1613" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_AdditionalPaidInCapital_1610" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1595" xlink:to="us-gaap_ClassOfStockDomain_1596" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_WarrantsDetailsTable_1594" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1598" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_WarrantsDetailsTable_1594" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_1603" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_WarrantsDetailsTable_1594" xlink:to="us-gaap_StatementClassOfStockAxis_1595" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1604" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="jspr_PercentageOfCommonWarrants_1611" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="jspr_PercentageOfElectionHolderWarrants_1608" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="jspr_PercentagePreFundedWarrants_1609" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1603" xlink:to="jspr_PreFundedWarrantPercentage_1607" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1599" xlink:to="jspr_PreFundedWarrantsMember_1602" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1599" xlink:to="jspr_September2025OfferingMember_1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1593" xlink:to="jspr_WarrantsDetailsTable_1594" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommitmentsandContingenciesDetailsTable" xlink:label="jspr_CommitmentsandContingenciesDetailsTable_1616" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand_1618" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1615" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_1620" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent_1619" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_1622" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_1617" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees_1625" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties_1624" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1621" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1615" xlink:to="jspr_CommitmentsandContingenciesDetailsTable_1616" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1617" xlink:to="us-gaap_AreaOfLand_1618" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1617" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_1620" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1617" xlink:to="us-gaap_LinesOfCreditCurrent_1619" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1617" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_1622" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CommitmentsandContingenciesDetailsTable_1616" xlink:to="us-gaap_OtherCommitmentsLineItems_1617" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1617" xlink:to="us-gaap_PaymentsForFees_1625" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1617" xlink:to="us-gaap_PaymentsForRoyalties_1624" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1617" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1621" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoZeroOneNinePlanMember" xlink:label="jspr_TwoZeroOneNinePlanMember_1675" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoZeroTwoFourESPPMember" xlink:label="jspr_TwoZeroTwoFourESPPMember_1677" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoZeroTwoTwoInducementPlanMember" xlink:label="jspr_TwoZeroTwoTwoInducementPlanMember_1673" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1712" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1702" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1701" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1671" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1672" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1669" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1695" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_1704" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1705" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1708" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1706" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1707" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_EmployeeStockPurchasePlanMember" xlink:label="jspr_EmployeeStockPurchasePlanMember_1685" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_1713" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1681" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1692" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_1697" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_1679" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_1678" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1693" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1698" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1694" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1699" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1700" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1710" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1711" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_1680" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceBasedStockOptionActivity" xlink:label="jspr_PerformanceBasedStockOptionActivity_1972" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceBasedStockOptionsMember" xlink:label="jspr_PerformanceBasedStockOptionsMember_1684" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceRestrictedStockUnitsMember" xlink:label="jspr_PerformanceRestrictedStockUnitsMember_1686" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_RecognizedCompensationExpensePeriod" xlink:label="jspr_RecognizedCompensationExpensePeriod_1996" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationDetailsTable" xlink:label="jspr_StockBasedCompensationDetailsTable_1670" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TotalEstimatedFairValue" xlink:label="jspr_TotalEstimatedFairValue_1995" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_TwoThousandTwentyFourPlanMember" xlink:label="jspr_TwoThousandTwentyFourPlanMember_1674" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1672" xlink:to="jspr_TwoZeroOneNinePlanMember_1675" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1672" xlink:to="jspr_TwoZeroTwoFourESPPMember_1677" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1672" xlink:to="jspr_TwoZeroTwoTwoInducementPlanMember_1673" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="34.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1712" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1702" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1701" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_StockBasedCompensationDetailsTable_1670" xlink:to="us-gaap_PlanNameAxis_1671" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_1671" xlink:to="us-gaap_PlanNameDomain_1672" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1703" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1695" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_1704" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1705" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1708" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1706" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1707" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_StockBasedCompensationDetailsTable_1670" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682" xlink:to="jspr_EmployeeStockPurchasePlanMember_1685" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="35.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_1713" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_StockBasedCompensationDetailsTable_1670" xlink:to="us-gaap_AwardTypeAxis_1681" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1692" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_1697" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_1678" xlink:to="us-gaap_DerivativeContractTypeDomain_1679" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_StockBasedCompensationDetailsTable_1670" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_1678" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1693" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1698" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1694" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1699" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_1681" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="32.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1710" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="33.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1711" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_1679" xlink:to="us-gaap_StockOptionMember_1680" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="87.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="jspr_PerformanceBasedStockOptionActivity_1972" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682" xlink:to="jspr_PerformanceBasedStockOptionsMember_1684" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1682" xlink:to="jspr_PerformanceRestrictedStockUnitsMember_1686" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="105.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="jspr_RecognizedCompensationExpensePeriod_1996" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1669" xlink:to="jspr_StockBasedCompensationDetailsTable_1670" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="104.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1687" xlink:to="jspr_TotalEstimatedFairValue_1995" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1672" xlink:to="jspr_TwoThousandTwentyFourPlanMember_1674" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_1650" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1964" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_1962" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_UnderwrittenOfferingRemainedAvailable" xlink:label="jspr_UnderwrittenOfferingRemainedAvailable_1660" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_UnderwrittenOfferingsMember" xlink:label="jspr_UnderwrittenOfferingsMember_1632" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_VotingCommonStockMember" xlink:label="jspr_VotingCommonStockMember_1635" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_VotingCommonStockPercent" xlink:label="jspr_VotingCommonStockPercent_1652" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1634" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_1644" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1641" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1642" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1961" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_1653" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1637" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_1645" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_1647" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_1648" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1628" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_AggregateOfferingPrice" xlink:label="jspr_AggregateOfferingPrice_1657" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_AvailableOfferingAmount" xlink:label="jspr_AvailableOfferingAmount_1667" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonStockDetailsTable" xlink:label="jspr_CommonStockDetailsTable_1629" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonWarrantsToPurchaseShares" xlink:label="jspr_CommonWarrantsToPurchaseShares_1665" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_NumberOfSharePurchase" xlink:label="jspr_NumberOfSharePurchase_1651" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PreFundedWarrantsToPurchase" xlink:label="jspr_PreFundedWarrantsToPurchase_1664" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PublicWarrantsMember" xlink:label="jspr_PublicWarrantsMember_1963" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PurchaseAnAggregateShares" xlink:label="jspr_PurchaseAnAggregateShares_1654" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi_1656" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember_1636" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_1646" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_1649" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1631" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1658" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1633" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_1663" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1630" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_1643" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_PreferredStockSharesOutstanding_1650" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="33.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1964" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_1962" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_UnderwrittenOfferingRemainedAvailable_1660" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1631" xlink:to="jspr_UnderwrittenOfferingsMember_1632" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1634" xlink:to="jspr_VotingCommonStockMember_1635" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_VotingCommonStockPercent_1652" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1633" xlink:to="us-gaap_ClassOfStockDomain_1634" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CommonStockDetailsTable_1629" xlink:to="us-gaap_ClassOfStockLineItems_1644" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CommonStockDetailsTable_1629" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1641" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1641" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1642" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1961" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_1653" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1634" xlink:to="us-gaap_CommonStockMember_1637" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_CommonStockSharesAuthorized_1645" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_CommonStockSharesIssued_1647" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_CommonStockSharesOutstanding_1648" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_AggregateOfferingPrice_1657" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="32.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_AvailableOfferingAmount_1667" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1628" xlink:to="jspr_CommonStockDetailsTable_1629" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="31.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_CommonWarrantsToPurchaseShares_1665" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_NumberOfSharePurchase_1651" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_PreFundedWarrantsToPurchase_1664" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1642" xlink:to="jspr_PublicWarrantsMember_1963" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="jspr_PurchaseAnAggregateShares_1654" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_EquitySecuritiesFvNi_1656" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1634" xlink:to="us-gaap_NonvotingCommonStockMember_1636" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_PreferredStockSharesAuthorized_1646" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_PreferredStockSharesIssued_1649" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1630" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1631" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1658" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CommonStockDetailsTable_1629" xlink:to="us-gaap_StatementClassOfStockAxis_1633" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1644" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_1663" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CommonStockDetailsTable_1629" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1630" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1642" xlink:to="us-gaap_WarrantMember_1643" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember" xlink:label="jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember_1340" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember" xlink:label="jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember_1336" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_OutstandingAndIssuedRestrictedStockUnitsMember" xlink:label="jspr_OutstandingAndIssuedRestrictedStockUnitsMember_1335" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:label="jspr_ScheduleOfCommonStockReservedForFutureIssuanceAbstract_1330" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember" xlink:label="jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember_1342" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember" xlink:label="jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember_1341" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember" xlink:label="jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember_1338" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember" xlink:label="jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember_1339" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesIssuableUponExerciseOfPublicWarrantsMember" xlink:label="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember_1337" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_1343" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1344" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1332" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1333" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:label="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable_1331" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_OutstandingAndIssuedCommonStockOptionsMember" xlink:label="jspr_OutstandingAndIssuedCommonStockOptionsMember_1334" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember_1340" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember_1336" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_OutstandingAndIssuedRestrictedStockUnitsMember_1335" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember_1342" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember_1341" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember_1338" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember_1339" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember_1337" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable_1331" xlink:to="us-gaap_ClassOfStockLineItems_1343" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1343" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1344" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable_1331" xlink:to="us-gaap_PlanNameAxis_1332" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_1332" xlink:to="us-gaap_PlanNameDomain_1333" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfCommonStockReservedForFutureIssuanceAbstract_1330" xlink:to="jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable_1331" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1333" xlink:to="jspr_OutstandingAndIssuedCommonStockOptionsMember_1334" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:label="jspr_ScheduleOfStockBasedCompensationExpenseAbstract_1385" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_1394" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1387" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1393" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:label="us-gaap_StatementOfIncomeLocationBalanceAxis_1983" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceShareUnitsPSUsMember" xlink:label="jspr_PerformanceShareUnitsPSUsMember_1388" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1393" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_1394" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" xlink:to="us-gaap_AwardTypeAxis_1387" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1393" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfStockBasedCompensationExpenseAbstract_1385" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="95.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_1387" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1386" xlink:to="us-gaap_StatementOfIncomeLocationBalanceAxis_1983" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1981" xlink:to="jspr_PerformanceShareUnitsPSUsMember_1388" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_1313" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_1314" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_1318" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1320" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1319" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_1315" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfComponentsOfLeaseCostsAbstract" xlink:label="jspr_ScheduleOfComponentsOfLeaseCostsAbstract_1312" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_1317" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_1316" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfComponentsOfLeaseCostsAbstract_1312" xlink:to="us-gaap_LeaseCostAbstract_1313" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_1313" xlink:to="us-gaap_OperatingLeaseCost_1314" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfComponentsOfLeaseCostsAbstract_1312" xlink:to="us-gaap_OperatingLeasePayments_1318" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfComponentsOfLeaseCostsAbstract_1312" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1320" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfComponentsOfLeaseCostsAbstract_1312" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1319" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_1313" xlink:to="us-gaap_ShortTermLeaseCost_1315" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableLeaseCost_1316" xlink:to="us-gaap_LeaseCost_1317" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_1313" xlink:to="us-gaap_VariableLeaseCost_1316" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1348" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1363" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable" xlink:label="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable_1347" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1360" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1361" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1967" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1976" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1353" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1354" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1359" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PerformanceBasedStockOptionsMember" xlink:label="jspr_PerformanceBasedStockOptionsMember_1350" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfStockOptionActivitiesAbstract" xlink:label="jspr_ScheduleOfStockOptionActivitiesAbstract_1346" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1362" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1366" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1364" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1971" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1355" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1968" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1356" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1357" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1358" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1980" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1367" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1365" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_1349" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable_1347" xlink:to="us-gaap_AwardTypeAxis_1348" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable_1347" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1363" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfStockOptionActivitiesAbstract_1346" xlink:to="jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable_1347" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1360" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1361" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1967" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1976" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1353" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1354" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1359" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1980" xlink:to="jspr_PerformanceBasedStockOptionsMember_1350" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1362" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1366" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1364" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1971" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1355" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1968" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1356" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1357" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1358" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="94.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_1348" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1980" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1367" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1351" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1365" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1980" xlink:to="us-gaap_StockOptionMember_1349" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract" xlink:label="jspr_ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract_1396" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable" xlink:label="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable_1397" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1406" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1407" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1408" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1982" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1409" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ValuationOfStockOptionsMember" xlink:label="jspr_ValuationOfStockOptionsMember_1399" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_1404" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_1403" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1401" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1402" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1398" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract_1396" xlink:to="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable_1397" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1406" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1407" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1408" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable_1397" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="96.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_1398" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1982" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1405" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1409" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1982" xlink:to="jspr_ValuationOfStockOptionsMember_1399" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_1402" xlink:to="srt_MaximumMember_1404" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_1402" xlink:to="srt_MinimumMember_1403" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable_1397" xlink:to="srt_RangeAxis_1401" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_1401" xlink:to="srt_RangeMember_1402" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable_1397" xlink:to="us-gaap_AwardTypeAxis_1398" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/DocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_1930" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_1955" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_DocumentAndEntityInformationAbstract" xlink:label="jspr_DocumentAndEntityInformationAbstract_1760" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1762" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1763" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_VotingCommonStockParValue00001PerShareMember" xlink:label="jspr_VotingCommonStockParValue00001PerShareMember_1764" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_1948" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_1947" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_1931" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_1761" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_1766" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_1932" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member" xlink:label="jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member_1765" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_1938" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_1934" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_1937" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_1936" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_1945" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_1943" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_1941" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_1939" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_1952" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_1940" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_1935" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_1950" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_1949" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_1928" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_1929" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType_1927" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_1986" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_1957" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_1933" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_1942" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_1944" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_1953" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_1954" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_1956" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_AmendmentFlag_1930" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="38.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_TradingSymbol_1955" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_1761" xlink:to="us-gaap_StatementClassOfStockAxis_1762" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1762" xlink:to="us-gaap_ClassOfStockDomain_1763" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1763" xlink:to="jspr_VotingCommonStockParValue00001PerShareMember_1764" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityAddressAddressLine2_1948" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityAddressAddressLine1_1947" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentPeriodEndDate_1931" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_DocumentAndEntityInformationAbstract_1760" xlink:to="dei_DocumentInformationTable_1761" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_1761" xlink:to="dei_DocumentInformationLineItems_1766" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentFiscalYearFocus_1932" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1763" xlink:to="jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member_1765" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityTaxIdentificationNumber_1938" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityRegistrantName_1934" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityIncorporationStateCountryCode_1937" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityFileNumber_1936" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="35.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityEmergingGrowthCompany_1945" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="33.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityFilerCategory_1943" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="32.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityInteractiveDataCurrent_1941" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_CurrentFiscalYearEndDate_1939" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_CityAreaCode_1952" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="31.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityCurrentReportingStatus_1940" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityCentralIndexKey_1935" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityAddressStateOrProvince_1950" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityAddressCityOrTown_1949" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentQuarterlyReport_1928" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentTransitionReport_1929" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentType_1927" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityAddressPostalZipCode_1986" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="40.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityCommonStockSharesOutstanding_1957" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_DocumentFiscalPeriodFocus_1933" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="36.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntityShellCompany_1942" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="34.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_EntitySmallBusiness_1944" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_LocalPhoneNumber_1953" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="37.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_Security12bTitle_1954" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="39.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1766" xlink:to="dei_SecurityExchangeName_1956" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/OrganizationandDescriptionofBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_1125" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1124" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1124" xlink:to="us-gaap_NatureOfOperations_1125" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1127" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_1128" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1127" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_1128" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/SignificantAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_1140" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollateralizedAgreementsAbstract" xlink:label="us-gaap_CollateralizedAgreementsAbstract_1139" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralizedAgreementsAbstract_1139" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_1140" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/Warrants" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_WarrantsTextBlock" xlink:label="jspr_WarrantsTextBlock_1143" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1142" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1142" xlink:to="jspr_WarrantsTextBlock_1143" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CIndUMember" xlink:label="jspr_CIndUMember_1498" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_MDSAMLMember" xlink:label="jspr_MDSAMLMember_1500" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PersonnelCosts" xlink:label="jspr_PersonnelCosts_1502" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SCIDMember" xlink:label="jspr_SCIDMember_1499" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1492" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_1506" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1507" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1493" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1491" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_1504" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_BriquilimabPlatformMember" xlink:label="jspr_BriquilimabPlatformMember_1494" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CMOMember" xlink:label="jspr_CMOMember_1495" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CSUMember" xlink:label="jspr_CSUMember_1496" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_FacilitiesAndOverheadCosts" xlink:label="jspr_FacilitiesAndOverheadCosts_1503" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:label="jspr_ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract_1490" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_1505" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_AsthmaMember" xlink:label="jspr_AsthmaMember_1497" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_1501" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_CIndUMember_1498" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_MDSAMLMember_1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="jspr_PersonnelCosts_1502" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_SCIDMember_1499" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1491" xlink:to="srt_ProductOrServiceAxis_1492" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="us-gaap_NonoperatingIncomeExpense_1506" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="us-gaap_NetIncomeLoss_1507" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_1492" xlink:to="srt_ProductsAndServicesDomain_1493" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract_1490" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1491" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="us-gaap_CostOfRevenue_1504" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_BriquilimabPlatformMember_1494" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_CMOMember_1495" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_CSUMember_1496" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="jspr_FacilitiesAndOverheadCosts_1503" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems_1501" xlink:to="us-gaap_OperatingExpenses_1505" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_1493" xlink:to="jspr_AsthmaMember_1497" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1491" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems_1501" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_1035" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_1031" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_1034" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1030" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_1033" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_1032" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_1038" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_1037" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_1036" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1030" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_1035" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1030" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_1031" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1030" xlink:to="us-gaap_PreferredStockSharesOutstanding_1034" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1030" xlink:to="us-gaap_PreferredStockSharesIssued_1033" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1030" xlink:to="us-gaap_PreferredStockSharesAuthorized_1032" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1030" xlink:to="us-gaap_CommonStockSharesOutstanding_1038" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1030" xlink:to="us-gaap_CommonStockSharesIssued_1037" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1030" xlink:to="us-gaap_CommonStockSharesAuthorized_1036" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_1110" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_1106" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense_1096" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1109" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1102" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1101" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1107" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1121" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_1120" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1117" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1093" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1092" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_1103" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1091" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_1094" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_1098" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1119" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1118" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_1090" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1104" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1105" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_1097" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1107" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_1110" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1100" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_1106" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1093" xlink:to="us-gaap_OtherNoncashExpense_1096" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1107" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1109" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1100" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1102" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1100" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1101" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1091" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1107" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_1120" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1121" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1090" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_1120" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1090" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1117" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1091" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1093" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1091" xlink:to="us-gaap_NetIncomeLoss_1092" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1091" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1100" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_1103" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1090" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1091" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1093" xlink:to="us-gaap_DepreciationAndAmortization_1094" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1093" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_1098" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1090" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1119" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1090" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1118" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1100" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1104" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1100" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1105" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1093" xlink:to="us-gaap_ShareBasedCompensation_1097" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CirmGrant" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CirmGrantDisclosureTextBlock" xlink:label="jspr_CirmGrantDisclosureTextBlock_1137" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CirmGrantDisclosureAbstract" xlink:label="jspr_CirmGrantDisclosureAbstract_1136" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CirmGrantDisclosureAbstract_1136" xlink:to="jspr_CirmGrantDisclosureTextBlock_1137" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1082" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1056" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1057" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1064" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1065" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1058" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1063" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_1060" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1080" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1062" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1081" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_1061" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1083" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1059" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1063" xlink:to="us-gaap_StockholdersEquity_1082" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1056" xlink:to="us-gaap_StatementTable_1057" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1063" xlink:to="us-gaap_StockholdersEquity_1064" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1063" xlink:to="us-gaap_SharesOutstanding_1065" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1057" xlink:to="us-gaap_StatementEquityComponentsAxis_1058" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1057" xlink:to="us-gaap_StatementLineItems_1063" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1058" xlink:to="us-gaap_AdditionalPaidInCapitalMember_1060" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1063" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1080" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1058" xlink:to="us-gaap_EquityComponentDomain_1062" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1063" xlink:to="us-gaap_NetIncomeLoss_1081" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1058" xlink:to="us-gaap_RetainedEarningsMember_1061" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1063" xlink:to="us-gaap_SharesOutstanding_1083" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1058" xlink:to="us-gaap_CommonStockMember_1059" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/RelatedParties" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_1163" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1164" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_1163" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1164" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CommitmentsandContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1145" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1146" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1145" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1146" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CommonStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1148" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_1149" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1148" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_1149" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_1018" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_1022" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_1020" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1027" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1002" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_1026" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_1009" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1007" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1005" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1012" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_1016" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_1028" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_1024" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_1021" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_1004" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_1003" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_1006" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_1011" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_1023" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_1019" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_1010" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_1008" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_1014" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_1025" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_1013" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1015" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1012" xlink:to="us-gaap_WarrantsAndRightsOutstanding_1018" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_StockholdersEquityAbstract_1022" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrent_1019" xlink:to="us-gaap_Liabilities_1020" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1022" xlink:to="us-gaap_StockholdersEquity_1027" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1022" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_1026" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_RestrictedCashNoncurrent_1009" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_1007" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1005" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_LiabilitiesCurrentAbstract_1012" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1015" xlink:to="us-gaap_LiabilitiesCurrent_1016" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1022" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_1028" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1022" xlink:to="us-gaap_CommonStockValue_1024" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_CommitmentsAndContingencies_1021" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_1004" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_AssetsCurrentAbstract_1003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1005" xlink:to="us-gaap_AssetsCurrent_1006" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_Assets_1011" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1022" xlink:to="us-gaap_PreferredStockValue_1023" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1012" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_1019" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_OtherAssetsNoncurrent_1010" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_1008" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1012" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_1014" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1022" xlink:to="us-gaap_AdditionalPaidInCapital_1025" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1012" xlink:to="us-gaap_AccountsPayableCurrent_1013" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1012" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1015" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1201" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1203" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1204" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1202" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1201" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1203" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1201" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1204" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1201" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1202" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/AccountingPoliciesbyPolicyPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1175" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1196" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_1179" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_GoingConcernPolicyTextBlock" xlink:label="jspr_GoingConcernPolicyTextBlock_1177" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1176" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1180" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_1181" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1175" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1196" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1175" xlink:to="us-gaap_UseOfEstimates_1179" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1175" xlink:to="jspr_GoingConcernPolicyTextBlock_1177" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1175" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1176" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1175" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1180" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1175" xlink:to="us-gaap_ConcentrationRiskCreditRisk_1181" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1198" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_1199" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1198" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_1199" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1411" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_1419" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_1420" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_1412" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1413" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1415" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1414" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1418" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1417" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1414" xlink:to="us-gaap_EarningsPerShareBasic_1419" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1414" xlink:to="us-gaap_EarningsPerShareDiluted_1420" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1411" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_1412" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_1412" xlink:to="us-gaap_NetIncomeLoss_1413" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1414" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1415" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1411" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1414" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1414" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1418" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1414" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1417" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/RestructuringDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts_1749" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1_1973" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges_1974" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SeveranceCostsPeriod" xlink:label="jspr_SeveranceCostsPeriod_1975" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringCostsAbstract" xlink:label="us-gaap_RestructuringCostsAbstract_1747" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAbstract_1747" xlink:to="us-gaap_RestructuringCosts_1749" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="88.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAbstract_1747" xlink:to="us-gaap_SeveranceCosts1_1973" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="89.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAbstract_1747" xlink:to="us-gaap_OtherAssetImpairmentCharges_1974" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="90.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAbstract_1747" xlink:to="jspr_SeveranceCostsPeriod_1975" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1130" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_1131" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1130" xlink:to="us-gaap_FairValueDisclosuresTextBlock_1131" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/SegmentInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1166" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_1167" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1166" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_1167" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholders" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1154" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_1155" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1154" xlink:to="us-gaap_EarningsPerShareTextBlock_1155" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_1556" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1550" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1550" xlink:to="us-gaap_Depreciation_1556" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PrepaidTravelExpenses" xlink:label="jspr_PrepaidTravelExpenses_1287" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ResearchAndDevelopmentPrepaidExpenses" xlink:label="jspr_ResearchAndDevelopmentPrepaidExpenses_1285" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_1288" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1289" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1284" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_1286" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1284" xlink:to="jspr_PrepaidTravelExpenses_1287" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1284" xlink:to="jspr_ResearchAndDevelopmentPrepaidExpenses_1285" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1284" xlink:to="us-gaap_OtherAssetsCurrent_1288" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1284" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1289" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1284" xlink:to="us-gaap_PrepaidInsurance_1286" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:label="jspr_ScheduleOfPropertyAndEquipmentNetAbstract_1291" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1302" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_1298" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_1296" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_1297" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_1295" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1293" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_1301" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_1300" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1292" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_1300" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1302" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" xlink:to="us-gaap_ComputerEquipmentMember_1298" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" xlink:to="us-gaap_EquipmentMember_1296" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" xlink:to="us-gaap_FurnitureAndFixturesMember_1297" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" xlink:to="us-gaap_LeaseholdImprovementsMember_1295" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1292" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1293" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_1300" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_1301" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1292" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_1300" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_1300" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_1303" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1293" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1294" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfPropertyAndEquipmentNetAbstract_1291" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1292" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ResearchAndDevelopmentAccruedExpensesCurrent" xlink:label="jspr_ResearchAndDevelopmentAccruedExpensesCurrent_1306" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1310" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1305" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_1308" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_1307" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_1309" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1305" xlink:to="jspr_ResearchAndDevelopmentAccruedExpensesCurrent_1306" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1305" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1310" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1305" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_1308" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1305" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_1307" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1305" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_1309" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CirmGrantDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="jspr_CaliforniaInstituteForRegenerativeMedicineMember_1565" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CirmGrantDetailsTable" xlink:label="jspr_CirmGrantDetailsTable_1562" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CirmGrantDisclosureAbstract" xlink:label="jspr_CirmGrantDisclosureAbstract_1561" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_CirmGrantLineItems" xlink:label="jspr_CirmGrantLineItems_1566" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_NetSales" xlink:label="jspr_NetSales_1569" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_PercentageOfLicensingFees" xlink:label="jspr_PercentageOfLicensingFees_1568" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ReceivedAggregateFromCIRM" xlink:label="jspr_ReceivedAggregateFromCIRM_1572" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1563" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1564" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_1570" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate_1571" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_1573" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1567" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_1564" xlink:to="jspr_CaliforniaInstituteForRegenerativeMedicineMember_1565" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CirmGrantDisclosureAbstract_1561" xlink:to="jspr_CirmGrantDetailsTable_1562" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CirmGrantDetailsTable_1562" xlink:to="jspr_CirmGrantLineItems_1566" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="jspr_NetSales_1569" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="jspr_PercentageOfLicensingFees_1568" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="jspr_ReceivedAggregateFromCIRM_1572" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CirmGrantDetailsTable_1562" xlink:to="srt_ProductOrServiceAxis_1563" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_1563" xlink:to="srt_ProductsAndServicesDomain_1564" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_1570" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="us-gaap_InvestmentInterestRate_1571" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_1573" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_CirmGrantLineItems_1566" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1567" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1381" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1383" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1375" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1966" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfRsuActivityAbstract" xlink:label="jspr_ScheduleOfRsuActivityAbstract_1369" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable" xlink:label="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable_1370" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1371" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_1965" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1382" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1374" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1380" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1381" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1383" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1375" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="86.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_1371" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1966" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfRsuActivityAbstract_1369" xlink:to="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable_1370" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable_1370" xlink:to="us-gaap_AwardTypeAxis_1371" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable_1370" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1966" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_1965" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1382" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1374" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_1373" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1380" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1960" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1959" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1325" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1322" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_1326" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_1327" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_1328" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1322" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1960" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1322" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1959" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1322" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1325" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1325" xlink:to="us-gaap_OperatingLeaseLiability_1326" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1322" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_1327" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent_1327" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_1328" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/SegmentInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1741" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_1745" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_1744" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_1743" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_1742" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1741" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_1745" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1741" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_1744" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1741" xlink:to="us-gaap_NumberOfOperatingSegments_1743" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1741" xlink:to="us-gaap_NumberOfReportableSegments_1742" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract" xlink:label="jspr_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract_1422" />
    <link:loc xlink:type="locator" xlink:href="jspr-20260331.xsd#jspr_SharesIssuableUponExerciseOfPublicWarrantsMember" xlink:label="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember_1428" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1432" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1424" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1431" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1425" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_1430" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_1427" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1423" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_1426" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_1429" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_1425" xlink:to="jspr_SharesIssuableUponExerciseOfPublicWarrantsMember_1428" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1431" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1432" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1423" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1424" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1423" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1431" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1424" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1425" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_1425" xlink:to="us-gaap_PerformanceSharesMember_1430" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_1425" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_1427" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jspr_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract_1422" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1423" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_1425" xlink:to="us-gaap_StockOptionMember_1426" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_1425" xlink:to="us-gaap_WarrantMember_1429" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/RelatedPartiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_1739" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred_1738" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_1727" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_1727" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_1739" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_1727" xlink:to="us-gaap_InterestCostsIncurred_1738" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/StockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1152" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1151" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1151" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1152" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/Restructuring" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1170" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringCostsAbstract" xlink:label="us-gaap_RestructuringCostsAbstract_1169" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAbstract_1169" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1170" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_1044" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_1049" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_1046" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_1040" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_1043" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_1052" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_1045" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_1041" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_1048" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_1042" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1054" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1050" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_1051" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1053" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_1047" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1040" xlink:to="us-gaap_OperatingExpenses_1044" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1040" xlink:to="us-gaap_NonoperatingIncomeExpense_1049" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss_1045" xlink:to="us-gaap_InvestmentIncomeInterest_1046" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_1041" xlink:to="us-gaap_GeneralAndAdministrativeExpense_1043" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1040" xlink:to="us-gaap_EarningsPerShareDiluted_1052" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1040" xlink:to="us-gaap_OperatingIncomeLoss_1045" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1040" xlink:to="us-gaap_OperatingExpensesAbstract_1041" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss_1045" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_1048" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_1041" xlink:to="us-gaap_ResearchAndDevelopmentExpense_1042" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1040" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1054" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1040" xlink:to="us-gaap_NetIncomeLoss_1050" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1040" xlink:to="us-gaap_EarningsPerShareBasic_1051" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1040" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1053" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss_1045" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_1047" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CondensedFinancialStatementsTextBlock" xlink:label="srt_CondensedFinancialStatementsTextBlock_1134" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1133" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1133" xlink:to="srt_CondensedFinancialStatementsTextBlock_1134" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_1997" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_1998" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1993" />
    <link:presentationArc xlink:type="arc" order="106.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1993" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_1997" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="107.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1993" xlink:to="us-gaap_SharesIssuedPricePerShare_1998" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/ConsolidatedBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1206" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1207" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_1208" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1209" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1206" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1207" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1206" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_1208" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1206" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1209" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://jaspertx.com/20260331/role/CommitmentsandContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1211" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_1212" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1213" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1211" xlink:to="us-gaap_LeaseCostTableTextBlock_1212" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1211" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1213" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>May 11, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">JASPER THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001788028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-2984849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2200 Bridge Pkwy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite #102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">549-1400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,996,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jspr_VotingCommonStockParValue00001PerShareMember', window );">Voting Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Voting Common Stock, par     value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JSPR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member', window );">Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each     ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JSPRW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jspr_VotingCommonStockParValue00001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jspr_VotingCommonStockParValue00001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,144<span></span>
</td>
<td class="nump">$ 28,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,148<span></span>
</td>
<td class="nump">5,953<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">20,292<span></span>
</td>
<td class="nump">34,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">21,184<span></span>
</td>
<td class="nump">35,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">6,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">1,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">5,745<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,996<span></span>
</td>
<td class="nump">13,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">6,524<span></span>
</td>
<td class="nump">16,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">2,264<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">17,784<span></span>
</td>
<td class="nump">31,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.0001 par value &#8212; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; none issued and outstanding at March 31, 2026 and December 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.0001 par value &#8212; 492,000,000 shares authorized at March 31, 2026 and December 31, 2025; 27,996,819 shares issued and outstanding at March 31, 2026 and December 31, 2025</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">321,241<span></span>
</td>
<td class="nump">320,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(317,844)<span></span>
</td>
<td class="num">(316,670)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">4,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 21,184<span></span>
</td>
<td class="nump">$ 35,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in Shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in Shares)</a></td>
<td class="nump">492,000,000<span></span>
</td>
<td class="nump">492,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in Shares)</a></td>
<td class="nump">27,996,819<span></span>
</td>
<td class="nump">27,996,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in Shares)</a></td>
<td class="nump">27,996,819<span></span>
</td>
<td class="nump">27,996,819<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 5,814<span></span>
</td>
<td class="nump">$ 16,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,138<span></span>
</td>
<td class="nump">5,645<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,952<span></span>
</td>
<td class="nump">21,802<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,952)<span></span>
</td>
<td class="num">(21,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">9,640<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">9,778<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (1,174)<span></span>
</td>
<td class="num">$ (21,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in Dollars per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (1.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in Dollars per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (1.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in Shares)</a></td>
<td class="nump">28,671,819<span></span>
</td>
<td class="nump">15,022,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in Shares)</a></td>
<td class="nump">28,671,819<span></span>
</td>
<td class="nump">15,022,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 302,541<span></span>
</td>
<td class="num">$ (240,869)<span></span>
</td>
<td class="nump">$ 61,674<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">15,022,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,811<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21,241)<span></span>
</td>
<td class="num">(21,241)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">304,352<span></span>
</td>
<td class="num">(262,110)<span></span>
</td>
<td class="nump">42,244<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="nump">15,022,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">320,818<span></span>
</td>
<td class="num">(316,670)<span></span>
</td>
<td class="nump">4,151<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2025</a></td>
<td class="nump">27,996,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,174)<span></span>
</td>
<td class="num">(1,174)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2026</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 321,241<span></span>
</td>
<td class="num">$ (317,844)<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2026</a></td>
<td class="nump">27,996,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,174)<span></span>
</td>
<td class="num">$ (21,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(9,640)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,781)<span></span>
</td>
<td class="num">(1,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(2,617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(478)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,548)<span></span>
</td>
<td class="num">(22,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows provided by investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(14,548)<span></span>
</td>
<td class="num">(22,838)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of the period</a></td>
<td class="nump">29,109<span></span>
</td>
<td class="nump">72,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the period</a></td>
<td class="nump">14,561<span></span>
</td>
<td class="nump">49,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental and non-cash items reconciliations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Description of Business </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Jasper Therapeutics, Inc. and its consolidated subsidiary, Jasper Tx Corp. (collectively, &#8220;Jasper&#8221; or the &#8220;Company&#8221;), is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases, such as chronic spontaneous urticaria, chronic inducible urticaria and asthma. Briquilimab has been evaluated in clinical studies in chronic spontaneous urticaria, chronic inducible urticaria and allergic asthma. The Company&#8217;s clinical development activities are currently focused on chronic urticarias, and while the clinical data generated in allergic asthma supports further development in the broader asthma population, advancing any future clinical studies in asthma would be based on an evaluation of the competitive landscape, the potential for strategic partnerships and capital availability. The Company has also historically explored diseases where targeting diseased hematopoietic stem cells can provide benefits, such as stem cell transplant conditioning regimens, but is currently focused on development of briquilimab in mast cell driven diseases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is headquartered in Redwood City, California. The Company is a Delaware corporation and was incorporated in March 2018. In September 2021, the Company completed a merger with Amplitude Healthcare Acquisition Corporation and became a public company.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Basis of Presentation</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) for financial reporting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The accompanying condensed financial statements are consolidated and include the accounts of Jasper Therapeutics, Inc. and its wholly-owned subsidiary, Jasper Tx Corp, which had no operations during the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2025 included in the Company&#8217;s Annual Report on the Form 10-K filed with the SEC on March 30, 2026. There were no changes to the Company&#8217;s significant accounting policies as described in the Annual Report on Form 10-K. The information as of December 31, 2025, included in the condensed consolidated balance sheets was derived from the Company&#8217;s audited financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company&#8217;s consolidated financial statements. The results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026 or for any other interim period or for any other future year.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Going Concern</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, <i>Going Concern</i>, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of the Company&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating effect of the Company&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. In performing this analysis, the Company excluded certain elements of its operating plan that cannot be considered probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company has incurred significant losses and negative cash flows from operations since its inception. During the three months ended March 31, 2026 and 2025, the Company incurred net losses of $1.2 million and $21.2 million, respectively. During the three months ended March 31, 2026 and 2025, the Company had negative cash flows from operations of $14.5 million and $22.8 million, respectively. As of March 31, 2026, the Company had an accumulated deficit of $317.8 million. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support the Company&#8217;s cost structure. As of March 31, 2026, the Company had cash and cash equivalents of $14.1 million. The Company&#8217;s management expects that the existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management expects to finance the Company&#8217;s future cash needs through equity or debt financings, collaborations or a combination of these approaches, and given the imminent need for additional funding to continue to fund operations in the near-term, the Company is actively seeking additional capital to extend the cash runway. However, due to several factors, including those outside management&#8217;s control, there can be no assurance that the Company will be able to complete additional financings. The Company&#8217;s ability to raise additional funds may be adversely impacted by negative global economic conditions and any disruptions to and volatility in the credit and financial markets in the United States and worldwide or other factors. There can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms favorable or acceptable to the Company. The Company routinely evaluates cost reduction measures to proactively manage cash burn, but if the Company is unable to obtain adequate financing when needed or on terms favorable or acceptable to it, the Company may be forced to take broader actions such as to delay, reduce the scope of or eliminate one or more of its research and development programs. The Company concluded the likelihood that its plan to successfully obtain sufficient funding or adequately delay or reduce expenditures, while reasonably possible, is less than probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The accompanying unaudited interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. These unaudited interim condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Use of Estimates</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the condensed consolidated financial statements include, but are not limited to, the determination of the accrued research and development expenses, the measurement of stock-based compensation expense and the valuation of warrant liability. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Cash, Cash Equivalents, and Restricted Cash</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total amount shown in the condensed consolidated statements of cash flows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Cash and cash equivalents</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">14,144</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">28,692</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">417</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">417</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total cash, cash equivalents and restricted cash</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">14,561</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">29,109</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cash and cash equivalents consist of cash held in operating accounts and investments in money market funds. Restricted cash relates to the letter of credit secured in conjunction with the operating lease (Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Concentrations of Credit Risk and Other Risks and Uncertainties</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company&#8217;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America. Cash balances are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced any losses on its cash, cash equivalents and marketable securities&#8217; balances and periodically evaluates the creditworthiness of its financial institutions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is subject to risks common to companies in the development stage, including, but not limited to, development and regulatory approval of new product candidates, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product plans. To achieve profitable operations, the Company must successfully develop and obtain requisite regulatory approvals for, manufacture, and market its product candidates. There can be no assurance that any such product candidate can be developed and approved or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product will be successfully marketed. These factors could have a material adverse effect on the Company&#8217;s future financial results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Products developed by the Company require approval from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#8217;s future products will receive the necessary clearances. If the Company were denied such clearances or such clearances were delayed, it could have a materially adverse impact on the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Recent Accounting Pronouncements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Accounting Pronouncements Not Yet Adopted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;In November 2024, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date (&#8220;ASU 2025-01&#8221;). The amendments do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In September 2025, the FASB issued ASU No. 2025-06, Intangibles - Goodwill and Other - Internal - Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (&#8220;ASU 2025-06&#8221;). The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages. This ASU requires entities to begin capitalizing software costs when management authorizes and commits to funding the software project, and it is probable that the project will be completed, and the software will be used for its intended purpose. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2025, the FASB issued ASU No. 2025-10, Accounting for Government Grants Received by Business Entities (Topic 832). This ASU provides recognition, measurement, presentation, and disclosure requirements for government grants, including guidance for grants related to an asset and grants related to income. ASU No. 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting: Narrow-Scope Improvements (Topic 270). This ASU improves clarity for interim financial reporting requirements under the existing guidance within ASC Topic 270, by creating a comprehensive list of interim disclosure requirements, clarifying scope and applicability, along with adding a principle to disclose all material events that have occurred since the most recently filed Annual Report on Form 10-K. ASU No. 2025-11 is effective for interim reporting for fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 3. FAIR VALUE MEASUREMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"><td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 &#8211; Inputs are unadjusted, quoted prices     in active markets for identical assets or liabilities at the measurement date;</span></td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"><td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 &#8211; Inputs are observable, unadjusted quoted     prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities     in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially     the full term of the related assets or liabilities; and</span></td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"><td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 &#8211; Unobservable inputs that are significant     to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value and is a Level 1 financial instrument under the fair value hierarchy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. The Company had no financial instruments classified at Level 2 as of March 31, 2026 and December 31, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques and at least one significant model assumption or input is unobservable. As of March 31, 2026 and December 31, 2025, the Company&#8217;s Level 3 liabilities consisted of the warrant liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There were no transfers within the hierarchy during the three months ended March 31, 2026 and 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>Financial assets</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Money market funds</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,144</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_111159347">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1894122814">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,144</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Total fair value of assets</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">13,144</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1072361442">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_804810147">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">13,144</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Financial liabilities</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Warrant liability</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1196049397">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1867564296">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">6,524</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">6,524</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt">Total fair value of financial liabilities</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1620055900">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1092525917">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">6,524</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">6,524</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>Financial assets</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Money market funds</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">27,692</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1276276239">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_707032855">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">27,692</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Total fair value of assets</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">27,692</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1289593603">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1353737602">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">27,692</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Financial liabilities</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Warrant liability</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_166082834">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1176672139">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">16,164</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">16,164</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt">Total fair value of financial liabilities</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1449616030">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_978200156">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">16,164</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">16,164</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the three months ended March 31, 2026, the changes in the Company&#8217;s warrant liability were as follows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant<br/> Liability</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; font-weight: bold">Fair Value as of December 31, 2025</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">16,164</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in the fair value</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(9,640</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; padding-bottom: 4pt">Fair Value as of March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">6,524</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company uses the Black-Scholes pricing model to determine the fair value of its warrant liability using Level 3 inputs. Inputs used to determine estimated fair value of the warrant liability include the fair value of the underlying stock at the valuation date, the term of the warrants, and the expected volatility of the underlying stock. The significant unobservable input used in the fair value measurement of the warrant liability is the expected volatility of the warrants. The estimates of fair value are uncertain and&#160;changes in&#160;any of the estimated inputs used as of the date of this report could have resulted in significant adjustments to the fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The key inputs into valuation models used to estimate the fair value of the warrant liability as of March 31,2026 and December 31, 2025 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%">Common stock price</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">.88</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">1.83</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Expected term (in years)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3.98</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">4.22</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Expected volatility</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">115.68</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">113.30</td> <td style="text-align: left">%</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3.86</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3.66</td> <td style="text-align: left">%</td> </tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Condensed Consolidated Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsTextBlock', window );">CONDENSED CONSOLIDATED BALANCE SHEET COMPONENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 4. CONDENSED CONSOLIDATED BALANCE SHEET COMPONENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Prepaid expenses and other current assets</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the details of prepaid expenses and other current assets as of the dates set forth below (in thousands):&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Research and development prepaid expenses</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,847</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,320</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Prepaid insurance</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">653</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">866</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Prepaid travel expenses</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">243</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">103</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and current assets</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">405</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">664</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 4pt">Total</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">6,148</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">5,953</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Property and equipment, net</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the details of property and equipment, net as of the dates set forth below (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Leasehold improvements</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,711</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,711</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Lab equipment</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,513</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,513</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Office furniture &amp; fixtures</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">522</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">522</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Computer equipment</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">170</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">170</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-left: 9pt">Property and equipment, gross</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">4,916</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">4,916</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(4,835</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(4,814</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Property and equipment, net</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">81</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">102</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Depreciation and amortization expense was $21,000 and $0.3 million for the three months ended March 31, 2026 and 2025, respectively. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Accrued expenses and other current liabilities</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the details of accrued expenses and other current liabilities as of the dates set forth below (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Research and development accrued expenses</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">3,422</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">3,775</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Accrued employee and related compensation expenses</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,889</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,589</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Accrued legal and professional expenses</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">321</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">261</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 1.5pt">Other</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">168</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">120</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 4pt">Total</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">5,800</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">5,745</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cirm Grant<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_CirmGrantDisclosureAbstract', window );"><strong>Cirm Grant [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_CirmGrantDisclosureTextBlock', window );">CIRM GRANT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 5. CIRM GRANT</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In November 2020, California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) awarded the Company $2.3 million in support of the research project related to a monoclonal antibody that depletes blood stem cells and enables chemotherapy-free transplants. The Company has received an aggregate of $2.3 million from CIRM through March 31, 2026. &#160;&#160;There are no further amounts available for future distribution to the Company under the grant. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the terms of the grant, both CIRM and the Company agreed to co-fund the research project and the amount of the Company&#8217;s co-funding requirement was predetermined as a part of the award. Under the terms of the CIRM grant, the Company is obligated to pay royalties and licensing fees based on 0.1% of net sales of CIRM-funded inventions per $1.0 million of CIRM grant. As an alternative to revenue sharing, the Company has the option to convert the award to a loan. In the event the Company exercises its right to convert the award to a loan, it would be obligated to repay the loan within ten business days of making such election. Repayment amounts vary dependent on when the award is converted to a loan, ranging from 60% of the award granted to amounts received plus interest at the rate of the three-month LIBOR rate plus 25% per annum. Since the Company may be required to repay some or all of the amounts awarded by CIRM, the Company accounted for this award as a liability. Given the uncertainty in amounts due upon repayment, the Company has recorded amounts received without any discount or interest recorded, and upon determination of amounts that would become due, the Company will adjust accordingly. In the absence of explicit U.S. GAAP guidance on contributions received by business entities from government entities, the Company has applied to the CIRM grant the recognition and measurement guidance in ASC Topic 958-605 Not-for-Profit Entities: Revenue Recognition&#8212;Contributions by analogy. As of each of March 31, 2026 and December 31, 2025, the amount of CIRM grant received of $2.3 million is included in other non-current liabilities in the condensed consolidated balance sheets. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_CirmGrantDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_CirmGrantDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_CirmGrantDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure about Cirm Grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_CirmGrantDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollateralizedAgreementsAbstract', window );"><strong>Significant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">SIGNIFICANT AGREEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 6. SIGNIFICANT AGREEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Stanford License Agreements</i></span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March 2021, the Company entered into an exclusive license agreement with Stanford (the &#8220;2021 Stanford License Agreement&#8221;). In July 2023, the Company entered into an amendment to the 2021 Stanford License Agreement to modify certain milestones set forth thereunder. The Company received a worldwide, exclusive license, with a right to sublicense, for briquilimab in the field of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated. Stanford transferred to the Company certain know-how and patents related to briquilimab (together, the &#8220;Licensed Technology&#8221;). Under the terms of this agreement, the Company is required to use commercially reasonable efforts to develop, manufacture and sell licensed product and to develop markets for a licensed product. In addition, the Company is required to use commercially reasonable efforts to meet the milestones as specified in the agreement over the six years from execution of the 2021 Stanford License Agreement and must notify Stanford in writing as each milestone is met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company is obligated to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and second year, $35,000 for each third and fourth year and $50,000 at each anniversary thereafter ending upon the first commercial sale. The Company is also obligated to pay late-stage clinical development milestone payments and first commercial sales milestone payments of up to $9.0 million in total. The Company will also pay low single-digit royalties on net sales of licensed products, if approved. As of March 31, 2026, the Company recorded $50,000 in accrued expenses and other current liabilities in the condensed consolidated balance sheets related to annual license maintenance fees, with corresponding recognition of such amount as research and development expense in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026. The Company recognized $35,000 in annual license maintenance fees as research and development expense in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2025.&#160;&#160; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The 2021 Stanford License Agreement expires on a country-by-country basis on the last-to-expire valid claim of a licensed patent in such country. The Company may terminate the agreement by giving Stanford written notice at least 12 months in advance of the effective date of termination. The Company may also terminate the agreement solely with respect to any particular patent application or patent by giving Stanford written notice at least 60 days in advance of the effective date of termination. Stanford may terminate the agreement after 90 days from a written notice by Stanford, specifying a problem, including a delinquency on any report required pursuant to the agreement or any payment, missing a milestone or a material breach, unless the Company remediates the problem in that 90-day period.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In December 2024, the Company entered into a co-exclusive license agreement with Stanford (the &#8220;2024 Stanford License Agreement&#8221;). The Company received a co-exclusive license in the United States, with a right to sublicense, for a certain patent to be used in the field of the treatment and prevention of human diseases, including the use of anti-CD117 antibodies (other than JSP191) for the purpose of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated (the &#8220;Co-Exclusive Licensed Field of Use&#8221;) and an exclusive license in the United States for the use of the same patent in the field provided in the 2021 Stanford License Agreement (the &#8220;Exclusive Licensed Field of Use&#8221;). Stanford will have at most one other commercial license for the licensed patent in the Co-Exclusive Licensed Field of Use. Under the terms of this agreement, the Company is required to use commercially reasonable efforts to develop, manufacture and sell a licensed product and to develop markets for a licensed product. In addition, the Company is required to use commercially reasonable efforts to meet the milestones as specified in the agreement over approximately 4.5 years from the execution of the agreement and must notify Stanford in writing when, and if, each milestone is met. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company paid a license issue fee of $75,000, following the execution of the agreement, in January 2025. The Company is also obligated to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement, as follows: $25,000 for each of the first through third years, $50,000 for each of the fourth through sixth years and $65,000 at each anniversary thereafter. The Company is also obligated to pay clinical development milestone payments of up to $1.3 million and sales milestone payments of up to $7.0 million in total. The Company will pay low single-digit royalties on net sales of licensed products, if approved. The Company will pay Stanford a portion of sublicensee consideration if a sublicense is granted. As of March 31, 2026 and December 31, 2025, there was $0 and $25,000, respectively, of accounts payable recorded in the condensed consolidated balance sheets related to the annual license maintenance fee.  </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company may terminate the agreement by giving Stanford written notice at least 30 days in advance of the effective date of termination. Stanford may terminate the agreement by giving the Company 90 days written notice for a problem, including a delinquency on any report required pursuant to the agreement, missing a milestone or a material breach, and by giving the Company 30 days written notice for a payment default, unless the Company remediates the problem in that 90-day or 30-day period.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralizedAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralizedAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_WarrantsTextBlock', window );">WARRANTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 7. WARRANTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In September 2025, in connection and together with the issuance of 11,670,707 shares of the Company&#8217;s voting common stock through the underwritten offering (the &#8220;September 2025 Offering&#8221;), the Company issued pre-funded warrants to purchase 675,000 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) and common stock warrants to purchase 12,345,707&#160;shares of common stock (the &#8220;Common Warrants&#8221;). See Note 9 for additional details about the September 2025 Offering. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Pre-Funded Warrants</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The exercise price of each Pre-Funded Warrant is $0.0001 per share. The Pre-Funded Warrants are exercisable at the option of each holder in whole or in part at any time after their original issuance and have no expiration date. The Pre-Funded Warrants may be exercised by means of cash or the cashless settlement of the net number of shares of common stock determined according to a formula set forth in the Pre-Funded Warrants. However, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99% or 19.99%) of the number of issued and outstanding shares of common stock following such exercise. However, any holder of a Pre-Funded Warrant may increase or decrease such percentage to any other percentage not in excess of 19.99%, provided that the holder shall provide at least 61 days&#8217; prior written notice to the Company prior to the date such increase shall be effective. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the terms of the Pre-Funded Warrant, upon the consummation of a Fundamental Transaction, as defined in the Pre-Funded Warrants, the holders of the Pre-Funded Warrants are entitled to receive, upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or other property that such holders would have received had they exercised the Pre-Funded Warrants immediately prior to such Fundamental Transaction, without regard to any limitations on exercise contained in the Pre-Funded Warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company concluded that the Pre-Funded Warrants met the equity indexation criteria and the Pre-Funded Warrants are therefore accounted for in stockholders&#8217; equity. The Company recorded $0.3&#160;million to additional paid-in capital upon issuance of the Pre-Funded Warrants. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026,&#160;<span style="-sec-ix-hidden:fc_554114115">none</span>&#160;of the Pre-Funded Warrants have been exercised. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Common Warrants</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The exercise price of each Common Warrant is $2.92 per share. Each Common Warrant is exercisable commencing on the six month anniversary of the date of issuance and thereafter for a period of four years. The Common Warrants may be exercised by means of cash or the cashless settlement of the net number of shares of common stock determined according to a formula set forth in the Common Warrants. However, a holder will not be entitled to exercise any portion of any Common Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99% or 19.99%) of the number of issued and outstanding shares of common stock following such exercise. However, any holder of a Common Warrant may increase or decrease such percentage to any other percentage not in excess of 19.99%, provided that the holder shall provide at least 61 days&#8217; prior written notice to the Company prior to the date such increase shall be effective.&#160; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the terms of the Common Warrant, upon the consummation of a Fundamental Transaction, as defined in the Common Warrants, the holders of the Common Warrants are entitled to receive, upon exercise of the Common Warrant, the kind and amount of securities, cash or other property that such holders would have received had they exercised the Common Warrants immediately prior to such Fundamental Transaction, without regard to any limitations on exercise contained in the Common Warrants or the holder may require the Company or the successor entity to repurchase the unexercised portion of the Common Warrant for its Black Scholes Value, as defined in the Common Warrant; provided, however, if the holder shall only be entitled to receive from the Company or any successor entity the same type or form of consideration (and in the same proportion) at the Black Scholes Value of the unexercised portion of the Common Warrant, that is being offered and paid to the holders of common stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, shares or any combination thereof, or whether the holders of common stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of common stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of common stock will be deemed to have received common stock of the successor entity (which successor entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company concluded that the Common Warrants did not meet the equity indexation criteria due to the certain inputs to estimate the number of shares issuable in a Fundamental Transaction and the Common Warrants are therefore accounted for as liabilities. The Company recorded $24.7&#160;million to warrant liability upon issuance of the Common Warrants. The Company estimated fair value of the Common Warrants at the issuance date using the Black-Scholes valuation model and will remeasure the liability at each reporting date. The Company recorded a change in fair value of warrant liability of $9.6&#160;million in its condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2026. Refer to Note 3 for assumptions used to estimate the Common Warrants fair value. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2026,&#160;none&#160;of the Common Warrants have been exercised.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity disclosure of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 8. COMMITMENTS AND CONTINGENCIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Operating Leases</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026, the Company leased approximately&#160;25,900&#160;square feet of laboratory and office space in Redwood City, California, under an operating lease that expires in August 2026. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In conjunction with signing the lease, the Company secured a letter of credit in favor of the lessor in the amount of $0.4 million. The funds related to this letter of credit are presented as restricted cash on the Company&#8217;s condensed consolidated balance sheets. The lease agreement includes an escalation clause for increased base rent and a renewal provision allowing the Company to extend this lease for an additional 60 months at the prevailing rental rate, which the Company is not reasonably certain to exercise. In addition to base rent, the Company pays its share of operating expenses and taxes. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In March 2025, the Company extended its existing short-term lease for 12,500 square feet of laboratory and office space in Redwood City, California, through August 2026. As a result, the Company recorded a right-of-use asset and lease liability of $1.1 million in March 2025. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In December 2025, in connection with the cessation of the Company&#8217;s vivarium operations and consolidation of personnel office space, the Company ceased use of a portion of its leased headquarters space. As a result, the right-of-use asset associated with that lease was impaired by $0.4 million. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company also pays variable costs related to its share of operating expenses and taxes. These variable costs are recorded as lease expense as incurred and presented as operating expenses in the condensed consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease costs, which were included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss, are as follows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="font-weight: bold">Lease cost</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Operating lease cost</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">203</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">232</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Short-term lease cost</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1783648313">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">169</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Variable lease cost</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">178</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">118</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: 9.05pt">Total lease cost</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">381</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">519</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental information related to the Company&#8217;s operating leases is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">496</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">356</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Weighted average remaining lease term (years)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">0.39</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1.4</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Weighted average discount rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">8.00</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">8.00</td> <td style="text-align: left">%</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments as of March 31, 2026 (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="font-weight: bold; border-bottom: Black 1.5pt solid">Year Ending December 31,</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: left; padding-bottom: 1.5pt">2026 (remainder of the year)</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">764</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-left: 9pt">Total undiscounted lease payments</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">764</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-left: 9pt">Total discounted lease payments</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">757</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Less current portion of lease liability</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(757</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Noncurrent portion of lease liability</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_357656926">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>License Agreements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In March 2021, the Company entered into the 2021 Stanford License Agreement (Note 6), which was amended in July 2023, pursuant to which the Company is required to pay annual license maintenance fees, clinical development and commercial sales milestone payments of up to an aggregate of $9.0 million, and low single-digit royalties on net sales of licensed products. All products were in development as of March 31, 2026, and no royalties were due as of such date. The Company recognized $50,000 and $35,000 in annual license maintenance fees as research and development expense in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026 and 2025, respectively. As of each of March 31, 2026 and December 31, 2025, no milestones were probable to be achieved and payable. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In December 2024, the Company entered into the 2024 Stanford License Agreement (Note 6), pursuant to which the Company is required to pay a license issue and annual license maintenance fees, clinical development and commercial sales milestone payments of up to an aggregate of $8.3 million and low single-digit royalties on net sales of licensed products. All products were in development as of March 31, 2026, and no royalties were due as of such date. As of March 31, 2026, no milestones were probable to be achieved and payable. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Legal Proceedings</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company, from time to time, may be party to litigation arising in the ordinary course of business. On September 19, 2025, a shareholder class action complaint captioned&#160;<i>Grant v. Jasper Therapeutics, Inc., et al.</i>&#160;(Case No. 25-cv-08010) was filed in the United States District Court for the Northern District of California against the Company and certain of the Company&#8217;s current and former officers. The complaint alleges that certain material misstatements or omissions related to the ongoing clinical trials of briquilimab were made in violation of federal securities laws. The plaintiffs are seeking unspecified monetary&#160;damages&#160;and an award of costs and expenses, including reasonable attorneys&#8217; fees, expert fees and other costs. On December 3, 2025, a stipulated order was entered appointing co-lead plaintiffs and approving their selection of co-lead counsel, and on December 16, 2025, a stipulated order was entered setting a schedule for the filing and responses to an amended complaint. Per the terms of the December 16, 2025 stipulated order, an amended complaint captioned <i>Allard, et al. v. Jasper Therapeutics, Inc., et al.</i> (Case No. 25-cv-08010) was filed, and defendants&#8217; motion to dismiss was filed on April 20, 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, on November 5, 2025, a shareholder derivative complaint captioned <i>Bardauskas v. Martell, et al</i>. (Case No. 25-cv-09561) was filed in the United States District Court for the Northern District of California, and on December 22, 2025, another shareholder derivative complaint was filed in the same court and captioned <i>Walsh v. Martell, et al.</i> (Case No. 25-cv-10899).&#160;The derivative complaints name as defendants certain of the Company&#8217;s current and former officers and directors, and allege claims related to the allegations raised in the shareholder class action complaint. On January 21, 2026, a stipulated order was entered, among other things, consolidating and staying the derivative actions.&#160;The Company believes the claims raised in these lawsuits are without merit, and intends to defend these matters vigorously.&#160;However, there can be no assurance that the Company will prevail.&#160;The Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore, no amount of loss has been accrued in the Company&#8217;s condensed consolidated financial statements as of and for the three months ended March 31, 2026. Regardless of outcome, litigation can have an adverse impact on the Company due to costs involved, diversion of management resources, negative publicity, reputational harm, and other factors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company believes that it is not currently a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations&#160; or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Guarantees and Indemnifications </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of each of March 31, 2026 and December 31, 2025, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">COMMON STOCK</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 9. COMMON STOCK</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company is authorized to issue 490,000,000&#160;shares of voting common stock, 2,000,000&#160;shares of non-voting&#160;common stock, and 10,000,000&#160;shares of undesignated preferred stock. There were&#160;27,996,819 shares of voting common stock, <span style="-sec-ix-hidden:fc_1765267982"><span style="-sec-ix-hidden:fc_1111002203">no</span></span> shares of non-voting common stock&#160;and <span style="-sec-ix-hidden:fc_2072766674"><span style="-sec-ix-hidden:fc_549550349">no</span></span> shares of preferred stock issued and outstanding as of March 31, 2026. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Holders of the voting common stock and the non-voting&#160;common stock have similar rights, except that non-voting stockholders are not entitled to vote, including for the election of directors. Holders of voting common stock do not have conversion rights, while holders of non-voting&#160;common stock have the right to convert each share of non-voting&#160;common stock held by such holder into one share of voting common stock at such holder&#8217;s election by providing written notice to the Company, provided that as a result of such conversion, such holder, together with its affiliates, would not beneficially own in excess of 9.9% of the Company&#8217;s voting common stock following such conversion. There were <span style="-sec-ix-hidden:fc_2048509785"><span style="-sec-ix-hidden:fc_1054403778">no</span></span> outstanding shares of non-voting common stock as of March 31, 2026 and December 31, 2025. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;As of March 31, 2026 and December 31, 2025, the Company had common stock reserved for future issuance as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Outstanding and issued common stock options</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">2,671,358</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">2,246,206</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Outstanding and issued restricted stock units</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">170,100</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">198,900</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Outstanding and issued performance-based restricted stock units</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1844764249">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">20,000</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Shares issuable upon exercise of Public Warrants (1)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">499,986</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">499,986</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Shares issuable upon exercise of Common Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">12,345,707</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">12,345,707</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Shares issuable upon exercise of Pre-Funded Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">675,000</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">675,000</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Shares available for grant under Equity Incentive Plans</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">418,817</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">843,360</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Shares available for grant under Employee Stock Purchase Plan</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">920,827</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">920,827</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Shares available for grant under 2022 Inducement Equity Incentive Plan</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">180,960</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">132,769</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Total shares of common stock reserved</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">17,882,755</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">17,882,755</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><sup>&#160;</sup></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"><td style="width: 0in"></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The                                             Company has 4,999,863 outstanding warrants to purchase an aggregate of&#160;499,986&#160;shares                                             of its common stock (the &#8220;Public Warrants&#8221;). A holder may purchase&#160;one&#160;share                                             of the Company&#8217;s common stock for every&#160;ten&#160;Public Warrants at an exercise                                             price of $115.00&#160;per share. The Public Warrants are publicly traded and exercisable                                             during the exercise period, which commenced on October 24, 2021 and ends on September 24,                                             2026, for cash or, in certain circumstances, on a cashless basis. The Public Warrants were                                             reclassified to equity in January 2023.</span></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Shelf Registration Statement</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 19, 2025, the Company filed a new shelf registration statement on Form S-3 (the &#8220;S-3&#8221;) with the SEC, which was declared effective on March 26, 2025. As of March 31, 2026, the Company can sell from time to time up to $263.5 million of common stock, preferred stock, debt securities, warrants, rights, units and depositary shares comprised of any combination of these securities, for the Company&#8217;s own account in one or more offerings under the S-3. The terms of any offering under the S-3 will be established at the time of such offering and will be described in a prospectus supplement to the S-3 filed with the SEC prior to the completion of any such offering. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>ATM Offerings</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On March 19, 2025, the Company entered into an Open Market Sale Agreement<sup>SM</sup>&#160;with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which the Company may offer and sell through or to Jefferies, as sales agent or principal, shares of common stock from time to time (the &#8220;ATM Offering&#8221;). On March 26, 2025, the Company filed with the SEC a prospectus under the S-3 in connection with the ATM Offering (the &#8220;ATM Prospectus&#8221;), pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to $100.0 million. As of March 31, 2026, the Company issued and sold an aggregate of 1,231,447 shares of common stock for net proceeds of approximately $6.5 million pursuant to the ATM Prospectus. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026, $93.5 million remained available under the ATM Prospectus. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Underwritten Offering</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On September 18, 2025, the Company entered into an underwriting agreement with TD Securities (USA) LLC as the representative of the several underwriters, relating to an underwritten public offering under the S-3 of an aggregate of 11,670,707 shares of common stock, Pre-Funded Warrants to purchase 675,000 shares of common stock and Common Warrants to purchase 12,345,707 shares of common stock. The Company received net proceeds of $27.5&#160;million. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026, $170.0 million remained available and unallocated under the S-3. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.D.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.B.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 10. STOCK-BASED COMPENSATION</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026, 2,750,719 shares were reserved for issuance under the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), of which 418,817 shares were available for future grant and 2,331,902 shares were subject to outstanding options and restricted stock units (&#8220;RSUs&#8221;), including 30,894 shares subject to performance-based awards. As of March 31, 2026, options to purchase 140,516 shares of common stock remained outstanding and unexercised, and continue to be governed by the 2019 Equity Incentive Plan (the &#8220;2019 EIP&#8221;). As of March 31, 2026, 1,000,000 shares were reserved under the 2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), of which 920,827 shares were available for future issuance and 79,173 shares had been issued. As of March 31, 2026, 550,000 shares were reserved for issuance under the 2022 Inducement Equity Incentive Plan (the &#8220;2022 Inducement Plan&#8221;), of which 180,960 shares were available for future grant and 369,040 shares were subject to outstanding stock options. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Stock Option Activity</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the stock option activities, including performance-based stock options, under the 2024 Plan, the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), the 2022 Inducement Plan and the 2019 EIP for the three months ended March 31, 2026:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Outstanding</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise     Price</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average<br/> Remaining<br/>     Contractual<br/> Life&#160;(Years)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic Value <br/>     (in thousands)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%">Balance, December 31, 2025</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">2,246,206</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">13.72</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">4.81</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_838649266">&#8212;</span></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Options granted</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,262,300</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1.65</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Options cancelled/forfeited</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(837,148</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">7.08</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Balance, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">2,671,358</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">10.10</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">7.43</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1603413953">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">2,671,358</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">10.10</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">7.43</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1454690266">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Exercisable, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">1,018,023</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">18.93</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">4.33</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1900409824">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. <span style="-sec-ix-hidden:fc_577259707"><span style="-sec-ix-hidden:fc_729631792">No</span></span> options were exercised during the three months ended March 31, 2026 and 2025. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The total fair value of options that vested during the three months ended March 31, 2026 and 2025 was $0.9 million and $2.7 million, respectively. The weighted-average grant date fair value of options granted during the three months ended March 31, 2026 and 2025 was $1.33 and $4.92 per share, respectively. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Unamortized stock-based compensation expense as of March 31, 2026 was $5.6 million, which is expected to be recognized over a weighted-average period of 3.0 years. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Performance-Based Stock Options&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> There was <span style="-sec-ix-hidden:fc_597754003">no</span> performance-based stock option activity under the 2024 Plan or the 2021 Plan during the three months ended March 31, 2026. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Outstanding</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise&#160;Price</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/>     Contractual<br/> Life&#160;(Years)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value     &#160;(in thousands)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%; padding-bottom: 1.5pt">Balance, December 31, 2025</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">30,894</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td> <td style="width: 9%; padding-bottom: 1.5pt; text-align: right">7.33</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 9%; padding-bottom: 1.5pt; text-align: right">4.43</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td> <td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden:fc_1799126299">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Balance, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">30,894</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right">7.33</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">4.18</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_723560973">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">30,894</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right">7.33</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">4.18</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1792648283">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Exercisable, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">30,894</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right">7.33</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">4.18</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1994038587">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Restricted Stock Units (RSUs)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides a summary of RSU activity under the 2024 Plan during the three months ended March 31, 2026:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Share</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Grant Date     <br/> Fair Value</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Unvested restricted stock units at December 31, 2025</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">198,900</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">6.00</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 1.5pt">Forfeited</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(28,800</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td> <td style="padding-bottom: 1.5pt; text-align: right">6.00</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Unvested restricted stock units at March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">170,100</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right">6.00</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Performance Restricted Stock Units (PSUs) </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &#160;In June 2024, the Company granted PSUs for 20,000 shares that would vest in full if the closing price of the Company&#8217;s common stock on the Nasdaq Capital Market reached or exceeded $35.00 per share (subject to adjustment for recapitalizations, stock splits and similar transactions) for thirty consecutive calendar days within two years from the grant date. If the vesting condition was not met within two years from the grant date, the PSUs would be forfeited. The Company concluded that issued PSUs were equity-based awards and include a market based vesting condition. The Company used a Monte Carlo simulation model to estimate the fair value of the PSUs with the following assumptions: common stock fair value of $23.95, which was the closing market price of the Company&#8217;s common stock at the grant date, volatility of 133.00%, risk free rate of 4.87%, and vesting term of 2.0 years. Total estimated fair value of $0.4 million was recognized as stock-based compensation expense over 0.4 years, the derived requisite service period from the grant date. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In January 2026, the employee holding the PSUs was terminated and the award was forfeited. <span style="-sec-ix-hidden:fc_1423726112">No</span> stock-based compensation expense was reversed upon forfeiture, as the award included only a market-based vesting condition and the derived requisite service period had been completed.  </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Employee Stock Purchase Plan</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company did not issue any shares of common stock under the ESPP during the three months ended March 31, 2026 and 2025, and recognized less than $0.1 million and $0.1 million compensation expense related to the ESPP during the three months ended March 31, 2026 and 2025, respectively. There was $0.2 million unamortized stock-based compensation for shares issuable under the ESPP as of March 31, 2026, which is expected to be recognized over a weighted-average period of 1.7 years. The Company recorded $0.1 million in accrued expenses and other current liabilities related to contributions withheld as of March 31, 2026.&#160; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Stock-Based Compensation Expense</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table presents stock-based compensation expenses related to options, PSUs and RSUs granted to employees and non-employees, employee stock purchase plan awards and restricted common stock shares issued to founders (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">General and administrative</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">202</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">1,240</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Research and development</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">221</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">571</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 4pt; padding-left: 9pt">Total</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">423</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">1,811</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company recognized $0.1&#160;million and zero stock-based compensation expense related to performance-based options, PSUs and RSUs during the three months ended March 31, 2026 and 2025, respectively. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Valuation of Stock Options</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 70%; text-align: left">Expected term (in years)</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 12%; text-align: right">6.08</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 12%; text-align: right">6.01 &#8211; 6.08</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Expected volatility</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">99.87% &#8211; 100.05</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">97.37% &#8211; 97.93</td> <td style="text-align: left">%</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3.85% &#160;&#8211; 3.88</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3.93% &#8211; 4.35</td> <td style="text-align: left">%</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Expected dividend yield</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1964576807">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_402018995">&#8212;</span></td> <td style="text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share Attributable to Common Stockholders [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 11. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>Numerator:</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left; padding-bottom: 4pt">Net loss attributable to common stockholders</td> <td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(1,174</td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td> <td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(21,241</td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Denominator:</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Weighted average common shares and pre-funded warrant shares outstanding</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">28,671,819</td> <td style="text-align: left">(a)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">15,022,122</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt">Weighted average shares used to compute basic and diluted net loss per share</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">28,671,819</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">15,022,122</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Net loss per share attributable to common stockholders &#8211; basic and diluted</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(0.04</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(1.41</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"><td style="width: 0in"></td> <td style="width: 0.25in; text-align: left">(a)</td> <td style="text-align: justify">Includes 675,000 weighted-average shares underlying pre-funded warrants outstanding during the period, as such warrants are exercisable at any time for nominal consideration ($0.0001 per share).</td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Outstanding and issued common stock options</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">2,671,358</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">2,186,226</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Outstanding and issued restricted stock units</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">170,100</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1768916711">&#8212;</span></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Shares issuable upon exercise of Public Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">499,986</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">499,986</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Shares issuable upon exercise of Common Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">12,345,707</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1479140823">&#8212;</span></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Unvested performance-based restricted stock units</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1505739634">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="font-weight: bold; padding-bottom: 4pt">Total</td> <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">15,687,151</td> <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td> <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,706,212</td> <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 12. RELATED PARTIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In the first quarter of 2024, a senior executive of the Company joined the board of directors of an information technology service provider that the Company has utilized to support a broad array of the Company&#8217;s systems infrastructure as well as for general information technology support services. For the three months ended March 31, 2026 and 2025, the Company incurred $0.3 million and $0.2&#160;million, respectively, for various information technology support services performed by this service provider. There was $0.1 million of accounts payable recognized in the condensed consolidated balance sheets as of each of March 31, 2026 and December 31, 2025. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 13. SEGMENT INFORMATION</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company has determined it operates as a <span style="-sec-ix-hidden:fc_1666881356"><span style="-sec-ix-hidden:fc_975557945">single</span></span> operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma. The Company&#8217;s chief operating decision maker, its <span style="-sec-ix-hidden:fc_743175501">Chief Executive Officer</span> (the &#8220;CEO&#8221;), manages the Company&#8217;s operations on a consolidated basis. The CEO assesses the segment&#8217;s performance and allocates resources based on review of various development, manufacturing and clinical programs expenses, along with the segment&#8217;s personnel and general and overhead costs. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the significant expense categories included within net loss presented in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise total operating expenses (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Personnel-related costs</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,038</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">8,431</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">General and overhead costs</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3,291</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3,611</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Program costs</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-left: 9pt">Briquilimab platform</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">266</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,957</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-left: 9pt">CMO</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">882</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">2,138</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 9pt">CSU</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">2,378</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">2,746</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-left: 9pt">Asthma</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">(327</td> <td style="text-align: left">)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,393</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 9pt">CIndU</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">424</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">885</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-left: 9pt">SCID</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1357899928">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">523</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 1.5pt; padding-left: 9pt">MDS/AML</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1112529675">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">118</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total program costs</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">3,623</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">9,760</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expense</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">10,952</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">21,802</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Other income, net</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">9,778</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">561</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Net loss</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(1,174</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(21,241</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All long-lived assets are located in the United States.&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAbstract', window );"><strong>Restructuring [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 14. RESTRUCTURING</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Starting in July 2025, the Company implemented a corporate reorganization and other cost reduction measures to extend its cash runway. These actions included a workforce reduction, refinement of the Company&#8217;s operating plan to focus on briquilimab clinical development programs in chronic urticaria, halting enrollment in its Phase 1b asthma study, discontinuation of other clinical and preclinical programs and cessation of vivarium operations. In 2025, the Company incurred restructuring charges related to workforce reduction of approximately $2.3 million, primarily related to severance payments, and recognized impairment charges of $1.1 million related to the abandonment of certain fixed assets and a right-of-use asset associated with vivarium operations. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 31, 2026 and December 31, 2025, the Company had $0.3 million and $0.4 million, respectively, of accrued severance costs related to the termination of one employee in connection with the restructuring, which are included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. The related severance payments are expected to be made over a period of approximately 12 months, through January 2027.&#160;&#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (1,174)<span></span>
</td>
<td class="num">$ (21,241)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Basis of Presentation</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) for financial reporting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The accompanying condensed financial statements are consolidated and include the accounts of Jasper Therapeutics, Inc. and its wholly-owned subsidiary, Jasper Tx Corp, which had no operations during the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2025 included in the Company&#8217;s Annual Report on the Form 10-K filed with the SEC on March 30, 2026. There were no changes to the Company&#8217;s significant accounting policies as described in the Annual Report on Form 10-K. The information as of December 31, 2025, included in the condensed consolidated balance sheets was derived from the Company&#8217;s audited financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company&#8217;s consolidated financial statements. The results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026 or for any other interim period or for any other future year.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Going Concern</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, <i>Going Concern</i>, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of the Company&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating effect of the Company&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. In performing this analysis, the Company excluded certain elements of its operating plan that cannot be considered probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company has incurred significant losses and negative cash flows from operations since its inception. During the three months ended March 31, 2026 and 2025, the Company incurred net losses of $1.2 million and $21.2 million, respectively. During the three months ended March 31, 2026 and 2025, the Company had negative cash flows from operations of $14.5 million and $22.8 million, respectively. As of March 31, 2026, the Company had an accumulated deficit of $317.8 million. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support the Company&#8217;s cost structure. As of March 31, 2026, the Company had cash and cash equivalents of $14.1 million. The Company&#8217;s management expects that the existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management expects to finance the Company&#8217;s future cash needs through equity or debt financings, collaborations or a combination of these approaches, and given the imminent need for additional funding to continue to fund operations in the near-term, the Company is actively seeking additional capital to extend the cash runway. However, due to several factors, including those outside management&#8217;s control, there can be no assurance that the Company will be able to complete additional financings. The Company&#8217;s ability to raise additional funds may be adversely impacted by negative global economic conditions and any disruptions to and volatility in the credit and financial markets in the United States and worldwide or other factors. There can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms favorable or acceptable to the Company. The Company routinely evaluates cost reduction measures to proactively manage cash burn, but if the Company is unable to obtain adequate financing when needed or on terms favorable or acceptable to it, the Company may be forced to take broader actions such as to delay, reduce the scope of or eliminate one or more of its research and development programs. The Company concluded the likelihood that its plan to successfully obtain sufficient funding or adequately delay or reduce expenditures, while reasonably possible, is less than probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The accompanying unaudited interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. These unaudited interim condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Use of Estimates</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the condensed consolidated financial statements include, but are not limited to, the determination of the accrued research and development expenses, the measurement of stock-based compensation expense and the valuation of warrant liability. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Cash, Cash Equivalents, and Restricted Cash</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total amount shown in the condensed consolidated statements of cash flows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Cash and cash equivalents</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">14,144</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">28,692</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">417</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">417</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total cash, cash equivalents and restricted cash</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">14,561</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">29,109</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cash and cash equivalents consist of cash held in operating accounts and investments in money market funds. Restricted cash relates to the letter of credit secured in conjunction with the operating lease (Note 8).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Concentrations of Credit Risk and Other Risks and Uncertainties</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company&#8217;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America. Cash balances are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced any losses on its cash, cash equivalents and marketable securities&#8217; balances and periodically evaluates the creditworthiness of its financial institutions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is subject to risks common to companies in the development stage, including, but not limited to, development and regulatory approval of new product candidates, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product plans. To achieve profitable operations, the Company must successfully develop and obtain requisite regulatory approvals for, manufacture, and market its product candidates. There can be no assurance that any such product candidate can be developed and approved or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product will be successfully marketed. These factors could have a material adverse effect on the Company&#8217;s future financial results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Products developed by the Company require approval from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#8217;s future products will receive the necessary clearances. If the Company were denied such clearances or such clearances were delayed, it could have a materially adverse impact on the Company.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Recent Accounting Pronouncements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Accounting Pronouncements Not Yet Adopted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;In November 2024, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date (&#8220;ASU 2025-01&#8221;). The amendments do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In September 2025, the FASB issued ASU No. 2025-06, Intangibles - Goodwill and Other - Internal - Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (&#8220;ASU 2025-06&#8221;). The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages. This ASU requires entities to begin capitalizing software costs when management authorizes and commits to funding the software project, and it is probable that the project will be completed, and the software will be used for its intended purpose. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2025, the FASB issued ASU No. 2025-10, Accounting for Government Grants Received by Business Entities (Topic 832). This ASU provides recognition, measurement, presentation, and disclosure requirements for government grants, including guidance for grants related to an asset and grants related to income. ASU No. 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting: Narrow-Scope Improvements (Topic 270). This ASU improves clarity for interim financial reporting requirements under the existing guidance within ASC Topic 270, by creating a comprehensive list of interim disclosure requirements, clarifying scope and applicability, along with adding a principle to disclose all material events that have occurred since the most recently filed Annual Report on Form 10-K. ASU No. 2025-11 is effective for interim reporting for fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total amount shown in the condensed consolidated statements of cash flows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Cash and cash equivalents</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">14,144</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">28,692</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">417</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">417</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total cash, cash equivalents and restricted cash</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">14,561</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">29,109</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured on a Recurring Basis</a></td>
<td class="text"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>Financial assets</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Money market funds</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,144</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_111159347">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1894122814">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,144</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Total fair value of assets</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">13,144</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1072361442">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_804810147">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">13,144</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Financial liabilities</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Warrant liability</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1196049397">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1867564296">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">6,524</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">6,524</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt">Total fair value of financial liabilities</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1620055900">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1092525917">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">6,524</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">6,524</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>Financial assets</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Money market funds</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">27,692</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1276276239">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_707032855">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">27,692</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Total fair value of assets</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">27,692</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1289593603">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1353737602">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">27,692</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Financial liabilities</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Warrant liability</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_166082834">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1176672139">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">16,164</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">16,164</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt">Total fair value of financial liabilities</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1449616030">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_978200156">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">16,164</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">16,164</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in the Company&#8217;s Warrant Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the three months ended March 31, 2026, the changes in the Company&#8217;s warrant liability were as follows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant<br/> Liability</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; font-weight: bold">Fair Value as of December 31, 2025</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">16,164</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in the fair value</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(9,640</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; padding-bottom: 4pt">Fair Value as of March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">6,524</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Estimate the Fair Value of the Warrant Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The key inputs into valuation models used to estimate the fair value of the warrant liability as of March 31,2026 and December 31, 2025 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%">Common stock price</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">.88</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">1.83</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Expected term (in years)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3.98</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">4.22</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Expected volatility</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">115.68</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">113.30</td> <td style="text-align: left">%</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3.86</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3.66</td> <td style="text-align: left">%</td> </tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Condensed Consolidated Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the details of prepaid expenses and other current assets as of the dates set forth below (in thousands):&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Research and development prepaid expenses</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,847</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,320</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Prepaid insurance</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">653</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">866</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Prepaid travel expenses</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">243</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">103</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and current assets</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">405</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">664</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 4pt">Total</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">6,148</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">5,953</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the details of property and equipment, net as of the dates set forth below (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Leasehold improvements</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,711</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,711</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Lab equipment</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,513</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,513</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Office furniture &amp; fixtures</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">522</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">522</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Computer equipment</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">170</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">170</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-left: 9pt">Property and equipment, gross</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">4,916</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">4,916</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(4,835</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(4,814</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Property and equipment, net</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">81</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">102</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the details of accrued expenses and other current liabilities as of the dates set forth below (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Research and development accrued expenses</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">3,422</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">3,775</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Accrued employee and related compensation expenses</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,889</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,589</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Accrued legal and professional expenses</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">321</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">261</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 1.5pt">Other</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">168</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">120</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 4pt">Total</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">5,800</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">5,745</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease costs, which were included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss, are as follows (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="font-weight: bold">Lease cost</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Operating lease cost</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">203</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">232</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Short-term lease cost</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1783648313">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">169</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Variable lease cost</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">178</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">118</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: 9.05pt">Total lease cost</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">381</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">519</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental information related to the Company&#8217;s operating leases is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">496</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">356</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Weighted average remaining lease term (years)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">0.39</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1.4</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Weighted average discount rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">8.00</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">8.00</td> <td style="text-align: left">%</td> </tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments as of March 31, 2026 (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="font-weight: bold; border-bottom: Black 1.5pt solid">Year Ending December 31,</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: left; padding-bottom: 1.5pt">2026 (remainder of the year)</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">764</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-left: 9pt">Total undiscounted lease payments</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">764</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-left: 9pt">Total discounted lease payments</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">757</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Less current portion of lease liability</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(757</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Noncurrent portion of lease liability</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_357656926">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;As of March 31, 2026 and December 31, 2025, the Company had common stock reserved for future issuance as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td> <td style="font-weight: bold">&#160;</td> <td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td> <td style="font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Outstanding and issued common stock options</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">2,671,358</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">2,246,206</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Outstanding and issued restricted stock units</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">170,100</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">198,900</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Outstanding and issued performance-based restricted stock units</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1844764249">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">20,000</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Shares issuable upon exercise of Public Warrants (1)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">499,986</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">499,986</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Shares issuable upon exercise of Common Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">12,345,707</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">12,345,707</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Shares issuable upon exercise of Pre-Funded Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">675,000</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">675,000</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Shares available for grant under Equity Incentive Plans</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">418,817</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">843,360</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Shares available for grant under Employee Stock Purchase Plan</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">920,827</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">920,827</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Shares available for grant under 2022 Inducement Equity Incentive Plan</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">180,960</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">132,769</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Total shares of common stock reserved</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">17,882,755</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">17,882,755</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><sup>&#160;</sup></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"><td style="width: 0in"></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The                                             Company has 4,999,863 outstanding warrants to purchase an aggregate of&#160;499,986&#160;shares                                             of its common stock (the &#8220;Public Warrants&#8221;). A holder may purchase&#160;one&#160;share                                             of the Company&#8217;s common stock for every&#160;ten&#160;Public Warrants at an exercise                                             price of $115.00&#160;per share. The Public Warrants are publicly traded and exercisable                                             during the exercise period, which commenced on October 24, 2021 and ends on September 24,                                             2026, for cash or, in certain circumstances, on a cashless basis. The Public Warrants were                                             reclassified to equity in January 2023.</span></td> </tr></tbody> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the stock option activities, including performance-based stock options, under the 2024 Plan, the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), the 2022 Inducement Plan and the 2019 EIP for the three months ended March 31, 2026:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Outstanding</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise     Price</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average<br/> Remaining<br/>     Contractual<br/> Life&#160;(Years)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic Value <br/>     (in thousands)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%">Balance, December 31, 2025</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">2,246,206</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">13.72</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">4.81</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_838649266">&#8212;</span></td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Options granted</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,262,300</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1.65</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Options cancelled/forfeited</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(837,148</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">7.08</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Balance, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">2,671,358</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">10.10</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">7.43</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1603413953">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">2,671,358</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">10.10</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">7.43</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1454690266">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Exercisable, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">1,018,023</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">18.93</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">4.33</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1900409824">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> There was <span style="-sec-ix-hidden:fc_597754003">no</span> performance-based stock option activity under the 2024 Plan or the 2021 Plan during the three months ended March 31, 2026. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Outstanding</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise&#160;Price</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/>     Contractual<br/> Life&#160;(Years)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value     &#160;(in thousands)</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%; padding-bottom: 1.5pt">Balance, December 31, 2025</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">30,894</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td> <td style="width: 9%; padding-bottom: 1.5pt; text-align: right">7.33</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 9%; padding-bottom: 1.5pt; text-align: right">4.43</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">$</td> <td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden:fc_1799126299">&#8212;</span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Balance, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">30,894</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right">7.33</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">4.18</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_723560973">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">30,894</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right">7.33</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">4.18</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1792648283">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 4pt">Exercisable, March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">30,894</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right">7.33</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt; text-align: right">4.18</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden:fc_1994038587">&#8212;</span></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides a summary of RSU activity under the 2024 Plan during the three months ended March 31, 2026:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Share</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Grant Date     <br/> Fair Value</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Unvested restricted stock units at December 31, 2025</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">198,900</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">6.00</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 1.5pt">Forfeited</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(28,800</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td> <td style="padding-bottom: 1.5pt; text-align: right">6.00</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Unvested restricted stock units at March 31, 2026</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">170,100</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right">6.00</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table presents stock-based compensation expenses related to options, PSUs and RSUs granted to employees and non-employees, employee stock purchase plan awards and restricted common stock shares issued to founders (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">General and administrative</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">202</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">1,240</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Research and development</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">221</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">571</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 4pt; padding-left: 9pt">Total</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">423</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">1,811</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 70%; text-align: left">Expected term (in years)</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 12%; text-align: right">6.08</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 12%; text-align: right">6.01 &#8211; 6.08</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Expected volatility</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">99.87% &#8211; 100.05</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">97.37% &#8211; 97.93</td> <td style="text-align: left">%</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3.85% &#160;&#8211; 3.88</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3.93% &#8211; 4.35</td> <td style="text-align: left">%</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Expected dividend yield</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1964576807">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_402018995">&#8212;</span></td> <td style="text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share Attributable to Common Stockholders [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>Numerator:</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left; padding-bottom: 4pt">Net loss attributable to common stockholders</td> <td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(1,174</td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td> <td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td> <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(21,241</td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Denominator:</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Weighted average common shares and pre-funded warrant shares outstanding</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">28,671,819</td> <td style="text-align: left">(a)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">15,022,122</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 4pt">Weighted average shares used to compute basic and diluted net loss per share</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">28,671,819</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: right">15,022,122</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Net loss per share attributable to common stockholders &#8211; basic and diluted</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(0.04</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(1.41</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"><td style="width: 0in"></td> <td style="width: 0.25in; text-align: left">(a)</td> <td style="text-align: justify">Includes 675,000 weighted-average shares underlying pre-funded warrants outstanding during the period, as such warrants are exercisable at any time for nominal consideration ($0.0001 per share).</td> </tr></tbody> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td>&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Outstanding and issued common stock options</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">2,671,358</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">2,186,226</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Outstanding and issued restricted stock units</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">170,100</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1768916711">&#8212;</span></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Shares issuable upon exercise of Public Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">499,986</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">499,986</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td>Shares issuable upon exercise of Common Warrants</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">12,345,707</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1479140823">&#8212;</span></td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Unvested performance-based restricted stock units</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1505739634">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="font-weight: bold; padding-bottom: 4pt">Total</td> <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">15,687,151</td> <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td> <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,706,212</td> <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td> </tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the significant expense categories included within net loss presented in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise total operating expenses (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Personnel-related costs</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,038</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">8,431</td> <td style="width: 1%; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">General and overhead costs</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3,291</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">3,611</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Program costs</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-left: 9pt">Briquilimab platform</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">266</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,957</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-left: 9pt">CMO</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">882</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">2,138</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 9pt">CSU</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">2,378</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">2,746</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-left: 9pt">Asthma</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">(327</td> <td style="text-align: left">)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">1,393</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 9pt">CIndU</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">424</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">885</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="padding-left: 9pt">SCID</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="-sec-ix-hidden:fc_1357899928">&#8212;</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">523</td> <td style="text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 1.5pt; padding-left: 9pt">MDS/AML</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1112529675">&#8212;</span></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">118</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total program costs</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">3,623</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">9,760</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expense</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">10,952</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">21,802</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Other income, net</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">9,778</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">561</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Net loss</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(1,174</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(21,241</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> </tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (1,174)<span></span>
</td>
<td class="num">$ (21,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Operating cash flows</a></td>
<td class="num">(14,548)<span></span>
</td>
<td class="num">$ (22,842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(317,844)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (316,670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,144<span></span>
</td>
<td class="nump">$ 28,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 14,561<span></span>
</td>
<td class="nump">$ 29,109<span></span>
</td>
<td class="nump">$ 49,216<span></span>
</td>
<td class="nump">$ 72,054<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">$ 13,144<span></span>
</td>
<td class="nump">$ 27,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of financial liabilities</a></td>
<td class="nump">6,524<span></span>
</td>
<td class="nump">16,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">13,144<span></span>
</td>
<td class="nump">27,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of financial liabilities</a></td>
<td class="nump">6,524<span></span>
</td>
<td class="nump">16,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">13,144<span></span>
</td>
<td class="nump">27,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">13,144<span></span>
</td>
<td class="nump">27,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of financial liabilities</a></td>
<td class="nump">6,524<span></span>
</td>
<td class="nump">16,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant liability [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant liability [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant liability [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of financial liabilities</a></td>
<td class="nump">$ 6,524<span></span>
</td>
<td class="nump">$ 16,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=jspr_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=jspr_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Changes in the Company&#8217;s Warrant Liability (Details) - Warrant liability [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Schedule of Changes in the Company&#8217;s Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value, as of beginning</a></td>
<td class="nump">$ 16,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in the fair value</a></td>
<td class="num">(9,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value, as of ending</a></td>
<td class="nump">$ 6,524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=jspr_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=jspr_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Estimate the Fair Value of the Warrant Liability (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Common stock price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Estimate the fair value of the warrant liability</a></td>
<td class="nump">0.88<span></span>
</td>
<td class="nump">1.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (in years) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Estimate the fair value of the warrant liability</a></td>
<td class="nump">3.98<span></span>
</td>
<td class="nump">4.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Expected volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Estimate the fair value of the warrant liability</a></td>
<td class="nump">115.68<span></span>
</td>
<td class="nump">113.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Estimate the fair value of the warrant liability</a></td>
<td class="nump">3.86<span></span>
</td>
<td class="nump">3.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481229/860-50-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Condensed Consolidated Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Schedule of Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_ResearchAndDevelopmentPrepaidExpenses', window );">Research and development prepaid expenses</a></td>
<td class="nump">$ 4,847<span></span>
</td>
<td class="nump">$ 4,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PrepaidTravelExpenses', window );">Prepaid travel expenses</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other prepaid expenses and current assets</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 6,148<span></span>
</td>
<td class="nump">$ 5,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_PrepaidTravelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid travel expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_PrepaidTravelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_ResearchAndDevelopmentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_ResearchAndDevelopmentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,916<span></span>
</td>
<td class="nump">$ 4,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(4,835)<span></span>
</td>
<td class="num">(4,814)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,513<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture &amp; fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion, and amortization of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480204/360-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 905<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478704/905-360-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482222/360-10-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Schedule of Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_ResearchAndDevelopmentAccruedExpensesCurrent', window );">Research and development accrued expenses</a></td>
<td class="nump">$ 3,422<span></span>
</td>
<td class="nump">$ 3,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee and related compensation expenses</a></td>
<td class="nump">1,889<span></span>
</td>
<td class="nump">1,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and professional expenses</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 5,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_ResearchAndDevelopmentAccruedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_ResearchAndDevelopmentAccruedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cirm Grant (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_CirmGrantLineItems', window );"><strong>Cirm Grant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Other research and development</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PercentageOfLicensingFees', window );">Percentage of licensing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Percentage of converted loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Received from interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_ReceivedAggregateFromCIRM', window );">Received aggregate from CIRM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">CIRM grant received in other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
<td class="nump">$ 2,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jspr_CaliforniaInstituteForRegenerativeMedicineMember', window );">CIRM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_CirmGrantLineItems', window );"><strong>Cirm Grant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_NetSales', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_CirmGrantLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_CirmGrantLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_NetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_NetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_PercentageOfLicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The 25% rule can be used as a starting point for valuing and setting fair royalty rates for intellectual property assets including copyrights, trademarks and patents in licensing deals. It is an example of an income-based approach licensing fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_PercentageOfLicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_ReceivedAggregateFromCIRM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_ReceivedAggregateFromCIRM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jspr_CaliforniaInstituteForRegenerativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jspr_CaliforniaInstituteForRegenerativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=jspr_TwentyTwentyOneStanfordLicenseAgreementMember', window );">2021 Stanford License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear', window );">Milestone payments obligation to be paid first and second year</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear', window );">Milestone payments obligation to be paid third and fourth year</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_MilestonePaymentsObligationToBePaidThereafter', window );">Milestone payments obligation to be paid thereafter</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_SalesMilestonePayments', window );">Commercial sales milestone payments</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=jspr_TwentyTwentyFourStanfordLicenseAgreementMember', window );">2024 Stanford License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_MilestonePaymentsObligationToBePaidThereafter', window );">Milestone payments obligation to be paid thereafter</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_SalesMilestonePayments', window );">Commercial sales milestone payments</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_ApproximatelyAgreement', window );">Approximately agreement</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_LicenseMaintenanceFee', window );">Annual license maintenance fees</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear', window );">Milestone payments obligation to be paid first through third year</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear', window );">Milestone payments obligation to be paid fourth through sixth year</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_ClinicalDevelopmentMilestonePayments', window );">Clinical development milestone payments</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_ApproximatelyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Approximately agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_ApproximatelyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_ClinicalDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of clinical development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_ClinicalDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_LicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_LicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments obligation to be paid first and second year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payments obligation to be paid first through the third year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments obligation to be paid fourth through sixth year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_MilestonePaymentsObligationToBePaidThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments obligation to be paid thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_MilestonePaymentsObligationToBePaidThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments obligation to be paid third and fourth year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_SalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_SalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=jspr_TwentyTwentyOneStanfordLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=jspr_TwentyTwentyOneStanfordLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=jspr_TwentyTwentyFourStanfordLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=jspr_TwentyTwentyFourStanfordLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PreFundedWarrantPercentage', window );">Pre funded warrant percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PercentageOfElectionHolderWarrants', window );">Percentage of election holder warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PercentagePreFundedWarrants', window );">Percentage pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PercentageOfCommonWarrants', window );">Percentage of common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,640)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=jspr_September2025OfferingMember', window );">September 2025 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares (in Shares)</a></td>
<td class="nump">11,670,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=jspr_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase shares (in Shares)</a></td>
<td class="nump">12,345,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PreFundedWarrantPercentage', window );">Pre funded warrant percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PercentageOfElectionHolderWarrants', window );">Percentage of election holder warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=jspr_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase shares (in Shares)</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PercentageOfElectionHolderWarrants', window );">Percentage of election holder warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PercentageOfElectionHolderWarrants', window );">Percentage of election holder warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_PercentageOfCommonWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_PercentageOfCommonWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_PercentageOfElectionHolderWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of election holder warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_PercentageOfElectionHolderWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_PercentagePreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_PercentagePreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_PreFundedWarrantPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre funded warrant percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_PreFundedWarrantPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=jspr_September2025OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=jspr_September2025OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=jspr_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=jspr_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=jspr_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=jspr_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Laboratory and office space area of land (in Square Feet) | ft&#178;</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,900<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Secured letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and lease liability</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 970<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-28(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478979/970-360-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Components of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">4 months 20 days<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2026 (remainder of the year)</a></td>
<td class="nump">$ 764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total discounted lease payments</a></td>
<td class="nump">757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liability</a></td>
<td class="num">(757)<span></span>
</td>
<td class="num">$ (1,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent portion of lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 18, 2025</div></th>
<th class="th"><div>Mar. 26, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,000,000<span></span>
</td>
<td class="nump">492,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Voting common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,996,819<span></span>
</td>
<td class="nump">27,996,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,996,819<span></span>
</td>
<td class="nump">27,996,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_NumberOfSharePurchase', window );">Number of share of voting common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_VotingCommonStockPercent', window );">Voting common stock percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Sell from time to time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_AggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_UnderwrittenOfferingRemainedAvailable', window );">Remained available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Outstanding Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,999,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=jspr_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PurchaseAnAggregateShares', window );">Purchase an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jspr_VotingCommonStockMember', window );">Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Voting common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=jspr_UnderwrittenOfferingsMember', window );">Underwritten Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate shares</a></td>
<td class="nump">$ 11,670,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PreFundedWarrantsToPurchase', window );">Pre funded warrants to purchase shares</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_CommonWarrantsToPurchaseShares', window );">Common warrants to purchase shares</a></td>
<td class="nump">12,345,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_AvailableOfferingAmount', window );">Available offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_AggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_AggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_AvailableOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of available offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_AvailableOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_CommonWarrantsToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common warrants to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_CommonWarrantsToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_NumberOfSharePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The share purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_NumberOfSharePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_PreFundedWarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pre funded warrants to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_PreFundedWarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_PurchaseAnAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of purchase an aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_PurchaseAnAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_UnderwrittenOfferingRemainedAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of underwritten offering remained available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_UnderwrittenOfferingRemainedAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_VotingCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_VotingCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=jspr_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=jspr_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jspr_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jspr_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=jspr_UnderwrittenOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=jspr_UnderwrittenOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,882,755<span></span>
</td>
<td class="nump">17,882,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_OutstandingAndIssuedCommonStockOptionsMember', window );">Outstanding and issued common stock options [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,671,358<span></span>
</td>
<td class="nump">2,246,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_OutstandingAndIssuedRestrictedStockUnitsMember', window );">Outstanding and issued restricted stock units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170,100<span></span>
</td>
<td class="nump">198,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember', window );">Outstanding and issued performance-based restricted stock units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_SharesIssuableUponExerciseOfPublicWarrantsMember', window );">Shares issuable upon exercise of Public Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">499,986<span></span>
</td>
<td class="nump">499,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember', window );">Shares issuable upon exercise of Common Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,345,707<span></span>
</td>
<td class="nump">12,345,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember', window );">Shares issuable upon exercise of Pre-Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">675,000<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember', window );">Shares available for grant under Equity Incentive Plans [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">418,817<span></span>
</td>
<td class="nump">843,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember', window );">Shares available for grant under Employee Stock Purchase Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">920,827<span></span>
</td>
<td class="nump">920,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember', window );">Shares available for grant under 2022 Inducement Equity Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">180,960<span></span>
</td>
<td class="nump">132,769<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The                                             Company has 4,999,863 outstanding warrants to purchase an aggregate of&#160;499,986&#160;shares                                             of its common stock (the &#8220;Public Warrants&#8221;). A holder may purchase&#160;one&#160;share                                             of the Company&#8217;s common stock for every&#160;ten&#160;Public Warrants at an exercise                                             price of $115.00&#160;per share. The Public Warrants are publicly traded and exercisable                                             during the exercise period, which commenced on October 24, 2021 and ends on September 24,                                             2026, for cash or, in certain circumstances, on a cashless basis. The Public Warrants were                                             reclassified to equity in January 2023.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_OutstandingAndIssuedCommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_OutstandingAndIssuedCommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_OutstandingAndIssuedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_OutstandingAndIssuedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_SharesIssuableUponExerciseOfPublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_SharesIssuableUponExerciseOfPublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,882,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,882,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of the options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value option vested amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,745,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PerformanceBasedStockOptionActivity', window );">Performance-based stock option activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_TotalEstimatedFairValue', window );">Total estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_RecognizedCompensationExpensePeriod', window );">Recognized compensation expense period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jspr_PerformanceBasedStockOptionsMember', window );">Performance-Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock remained outstanding and unexercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jspr_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jspr_PerformanceRestrictedStockUnitsMember', window );">Performance Restricted Stock Units (PSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted shares</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Price per share</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Assumptions common stock fair value per share</a></td>
<td class="nump">$ 23.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">133.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">4.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_TwoZeroTwoTwoInducementPlanMember', window );">2022 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Reserved share issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_TwoThousandTwentyFourPlanMember', window );">2024 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock remained outstanding and unexercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,331,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares subject to performance-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_TwoZeroOneNinePlanMember', window );">2019 Plan [Member] | Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock remained outstanding and unexercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_TwoZeroTwoFourESPPMember', window );">2024 ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock remained outstanding and unexercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jspr_TwoZeroTwoFourESPPMember', window );">2024 ESPP [Member] | Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_PerformanceBasedStockOptionActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares performance based stock option activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_PerformanceBasedStockOptionActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_RecognizedCompensationExpensePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognized compensation expense period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_RecognizedCompensationExpensePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_TotalEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total estimated fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_TotalEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=jspr_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=jspr_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=jspr_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=jspr_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=jspr_PerformanceRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=jspr_PerformanceRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_TwoZeroTwoTwoInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_TwoZeroTwoTwoInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_TwoThousandTwentyFourPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_TwoThousandTwentyFourPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_TwoZeroOneNinePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_TwoZeroOneNinePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jspr_TwoZeroTwoFourESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jspr_TwoZeroTwoFourESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Option Activities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Stock Option Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,246,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years), Balance</a></td>
<td class="text">4 years 9 months 21 days<span></span>
</td>
<td class="text">7 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,262,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Outstanding, Options cancelled/forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(837,148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options cancelled/forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending balance</a></td>
<td class="nump">2,246,206<span></span>
</td>
<td class="nump">2,671,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 13.72<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,671,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years), Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,018,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jspr_PerformanceBasedStockOptionsMember', window );">Performance-Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Stock Option Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years), Balance</a></td>
<td class="text">4 years 5 months 4 days<span></span>
</td>
<td class="text">4 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending balance</a></td>
<td class="nump">30,894<span></span>
</td>
<td class="nump">30,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 7.33<span></span>
</td>
<td class="nump">$ 7.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years), Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=jspr_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=jspr_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of RSU Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Schedule of RSU Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Share, Unvested restricted stock units, Beginning balance | shares</a></td>
<td class="nump">198,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, Unvested restricted stock units, Beginning balance | $ / shares</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Share, Forfeited | shares</a></td>
<td class="num">(28,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Share, Unvested restricted stock units, Ending balance | shares</a></td>
<td class="nump">170,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, Unvested restricted stock units, Ending balance | $ / shares</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - PSUs [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">$ 1,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jspr_PerformanceShareUnitsPSUsMember', window );">Location, Statement of Income, Balance [Axis]: GeneralandadministrativeMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jspr_PerformanceShareUnitsPSUsMember', window );">Location, Statement of Income, Balance [Axis]: ResearchanddevelopmentMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=jspr_PerformanceShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=jspr_PerformanceShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=GeneralandadministrativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=GeneralandadministrativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=ResearchanddevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=ResearchanddevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model (Details) - Valuation of Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jspr_ValuationOfStockOptionsMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.87%<span></span>
</td>
<td class="nump">97.37%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.85%<span></span>
</td>
<td class="nump">3.93%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jspr_ValuationOfStockOptionsMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.05%<span></span>
</td>
<td class="nump">97.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.88%<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=jspr_ValuationOfStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=jspr_ValuationOfStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share Attributable to Common Stockholders [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable', window );">Weighted average shares | shares</a></td>
<td class="nump">675,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (1,174)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (21,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted average common shares and pre-funded warrant shares outstanding</a></td>
<td class="nump">28,671,819<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15,022,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used to compute basic net loss per share</a></td>
<td class="nump">28,671,819<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,022,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used to compute diluted net loss per share</a></td>
<td class="nump">28,671,819<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,022,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders &#8211; basic</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders &#8211; diluted</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.41)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes 675,000 weighted-average shares underlying pre-funded warrants outstanding during the period, as such warrants are exercisable at any time for nominal consideration ($0.0001 per share).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive net loss per share attributable to common stockholders</a></td>
<td class="nump">15,687,151<span></span>
</td>
<td class="nump">2,706,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding and issued common stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive net loss per share attributable to common stockholders</a></td>
<td class="nump">2,671,358<span></span>
</td>
<td class="nump">2,186,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding and issued restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive net loss per share attributable to common stockholders</a></td>
<td class="nump">170,100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=jspr_SharesIssuableUponExerciseOfPublicWarrantsMember', window );">Shares issuable upon exercise of Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive net loss per share attributable to common stockholders</a></td>
<td class="nump">499,986<span></span>
</td>
<td class="nump">499,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Shares issuable upon exercise of Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive net loss per share attributable to common stockholders</a></td>
<td class="nump">12,345,707<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Unvested performance-based restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive net loss per share attributable to common stockholders</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=jspr_SharesIssuableUponExerciseOfPublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=jspr_SharesIssuableUponExerciseOfPublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsIncurred', window );">Services incurred</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total interest costs incurred during the period and either capitalized or charged against earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Chief operating decision segment manages description</a></td>
<td class="text"> The Company&#8217;s chief operating decision maker, its Chief Executive Officer (the &#8220;CEO&#8221;), manages the Company&#8217;s operations on a consolidated basis. The CEO assesses the segment&#8217;s performance and allocates resources based on review of various development, manufacturing and clinical programs expenses, along with the segment&#8217;s personnel and general and overhead costs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Significant Expense Categories Included Within Net Loss Presented on the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_PersonnelCosts', window );">Personnel-related costs</a></td>
<td class="nump">$ 4,038<span></span>
</td>
<td class="nump">$ 8,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_FacilitiesAndOverheadCosts', window );">General and overhead costs</a></td>
<td class="nump">3,291<span></span>
</td>
<td class="nump">3,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total program costs</a></td>
<td class="nump">3,623<span></span>
</td>
<td class="nump">9,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">10,952<span></span>
</td>
<td class="nump">21,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">9,778<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,174)<span></span>
</td>
<td class="num">(21,241)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jspr_BriquilimabPlatformMember', window );">Briquilimab platform [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total program costs</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jspr_CMOMember', window );">CMO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total program costs</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">2,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jspr_CSUMember', window );">CSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total program costs</a></td>
<td class="nump">2,378<span></span>
</td>
<td class="nump">2,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jspr_AsthmaMember', window );">Asthma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total program costs</a></td>
<td class="num">(327)<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jspr_CIndUMember', window );">CIndU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total program costs</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jspr_SCIDMember', window );">SCID [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total program costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jspr_MDSAMLMember', window );">MDS/AML [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total program costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_FacilitiesAndOverheadCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of facilities and overhead costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_FacilitiesAndOverheadCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_PersonnelCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of personnel costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_PersonnelCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 9<br> -Subsection 06<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 7<br> -Subsection 05<br> -Paragraph c<br> -Subparagraph Schedule II<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 5<br> -Subsection 04<br> -Paragraph c<br> -Subparagraph Schedule I<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.7-05(c)(Schedule II))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479913/944-10-S99-3<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(c)(Schedule I))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-6<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SAB Topic 1.B.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481003/205-10-S50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jspr_BriquilimabPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jspr_BriquilimabPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jspr_CMOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jspr_CMOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jspr_CSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jspr_CSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jspr_AsthmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jspr_AsthmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jspr_CIndUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jspr_CIndUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jspr_SCIDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jspr_SCIDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jspr_MDSAMLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jspr_MDSAMLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAbstract', window );"><strong>Restructuring [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring charges related to workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Accrued severance costs</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jspr_SeveranceCostsPeriod', window );">Severance costs period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jspr_SeveranceCostsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance costs period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jspr_SeveranceCostsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jspr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>258</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995300 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995304 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Condensed Consolidated Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponents</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Cirm Grant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CirmGrant</Role>
      <ShortName>Cirm Grant</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/SignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996320 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/AccountingPoliciesbyPolicyPolicies</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996321 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996322 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996323 - Disclosure - Consolidated Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/ConsolidatedBalanceSheetComponentsTables</Role>
      <ShortName>Consolidated Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996324 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/CommitmentsandContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996325 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/CommonStock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996326 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996327 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholders</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996328 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/SegmentInformation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996329 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996330 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996331 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996332 - Disclosure - Fair Value Measurements - Schedule of Changes in the Company???s Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Changes in the Company???s Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996333 - Disclosure - Fair Value Measurements - Schedule of Estimate the Fair Value of the Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Estimate the Fair Value of the Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996334 - Disclosure - Condensed Consolidated Balance Sheet Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponents</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996335 - Disclosure - Condensed Consolidated Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996336 - Disclosure - Condensed Consolidated Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996337 - Disclosure - Condensed Consolidated Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996338 - Disclosure - Cirm Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CirmGrantDetails</Role>
      <ShortName>Cirm Grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/CirmGrant</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996339 - Disclosure - Significant Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/SignificantAgreementsDetails</Role>
      <ShortName>Significant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/SignificantAgreements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996340 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/Warrants</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996341 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996342 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996343 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996344 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/CommonStockTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996345 - Disclosure - Common Stock - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996346 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/StockBasedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996347 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Option Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996348 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996349 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996350 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996351 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996352 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996353 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996354 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/RelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/RelatedParties</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996355 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/SegmentInformationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996356 - Disclosure - Segment Information - Schedule of Significant Expense Categories Included Within Net Loss Presented on the Company???s Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails</Role>
      <ShortName>Segment Information - Schedule of Significant Expense Categories Included Within Net Loss Presented on the Company???s Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0289477-10q_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996357 - Disclosure - Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jaspertx.com/20260331/role/RestructuringDetails</Role>
      <ShortName>Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jaspertx.com/20260331/role/Restructuring</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ea0289477-10q_jasper.htm">ea0289477-10q_jasper.htm</File>
    <File>jspr-20260331.xsd</File>
    <File>jspr-20260331_cal.xml</File>
    <File>jspr-20260331_def.xml</File>
    <File>jspr-20260331_lab.xml</File>
    <File>jspr-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2026</BaseTaxonomy>
    <BaseTaxonomy items="514">http://fasb.org/us-gaap/2026</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0289477-10q_jasper.htm": {
   "nsprefix": "jspr",
   "nsuri": "http://jaspertx.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "ea0289477-10q_jasper.htm"
     ]
    },
    "schema": {
     "local": [
      "jspr-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd",
      "https://xbrl.sec.gov/ecd/2026/ecd-sub-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "jspr-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jspr-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "jspr-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jspr-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 222,
   "keyCustom": 36,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 24,
   "memberCustom": 37,
   "hidden": {
    "total": 73,
    "http://fasb.org/us-gaap/2026": 68,
    "http://xbrl.sec.gov/dei/2026": 4,
    "http://jaspertx.com/20260331": 1
   },
   "contextCount": 178,
   "entityCount": 1,
   "segmentCount": 68,
   "elementCount": 537,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2026": 514,
    "http://xbrl.sec.gov/dei/2026": 33,
    "http://xbrl.sec.gov/ecd/2026": 4,
    "http://fasb.org/srt/2026": 1
   },
   "report": {
    "R1": {
     "role": "http://jaspertx.com/20260331/role/DocumentAndEntityInformation",
     "longName": "995300 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "longName": "995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
     "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "uref_1987543344",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "uref_1987543344",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
     "longName": "995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "longName": "995304 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "cref_1220156236",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1220156236",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://jaspertx.com/20260331/role/OrganizationandDescriptionofBusiness",
     "longName": "995306 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPolicies",
     "longName": "995307 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://jaspertx.com/20260331/role/FairValueMeasurements",
     "longName": "995308 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponents",
     "longName": "995309 - Disclosure - Condensed Consolidated Balance Sheet Components",
     "shortName": "Condensed Consolidated Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "srt:CondensedFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "srt:CondensedFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://jaspertx.com/20260331/role/CirmGrant",
     "longName": "995310 - Disclosure - Cirm Grant",
     "shortName": "Cirm Grant",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "jspr:CirmGrantDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "jspr:CirmGrantDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://jaspertx.com/20260331/role/SignificantAgreements",
     "longName": "995311 - Disclosure - Significant Agreements",
     "shortName": "Significant Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://jaspertx.com/20260331/role/Warrants",
     "longName": "995312 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "jspr:WarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "jspr:WarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://jaspertx.com/20260331/role/CommitmentsandContingencies",
     "longName": "995313 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://jaspertx.com/20260331/role/CommonStock",
     "longName": "995314 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://jaspertx.com/20260331/role/StockBasedCompensation",
     "longName": "995315 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholders",
     "longName": "995316 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://jaspertx.com/20260331/role/RelatedParties",
     "longName": "995317 - Disclosure - Related Parties",
     "shortName": "Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://jaspertx.com/20260331/role/SegmentInformation",
     "longName": "995318 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://jaspertx.com/20260331/role/Restructuring",
     "longName": "995319 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://jaspertx.com/20260331/role/AccountingPoliciesbyPolicyPolicies",
     "longName": "996320 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996321 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://jaspertx.com/20260331/role/FairValueMeasurementsTables",
     "longName": "996322 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://jaspertx.com/20260331/role/ConsolidatedBalanceSheetComponentsTables",
     "longName": "996323 - Disclosure - Consolidated Balance Sheet Components (Tables)",
     "shortName": "Consolidated Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "srt:CondensedFinancialStatementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "srt:CondensedFinancialStatementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://jaspertx.com/20260331/role/CommitmentsandContingenciesTables",
     "longName": "996324 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://jaspertx.com/20260331/role/CommonStockTables",
     "longName": "996325 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://jaspertx.com/20260331/role/StockBasedCompensationTables",
     "longName": "996326 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersTables",
     "longName": "996327 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://jaspertx.com/20260331/role/SegmentInformationTables",
     "longName": "996328 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996329 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails",
     "longName": "996330 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "longName": "996331 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "cref_1966633800",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1966633800",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails",
     "longName": "996332 - Disclosure - Fair Value Measurements - Schedule of Changes in the Company\u2019s Warrant Liability (Details)",
     "shortName": "Fair Value Measurements - Schedule of Changes in the Company\u2019s Warrant Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "cref_1378325364",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1378325364",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails",
     "longName": "996333 - Disclosure - Fair Value Measurements - Schedule of Estimate the Fair Value of the Warrant Liability (Details)",
     "shortName": "Fair Value Measurements - Schedule of Estimate the Fair Value of the Warrant Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "cref_1826855759",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "uref_1055712422",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1826855759",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "uref_1055712422",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsDetails",
     "longName": "996334 - Disclosure - Condensed Consolidated Balance Sheet Components (Details)",
     "shortName": "Condensed Consolidated Balance Sheet Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:Depreciation",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "srt:CondensedFinancialStatementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:Depreciation",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "srt:CondensedFinancialStatementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "996335 - Disclosure - Condensed Consolidated Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Condensed Consolidated Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "cref_438560971",
      "name": "jspr:ResearchAndDevelopmentPrepaidExpenses",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "srt:CondensedFinancialStatementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_438560971",
      "name": "jspr:ResearchAndDevelopmentPrepaidExpenses",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "srt:CondensedFinancialStatementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
     "longName": "996336 - Disclosure - Condensed Consolidated Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Condensed Consolidated Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "srt:CondensedFinancialStatementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "srt:CondensedFinancialStatementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "996337 - Disclosure - Condensed Consolidated Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Condensed Consolidated Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "cref_438560971",
      "name": "jspr:ResearchAndDevelopmentAccruedExpensesCurrent",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "srt:CondensedFinancialStatementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_438560971",
      "name": "jspr:ResearchAndDevelopmentAccruedExpensesCurrent",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "srt:CondensedFinancialStatementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://jaspertx.com/20260331/role/CirmGrantDetails",
     "longName": "996338 - Disclosure - Cirm Grant (Details)",
     "shortName": "Cirm Grant (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "cref_1842275578",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "jspr:CirmGrantDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1842275578",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "jspr:CirmGrantDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://jaspertx.com/20260331/role/SignificantAgreementsDetails",
     "longName": "996339 - Disclosure - Significant Agreements (Details)",
     "shortName": "Significant Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:CostMaintenance",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:CostMaintenance",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://jaspertx.com/20260331/role/WarrantsDetails",
     "longName": "996340 - Disclosure - Warrants (Details)",
     "shortName": "Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "jspr:PreFundedWarrantPercentage",
      "unitRef": "uref_1055712422",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "jspr:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "jspr:PreFundedWarrantPercentage",
      "unitRef": "uref_1055712422",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "jspr:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails",
     "longName": "996341 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "cref_1406915345",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "uref_1104703976",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "uref_1104703976",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails",
     "longName": "996342 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Components of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails",
     "longName": "996343 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://jaspertx.com/20260331/role/CommonStockDetails",
     "longName": "996344 - Disclosure - Common Stock (Details)",
     "shortName": "Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_438560971",
      "name": "jspr:NumberOfSharePurchase",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails",
     "longName": "996345 - Disclosure - Common Stock - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "shortName": "Common Stock - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_841215262",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://jaspertx.com/20260331/role/StockBasedCompensationDetails",
     "longName": "996346 - Disclosure - Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "cref_438560971",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails",
     "longName": "996347 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activities (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock Option Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "cref_1840882305",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1367888496",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails",
     "longName": "996348 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of RSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "cref_384482861",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_384482861",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails",
     "longName": "996349 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "cref_155304082",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_155304082",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails",
     "longName": "996350 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "cref_502686246",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_502686246",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersDetails",
     "longName": "996351 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails",
     "longName": "996352 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails",
     "longName": "996353 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "uref_469718384",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://jaspertx.com/20260331/role/RelatedPartiesDetails",
     "longName": "996354 - Disclosure - Related Parties (Details)",
     "shortName": "Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:InterestCostsIncurred",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:InterestCostsIncurred",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://jaspertx.com/20260331/role/SegmentInformationDetails",
     "longName": "996355 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails",
     "longName": "996356 - Disclosure - Segment Information - Schedule of Significant Expense Categories Included Within Net Loss Presented on the Company\u2019s Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)",
     "shortName": "Segment Information - Schedule of Significant Expense Categories Included Within Net Loss Presented on the Company\u2019s Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "cref_784925054",
      "name": "jspr:PersonnelCosts",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_784925054",
      "name": "jspr:PersonnelCosts",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://jaspertx.com/20260331/role/RestructuringDetails",
     "longName": "996357 - Disclosure - Restructuring (Details)",
     "shortName": "Restructuring (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "cref_1417501004",
      "name": "us-gaap:RestructuringCosts",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1417501004",
      "name": "us-gaap:RestructuringCosts",
      "unitRef": "uref_668202531",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0289477-10q_jasper.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total",
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r816",
      "r818"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r1025",
      "r1026",
      "r1027",
      "r1031"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued legal and professional expenses",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion, and amortization of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r195",
      "r197",
      "r490",
      "r491",
      "r500",
      "r917"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital (in Dollars)",
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r260",
      "r474",
      "r475",
      "r481",
      "r699",
      "r1075"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r531",
      "r889",
      "r890",
      "r891",
      "r892",
      "r999",
      "r1077"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r944"
     ]
    },
    "jspr_AggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "AggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price",
        "label": "Aggregate Offering Price",
        "documentation": "Aggregate offering price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r737",
      "r747",
      "r779"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r740",
      "r750",
      "r782"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r741",
      "r751",
      "r775",
      "r783",
      "r787",
      "r795"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r331",
      "r332"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Antidilutive net loss per share attributable to common stockholders",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "jspr_ApproximatelyAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ApproximatelyAgreement",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Approximately agreement",
        "label": "Approximately Agreement",
        "documentation": "Approximately agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AreaOfLand",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory and office space area of land (in Square Feet)",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r71",
      "r105",
      "r107",
      "r108",
      "r143",
      "r157",
      "r176",
      "r180",
      "r187",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r263",
      "r347",
      "r349",
      "r423",
      "r474",
      "r475",
      "r476",
      "r486",
      "r487",
      "r494",
      "r567",
      "r656",
      "r657",
      "r671",
      "r699",
      "r705",
      "r706",
      "r718",
      "r930",
      "r931",
      "r1019"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r91",
      "r105",
      "r107",
      "r108",
      "r187",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r263",
      "r347",
      "r349",
      "r423",
      "r699",
      "r813",
      "r930",
      "r931",
      "r1019"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r689"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_AsthmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "AsthmaMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asthma [Member]",
        "label": "Asthma Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_AvailableOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "AvailableOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available offering amount",
        "label": "Available Offering Amount",
        "documentation": "The amount of available offering."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheet Components [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "jspr_BriquilimabPlatformMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "BriquilimabPlatformMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Briquilimab platform [Member]",
        "label": "Briquilimab Platform Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_CIndUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CIndUMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIndU [Member]",
        "label": "CInd UMember"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_CMOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CMOMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CMO [Member]",
        "label": "CMOMember"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_CSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CSUMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CSU [Member]",
        "label": "CSUMember"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_CaliforniaInstituteForRegenerativeMedicineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CaliforniaInstituteForRegenerativeMedicineMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIRM [Member]",
        "label": "California Institute For Regenerative Medicine Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r101",
      "r102",
      "r630",
      "r1021"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://jaspertx.com/20260331/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r101",
      "r102"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r15"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "jspr_CirmGrantDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CirmGrantDetailsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cirm Grant (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_CirmGrantDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CirmGrantDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cirm Grant [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_CirmGrantDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CirmGrantDisclosureTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrant"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIRM GRANT",
        "label": "Cirm Grant Disclosure Text Block",
        "documentation": "The entire disclosure about Cirm Grant."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_CirmGrantLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CirmGrantLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cirm Grant [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation",
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r61",
      "r62",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r105",
      "r108",
      "r132",
      "r133",
      "r135",
      "r137",
      "r145",
      "r146",
      "r187",
      "r212",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r224",
      "r225",
      "r227",
      "r228",
      "r230",
      "r233",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r262",
      "r263",
      "r264",
      "r423",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r492",
      "r523",
      "r524",
      "r525",
      "r526",
      "r531",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r555",
      "r575",
      "r595",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r806",
      "r885",
      "r886",
      "r894",
      "r939",
      "r941"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Line Items]",
        "label": "Schedule of Common Stock Reserved for Future Issuance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r79",
      "r83",
      "r84",
      "r145",
      "r227",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r249",
      "r252",
      "r253",
      "r255",
      "r256",
      "r258",
      "r259",
      "r262",
      "r264",
      "r377",
      "r474",
      "r475",
      "r479",
      "r480",
      "r523",
      "r524",
      "r525",
      "r526",
      "r806",
      "r883",
      "r885",
      "r939"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails",
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails",
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per shares (in Dollars per share)",
        "verboseLabel": "Exercise price per share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r109",
      "r253"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase shares (in Shares)",
        "verboseLabel": "Outstanding warrants",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_ClinicalDevelopmentMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ClinicalDevelopmentMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical development milestone payments",
        "label": "Clinical Development Milestone Payments",
        "documentation": "The amount of clinical development milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT AGREEMENTS",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r344",
      "r345"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Agreements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_CollateralizedAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollateralizedAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 8)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r474",
      "r475",
      "r477",
      "r495",
      "r554"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r625",
      "r924",
      "r926",
      "r927"
     ]
    },
    "jspr_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total shares of common stock reserved",
        "verboseLabel": "Reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "jspr_CommonStockDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CommonStockDetailsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r259",
      "r474",
      "r475",
      "r480",
      "r708",
      "r709",
      "r710",
      "r712",
      "r713",
      "r714",
      "r715",
      "r889",
      "r890",
      "r892",
      "r999",
      "r1074",
      "r1077"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r937",
      "r1025",
      "r1026",
      "r1029"
     ]
    },
    "jspr_CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CommonStockScheduleofCommonStockReservedforFutureIssuanceDetailsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock - Schedule of Common Stock Reserved for Future Issuance (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized",
        "terseLabel": "Common stock, shares authorized (in Shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r259",
      "r474",
      "r475",
      "r480",
      "r555"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Voting common stock",
        "terseLabel": "Common stock, shares issued (in Shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r259",
      "r474",
      "r475",
      "r480"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares outstanding",
        "terseLabel": "Common stock, shares outstanding (in Shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r259",
      "r474",
      "r475",
      "r480",
      "r555",
      "r573",
      "r934",
      "r1077",
      "r1078"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock: $0.0001 par value \u2014 492,000,000 shares authorized at March 31, 2026 and December 31, 2025; 27,996,819 shares issued and outstanding at March 31, 2026 and December 31, 2025",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r225",
      "r232",
      "r259",
      "r474",
      "r475",
      "r480",
      "r497",
      "r699"
     ]
    },
    "jspr_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Warrants [Member]",
        "label": "Common Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_CommonWarrantsToPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "CommonWarrantsToPurchaseShares",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common warrants to purchase shares",
        "label": "Common Warrants To Purchase Shares",
        "documentation": "Number of common warrants to purchase shares."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": [
      "r921",
      "r922"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://jaspertx.com/20260331/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422"
     ]
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]",
        "label": "Schedule of Significant Expense Categories Included Within Net Loss Presented on the Company\u2019s Condensed Consolidated Statements of Operations and Comprehensive Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r44",
      "r45",
      "r46",
      "r52",
      "r53",
      "r493",
      "r807",
      "r810",
      "r884",
      "r888",
      "r1030"
     ]
    },
    "srt_CondensedFinancialStatementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "CondensedFinancialStatementsTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONDENSED CONSOLIDATED BALANCE SHEET COMPONENTS",
        "label": "Condensed Financial Statements [Text Block]",
        "documentation": "The entire disclosure for condensed financial statements."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r106",
      "r111",
      "r489"
     ]
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License maintenance fees",
        "label": "Cost, Maintenance",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total program costs",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r105",
      "r107",
      "r108",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r263",
      "r423",
      "r656",
      "r811",
      "r812",
      "r914",
      "r930"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtConversionConvertedInstrumentRate",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of converted loan",
        "label": "Debt Conversion, Converted Instrument, Rate",
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserved share issuance",
        "label": "Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance",
        "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/ConsolidatedBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r99",
      "r193",
      "r638",
      "r639",
      "r641",
      "r643"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r916",
      "r920"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r468",
      "r544",
      "r546",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r583",
      "r584",
      "r585",
      "r586",
      "r589",
      "r590",
      "r591",
      "r592",
      "r609",
      "r610",
      "r611",
      "r612",
      "r635",
      "r636",
      "r637",
      "r686",
      "r687",
      "r700",
      "r708",
      "r710",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r995",
      "r996",
      "r997",
      "r998",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r468",
      "r544",
      "r546",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r583",
      "r584",
      "r585",
      "r586",
      "r589",
      "r590",
      "r591",
      "r592",
      "r609",
      "r610",
      "r611",
      "r612",
      "r635",
      "r636",
      "r637",
      "r686",
      "r687",
      "r700",
      "r708",
      "r710",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r995",
      "r996",
      "r997",
      "r998",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r297",
      "r326",
      "r327",
      "r329",
      "r680"
     ]
    },
    "jspr_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "DocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": ""
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share Attributable to Common Stockholders [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share attributable to common stockholders \u2013 basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r97",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r130",
      "r132",
      "r135",
      "r136",
      "r137",
      "r142",
      "r191",
      "r223",
      "r280",
      "r330",
      "r340",
      "r343",
      "r394",
      "r395",
      "r485",
      "r504",
      "r645"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share attributable to common stockholders \u2013 diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r97",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r132",
      "r135",
      "r136",
      "r137",
      "r142",
      "r191",
      "r223",
      "r280",
      "r330",
      "r340",
      "r343",
      "r394",
      "r395",
      "r485",
      "r504",
      "r645"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r138",
      "r139",
      "r140",
      "r141",
      "r268"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued employee and related compensation expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSU Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "jspr_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquipmentMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r921",
      "r922"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r61",
      "r83",
      "r84",
      "r94",
      "r95",
      "r96",
      "r112",
      "r113",
      "r114",
      "r116",
      "r123",
      "r125",
      "r127",
      "r144",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r222",
      "r252",
      "r257",
      "r258",
      "r259",
      "r262",
      "r264",
      "r267",
      "r278",
      "r279",
      "r281",
      "r282",
      "r330",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r435",
      "r449",
      "r470",
      "r474",
      "r475",
      "r479",
      "r480",
      "r492",
      "r503",
      "r516",
      "r517",
      "r518",
      "r531",
      "r595",
      "r941"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sell from time to time",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r73",
      "r419",
      "r632"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r737",
      "r747",
      "r779"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r734",
      "r744",
      "r776"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "jspr_FacilitiesAndOverheadCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "FacilitiesAndOverheadCosts",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and overhead costs",
        "label": "Facilities And Overhead Costs",
        "documentation": "Amount of facilities and overhead costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      },
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Fair value of warrant liability (in Dollars)",
        "terseLabel": "Change in fair value of warrant liability",
        "negatedLabel": "Change in fair value of warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Liabilities Measured on a Recurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r398",
      "r399",
      "r412",
      "r689"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r681",
      "r683",
      "r692",
      "r1022"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r681",
      "r683",
      "r692",
      "r1022"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimate the Fair Value of the Warrant Liability",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r692"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in the Company\u2019s Warrant Liability [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r413",
      "r690"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r411",
      "r412",
      "r414",
      "r420",
      "r456",
      "r457",
      "r458",
      "r463",
      "r669",
      "r670",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r689",
      "r692",
      "r696",
      "r697"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r402",
      "r689",
      "r1003",
      "r1013"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r407",
      "r409",
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r473",
      "r689",
      "r693"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r284",
      "r289",
      "r290",
      "r399",
      "r412",
      "r420",
      "r456",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r689",
      "r696",
      "r697"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r284",
      "r289",
      "r290",
      "r292",
      "r399",
      "r400",
      "r412",
      "r420",
      "r457",
      "r669",
      "r670",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r689",
      "r696",
      "r697"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r399",
      "r400",
      "r401",
      "r402",
      "r412",
      "r420",
      "r458",
      "r669",
      "r670",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r689",
      "r692",
      "r696",
      "r697"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r413"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in the Company\u2019s Warrant Liability",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r408",
      "r413"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r402",
      "r689",
      "r1003",
      "r1013"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r411",
      "r412",
      "r414",
      "r420",
      "r456",
      "r457",
      "r458",
      "r463",
      "r669",
      "r670",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r689",
      "r692",
      "r696",
      "r697"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1013"
     ]
    },
    "jspr_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetailsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on a Recurring Basis (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueNetAssetLiabilityAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities",
        "label": "Fair Value, Net Asset (Liability) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in the fair value",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r696",
      "r697"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r741",
      "r751",
      "r783"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r741",
      "r751",
      "r783"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r741",
      "r751",
      "r783"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r741",
      "r751",
      "r783"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r741",
      "r751",
      "r783"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture &amp; fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r921",
      "r922"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r577"
     ]
    },
    "jspr_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going Concern",
        "label": "Going Concern Policy Text Block",
        "documentation": "Disclosure of accounting policy for going concern."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeLossFromContinuingOperationsAttributableToParentAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r878"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r741",
      "r751",
      "r775",
      "r783",
      "r787",
      "r795"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r799"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r799"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r799"
     ]
    },
    "us-gaap_InterestCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services incurred",
        "label": "Interest Costs Incurred",
        "documentation": "Total interest costs incurred during the period and either capitalized or charged against earnings."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r160",
      "r180",
      "r656",
      "r835"
     ]
    },
    "us-gaap_InvestmentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentInterestRate",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Received from interest rate",
        "label": "Investment Interest Rate",
        "documentation": "Rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r613",
      "r614",
      "r710",
      "r912",
      "r913"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r698"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease cost",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r921",
      "r922"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r884",
      "r888",
      "r1030"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026 (remainder of the year)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r105",
      "r107",
      "r108",
      "r187",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r263",
      "r348",
      "r349",
      "r350",
      "r423",
      "r553",
      "r649",
      "r671",
      "r718",
      "r824",
      "r930",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r474",
      "r475",
      "r482",
      "r499",
      "r699",
      "r705",
      "r706",
      "r883",
      "r887",
      "r914",
      "r1014"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r59",
      "r74",
      "r105",
      "r107",
      "r108",
      "r187",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r263",
      "r348",
      "r349",
      "r350",
      "r423",
      "r699",
      "r930",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails",
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value, as of beginning",
        "periodEndLabel": "Fair value, as of ending",
        "terseLabel": "Total fair value of financial liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r1000"
     ]
    },
    "jspr_LicenseMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "LicenseMaintenanceFee",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance fees",
        "label": "License Maintenance Fee",
        "documentation": "Amount of license maintenance fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured letter of credit",
        "label": "Line of Credit, Current",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_MDSAMLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "MDSAMLMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MDS/AML [Member]",
        "label": "MDSAMLMember"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MaximumMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r41",
      "r42",
      "r43",
      "r48",
      "r49",
      "r57",
      "r58",
      "r151",
      "r208",
      "r209",
      "r210",
      "r211",
      "r293",
      "r321",
      "r322",
      "r323",
      "r333",
      "r402",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467",
      "r471",
      "r512",
      "r514",
      "r521",
      "r545",
      "r546",
      "r602",
      "r604",
      "r607",
      "r608",
      "r613",
      "r621",
      "r622",
      "r623",
      "r624",
      "r626",
      "r627",
      "r663",
      "r679",
      "r681",
      "r683",
      "r684",
      "r692",
      "r693",
      "r694",
      "r695",
      "r702",
      "r932",
      "r933"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)\t[Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility [Member]",
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate [Member]",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock price [Member]",
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r400",
      "r401",
      "r402",
      "r681",
      "r683",
      "r684",
      "r692",
      "r1022"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r681",
      "r683",
      "r684",
      "r692",
      "r1022"
     ]
    },
    "jspr_MilestonePaymentsObligationToBePaidFirstAndSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "MilestonePaymentsObligationToBePaidFirstAndSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments obligation to be paid first and second year",
        "label": "Milestone Payments Obligation To Be Paid First And Second Year",
        "documentation": "Milestone payments obligation to be paid first and second year."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_MilestonePaymentsObligationToBePaidFirstThroughThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "MilestonePaymentsObligationToBePaidFirstThroughThirdYear",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments obligation to be paid first through third year",
        "label": "Milestone Payments Obligation To Be Paid First Through Third Year",
        "documentation": "Amount of milestone payments obligation to be paid first through the third year."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_MilestonePaymentsObligationToBePaidFourthThroughSixthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "MilestonePaymentsObligationToBePaidFourthThroughSixthYear",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments obligation to be paid fourth through sixth year",
        "label": "Milestone Payments Obligation To Be Paid Fourth Through Sixth Year",
        "documentation": "Milestone payments obligation to be paid fourth through sixth year."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_MilestonePaymentsObligationToBePaidThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "MilestonePaymentsObligationToBePaidThereafter",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments obligation to be paid thereafter",
        "label": "Milestone Payments Obligation To Be Paid Thereafter",
        "documentation": "Milestone payments obligation to be paid thereafter."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_MilestonePaymentsObligationToBePaidThirdAndFourthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "MilestonePaymentsObligationToBePaidThirdAndFourthYear",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments obligation to be paid third and fourth year",
        "label": "Milestone Payments Obligation To Be Paid Third And Fourth Year",
        "documentation": "Milestone payments obligation to be paid third and fourth year."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MinimumMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r41",
      "r42",
      "r43",
      "r48",
      "r49",
      "r57",
      "r58",
      "r151",
      "r208",
      "r209",
      "r210",
      "r211",
      "r293",
      "r321",
      "r322",
      "r323",
      "r333",
      "r402",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467",
      "r471",
      "r512",
      "r514",
      "r521",
      "r545",
      "r546",
      "r602",
      "r604",
      "r607",
      "r608",
      "r613",
      "r621",
      "r622",
      "r623",
      "r624",
      "r626",
      "r627",
      "r663",
      "r679",
      "r681",
      "r683",
      "r684",
      "r692",
      "r693",
      "r694",
      "r702",
      "r932",
      "r933"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r943"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://jaspertx.com/20260331/role/OrganizationandDescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r148",
      "r646",
      "r647"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows",
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r17"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails",
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "netLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net loss and comprehensive loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r17",
      "r22",
      "r51",
      "r55",
      "r56",
      "r92",
      "r93",
      "r96",
      "r105",
      "r107",
      "r108",
      "r110",
      "r115",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r126",
      "r127",
      "r134",
      "r187",
      "r191",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r226",
      "r229",
      "r234",
      "r263",
      "r280",
      "r330",
      "r340",
      "r343",
      "r395",
      "r423",
      "r502",
      "r574",
      "r593",
      "r594",
      "r640",
      "r642",
      "r644",
      "r716",
      "r930"
     ]
    },
    "jspr_NetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "NetSales",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales",
        "label": "Net Sales",
        "documentation": "Represent of net sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r741",
      "r751",
      "r775",
      "r783"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r811",
      "r812",
      "r914"
     ]
    },
    "us-gaap_NonvotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonvotingCommonStockMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Voting Common Stock [Member]",
        "label": "Nonvoting Common Stock [Member]",
        "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r937"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r899"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of reportable segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r651",
      "r661",
      "r899"
     ]
    },
    "jspr_NumberOfSharePurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "NumberOfSharePurchase",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share of voting common stock",
        "label": "Number Of Share Purchase",
        "documentation": "The share purchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating expense",
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r811",
      "r812",
      "r914"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r644",
      "r650",
      "r811",
      "r812",
      "r897",
      "r900",
      "r906",
      "r909",
      "r910",
      "r914"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r698"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total discounted lease payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less current portion of lease liability",
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r634"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Noncurrent portion of lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities (in thousands)",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r443"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r698"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r698"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/RestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Other Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r923"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses and current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r699"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r70"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "CIRM grant received in other non-current liabilities",
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r820"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Other Noncash Expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r685"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r739",
      "r749",
      "r781"
     ]
    },
    "jspr_OutstandingAndIssuedCommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "OutstandingAndIssuedCommonStockOptionsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding and issued common stock options [Member]",
        "label": "Outstanding And Issued Common Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding and issued performance-based restricted stock units [Member]",
        "label": "Outstanding And Issued Performancebased Restricted Stock Units Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_OutstandingAndIssuedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "OutstandingAndIssuedRestrictedStockUnitsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding and issued restricted stock units [Member]",
        "label": "Outstanding And Issued Restricted Stock Units Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r742",
      "r752",
      "r784"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r742",
      "r752",
      "r784"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License maintenance fees",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales milestone payments",
        "label": "Payments for Royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "jspr_PercentageOfCommonWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PercentageOfCommonWarrants",
     "presentation": [
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of common warrants",
        "label": "Percentage Of Common Warrants",
        "documentation": "Percentage of common warrants."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_PercentageOfElectionHolderWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PercentageOfElectionHolderWarrants",
     "presentation": [
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of election holder warrants",
        "label": "Percentage Of Election Holder Warrants",
        "documentation": "Percentage of election holder warrants."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_PercentageOfLicensingFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PercentageOfLicensingFees",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of licensing fees",
        "label": "Percentage Of Licensing Fees",
        "documentation": "The 25% rule can be used as a starting point for valuing and setting fair royalty rates for intellectual property assets including copyrights, trademarks and patents in licensing deals. It is an example of an income-based approach licensing fees."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_PercentagePreFundedWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PercentagePreFundedWarrants",
     "presentation": [
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage pre-funded warrants",
        "label": "Percentage Pre Funded Warrants",
        "documentation": "Percentage pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_PerformanceBasedStockOptionActivity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PerformanceBasedStockOptionActivity",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-based stock option activity",
        "label": "Performance Based Stock Option Activity",
        "documentation": "Number of shares performance based stock option activity."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_PerformanceBasedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PerformanceBasedStockOptionsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-Based Stock Options [Member]",
        "label": "Performance Based Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_PerformanceRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PerformanceRestrictedStockUnitsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Performance Restricted Stock Units (PSUs) [Member]",
        "label": "Performance Restricted Stock Units Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_PerformanceShareUnitsPSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PerformanceShareUnitsPSUsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs [Member]",
        "label": "Performance Share Units PSUs Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested performance-based restricted stock units [Member]",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ]
    },
    "jspr_PersonnelCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PersonnelCosts",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel-related costs",
        "label": "Personnel Costs",
        "documentation": "The amount of personnel costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "jspr_PreFundedWarrantPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PreFundedWarrantPercentage",
     "presentation": [
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre funded warrant percentage",
        "label": "Pre Funded Warrant Percentage",
        "documentation": "Pre funded warrant percentage."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "label": "Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_PreFundedWarrantsToPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PreFundedWarrantsToPurchase",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre funded warrants to purchase shares",
        "label": "Pre Funded Warrants To Purchase",
        "documentation": "Number of pre funded warrants to purchase."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r814",
      "r821",
      "r936",
      "r1025",
      "r1026",
      "r1028"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock shares authorized",
        "terseLabel": "Preferred stock, shares authorized (in Shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r83",
      "r258",
      "r474",
      "r475",
      "r479",
      "r555"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares issued",
        "terseLabel": "Preferred stock, shares issued (in Shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r83",
      "r239",
      "r258",
      "r474",
      "r475",
      "r479"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in Shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r83",
      "r258",
      "r474",
      "r475",
      "r479",
      "r555",
      "r573",
      "r934",
      "r1077",
      "r1078"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock: $0.0001 par value \u2014 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; none issued and outstanding at March 31, 2026 and December 31, 2025",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r83",
      "r225",
      "r231",
      "r258",
      "r474",
      "r475",
      "r479",
      "r496",
      "r699"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r664",
      "r915"
     ]
    },
    "jspr_PrepaidTravelExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PrepaidTravelExpenses",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid travel expenses",
        "label": "Prepaid Travel Expenses",
        "documentation": "Amount of prepaid travel expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails",
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r47",
      "r183",
      "r472",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r629",
      "r639",
      "r642",
      "r644",
      "r672",
      "r673",
      "r701",
      "r702",
      "r703",
      "r704",
      "r707",
      "r809",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r928",
      "r929",
      "r1033",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails",
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r47",
      "r183",
      "r472",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r629",
      "r639",
      "r642",
      "r644",
      "r672",
      "r673",
      "r701",
      "r702",
      "r703",
      "r704",
      "r707",
      "r809",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r928",
      "r929",
      "r1033",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r448",
      "r665",
      "r666",
      "r667",
      "r668",
      "r917",
      "r918",
      "r1023"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount, before accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68",
      "r194",
      "r501",
      "r917"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r448",
      "r665",
      "r666",
      "r667",
      "r668",
      "r917",
      "r918",
      "r1023"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r474",
      "r475",
      "r484",
      "r490",
      "r491",
      "r501",
      "r699",
      "r921"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/ConsolidatedBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r448",
      "r665",
      "r666",
      "r667",
      "r668",
      "r917",
      "r918",
      "r1023"
     ]
    },
    "jspr_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_PurchaseAnAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "PurchaseAnAggregateShares",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase an aggregate shares",
        "label": "Purchase An Aggregate Shares",
        "documentation": "Number of purchase an aggregate shares."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r41",
      "r42",
      "r43",
      "r48",
      "r49",
      "r57",
      "r58",
      "r151",
      "r208",
      "r209",
      "r210",
      "r211",
      "r283",
      "r293",
      "r321",
      "r322",
      "r323",
      "r329",
      "r333",
      "r402",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r471",
      "r512",
      "r514",
      "r521",
      "r545",
      "r546",
      "r602",
      "r604",
      "r607",
      "r608",
      "r613",
      "r621",
      "r622",
      "r623",
      "r624",
      "r626",
      "r627",
      "r663",
      "r679",
      "r681",
      "r683",
      "r684",
      "r692",
      "r693",
      "r694",
      "r695",
      "r702",
      "r710",
      "r925",
      "r932",
      "r933",
      "r1003"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r41",
      "r42",
      "r43",
      "r48",
      "r49",
      "r57",
      "r58",
      "r151",
      "r208",
      "r209",
      "r210",
      "r211",
      "r283",
      "r293",
      "r321",
      "r322",
      "r323",
      "r329",
      "r333",
      "r402",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r471",
      "r512",
      "r514",
      "r521",
      "r545",
      "r546",
      "r602",
      "r604",
      "r607",
      "r608",
      "r613",
      "r621",
      "r622",
      "r623",
      "r624",
      "r626",
      "r627",
      "r663",
      "r679",
      "r681",
      "r683",
      "r684",
      "r692",
      "r693",
      "r694",
      "r695",
      "r702",
      "r710",
      "r925",
      "r932",
      "r933",
      "r1003"
     ]
    },
    "jspr_ReceivedAggregateFromCIRM": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ReceivedAggregateFromCIRM",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Received aggregate from CIRM",
        "label": "Received Aggregate From CIRM",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_RecognizedCompensationExpensePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "RecognizedCompensationExpensePeriod",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized compensation expense period",
        "label": "Recognized Compensation Expense Period",
        "documentation": "Recognized compensation expense period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r734",
      "r744",
      "r776"
     ]
    },
    "jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00",
        "label": "Redeemable Warrants Each Whole Warrant Exercisable For One Share Of Voting Common Stock At An Exercise Price Of1150 Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTIES",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r474",
      "r475",
      "r483",
      "r528",
      "r529",
      "r530",
      "r578",
      "r579",
      "r580",
      "r599",
      "r601"
     ]
    },
    "jspr_ResearchAndDevelopmentAccruedExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ResearchAndDevelopmentAccruedExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development accrued expenses",
        "label": "Research And Development Accrued Expenses Current",
        "documentation": "The amount of research and development accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r628",
      "r640",
      "r641",
      "r656",
      "r1024"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CirmGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "jspr_ResearchAndDevelopmentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ResearchAndDevelopmentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development prepaid expenses",
        "label": "Research And Development Prepaid Expenses",
        "documentation": "Amount of research and development prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r735",
      "r745",
      "r777"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r736",
      "r746",
      "r778"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r743",
      "r753",
      "r785"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashandCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r101",
      "r102",
      "r815",
      "r817"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Outstanding and issued restricted stock units [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/Restructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESTRUCTURING",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r203",
      "r205"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/RestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring charges related to workforce reduction",
        "label": "Restructuring Costs",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_RestructuringCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestructuringCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r260",
      "r474",
      "r475",
      "r481",
      "r498",
      "r519",
      "r520",
      "r527",
      "r556",
      "r699"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r112",
      "r113",
      "r114",
      "r116",
      "r123",
      "r125",
      "r127",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r222",
      "r257",
      "r267",
      "r278",
      "r279",
      "r281",
      "r282",
      "r330",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r386",
      "r393",
      "r435",
      "r470",
      "r492",
      "r516",
      "r518",
      "r531",
      "r938",
      "r940",
      "r1077"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesDetails",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset obtained in exchange for lease liabilities",
        "verboseLabel": "Right-of-use asset and lease liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r698",
      "r881"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "jspr_SCIDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "SCIDMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SCID [Member]",
        "label": "SCIDMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_SalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "SalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial sales milestone payments",
        "label": "Sales Milestone Payments",
        "documentation": "The amount of sales milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/ConsolidatedBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "jspr_ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfChangesInTheCompanySWarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Changes In The Company SWarrant Liability Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_ScheduleOfCommonStockReservedForFutureIssuanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Common Stock Reserved For Future Issuance Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_ScheduleOfComponentsOfLeaseCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfComponentsOfLeaseCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Lease Costs [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Attributable To Common Stockholders Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expenses",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "jspr_ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfEstimateTheFairValueOfTheWarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimate The Fair Value Of The Warrant Liability Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1001"
     ]
    },
    "jspr_ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of Stock Options Was Estimated Using ABlack Scholes Option Pricing Model Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnARecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Assets And Liabilities Measured On ARecurring Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r448",
      "r665",
      "r666",
      "r667",
      "r668",
      "r917",
      "r918",
      "r1023"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r1032"
     ]
    },
    "jspr_ScheduleOfRsuActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfRsuActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rsu Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationScheduleofSignificantExpenseCategoriesIncludedWithinNetLossPresentedontheCompanysCondensedConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Expense Categories Included Net Loss Presented on Condensed Consolidated Statements of Operations and Comprehensive Loss",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r907",
      "r908",
      "r911"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activities",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r19"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "jspr_ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfSignificantExpenseCategoriesIncludedWithinNetLossPresentedOnTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Significant Expense Categories Included Within Net Loss Presented On The Company SCondensed Consolidated Statements Of Operations And Comprehensive Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_ScheduleOfStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfStockBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_ScheduleOfStockOptionActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ScheduleOfStockOptionActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Option Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r655",
      "r662"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief operating decision segment manages description",
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r652",
      "r659"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r169",
      "r171",
      "r172",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r651",
      "r653",
      "r654",
      "r656",
      "r658",
      "r660",
      "r661"
     ]
    },
    "jspr_September2025OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "September2025OfferingMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "September 2025 Offering [Member]",
        "label": "September2025 Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/RestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued severance costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "jspr_SeveranceCostsPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "SeveranceCostsPeriod",
     "presentation": [
      "http://jaspertx.com/20260331/role/RestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance costs period",
        "label": "Severance Costs Period",
        "documentation": "Severance costs period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares subject to performance-based awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share",
        "documentation": "Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumptions common stock fair value per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Volatility rate",
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk free rate",
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation [Line Items]",
        "label": "Schedule of Stock Option Activities [Line Items]",
        "terseLabel": "Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of the options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options Outstanding, Options cancelled/forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r814",
      "r821",
      "r822",
      "r936",
      "r937"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding, Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r814",
      "r821",
      "r822",
      "r936",
      "r937"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options Outstanding, Beginning balance",
        "terseLabel": "Common stock remained outstanding and unexercised",
        "periodEndLabel": "Options Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options cancelled/forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting term",
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life (Years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Share, Unvested restricted stock units, Ending balance",
        "periodStartLabel": "Number of Share, Unvested restricted stock units, Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Share, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted- Average Grant Date Fair Value, Unvested restricted stock units, Ending balance",
        "periodStartLabel": "Weighted- Average Grant Date Fair Value, Unvested restricted stock units, Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life (Years), Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life (Years), Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value option vested amount",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average grant date fair value price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "jspr_SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant under 2022 Inducement Equity Incentive Plan [Member]",
        "label": "Shares Available For Grant Under2022 Inducement Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant under Employee Stock Purchase Plan [Member]",
        "label": "Shares Available For Grant Under Employee Stock Purchase Plans Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_SharesAvailableForGrantUnderEquityIncentivePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "SharesAvailableForGrantUnderEquityIncentivePlansMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant under Equity Incentive Plans [Member]",
        "label": "Shares Available For Grant Under Equity Incentive Plans Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_SharesIssuableUponExerciseOfCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "SharesIssuableUponExerciseOfCommonStockWarrantsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon exercise of Common Warrants [Member]",
        "label": "Shares Issuable Upon Exercise Of Common Stock Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_SharesIssuableUponExerciseOfPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "SharesIssuableUponExerciseOfPreFundedWarrantsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon exercise of Pre-Funded Warrants [Member]",
        "label": "Shares Issuable Upon Exercise Of Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_SharesIssuableUponExerciseOfPublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "SharesIssuableUponExerciseOfPublicWarrantsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon exercise of Public Warrants [Member]",
        "label": "Shares Issuable Upon Exercise Of Public Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r938",
      "r940"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r698"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104"
     ]
    },
    "jspr_SignificantAgreementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "SignificantAgreementsDetailsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Agreements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation",
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r61",
      "r62",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r105",
      "r108",
      "r132",
      "r133",
      "r135",
      "r137",
      "r145",
      "r146",
      "r187",
      "r212",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r224",
      "r225",
      "r227",
      "r228",
      "r230",
      "r233",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r262",
      "r263",
      "r264",
      "r423",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r492",
      "r523",
      "r524",
      "r525",
      "r526",
      "r531",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r555",
      "r575",
      "r595",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r806",
      "r885",
      "r886",
      "r894",
      "r939",
      "r941"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r61",
      "r83",
      "r84",
      "r94",
      "r95",
      "r96",
      "r112",
      "r113",
      "r114",
      "r116",
      "r123",
      "r125",
      "r127",
      "r144",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r222",
      "r252",
      "r257",
      "r258",
      "r259",
      "r262",
      "r264",
      "r267",
      "r278",
      "r279",
      "r281",
      "r282",
      "r330",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r435",
      "r449",
      "r470",
      "r474",
      "r475",
      "r479",
      "r480",
      "r492",
      "r503",
      "r516",
      "r517",
      "r518",
      "r531",
      "r595",
      "r941"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementLineItems",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r65",
      "r66",
      "r72",
      "r75",
      "r76",
      "r79",
      "r82",
      "r83",
      "r84",
      "r87",
      "r112",
      "r113",
      "r114",
      "r144",
      "r224",
      "r225",
      "r227",
      "r230",
      "r236",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r266",
      "r267",
      "r277",
      "r435",
      "r472",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r522",
      "r532",
      "r543",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r576",
      "r577",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r595",
      "r631",
      "r642",
      "r644",
      "r711",
      "r1076"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeLocationBalanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfIncomeLocationBalanceAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Location, Statement of Income, Balance [Axis]",
        "documentation": "Information by location in statement of income line item where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r198",
      "r202",
      "r204",
      "r352",
      "r358",
      "r375",
      "r376",
      "r404",
      "r408",
      "r413",
      "r424",
      "r425",
      "r426",
      "r513",
      "r515",
      "r580",
      "r628",
      "r681",
      "r682",
      "r687",
      "r688",
      "r691",
      "r696",
      "r697",
      "r977",
      "r978",
      "r1034"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r61",
      "r62",
      "r65",
      "r66",
      "r72",
      "r75",
      "r76",
      "r79",
      "r82",
      "r83",
      "r84",
      "r87",
      "r112",
      "r113",
      "r114",
      "r144",
      "r186",
      "r224",
      "r225",
      "r227",
      "r230",
      "r236",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r266",
      "r267",
      "r277",
      "r435",
      "r472",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r492",
      "r522",
      "r532",
      "r543",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r576",
      "r577",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r595",
      "r631",
      "r642",
      "r644",
      "r711",
      "r1076"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r738",
      "r748",
      "r780"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ]
    },
    "jspr_StockBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "StockBasedCompensationDetailsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetailsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of Fair Value of Stock Options Was Estimated Using a Black-Scholes Option-Pricing Model (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_StockBasedCompensationScheduleofRSUActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "StockBasedCompensationScheduleofRSUActivityDetailsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of RSU Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "StockBasedCompensationScheduleofStockOptionActivitiesDetailsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of Stock Option Activities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r821",
      "r822",
      "r934",
      "r936",
      "r937",
      "r938",
      "r940",
      "r1025",
      "r1026",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r595",
      "r616",
      "r814",
      "r821",
      "r822",
      "r934",
      "r936",
      "r937",
      "r938",
      "r940",
      "r1025",
      "r1026",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Compensation expense",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r821",
      "r822",
      "r934",
      "r936",
      "r937",
      "r938",
      "r940",
      "r1025",
      "r1026",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate shares",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r595",
      "r616",
      "r717",
      "r814",
      "r821",
      "r822",
      "r934",
      "r936",
      "r937",
      "r938",
      "r940",
      "r1025",
      "r1026",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockOptionMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails",
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Options [Member]",
        "terseLabel": "Stock Option Activity [Member]",
        "verboseLabel": "Outstanding and issued common stock options [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r557",
      "r573",
      "r596",
      "r597",
      "r699",
      "r718",
      "r824",
      "r883",
      "r886",
      "r887",
      "r914",
      "r1014",
      "r1077"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMON STOCK",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r83",
      "r84",
      "r88",
      "r235",
      "r238",
      "r240",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r258",
      "r259",
      "r262",
      "r264",
      "r265",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r377",
      "r391",
      "r392",
      "r455",
      "r598",
      "r600",
      "r620"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental and non-cash items reconciliations:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "jspr_TotalEstimatedFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "TotalEstimatedFairValue",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total estimated fair value",
        "label": "Total Estimated Fair Value",
        "documentation": "Total estimated fair value"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "jspr_TwentyTwentyFourStanfordLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "TwentyTwentyFourStanfordLicenseAgreementMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Stanford License Agreement [Member]",
        "label": "Twenty Twenty Four Stanford License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_TwentyTwentyOneStanfordLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "TwentyTwentyOneStanfordLicenseAgreementMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Stanford License Agreement [Member]",
        "label": "Twenty Twenty One Stanford License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_TwoThousandTwentyFourPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "TwoThousandTwentyFourPlanMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Plan [Member]",
        "label": "Two Thousand Twenty Four Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_TwoZeroOneNinePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "TwoZeroOneNinePlanMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Plan [Member]",
        "label": "Two Zero One Nine Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_TwoZeroTwoFourESPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "TwoZeroTwoFourESPPMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2024 ESPP [Member]",
        "label": "Two Zero Two Four ESPPMember"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_TwoZeroTwoTwoInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "TwoZeroTwoTwoInducementPlanMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Inducement Plan [Member]",
        "label": "Two Zero Two Two Inducement Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://jaspertx.com/20260331/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "jspr_UnderwrittenOfferingRemainedAvailable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "UnderwrittenOfferingRemainedAvailable",
     "crdr": "credit",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remained available",
        "label": "Underwritten Offering Remained Available",
        "documentation": "Represent the amount of underwritten offering remained available."
       }
      }
     },
     "auth_ref": []
    },
    "jspr_UnderwrittenOfferingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "UnderwrittenOfferingsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Offering [Member]",
        "label": "Underwritten Offerings Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://jaspertx.com/20260331/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r147",
      "r149",
      "r150",
      "r151",
      "r486",
      "r488",
      "r648"
     ]
    },
    "jspr_ValuationOfStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "ValuationOfStockOptionsMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/StockBasedCompensationScheduleofFairValueofStockOptionsWasEstimatedUsingaBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation of Stock Options [Member]",
        "label": "Valuation Of Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CommitmentsandContingenciesScheduleofComponentsofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r698"
     ]
    },
    "jspr_VotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "VotingCommonStockMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting Common Stock [Member]",
        "label": "Voting Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_VotingCommonStockParValue00001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "VotingCommonStockParValue00001PerShareMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting Common Stock, par value $0.0001 per share",
        "label": "Voting Common Stock Par Value00001 Per Share Member"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_VotingCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "VotingCommonStockPercent",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting common stock percentage",
        "label": "Voting Common Stock Percent",
        "documentation": "The percentage of voting common stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "jspr_WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "WarrantLiabilityMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofChangesintheCompanysWarrantLiabilityDetails",
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability [Member]",
        "label": "Warrant Liability Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantMember",
     "presentation": [
      "http://jaspertx.com/20260331/role/CommonStockDetails",
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding Warrants [Member]",
        "terseLabel": "Shares issuable upon exercise of Common Warrants [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r709",
      "r712",
      "r713",
      "r714",
      "r715"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant liability (in Dollars)",
        "terseLabel": "Warrant liability",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://jaspertx.com/20260331/role/FairValueMeasurementsScheduleofEstimatetheFairValueoftheWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate the fair value of the warrant liability",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "jspr_WarrantsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "WarrantsDetailsTable",
     "presentation": [
      "http://jaspertx.com/20260331/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "jspr_WarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://jaspertx.com/20260331",
     "localname": "WarrantsTextBlock",
     "presentation": [
      "http://jaspertx.com/20260331/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WARRANTS",
        "label": "Warrants Text Block",
        "documentation": "The entity disclosure of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average common shares and pre-funded warrant shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares used to compute diluted net loss per share",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r137"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesContingentlyIssuable",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares",
        "label": "Weighted Average Number of Shares, Contingently Issuable",
        "documentation": "Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://jaspertx.com/20260331/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares used to compute basic net loss per share",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r137"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://jaspertx.com/20260331/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "5",
   "Subsection": "04",
   "Paragraph": "c",
   "Subparagraph": "Schedule I",
   "Publisher": "SEC"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "7",
   "Subsection": "05",
   "Paragraph": "c",
   "Subparagraph": "Schedule II",
   "Publisher": "SEC"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "9",
   "Subsection": "06",
   "Publisher": "SEC"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.Z.5.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-1"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-5"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480204/360-10-S45-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 5.Q.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.D.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479921/505-20-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "45",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480865/815-45-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.B.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480148/855-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478443/942-360-45-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.7-05(c)(Schedule II))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479913/944-10-S99-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "108",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481296/860-20-55-108"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.5-04(c)(Schedule I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-6"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482558/350-40-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482222/360-10-30-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "905",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478704/905-360-25-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001213900-26-056595-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-056595-xbrl.zip
M4$L#!!0    ( *Z KESJR><7)SH! +'!"P 8    96$P,C@Y-#<W+3$P<5]J
M87-P97(N:'1M[+UK5^-(DC#\O7^%7L_T;M4YAI)2=ZJ;Y[C ]+!;!0Q0,SO[
M98^PTEC=MN269"CFU[\1F;K9EK%L;%D2XLQT@:U+9&3<,RZ__+\?D['P1/W
M\=Q?_U,Z%O]3H.[ LQWW\=?_[-V=75[^Y_\[_>F740B7P:5N</)[,/5_[8S"
M<'KRZ=/O5C"E?OCC>.!-/A&1:*(L2YWHRK'C_I%<^?S\?/SCP1\?>_XC7"G*
MG_#K!RN@\>4_EJY_EMG5DFF:G]BWR:7P(-M)KLT^5_O$OTPN#9R\9\*5TJ?_
M^?;U;C"B$^O(<8/0<@<)+,Z/58!+\B?'!5CH_WRY_9I>'N9?GU[Z*?0M-QAZ
M_L0* =>(+'(DDB-)RSSD**"#N0?!W\>/WM.KSY'4(]$X2M$^"_V56#<_P;?)
M"P-/(9+^RA9%5V31[KQV^0(69\'1HV5-DSN&5O# KHZ^8!037VR'_E'X,J5!
M_@O@ZT_X-=ZC'(E29L%LP\-<:E Y-829EVS\>)LN4%J\*?#%W H"/UQ>*GPX
M=Q$=V/E/@R_F+W1G$Y*W*")^HC]"Z@;.PY@>X6749[00')%C,;I]-1\A*W=.
M?Q*$7T;4LO$7^#5TPC$]1=8^BKGXET_\0W[!A(:6@(\\HG_.G*=?.V>>"S"$
M1_> M(XPX'_]V@D!M$_L%9_8.S[%+_GEP;-?A"!\&=-?.T.X_$20Q&DHW#L3
M&@A7]%FX]2:6V^4?=(4[ZCO#3O1VVWF*;[6=8#JV7DY<SZ71UW"!\^,$7T3]
M^)/H,\>VJ9M^QC^%6R]\:X H$UQK @^-Z/'DPG+\?UCC&>W9O\^"< )+NA[^
MT_*!Y<(@6N6/\)8.?^T,?#K\/TG6#5D7%47M" [LZW#P?ZHB:9IAJK"/,]?A
MU\[P6O@44*LRN@J<$]<9 [;\&2SBET_S0!6'-P4SN/=ZMNW@-=;XQG+L2_?,
MFCJA-;X;63[] G+6/O,F4R ;1BMWH3?XXWK*R.86MS1P0@HX?W(&] 90[]FW
M=. ]NNR).2LGHDX4#=9C)"O/?M3DI>L:T163:%*R<DG3%2*KFEG&PJ]H> D:
M>D*_>D$>3>;LC"3*JB'*BBA5 4")F!*PC2:9"8":(HJ&I)IZLRE'5G31@)63
M9.&93YJ\<**8ABJ;LI@LW#" :32Q&A2YO"^2:)J:J:M:*;)L+<>(.KQ0D@TE
M!1#@)1)19+4, '>B%XD,-J)8!K@WOC>@U XN?&]R9XWI]1 ^03_EY68,$/=<
MNP\T/,5EY,EW Z2[*JHILE4@$%-5S%)P#<1P9@4C@/C)L:G]Y>4[,..E>^D^
MT2 $MZP'-ST!H]$\Q"_#+JD$(-<ELQ2#Y-9Y' %I ,B](*#A]4-H@=\"X/=_
M#$:6^T@O//]ZRNQ5]_$K!3GSU;$>G+$3OA1;C2XIH,HTHQQ-@6L($N(_=X+!
MV O@=7DD#S^J"822PII^4C%0#5.1"#&DK#A)/ZH8L&#.@*V@*%GAG'Y4,6 !
M+!V834RIP! 50Q*E<J@@9B80#D6IUM1$Q93-+-FF'U418D,#M:P0E&<)\:8?
M51!B15(DT5"4#, :AB944RQ%&VZ.XCR6 T%,5%.JGC CZ(]I1$Z]B>Q'U0)6
M%W51)H::FD693ZH%JD0,$[27)LH9O*8?50M8T%ZR*L^YY/"W+H.'48J.V)S%
M-$TTB"%G-'#Z217AE71-TXF4Y;+,1U6$6#%D4U,E*:/9%,74)*TD)V1SB)<Y
MSM0-/*@H)YAX-K:"(''KKGUNR\]"C.GC>5 .R*:L$R(3/?7K55610-])2_),
M 7=:,I@+NS.([T:>']Y3?\(\B3,O*.;.L>@3D(=4BAQ;X>Y<>>Y@YOOY+J@B
M&ZHF L+20)&J:ZIFDG(HP9M,HJ!/-BP4W-* ^D_4!B?N8A;"ZR^#8,8/?'+L
M-$71P2A3,A(C\]'^B2.S" X] DOM/ H!GM-!-F3,'4 VT7336-(>I4#Z.M/E
M@ L_HDC(LF+>![@W\& *E&L7P>TR)6-\&C2'IB]INDKBEH#_IL("C%(DVH;@
M2B#6%%'6]6RL/_VH# F<%R[NH09YI!A?^_*27G)CO>!'O6?+MZ-@\C]H$%(;
M W(_IG0 O]Y[^%%FU;W'1Y\^6B&]=$/?<0-GP#1I+C(,338-$(<9C:_"JD6B
ME2(VV4H?UB/C804R^C^H/W "ZV&\L%BIX&K!H51$$%JEV)!5VGI%!Z8%%LW8
M>CKH2@4-ZL;M?,YB31-8WE#+B8J^=>,S.[R>IPU%!!J7Q=1C!@FFX?%K>2Q=
MUEIS.!J< 04\++4\*BYKL4341$4!WR'+LJ9$-&*6XE"6N=AECM4Q70"LBEKL
M:R2=P,IS^6'OO0<NP=I5YYRCZ3I135VLA9C:<M4Y1Y\Z,349%=(^EXVY6R<
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MA4T_\^S))9A23XX]L\;WF'8,?N&-%[!\LFO_-]^;3:]]#(XX84CI%3RMGZ1
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M&5ONE36A&2*]!@( G-K *4#,ET$PH_8-]8>>/['< 7VP FK?TB#TG4%(;9;
M\MUUPFI6;AS@6$]5%%'6]68GRRVG9,:77'GNTV)B9B5)XP!%/9IA2IK>S-KV
M'KS!=L:ST'FB=ZAJG="A0?_'8#RSJ7WA>Q/,A)L! <%MU\.XWBM.T_WRDO^
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MGTU!0T&6SF*C$$L3D>R8I6OGID0O<%P\C(#/CE7'!=%SZ=IX+D&%AQ=A,**
MBPFF03Z/*#NP03\E/7(^$3Y('SE,(RL0ALX8_!QK/(9+,,D'W9\_9PXZ/^#S
M/-#H GARY/_P6R49#W=8B@W_(/*',FY4O/_H(R&W8YZ-8,^PB1*[=.K3 66^
MI$0$EOP6"!_@H2A2@AD(GF#DX3EXG)T2CD".S*\%9-(\O @LOSE:S<<NB!Y;
M^$ R2WX NH*+'GZ'!>%-['JX$T&)'L9Z/C%(&*16$ JF*-C62W!<*$Q\-O-]
M> 3/FT*9$%KANA2\#*'+G=-_80U.7O1"B#(\A8@/O.S'RN>=IC&DA$88I56,
ME 7<3=C(B1.&L/]T#!OJ>R[JYO&+0$%/O\ #@82L 89!A7,KM'C>SP*-I\_(
M.OQ8[L!7K(@J4O M?9SQRA3A[NA>^(!?ZI^)3(ZC"\*1$P#8UA33-_9-ZQSH
MA'II\+$8;68P@@B)2+4P;2KOE38W(LV?@! L80Q/I8(U& !I^A;2%VZ4CS(I
M]U,!,'J4^T4P 9J&M_BQ1('MFH!">^FB'$;K"O;A$3\'5_$Y',5?'_]T1RF#
MS:9#QV7I?NR8  -]1/R\"D+VM?0YOFSM!:OABR[\"<5P=/$*6.-'.FZ&]<"8
M/2)QM"VK4G83=FM.B(VH/^_2O/N*A,%QD]E\_@&C@'5QG]V"DZ0-E_G2WB+5
M'WS-:WW1F$#0'2W#V$]38_TSP-.CY[]LEK3&Z^@9=@?1 Q:L?K5S>C4O%N>H
M\%6G:=>[H7W>WPON5HG0_;URS;8RB+[, L>EP0;U([G%24345A8G;19NF2/Q
M><]W\<_=8:J?K[(.MC4Q/+\Q<,XX-&\MT""BOK) HPS_N0PC;OB*L83GFPLV
MWD_,QG.&>9X'\S= -;@><Q=F 3>TX*VL9"ROP )L-7S7^ 5?_NS J^&U@@L+
M\I#QGYR J1K7<@>.-4:[#).!\>B%=56U?#L0,,/7L5<=3LH?K(]YYM)QG-,0
M[6Z-#?$-G41FB0<CL.+B?18^P.XQ>Y@GW1>P-F/?"ER?.43..SKKY"D"L3->
M-5;*TWK[64*/.2C?K!=!DKH"EAMVV7[P) 3\CO<HB??)7\Y>&/#P<\ "@U[:
MDY@YT=$N73 G&*Y:"MZDO6=Y_[M,4^.<;9,-HFJ2CG%,[+#!OECH72-@)29E
MWD-45!FP/XI571+1[)P2O6N:6M>0DASR&/[3##IX\]RYY7?3(S3+CP[5DL,T
M'AUSO<PCT 7=]#''"Q27UQ%B4QIYM2'&6\EP;<N*5:^M3%</:?IZ5X^DZ\>V
M73U*0&9%]A#7_AF>RH8!(,8_"U';L!-\>ZQ:7]E@B>2\2\MLW$+'E?P\]XQL
MG,--U&0F\^X'GUI_'#U0D!\ [Y3!GX5'RP$'85SYMO0]<Z110ZK810KZ*Z6#
M!^]P@=U%!.P#(L!OK+0Y;>H 0%]>GPO]J_/^>05 _=:[/?L;ZU7 6P8<'*#*
MM"FY[WWYVL?:\[/KJ_O^U7T5V@\M(Z<ZX="Y8-MK-1'&SRLSRUZ]3090HD4>
MC>D05F*B>)HS3X_,K'1:\_2%\HI:5%?<]'[K%\E2>R4A;0W"-]N<51NR/PQ9
MPLA'\_TOUO^)F)=Q Y)5N#P6+BZO>E=GE[VOH 50 /?N63<N:V7RXRIR6)>\
M$:.Z'$2^B;*++F475+.[+;X,Z028KNB^;8"^?9$A 9V?!(22$2J!\.&[:\UL
M)Z3VQUU1HM028:F+W1?)8)6AAV_":"+\QM0+.\7Z8HVQK;]P-Z(4:,B*(BUQ
M3RFTTUA$X)P.>-OEZ%.U);&6Q+(DIJPDL8R( MJZGE+>"R!@=(7!3Y^.L)/W
M$Q6^>D&:9!7"TVF<&\,#Z#F$N4M:)"TM-H(6U8*TR"*Z([!UJ1]$D6(!1RV&
M+P<D0GDS(IQ_R.^S('2&+^^*,DO#P+[(52M(KC@)5+@8>\^'E)%*2Y[OC#QU
M3+<)X0&A)ZR@TSQ_9%<$I[8$MQ."VZW+S*H<29W<9@-[Y;K6(Z/.Y%SXW D&
M,][_$25ES[7&+X'#Q&U*U$CU/&T#K[FEP6R\:,SNS 3=T 9MR7WGP2"Y3E1M
M=D[_CBD_#D[X P\*"10^&,=_(WV//1P $@B]!V\6QA51MT[PQ\Y,5NTM1+NF
M +REV0(TJ]2(9B61V;NA[XUY#.#&]P;4GK$A0X<AR'=&?/4Y<Y&2,Y?+8^$:
MS]_; Y<FR*LZ';A(I'/ZE3Z"'<@$%:O:VYVDTENR*Y'L>G6B.[ESBE::<&$-
M0L]O2:Z6)%<G'UE2.J??W4RWLSMKS'. HZAXII@?#;?O >O:$8G%G1&HLF&,
ML270]^+N2BIVK1]:+/[R?8IE]]1U/#]#F"T1UI$(:^6_:IW3;XY+03H.*0C%
M3(BE);XZ$I]:)^+3.Z?7K*CMTN7%0H[GMF171[+3ZD1V1N>T_V/D/#B[.]A3
M-CS9:R"UP8>(QU\[I%,2Y<WOJMDYO;O\[:IW__T6)Q[O:%_G@J]U;:FV&-]<
M4R)&<DO$/@O_P+I(@&+_Q6+;5[]EEA4OZ+. DXA/A*_>,_49SCX+V+:/+_S*
MP^4X<Y5A\9ULH6GQV#YKU!8KXG96J58)@EM7G,$OP)I@7IL07VL[P71L@6AP
MW#%8J4</8V_P!U[/61NCZ1SXU64,NRL].D@-UB)N2%'<K(4UBEVOR'<Y+-I^
MJ@8ARD61O;:F$B=MK7WY3V?75^?]J[O^.9;.W5U_O3SOW<,?7WI?@;+[PMW?
M^OU*5-/]XIQ^<%PA''FSP')M[*7[8T!1D+-&N1A.2ZKG?[*MT,)9%:<5 7R6
MJ2S9+5#;MUM;62BX4%!8%+"MVZT5[[^[A-YE S3'(ES>E-R-3/(^-WMK6>#%
M!23\B9N#6;0)U(YV)G4@$E,$S:[=8:2(<<>KI.<AS04K,O2WVN2JK%3=S4JW
MH9.<1_:"@*).#Y?:B"WB8DW'L0)87$^F6Z_P-&KF*EAL/2?[7=#;H<X;;N$_
M/GP@HM(ELM$EJOHQ=ZJ5KBV,%4&_/\?E7PP,Q$V,6&X]*N$!_H)-=9^L,3?K
MYJDRUBT_KV*PY()E>#JG?UUQM;EPM8^TF/1\6VA,- N.'BUK>H(P]UP;_^FG
M /?",\OWL9\8\SUS^A,ILJ%JHJDO]2?2-.RIKLI2TI](SO8G.I(+-RC"'"])
MZ4H845QH3K01OM:@N+Y[0#0#>R=)RA[W0 *Y:G0UD^QL#XKV8LQCXW^.P(!<
M/1:#\^L*F5^8C6]\.K4<&VSK*98I\&-J/J5X,"<)"RF;5>2U3I\5I^3-GE2(
M(B,4]#D&@#;9<0'79ZM;>Y<A$T!!:" 2C+7D^!H5%$#J>]_+,F2+W#E5NZ8J
M[V4OWR)F7K<6MK 0B([$<^^%UGB%#"DP;>4UNMF8*JK RPK:[%U20+>L0T/5
ML%<&]ZB=4UGI:HKZ-NSM0!TON<NOL<+BD5F>._#V[=N.'BH"2(4$%]NM&]^;
M @@OS!!"MV:*P>JNX-+P4 P8@W0SMMP0=%H_ANJ*'DJ::9U30ZJ=)-L0D64(
M-AW</O&-.F'O3D8QSHEJ.]U'N,L**-^2(V]XA&V]#VL )*!]1<AN\9;KX7<P
M$!&J [&0 2I-TFO'0YNBL@PF,L&V/B03[4<3W=(@]!W6'Q]C;(?:\!0,C-E<
M>>[@D'8T$3NG2@W99@,LEL Q1-H!%BL;V^+:B,6PL!7[>XEC94(=!^=2TCG5
MUY-7&[;:<.O*$ TR6*12_<-4B_ IQ44'#UT5$Q?*AA0'UPNV-WL8TT(G+1L]
M8X-HSH'$ @;!I*YDK#_D6KU]6PB&YFQ2&0( 8VUJ5]>7QZ2\?9-V'(!;DTZQ
MB;7]U;$>G'%:JKFZU6'% FB5 627LOVU913=T3B38YSN[.ITCG;O#AI BH^C
M>WQ<6P!?OV!NX\;NVI)PWESV1B#<< @.>FI$-%"8745>+XIWYN^6B, RE)F.
M1^B$B T*#L6\LAAOS<BY:@0'8Y7Z<E@>,L 75>L7,=H8EV6PDPG.(5#RX8]A
M]YL5!2+,G]%7LZ)RN*UY<8D%49[DTW#T9$SF@W*X+&)N#1!_&W J<6-+$#?P
M"-A8O4#61]6C45LE355 H5>&Q4GGU,#QK;53XY7A)8SKREU20$K6(=G@GY;/
M1E/'/)(;E2EC?R-  A"A[#!\S:CC,GA%09]')>N#K%7CE0UQ60;7J, U6E?2
MWHC,0YY\O/'8]%T8NFS9&5%]Z -4F05^2 &R:TW:;;:P#-&A[W,+*^M"9PW9
M=R$Z,B1W(%EA@([2N_H6IZKO5EB\OFEE2 <3TS^[&ME/<==N[8VVYJ%9IVW\
M>-2;3)R0STIC==S !7 )=0=X!/X!)U@)QL<]N@+9/BI' 1T<.3^.1HX-8)\,
M!_\GZY*L&JJJ+G7N.;@/\SK@IB9*1#1,\A; ]\R_6Y!+7CX$;?,A2N7R@@7=
M0^IC+_( =^Q$^.O:BEE^/=O@&\N_]EF++IL5XM]0_PX;+&UBV4BFH:N*+"M*
MHB7%K)94"BM)12Q0[[L=]"M5_ ZAESJGXC&^)4?%+WP F^D+3PBSP)B+?!8V
M63A;9=";A2//=_Y-[4VV2]'@0T,V5JQ7++Y>LMEN%0!ZY2[M#F@,BXI=> O^
MO\!&L7YCH#$3L 4KC$:(XL_K,\!A5U]7'I*J&:8.5J&R5L](JJHKABBA);GN
M4EDWB628VOHK%4W6-*)AM!B631/=E?./X 0!'I*RL]$T4)?B8]T\] ,I:$"<
M!OK1P-J[B-GJ8EM(Q""F:K+ZC3> ON=H9*'V06!]>FY!'<4OKJ*"4M:VN]D*
M]#*TD[I'[919=354D[;!/E5#+X%P4DQ2HF+:##V73/8?9C.-C3=S);0E;*2Y
M,;1;GB#N#&1UK=F](<C[Q[**K;MT3!#H&E)>MNS&'\3\5%DCI^@&';"IG0H>
MP?I*LJJ=0A? 70D!8E5^,^X.GZJ1Y%/:?!RX-1:P/1?<(PRLJ1-:XT-M<@K1
M#0!TZ9YQ< [$)V!&RD3J$J5^/56*([(,IL':-2*"#EA_K%+[?(U,LO)L,ANC
M7P%8&SH#)UQ<:YT.[CZL:Z006HY+[;[ENSA7-K/Z<[[X'?-P ,#!;\5I4&.-
M7;I&@5:NA8_V/K8[NCMALO&.ZKBC6E?3=YAA_K$^:1S!VJ.?.E+EZT29/>[B
M9;\',@VP3517:6L;=KQU91@CX/DK74E=;],=/L-CS[TTQ@O%]7D2!7^*297:
MM7/(9!OU7+LJHD43VVX<^]J^$L2+)I70IZ.<881%1BK%P)4QXNE^1 5K,/ F
M\!Z<22"X7HB2BXV=$ARXZ-%GH0P_%+SA3^&(!E1(1CXA-=A8-LI^8UJ,^6;#
M9 9:D,Q .][C*F*,'6S$H]S,$8\]'\3!8'F\HU1@O.-/[V"^8T7FZBG5F*MW
M=P__?.M?W=\)UQ?"-;R)S8R\$WI7>.6WF]O^W^"VRW_TA:_7=^W@O<H.WELK
M9.LUC&^%!;:#:6?:[J>=W8]\2H5O\+A1(/1!N]J,*7]"GV'E&+_]CT/;'P[;
MV7BUFXV7Z<<3MPU9F9#<T.%Q^4VL*6-05!LV?:)CCW7<7]R?"DTHBT$&7^\\
M!3@:*93CZ^F&8A)55/?IZQ'6X41J^G"X35$OR;HAZZ*BJ'O$O<Q+P NTD*KZ
M5+@<_OR-NA1]661/RYXXKA.$*,6>:"$)6LL <;1F(++>W(H/R^(*LK@DM\/>
M]KB/I<@+%3>RR*BJNH7]<Z5(G(7  _W>2ANH>>27V'L1O>55$I<A.#16P6*J
MZP>@M))C@ZTK15;H[ C&*#"\IH)-(CJG7[T@$(:^-XD9WW/WV*IL31Y)LJF7
M[L";4(1MQQRY:>*(9A1FS5=2?BJ*R#?QQ\:8- LSRCY2;;;5G!E#^Q*C%S0(
M!8<A]5#IFI?N$P"!7A7?W!BLP^@N':>>O[6W5K6Q6(8:T:7.J?;6?F^E.:79
M'A0CRWVDP!+"T'+B$C-O*#Q7I;O?!8#%CBM[]N\SON/7P[A-W8&UBTXZIR8X
M&F]LZ'B(.E95D0 A)J;*5K>,=<N("N^@%[D_<W-CZVA'KS,5<+%7GNO-FPS[
MB:1LS" R& WK.\:V2=C;;&2IYI^N@(+;X4RRPR9?OQI 8=*#VXBU%QZODUQ9
M8J,HC:FH3G6]#<#N90=+L8/!GE"U1N9;=TZO*-C#&&_AS=HF4Y^. -?.$V4?
MUS#K=HU*@@57)I*CXYSVKJ1OGBI-MK8FFK=CY=H,!@L9%:FIW7#/2K<;YOD_
M2;X3K##TG8<93SP+/90*25.=*$.]"S $SH"G7SCC64CMYM%=7#D8=]3Y@DO>
M1&*L:ZM#MB"_M7T_%J$^Y]MS8+@-D?4%RA-TK>1[,P6NEH#[V$II=R18+N $
MM.UQKN"NCB0OL8CNGRQ!D=I'%H"':?Q1;YH9UIA@+PVP!F?LU!U_W'HJBAT\
MJ-B0D0B9/8[+JQDV[+D>+O4QVEB)[*R9D2%ON8:(?8NT9"IA%0K87T97TZ6B
M+9G>6K36DFIAH;V[75;W3ZME+ .3:-2N2$A7(GEGS#6OL-Q[+6!;,KF3DDFE
ML=61Y%U71ZZM75L8%5"9*DJUBE64=_?79__]M^NOY_W;N[A]1/_OWR_O_U61
M*L17RB??3\'D3L5IL=4LUPDN=.G<_1JW[UU0KWK159:.N&CI+.K2C2L&Q8+5
MI;F0[*R(,&I0SKI]K+/V\M^\-Q20': @VY.3B68!VS<>7;K-7&O:4JZ1ZV.Y
M WP;<^;T[&+)FU3"5D54[ *W140%]V$;2%A%%M^;X"#Y=[KXL_DFQN]L]>?%
MFLTV=/7]0KWJ=B=;MR[65V*[,&_9:\\>OEAC"QUU*\#$[)4-[A?>N64Q^:NW
M;%517BB^:.*T7E,WC/W%%_4U\PEVA:0J5/$7ZI"W&NF[RP<SC"(]]-\#LG5%
MU$!(R&2/R#:+]UZO.LK7G/87P[DBJ431=+.,_#13+-ZB^E5$+>5FU(W42^B\
M:4I%&_M6IB'(6ET?9Z$S'!\]6/PH9H+9O*RL-RYHV5_)4%((5/':)2+JP-8B
MZ\Q=N?&!:T9UQ#5LP;VW8FY'G+U$[;/,[C.JB'IYWF*3Y@!H[H[Z3\X Q]@Y
MGGU+!]ZCRYZ8)PN!9W1#UB1SCUQ)@"M))<<-K1GJJ.D MXHESBT]%:.G$LI!
M3'D'Y%2!"L7"DC_.+ZYSN<H*'?*>"G;6R!I15@U15L2U V1;G,4XTQ11-"35
M7#LN^!VA[*VE.QK108)K9<QC O]KR]*==UD(7*6J*U/=T];MV-\J$+/>(-M[
M/N*ZF+_0Q#S70D%:!3Q[^)\L[BU(:VH;!6DKG*!<PE"4@C&P59NV0T-=+Q+D
M;3=K_689JJF8BBKM<>:0:12?=-KT+=M)D-DT54U5E%(F6YKF]I,M&U4,6(O1
M@;(H;CLZ\'#5"Q7,&57;G-$V9[3-&6US1ANVOC9GM,T9;7-&VYS1-F>TS1DM
M-6=4:43.*"&BI&I$UO85CI3QC.[5FO1ZY=3M(MJQ$ND[])I)Y[1%-B;228:D
MR"K97\J.+,J=4T!X5RT0#:PZQG<2S5,E22&RJ)70'T\6L3^+(G8-[8WYZ+5/
M&95,655E523Z'DE=[9QJ4E<K<);9)HTV+VE45G31,&2-M#E^A7-&11T83V*&
MU-ZX$MO^= UIO?JI'$49AJ3IFK@^D:NEJ!);4,NBOA.*:A-'V\312B5!2J)I
M@F.K:FNK'EJ<)3@#C0^( B>JQ=FNT@^)8AJJ;&Z54+2QA[1]!_$V=?3 [=]E
MT=S7YM4U>72I5O\=)8^*AJ@115^N?]Y9M%82-XK6-CVY;1=AF96;MCMS79**
M1'O;S2H0FI>QUEU6]KE9!,/%2E?>8M1UT[9L)^%FW3 ,4U75,HPIB0WC ^$H
M;9Z/V":/+J;5BYHIJ?(^ QF2@O6O8#]MGNO;D/31MM'U'AM=JXUM="VWC:Y7
MNS8I<%5K=)WF"%>HT?59[^YOPL77ZW_>5:1;=+:Q]?OH8KU6?M8K)7_[#+KE
MP-2J)/N=I<LMEV;P?.4DK%$PDK/#/.7]X8_L'G]%*H:+H:@&*UT;WMH],:Q<
M!F;Y!B-A./:>TRE=R:A< >WH)R=TT@3PUY#U^GGMMG?N.8%4UW+25XH&,5>=
M*%8IH:M"?1)DJ7"?A HG<M7I<$'2"A\N%,#X#@X4LM)H6Z[+)&;@C$"? HX'
M#M@VR4!!^!1_'Z!L6Y)J/^'LP0*2;1=)7]LDK%0$D/+R.@HG<)S3*6RVPU/V
M</ZC-?$ J'^7E,/W.M]G@>NY=B\#VD$:P\D2MG*N9,+8#O%81JJ4A,?K^OKD
MXYHDP5YY[A&3C&-J!?30;',=CJ@/("%$?0[*@=C%!-O$4&O'+\406 :?$#Q9
M-FO4B;(&>>,%4@J6TD\/PS]$JFQ;V]W@L!06(@?/RMVMLCD;6>XC1?M[:#F^
M\(1'*9CP\VSYON6"N>Y8#\XX4VNZ^^U?XZ]= %SLA"=U*ZZ'_^3@'=I?)G+G
MU.QJROJ3Z%><Y-(S_E4L#1-E\4T)_[O5 V]T.^>I.5@(D@4!!4\4_9&8FL&M
M/*F8.U<90 XMF8B.,80;GTXMQXX5.-\^#TTI83#S?;@[VM>#R:5+%\0-J*5S
MRO^]=".8S^F0 H1V9.R!C\1,P!X#]T"Z7T'+;QO;>8]2JBS\EF(7J'ATL(U5
M\/;(W<ZM:LZ!#*F"B\YH20RW*3TDGA6';R\,MK%%H'5.9:UV1O;VR"TU7$XP
M9&:L'PM5<>.;,UAO,,#N10%\^8)'_Q62M#%H-QRR0_,4]GKMZL;VXK4N6"V7
MF3"@UA7E;0*GE=5:@&-_1E^U&S-.0'7$;03WUQ2VV*ZYCAV9S'>'L2+18U2K
M&(#=AA/?ANU2&57&VI*N)ND'8=1"*F_;TN_(U$Q\=7[DL11T>C43IYXUCCD6
M5T)Z^'=,?WEI^V4J7QFGH>GK3:ZV</6-FUJN2,&&6=)Z65YB16MYW2:29A/Y
M^2<YN2<-)%58/Z86WOC>DV-3^\O+=\!#AEY["1(.+8 P=J5T5:650?O?V'*%
M$ ;-2-=0-J_"W']E_:MIN=MGI&;2>:?1#@D/+R!_GFA0-*6W/:"HN(HQ^0F&
M-Z#4#H2A[TV$ %B&=5* 70=.#%^88XJ]IZ9XHEEG>;3NM%%6=%-5S+9W3='H
M0$PY%T X=T WU\.;B&ANQI8;@JO:C^GF0,<=L@9.P>Z$=IG!V5V9C46E=RW)
M<TT[*I4 /^L2CKEK6;H02Z\PRBYCPMF?45:4H_4J<O3.@\1)59 =>>CH^2$_
M=SE7HT)^ D2Z4<*(#]OC.P-6< _?'RR$B<2#_^^G\-TFH.$7H!3F/\A<R5M:
M+L8F^C\&XQFB!GYA:3.W5DC[PR$=Y&F54CT^H[#'5Z4#GX/O4;G.F\F=-WG[
M3:JLKD\\M6)206 %2Z'P0!\=UT4S .S\<$2%*=O4YFJU-U%\7D]&S1!%49+V
M>(:EB$"V9E<2-Q_+^VZ-EUUO<QEM\A6I<ZJ3+BBLFADUA6)-;^CKN$*L,1&6
M(]I K%$\0=]$H-6N5]:N";R$F:P*X3:2UHX_+EEXE= R39'!&3.[1%J?2+A]
MR[3JQ<;O9M/IF+4LL\9,&+EQ)22\=1(DA>2\]K2-CU<N/KZ!&KK%]1UYPZ-9
M0'EBL> ]A);C\L-8&OD[R#%,-\TGAA2(KU514*T)J^F2HAJB9NB;AM7>ET1G
MI',]_!Y0EI1\'9'-I1L[R1>>7U+:15%YKK!,2W,?W6;WU0'SM79E\>N;T!MS
M[VO9^PO6=<C4&MLA4VD[9*XVPW(Z9%:C0:;^]@:9V+SOIZOK^_Z=<'\M?+_J
M?3^_Q*:7EU?W_=O+;T+2$Y-?.=<8\^+RJG=U=MG[FFF1N4L<;=6Z5(A4WM5L
M H\<+)X>62%HI.MAI-5 IKT>H:>@KZ;(C/Z,IGI(4C2Q4\KZ<&= 0 C7M[_U
MKB[_MW=_>7TE]*[.A?/^W=GMY0W[^_I"^/+][O*J?U<V^G]QDAW8;8O/8N\^
MA^WQ'39]#.,J7V8!T'X0"+N'9O>J)[;KH]/P_[("($D!U+4/!#<#-P-NOW0'
MQ\Q]<\)@7@$'LX? L1W+?^D*\:T_A#//GQX+'["!*<5C4#J&K]$ )N)G?A7[
M0_HL@"^ 4:CHNS-N'D1??NP*#E@(P@ D"?-V0,>#^'UPP'(8C%QP<!Y?A,BB
M +MMP-(^80=L"B_TIFADA)EE""&LGK(S_8D5A*P-JV#[ !W<X@1H5<)2@]E@
MA!-2!B/?@[<*P12P:[G4FP7"C'E=OF-UDZ\!>[.!@UU>DR]YFZP@'$VL8^&+
M[_PY T-U8CT((WCL X6W4>S)P-"'1Y71ZF WP=;AE>YO?3F@'39ZD$"!QE<&
MMY+^.4C?&Z%KPNI!DT-K9IE%]37C.?3&;T_>"5C#MSZ/L"$<[F;Z:"NTA$?J
MHHSCJUT #= ]G7H^4-40'H<E/5EH6$=AV'#?L\!:B6^9>M/9F,E,>*_]A/8?
MIFD@#<Q0J.9B-+KWV9N-;=@$@3>683W-XNV(F)<M -N2A Y2KC#&?L8H?+L\
M7@K$YX9H<:(?&X2X,EP/&JZPSF#D3/F)TH"/*Q2L)\L91\[*W$XP>@"_PQ-&
M3A!Z/H(,F*8_IN"Y W Q30)B*:PJI=[H"UL847!5O*GGP.= +&#_\M["\&XW
MSF:!Q;IT"'R;DG9RH0#0NZBO ==H8+/AB/@&'Y8$.P#W/,Q"9,)<0LAN%2#N
M(4/J@/&5/+:;WO4EB,+L7@$.1M2R_YS!-E.?T_(MM9\]SQ;.8&>[PAF84$ 2
MKC//;UR$G=.Q]<PX"B2CYZ?M])XM),_X4_Y<WL*8B))Q#)(7 )["ACT  X#O
M*G$JC!^.A#JF>)\E@)GQ"!<].^%(Z,''#E _%?Y&K7$X&N"[>P,^%Q/??;8
MQP,=@'T"3YF""P_$%(G5K"_U:<Z> 2]U/UA?]$?7&%)W8+<Z0^ =-XR*,8&
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M\_$P[B82*1C%)KH/]A9SACSW]YG+CPT8R(SJ(MFT4JKA13Y877@1%VKH7E
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M 0Z\8NI[#\SG2^B)K^K9 9V**H2]DATVS&U04>I<LVL\R/V!K $'-3IL;@:
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M>-_4Q_KSN%J8 0';AW85D'# NT>Q9#)V?I0!:CG7=AP; KQ? .;+Q;D,/-6
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M?!D;]+ ,B*,ZNX9AUO+,<!NDEL%*,DMDVP%2RTIDBUEI3!^M,>.CJ>\-:1
MT-9!B_TSQSD(X4T&K MZ:.910&22 H'S"K+.QO@L@V\P0UI[.SYWJ'5>*_FO
M^?EID8KPI8#)8?D-<ZZ+]&1N\]7>L)%E,#J>6A7I_U2E?+7W5>8/% .8"8,;
MZP5#<DF)>,4D F:4=XV<DZ_V\'H/.UJ&:,"<]JZN;)'IM+,C[7UUP5X(E&[=
MDGE%NVP6:#AS_,EOV,]\5]V&944KL4VV>BR<7=Y^$WZ[[5W=EWJ$M*<T@TM7
MN,*:59R.!BPB=H4S( -@!M>QX,L@=,)92-D!]RU]I"[U+3RR%KY1&X?3_O_L
MO6MSVT:R/_Q>GP+EY^0INXIB")  R&1+58HL9Y6U+:\E;^J\.@62H(08!+BX
M2&8^_;\O,\"  $A0(BE*8FHWD41B,-/3T[?I_K6KO?W__[^^871^1;+0C_JO
M[S3GWHGP\CM1FMRNN.:OCD")T-,YW29BK\71?U,O<L<7F! W L\ D:TK&T?U
M#,,V3;M!><)#LP(,X!IC658 =EI-9]2(5=QD13)J"^[K7^XHR<)!2:@YF#<0
MPID(R,5-/!0"\)238%ZL[^(=V- /0Y0O[I3OG#@E+4 Q$6NC6W=*UVG.;,[=
M(1(X:/',S[O1RKVX=;!%[,B%G1S#&)IS<Q.!:\T-9&LV2L0)^:%3^<"'*)SB
MUC\NL^3!6Z"OV(()3(]/;'(+IM3-[4(^1EOC(\;_!A)%W)HW"+%JCNXFG2FI
M)<VY<SR?KO_P,$Q2*J@;>W$2><.4Z"3:YV9=G;$W,?WE!@7>KG(\MB0HOF6K
MP597V=TL+:V%-NLMTUDV;994<(!1F,%'X?$D%9^6#H)\C*DM1Q>#H%S1[5]C
M.03>-D<N20*Z\\ LJ!E(!=G'FMHB.]K,R4\>2:1VW2IHYF(IZN0]^,80M*(\
MHS-GKD7AW/'YAAKF['N@+JG)]L3% ^I@AU3@A66PAFZ$*M:Y<2\G'^7C&-Q8
MYPQ5-.\X-M13U-RD@2%..NUR6.,GI Z"P,2.S_VKD4RT =1&^@X6 =\#T@-)
MEPF-SVYRA4-4=AOK]TRPIO0&U4</%A(8[FQ7))])(2%6)H_I:4PBT0<."5C9
MP<Y'H)."U-7B6P>;_!;9!,4I_A[.I!R A:);E[,>2W@_= )LO\X-O9& A7'<
M'\ :'J9&8#=WLII7#-:";VKWU.5[Z!9Y%2&TYO0,?E&[]Y);S)AP VV(7>%!
M=VIC9T[[.G6^4P?U% ZDZ[M$GC;H>QB [Q2%"+QSHCDJ(Y=D [+Y_:T;*//R
M8CE9MS!)(.P-G1$4QZO2_8;)&8V!4;\S.1J:(E&*L_D*"]SH26G<YZ9G]-Z<
M6&5&^JD@9)B-Q/H%X3)=._/3.&_:Y/">1EGG=I%!>$P9A-K'B]\NO_*G]-QR
MPET I;B1^X48OX92M7[O)BF%H=*RC_03R0HG@"?;VI6'V7$J_T^!88>N%.T*
M%\?A%"@$3_I^1FNIEH6I.9S3(2X>3(=]2OB8,S0]\7W6#UE[ZK;V.^P.,W(*
MDXH2!_8(>V%GKQG#V4]G0/1(GHJR"(!=#FDNI6W'PQ>FJ.7F:#*,6,=%2OLN
M\6B+E J]2&HSOB+$_"DQ*IF$\LR/D#(PN>)L[D&R:<[XKS2FA  8&DX?IID*
MT>,,8TI-A%'='S/082!%OK6O@ ZGIU^TF]0;._1Q0-PC#1QE04#M3(J@&B!]
M2*?[!KR)*""Q(3\H4\J9P4MY@XOJ5Q@'H_ &.%-F/D_S+E?YW&!O3J_.M.MP
M!@[FP.P?6QT37)GD&';Z&*\-8$GG8@*_@"QC\?TU'YJ,"N/7L\("AUCEX?CA
MS9ST -+' :&H]B[/\WA+S<M;"R:,LJZ,<O4&=B$BJL0[/H?!:!-!K ?K3ZM1
M#+?IC-<(TCQXQG:U6[#$54.I3!FK:-F(K$3XYG%59J+'AV@D6W_A3Q3^)M4[
M='QBT/C6=='ORE)B-QJR44W^FGB+W)TSS#H<ANRXGV(SN1LZ2QN+P,!GNXO
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MBK.L,E&M,N%>1QX6YKJIJ,/"?KS>B$-W8/2Z]J"4V[1)7ZBW5Q&'G2S9W&7
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MDDL=T[1UHV<8&>F/#97VO>:T1UC<;K=*,OW4 JLV!N;$.Z8(V7VW=/H*+_\
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M/1*7[(W1''S_L,-4#F;WNW:GURN%3;>QQ5@7AA5)#7*)'[/'&XC+G+QW@Y!
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MOEY\_GW[I;S;QY\!_J'20&2K/U)_7H68,IWY5 2'_ C;%,U"+"#6(C>,;IS
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MP#GY$4309#S4"V]I/V?9*TQD?D^M-R*$\%$IOD'49T^7FT>X/QR\R&9*HZ!
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M93ZQ9SKTO9%Z]<'7MMIG)QX[_]7.G)F'P V?F L_?CS3WHK(+G]#)O,<F/+
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M0;'K<X4,'T-P"EWJ=:SHK3PE5M[V^V&"27>>+*/ MB^!2W\&.HRC]";[*M^
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MXXMGMQ5 4 79Q?$WQ=,EMD-;D2^1%]W6EFAHJ?$?NVB#(EPJJ/TF!F:ATDA
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M6FF;+AC.Z32.Q#]A.UA5^KWH+%TK=*W0W4S!#<G$"GQP)<2L<7H85MI5SJG
M34A63:!:>7KL\E2 NS$L O!J,R6F)SGYKB2I+$<[;"-]DUO5M*VBQ(Z*XF:Q
MXO%*SK@5G%9P%K\APG#CQ(F^H=9Q?6-J:V:C,_D,\SBMH=0*U3+KO,SR4BV,
M53>&B'*IW0B+2D#<\L"TIGHK@6N_0>6X(Q'F #CS$@A6B!N@)(2[ D$:E(+&
M'6>AR?9H_*T;WU3-4NM70'X8BI4\C7E;-7NE"X,K&":WL?J@C.+13EH6O^K
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M3X0':<PACR_8YG>$>[A5YVP]I/E[[@HDA\'*Z^(EV$0;VTU869KURS%BF"A
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M,T1(M(KH<2DB:GS!.4U=4PX/ GV4)IPDI>XLF9(.T>0WD")R@HJ2AR[ 0+M
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MN0NE4%EH4)II =R&Z%K1=RF;M.D^+\-4A6 KHDGBK%"W0O3,A0@U#:'6=)H
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MR+^<OE;BEPDMCEA,3X,<H+'+!:[8*,K4T#+^_ "51<0 *3(5Z4@?:P"GL\4
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M?:^]YX% D3S!?R^+2?SV_P=02P,$%     @ KH"N7,^NN5M>!P  VRL  !4
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M1N516L:8$P!?0%H-Y%"\K1? )U.+*9>F#]RI8&L?+0UZQHHGKK%%F<( A-%
MM5_.>G\B:4<B2?7$SMAD:*BL,YR?23X9_(:7M052V)DS2]Z^\N++X,7Q9^-%
M_P,0_6CL^U*?V@KY51;+6ZY.$H7#7;OG$=85TI#',K"I!B@+@#E!(- @57;$
M(]@L@^*PZO!QK&R4:EMB'&N1T6D =6%T1#%.6[$+#,<$4@2@=NZCD<R'Y"L&
MKCUL*#[>[E+PXO!M'(["H>*B)0]DXOD%:\$"QP+FV9>U%TH^6"C!0ASG8^;!
M@E.\DY?)S(X/WG[CN=DLBE5<>"E*HL#]7)QLD\6M S1]1O1IWM0X68MD:=<?
MPEG3@,"!:J60A^G28 *(QEA9+T6PHMS/PX7L@X@M"J&A5'I258G8 S%JE4CR
M105!@R]6IRJ6SCLZL"I6TB@.0(5TT4MSSC.5EE,XOPU9G^]YX=*6X)"#4/*@
M0C+4RE2RWB(L[\1#*H@1(;%<S(?QOP&Q(201XRE^H7+J&R/MVAS=*"4'JRFY
M->JM+2A+#%Q?BM8F(L@[5C'S2UJ=2]9<:<%-+J28=-+$,P* DDH.5*K<E!/%
M5<OR=N"YXFD0F/R!Z4(AYJ7]O@JH*$T!&EJ?V$:1-K%WP)=D0\J1KZ9@(ZZ0
M[PVR"<K-P#AL!ZJ NKYR[NOA7+1USG7&,BV])C @*4FX@SP&E.R*,F>>H:ZA
M<>%P=>7C*8:!T"<;ZJN!+MW3'JRCPG)N35P\)I_N2XC!K"SUNP:%.P%_3GGR
M5Y9\-2R)MZ], 8#+0.:&7E6^^"LKV?(,/>)$3T=1:1BN"UG5BEDS;1W.\]LB
MS&7QF,3[T-<6NT\,2< [*,4CZ\KQ"&SPO4AN4^;EW*^]X-5(VGD*RAKC>4JQ
M%U]_/RIAG(I4W5%:-28?V=?^\RUZ$6Y^2X3<' G>KNZ3? G]$/^.)YZ1M/:P
ML[/0+!+E89-GJ#\CQ5RJK^;>2=183AL[S^K\"4R99<HYHH_(Z$ C;^3KL8)_
M?I)=T FJ95D5\9<KO=D>0.]+!?<]W\O<O^BU>Z]MCZ]'IYYH:FQPB5:*V@&W
M0($?W!SC-END"&BN,K)Y$V%"\HY3K%!+^"3+5T'^U=.L\?TLCE3U?FA-KA #
M&6.@I;D6/,FGJG;"$) ")4XMY'D6<=LR S@1L ^FTN"5KPA><[BOBQO;[RZT
MD*HE!IMS#4@E+RG NG^Y69&B%C(=E8]U.B9.=W(YK-[1FDJ%*"M2/25<G8QT
MT!WY >5 D8WD@@?;!N]G .<I%,_$9/8CG::RL'@VL_]]$K<#[9S.GH;N3XS]
M-9![S':;0U7=UA>^/5K]S)X1U$<C*&3,7:;], H>A(VGNJ<@-B9,9707+@C?
M[MUDK)\USDT&TNR>]0SD+B;NDU^,%"6B<T]1R8T'<1VRR_ VMUUE9LUZ]VP[
M46]R%^V%+A_VD:5P]KZ,HFE+J[2YA74"<$[%X7%-'#6.?OKO2P9*^6^QJA,S
M1"Y]G_7Q+U;K_'%N^%J7/^K]/U!+ P04    " "N@*Y<\^PUQ44'  !=*P
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M#;VJ??%7%K+E 7K$A9Z.HM(P7&>JJ@5>,VT=SO-+(OBR>$SB:]C.%NOW#$G
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M5;=+2@4:.P#IS/<<6'6P W]0WR4."K'S&;DL!IHN,0[I@X<BAX1LO\$P:]-
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M0E!Q@B>UL4UO0]O9T 4-"82C& 8[I?3G\&L;0VK-5&M-I?1>,VL2@G!;DII
M%2OIK>D%SQ;G#*9#.ZU-*%*&K4X:]V#O#NQL[M\&>(V(<_',DD^8!2H3F&K!
M&2S\[.8\#Q.ZFD:W7K2&I,AQMC.DO--)9+.$<#PHXN)9B7PB6NH-\$4,D+^W
M8@.CSG8]:[8N?,'A+FRNEK'6S$K9VFW-+!:'FU<JT'<\4=@;U@L8%NS"@PA7
M^1QIU[.]J;7N2FM\I7SR=L:7"%CGX^1M8&^/#6_WY$VG6*I%N91VSN[Z]!AT
MN?633Q_646BQ*2>3E7> >IP:W@;*05,LU*'QKI1Z%1SZ\>]^)J2P\&GIM"B5
MTI*:4R$]=%VAD[* Z9KOSZ\QHOC,IZ4MV]9\M-"7\H?UT!>RB%G< K]X[Q;O
MOC>179A(\OHB;\%'5@KTIDO_"8HA#APO8$5;0$C)26[1IKR<ODY76D-K=R^Q
M8&BI>(F1R4%O(B'/-*8R)G1"RMX>FY]D*QE/H5R+=.WUQQZ)YDCDG+PHO(-Q
M"!ZQ,_>#RRB$ ;ZB-&)[R2K<NG'1HEQ_8K&T3F15HFL+^K;BSBW1>V\=G8XZ
MYK=/M21:7%L<=NRQZH!5-AUY_82_Q6ILA^2QG-3:BH,6Z?([FJJ0SL_F>!K'
MW5I9O[T];&D/=].'9#0WK:Q T4Z+??G@9#/LH2\!>?\4=R<.H%2?Y'K;.P(=
M)ZU1E%-G+1R"BBP1H#>4+0U%.MTAN7SZ%5%Q\L)YH+ '0I]=Q ,^8$ICHMN
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M07R%CCJ,KA.>+J$^L*,9OGK)<;XA+H0SOI>>O9O,7+*(WY?C?X92XMPO2>"
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M\>F9ZK'?EI]Y8S6FX7*%\OXH7_;-7!)_YS>%L5^A3_\'4$L#!!0    ( *Z
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M52#3FYC'B;42F=(8E7EA_H7\\8 \[_\'4$L#!!0    ( *Z KES8;+&4*BP
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M!>QEJ<YD4LY1/@Y#K/O;MO I-G];MO\6^/Q)6/O:JJ6#QB63:8M;.&5TU+'
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MYF@ S&CETP[J; N0,11 ,EN4CYY*\F7\J^/)=(J8_95%PP&T/OK^"2OR:>-
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MJ3^S=&2K#4R[?R #G<T6@T>:K92,0<J])++=>NY(\P*;^&J_EGDITPA _\.
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MZX?1!\T^JXREOYS=CK]<L==N__YA=/Q>[VH"8W%LP!19FB*LP(MRNU:6,@(
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MUFP34#MT&@[#U3N%?N#_A0WUE/K@=4*%WC6*$Y0C8+8U'0O!#N[+&/5#O0,
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M,((9B0IFDNM)@A:&8W6M<+?@>!L/KW8=;E<XPTV7<:N:9Z>UBXUKA@U6$TM
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MK=PB7GL=%'RMH=_0UOG1FE>::XI=JS5RCG:YAAR@IL.[WFIBB.O"^)M;3HR
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ML:R\')RJYFFKE/>VYM;+=O/LS0\CN(7FF'P&'<]S'"#"R](O*#8QF.- ;!S
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MRCX2OOD0]G2%8Z:76]%NO1*3%B ]"7.,%*7%L$7B-<@]T,.]1:&D@&G9FV5
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M68C)U?)^M;C_?'-_M;BQZ[%OD\).,SF>X[[YMA_D]3X-<:OGKFL68.QN.^;
M\(@"A'8L+ZKPS+_QU]N?(/A5_* D) 4M5,PSC"TWM3"W63J+2RE&EIN/'__P
M0W_7U0+'/.O@A8<HFEZ*E.)AJ$"4J:UPC(I27+J(.1_4?+(;XJ4@H>U_HVC_
M[H<?OC661T9N>X"@QS"4OZEY:JFX2D!9(>(-EWINSU)(5%C.ZN)Q?.V%*!8Z
MFY7_91& /\TFY-5E>R6V$GH;"M0K0[67-+H@Y1&]AG LQ.F]OSM5\2$H*&!Y
M ,PJWF!V)WO,13_F(7D%OO3D<(6#GF240(NZP>"'*0;P8 2KM,W#GEG,!2$
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MS,^"BO+^47S6N<F;+[>U&A6#SVB.Q-X1U;/%_%@/$T>$OF9WH!UA%[):F7*
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M:EMVM];"$9)!YHM-U(?+V=/-M4?G[N'F_FFV6BSOOQYJY7-<YX*E>&E9GNH
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MI'L9)PN3YI63*)B6;2D$8-Y^IY]X+?X+W':3!]#@:W$1SDF<D0T4XI<;9BL
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M- #F-%>N@;I8 Q0,!9#</DPASSE;F?[IP^R!FLZB+FBJX0!:%]TYE*]2>.-
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MU4)BV7M[/&IDAT,[$*U>FB!XS'KIJ'1.?ZVW+B-)RM6P9@5TY;RU\=N$^M-
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MZB3RP[A#92M3=<)S(-B[*N+S.4:+VU4>B/;)K'NBCG"#X3[5MA[<%3ITTHG
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M;:F:!GN.U2&7I,Q5PQJ !*IFQ8+1L"-(4?P.7KF]QXH+;N_:ED=%KVNIBX\
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M,C@Y-#<W+3$P<5]J87-P97(N:'1M4$L! A0#%     @ KH"N7,^NN5M>!P
MVRL  !4              ( !73H! &5A,#(X.30W-S Q97@S,2TQ+FAT;5!+
M 0(4 Q0    ( *Z KESS[#7%10<  %TK   5              "  >Y! 0!E
M83 R.#DT-S<P,65X,S$M,BYH=&U02P$"% ,4    " "N@*Y<AQZ"#+T%  "<
M'   %0              @ %F20$ 96$P,C@Y-#<W,#%E>#,R+3$N:'1M4$L!
M A0#%     @ KH"N7$BT[GD;$@  W-@  !$              ( !5D\! &IS
M<'(M,C R-C S,S$N>'-D4$L! A0#%     @ KH"N7'(^'0'H"   $H(  !4
M             ( !H&$! &IS<'(M,C R-C S,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( *Z KES8;+&4*BP  +W, @ 5              "  ;MJ 0!J<W!R+3(P
M,C8P,S,Q7V1E9BYX;6Q02P$"% ,4    " "N@*Y<U[U2U3A\  "9SP4 %0
M            @ $8EP$ :G-P<BTR,#(V,#,S,5]L86(N>&UL4$L! A0#%
M  @ KH"N7.-OC.('1P  &Z@$ !4              ( !@Q," &IS<'(M,C R
C-C S,S%?<')E+GAM;%!+!08     "0 ) %H"  "]6@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>ea0289477-10q_jasper_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:_2="http://www.w3.org/1999/xhtml"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jspr="http://jaspertx.com/20260331"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jspr-20260331.xsd" xlink:type="simple"/>
    <context id="cref_784925054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_668202531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_486425029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2026-03-31</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1417501004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1378370445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_358966682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:MDSAMLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_543821224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:SCIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1187366974">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CIndUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1533989264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CIndUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_217583461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:AsthmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_2109719354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:AsthmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_158858565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_768267355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_199674710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_920960091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_585224753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:BriquilimabPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1773614604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:BriquilimabPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_268000114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_438560971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1722756702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1720545267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1107233758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_34643640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_565409357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_442461320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_887924682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1055712422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1143859271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1518267216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_2040753095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_502686246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_279398949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1680691002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1571420461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_155304082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1083033443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>_2:ResearchanddevelopmentMember</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1852720650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>_2:ResearchanddevelopmentMember</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_2045662903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>_2:GeneralandadministrativeMember</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1364903650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>_2:GeneralandadministrativeMember</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_784622662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1154412494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_664802157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_155106258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroTwoFourESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_2065545269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_714368909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1835780786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_2127221751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1227972248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_384482861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_477447857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_853288868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1206044327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1511983395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1086398820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1367888496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1840882305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_436942179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroTwoFourESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1757947245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroTwoTwoInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_517605843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroTwoFourESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1436491688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroOneNinePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1643317952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoThousandTwentyFourPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_343598538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">jspr:UnderwrittenOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_2042008173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">jspr:UnderwrittenOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-18</startDate>
            <endDate>2025-09-18</endDate>
        </period>
    </context>
    <context id="cref_1187790031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_648885515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2025-03-26</startDate>
            <endDate>2025-03-26</endDate>
        </period>
    </context>
    <context id="cref_415871009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_238056073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1422418476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1088620590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1516512986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1623292660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_671366674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1068906306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_835672883">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_467908750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_653971143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_749757817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_695848034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1665866085">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1365582304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1329622523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_166765776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1634329083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1455265214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_841215262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_736074492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_601785078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1989808306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_107187006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="cref_1406915345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_2133957400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_739243793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_143115946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_937223270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_400739651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1893484374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="cref_859966735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="cref_26166482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:September2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1282057323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyFourStanfordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1140767225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyFourStanfordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_549257824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyOneStanfordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_145174291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyOneStanfordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_862585213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyOneStanfordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1284574516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1842275578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="cref_753159246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1539753648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_671786867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1979065684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1742280107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_176880314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_445054501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_982217023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_2051178283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1331265187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1403457930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_823902052">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_940893104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1240913286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_634664125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1826855759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_566781871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_611083158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1378325364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1785879477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_894353261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_243881147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_739502903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1483965117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1288544829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1849531206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1966633800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1361797107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_13823206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_15337254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_414108446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_505402133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_10449924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1935535027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1788895550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_1234679342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_1080624732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_249853930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1075311384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1511423065">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_218143529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1220156236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1995654471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1859494511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1426826830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_762749261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1291783619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1415246794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1740623832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1982379788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_382561751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2026-05-11</instant>
        </period>
    </context>
    <context id="cref_2142854251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1847374087">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:VotingCommonStockParValue00001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_2072460258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_347088362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_111159347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1894122814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1072361442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1196049397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1867564296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1276276239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_707032855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1289593603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_166082834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1176672139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1844764249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1054403778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1768916711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1479140823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1505739634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1357899928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:SCIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1112529675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:MDSAMLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_402018995">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <unit id="uref_668202531">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="uref_469718384">
        <measure>shares</measure>
    </unit>
    <unit id="uref_1987543344">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="uref_1055712422">
        <measure>pure</measure>
    </unit>
    <unit id="uref_1104703976">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="uref_1666881356">
        <measure>jspr:Segment</measure>
    </unit>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_1378370445"
      id="fc_541668956"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_2072460258"
      id="fc_2072460258"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_762749261"
      id="fc_167423569"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2072460258"
      id="fc_1035803401"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1291783619"
      id="fc_640081597"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_347088362"
      id="fc_347088362"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_249853930"
      id="fc_881676001"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_347088362"
      id="fc_1099697568"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1075311384"
      id="fc_1883212435"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_1378370445"
      id="fc_54230030"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="cref_784925054"
      id="fc_534795495"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_784925054"
      id="fc_1525497196"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="cref_784925054"
      id="fc_1714580687"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_111159347"
      id="fc_111159347"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1894122814"
      id="fc_1894122814"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1072361442"
      id="fc_1072361442"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1361797107"
      id="fc_804810147"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1196049397"
      id="fc_1196049397"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1867564296"
      id="fc_1867564296"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_414108446"
      id="fc_1620055900"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1072361442"
      id="fc_1092525917"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1276276239"
      id="fc_1276276239"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_707032855"
      id="fc_707032855"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1289593603"
      id="fc_1289593603"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_894353261"
      id="fc_1353737602"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_166082834"
      id="fc_166082834"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1176672139"
      id="fc_1176672139"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1483965117"
      id="fc_1449616030"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1289593603"
      id="fc_978200156"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_937223270"
      id="fc_554114115"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:ShortTermLeaseCost
      contextRef="cref_784925054"
      id="fc_1783648313"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_438560971"
      id="fc_357656926"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1844764249"
      id="fc_1844764249"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_736074492"
      id="fc_1765267982"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_736074492"
      id="fc_1111002203"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_438560971"
      id="fc_2072766674"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_736074492"
      id="fc_2048509785"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1054403778"
      id="fc_1054403778"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="cref_1086398820"
      id="fc_1454690266"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="cref_1086398820"
      id="fc_1900409824"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="cref_477447857"
      id="fc_1792648283"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="cref_477447857"
      id="fc_1994038587"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1840882305"
      id="fc_838649266"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1086398820"
      id="fc_1603413953"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1206044327"
      id="fc_1799126299"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_477447857"
      id="fc_723560973"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="cref_784925054"
      id="fc_577259707"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="cref_1378370445"
      id="fc_729631792"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <jspr:PerformanceBasedStockOptionActivity
      contextRef="cref_784925054"
      id="fc_597754003"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_2065545269"
      id="fc_1423726112"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1768916711"
      id="fc_1768916711"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1479140823"
      id="fc_1479140823"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1505739634"
      id="fc_1505739634"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="cref_784925054"
      decimals="0"
      id="fc_1666881356"
      unitRef="uref_1666881356">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="cref_784925054"
      decimals="0"
      id="fc_975557945"
      unitRef="uref_1666881356">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CostOfRevenue
      contextRef="cref_1357899928"
      id="fc_1357899928"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="cref_1112529675"
      id="fc_1112529675"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration contextRef="cref_784925054" id="fc_743175501">http://fasb.org/srt/2026#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_438560971"
      id="fc_371358555"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_268000114"
      id="fc_960120892"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="cref_438560971"
      id="fc_549550349"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="cref_438560971"
      id="fc_1556204817"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="cref_268000114"
      id="fc_1282959221"
      unitRef="uref_668202531"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_438560971"
      id="fc_1568976284"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_268000114"
      id="fc_1557480139"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="cref_438560971"
      id="fc_137921896"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="cref_268000114"
      id="fc_1463662633"
      unitRef="uref_469718384"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_502686246"
      id="fc_1964576807"
      unitRef="uref_1055712422"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_402018995"
      id="fc_402018995"
      unitRef="uref_1055712422"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="cref_784925054" id="ixv-6813">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="cref_784925054" id="ixv-6814">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="cref_784925054" id="ixv-6815">0001788028</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="cref_784925054" id="ixv-6816">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="cref_784925054" id="ixv-8181">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="cref_784925054" id="ixv-8182">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="cref_784925054" id="ixv-8183">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="cref_784925054" id="ixv-8184">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="cref_784925054" id="ixv-8185">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="cref_784925054" id="ixv-8186">001-39138</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="cref_784925054" id="ixv-8187">JASPER THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="cref_784925054" id="ixv-8188">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="cref_784925054" id="ixv-8189">84-2984849</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="cref_784925054" id="ixv-8190">2200 Bridge Pkwy</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="cref_784925054" id="ixv-8191">Suite #102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="cref_784925054" id="ixv-8192">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="cref_784925054" id="ixv-8193">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="cref_784925054" id="ixv-8194">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="cref_784925054" id="ixv-8195">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="cref_784925054" id="ixv-8196">549-1400</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="cref_1847374087" id="ixv-8197">Voting Common Stock, par     value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_1847374087" id="ixv-8198">JSPR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_1847374087" id="ixv-8199">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="cref_2142854251" id="ixv-8200">Redeemable Warrants, each     ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_2142854251" id="ixv-8201">JSPRW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_2142854251" id="ixv-8202">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="cref_784925054" id="ixv-8203">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="cref_784925054" id="ixv-8204">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="cref_784925054" id="ixv-8205">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="cref_784925054" id="ixv-8206">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="cref_784925054" id="ixv-8207">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="cref_784925054" id="ixv-8208">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="cref_382561751"
      decimals="0"
      id="ixv-8209"
      unitRef="uref_469718384">27996819</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8210"
      unitRef="uref_668202531">14144000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8211"
      unitRef="uref_668202531">28692000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8212"
      unitRef="uref_668202531">6148000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8213"
      unitRef="uref_668202531">5953000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8214"
      unitRef="uref_668202531">20292000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8215"
      unitRef="uref_668202531">34645000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8216"
      unitRef="uref_668202531">81000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8217"
      unitRef="uref_668202531">102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8218"
      unitRef="uref_668202531">317000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8219"
      unitRef="uref_668202531">502000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8220"
      unitRef="uref_668202531">417000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8221"
      unitRef="uref_668202531">417000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8222"
      unitRef="uref_668202531">77000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8223"
      unitRef="uref_668202531">113000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8224"
      unitRef="uref_668202531">21184000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8225"
      unitRef="uref_668202531">35779000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8226"
      unitRef="uref_668202531">2439000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8227"
      unitRef="uref_668202531">6220000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8228"
      unitRef="uref_668202531">757000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8229"
      unitRef="uref_668202531">1235000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8230"
      unitRef="uref_668202531">5800000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8231"
      unitRef="uref_668202531">5745000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8232"
      unitRef="uref_668202531">8996000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8233"
      unitRef="uref_668202531">13200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8234"
      unitRef="uref_668202531">6524000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8235"
      unitRef="uref_668202531">16164000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8236"
      unitRef="uref_668202531">2264000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8237"
      unitRef="uref_668202531">2264000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8238"
      unitRef="uref_668202531">17784000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8239"
      unitRef="uref_668202531">31628000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_438560971"
      decimals="4"
      id="ixv-8240"
      unitRef="uref_1987543344">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_268000114"
      decimals="4"
      id="ixv-8241"
      unitRef="uref_1987543344">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_438560971"
      decimals="0"
      id="ixv-8242"
      unitRef="uref_469718384">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_268000114"
      decimals="0"
      id="ixv-8243"
      unitRef="uref_469718384">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_438560971"
      decimals="4"
      id="ixv-8244"
      unitRef="uref_1987543344">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_268000114"
      decimals="4"
      id="ixv-8245"
      unitRef="uref_1987543344">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_438560971"
      decimals="0"
      id="ixv-8246"
      unitRef="uref_469718384">492000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_268000114"
      decimals="0"
      id="ixv-8247"
      unitRef="uref_469718384">492000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_438560971"
      decimals="0"
      id="ixv-8248"
      unitRef="uref_469718384">27996819</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_268000114"
      decimals="0"
      id="ixv-8249"
      unitRef="uref_469718384">27996819</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_438560971"
      decimals="0"
      id="ixv-8250"
      unitRef="uref_469718384">27996819</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_268000114"
      decimals="0"
      id="ixv-8251"
      unitRef="uref_469718384">27996819</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8252"
      unitRef="uref_668202531">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8253"
      unitRef="uref_668202531">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8254"
      unitRef="uref_668202531">321241000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8255"
      unitRef="uref_668202531">320818000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8256"
      unitRef="uref_668202531">-317844000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8257"
      unitRef="uref_668202531">-316670000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8258"
      unitRef="uref_668202531">3400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8259"
      unitRef="uref_668202531">4151000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8260"
      unitRef="uref_668202531">21184000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8261"
      unitRef="uref_668202531">35779000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8262"
      unitRef="uref_668202531">5814000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8263"
      unitRef="uref_668202531">16157000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8264"
      unitRef="uref_668202531">5138000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8265"
      unitRef="uref_668202531">5645000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8266"
      unitRef="uref_668202531">10952000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8267"
      unitRef="uref_668202531">21802000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8268"
      unitRef="uref_668202531">-10952000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8269"
      unitRef="uref_668202531">-21802000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8270"
      unitRef="uref_668202531">164000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8271"
      unitRef="uref_668202531">624000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8272"
      unitRef="uref_668202531">-9640000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8273"
      unitRef="uref_668202531">-26000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8274"
      unitRef="uref_668202531">-63000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8275"
      unitRef="uref_668202531">9778000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8276"
      unitRef="uref_668202531">561000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8277"
      unitRef="uref_668202531">-1174000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8278"
      unitRef="uref_668202531">-21241000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_784925054"
      decimals="2"
      id="ixv-8279"
      unitRef="uref_1987543344">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_784925054"
      decimals="2"
      id="ixv-8280"
      unitRef="uref_1987543344">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1378370445"
      decimals="2"
      id="ixv-8281"
      unitRef="uref_1987543344">-1.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1378370445"
      decimals="2"
      id="ixv-8282"
      unitRef="uref_1987543344">-1.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_784925054"
      decimals="0"
      id="ixv-8283"
      unitRef="uref_469718384">28671819</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_784925054"
      decimals="0"
      id="ixv-8284"
      unitRef="uref_469718384">28671819</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1378370445"
      decimals="0"
      id="ixv-8285"
      unitRef="uref_469718384">15022122</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1378370445"
      decimals="0"
      id="ixv-8286"
      unitRef="uref_469718384">15022122</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="cref_1982379788"
      decimals="0"
      id="ixv-8287"
      unitRef="uref_469718384">27996819</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1982379788"
      decimals="-3"
      id="ixv-8288"
      unitRef="uref_668202531">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1740623832"
      decimals="-3"
      id="ixv-8289"
      unitRef="uref_668202531">320818000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1415246794"
      decimals="-3"
      id="ixv-8290"
      unitRef="uref_668202531">-316670000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8291"
      unitRef="uref_668202531">4151000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1291783619"
      decimals="-3"
      id="ixv-8292"
      unitRef="uref_668202531">423000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8293"
      unitRef="uref_668202531">423000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="cref_762749261"
      decimals="-3"
      id="ixv-8294"
      unitRef="uref_668202531">-1174000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8295"
      unitRef="uref_668202531">-1174000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_1426826830"
      decimals="0"
      id="ixv-8296"
      unitRef="uref_469718384">27996819</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1426826830"
      decimals="-3"
      id="ixv-8297"
      unitRef="uref_668202531">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1859494511"
      decimals="-3"
      id="ixv-8298"
      unitRef="uref_668202531">321241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1995654471"
      decimals="-3"
      id="ixv-8299"
      unitRef="uref_668202531">-317844000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8300"
      unitRef="uref_668202531">3400000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_1220156236"
      decimals="0"
      id="ixv-8301"
      unitRef="uref_469718384">15022122</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1220156236"
      decimals="-3"
      id="ixv-8302"
      unitRef="uref_668202531">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_218143529"
      decimals="-3"
      id="ixv-8303"
      unitRef="uref_668202531">302541000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1511423065"
      decimals="-3"
      id="ixv-8304"
      unitRef="uref_668202531">-240869000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1935535027"
      decimals="-3"
      id="ixv-8305"
      unitRef="uref_668202531">61674000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1075311384"
      decimals="-3"
      id="ixv-8306"
      unitRef="uref_668202531">1811000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8307"
      unitRef="uref_668202531">1811000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="cref_249853930"
      decimals="-3"
      id="ixv-8308"
      unitRef="uref_668202531">-21241000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8309"
      unitRef="uref_668202531">-21241000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_1080624732"
      decimals="0"
      id="ixv-8310"
      unitRef="uref_469718384">15022122</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1080624732"
      decimals="-3"
      id="ixv-8311"
      unitRef="uref_668202531">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1234679342"
      decimals="-3"
      id="ixv-8312"
      unitRef="uref_668202531">304352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1788895550"
      decimals="-3"
      id="ixv-8313"
      unitRef="uref_668202531">-262110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1406915345"
      decimals="-3"
      id="ixv-8314"
      unitRef="uref_668202531">42244000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8315"
      unitRef="uref_668202531">-1174000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8316"
      unitRef="uref_668202531">-21241000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8317"
      unitRef="uref_668202531">21000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8318"
      unitRef="uref_668202531">279000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashExpense
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8319"
      unitRef="uref_668202531">185000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8320"
      unitRef="uref_668202531">193000</us-gaap:OtherNoncashExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8321"
      unitRef="uref_668202531">423000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8322"
      unitRef="uref_668202531">1811000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8323"
      unitRef="uref_668202531">-9640000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8324"
      unitRef="uref_668202531">195000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8325"
      unitRef="uref_668202531">201000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8326"
      unitRef="uref_668202531">-36000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8327"
      unitRef="uref_668202531">-288000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8328"
      unitRef="uref_668202531">-3781000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8329"
      unitRef="uref_668202531">-1039000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8330"
      unitRef="uref_668202531">55000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8331"
      unitRef="uref_668202531">-2617000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8332"
      unitRef="uref_668202531">-478000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8333"
      unitRef="uref_668202531">-315000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8334"
      unitRef="uref_668202531">-14548000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8335"
      unitRef="uref_668202531">-22842000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8336"
      unitRef="uref_668202531">4000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8337"
      unitRef="uref_668202531">4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8338"
      unitRef="uref_668202531">-14548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8339"
      unitRef="uref_668202531">-22838000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8340"
      unitRef="uref_668202531">29109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1935535027"
      decimals="-3"
      id="ixv-8341"
      unitRef="uref_668202531">72054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8342"
      unitRef="uref_668202531">14561000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1406915345"
      decimals="-3"
      id="ixv-8343"
      unitRef="uref_668202531">49216000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8344"
      unitRef="uref_668202531">1092000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations contextRef="cref_784925054" id="ixv-1460">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Description of Business &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Jasper Therapeutics, Inc. and its consolidated subsidiary, Jasper Tx Corp. (collectively, &#x201c;Jasper&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases, such as chronic spontaneous urticaria, chronic inducible urticaria and asthma. Briquilimab has been evaluated in clinical studies in chronic spontaneous urticaria, chronic inducible urticaria and allergic asthma. The Company&#x2019;s clinical development activities are currently focused on chronic urticarias, and while the clinical data generated in allergic asthma supports further development in the broader asthma population, advancing any future clinical studies in asthma would be based on an evaluation of the competitive landscape, the potential for strategic partnerships and capital availability. The Company has also historically explored diseases where targeting diseased hematopoietic stem cells can provide benefits, such as stem cell transplant conditioning regimens, but is currently focused on development of briquilimab in mast cell driven diseases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Company is headquartered in Redwood City, California. The Company is a Delaware corporation and was incorporated in March 2018. In September 2021, the Company completed a merger with Amplitude Healthcare Acquisition Corporation and became a public company.&#160;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="cref_784925054" id="ixv-1474">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for financial reporting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The accompanying condensed financial statements are consolidated and include the accounts of Jasper Therapeutics, Inc. and its wholly-owned subsidiary, Jasper Tx Corp, which had no operations during the periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2025 included in the Company&#x2019;s Annual Report on the Form 10-K filed with the SEC on March 30, 2026. There were no changes to the Company&#x2019;s significant accounting policies as described in the Annual Report on Form 10-K. The information as of December 31, 2025, included in the condensed consolidated balance sheets was derived from the Company&#x2019;s audited financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company&#x2019;s consolidated financial statements. The results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026 or for any other interim period or for any other future year.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40, &lt;i&gt;Going Concern&lt;/i&gt;, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of the Company&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating effect of the Company&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. In performing this analysis, the Company excluded certain elements of its operating plan that cannot be considered probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The Company has incurred significant losses and negative cash flows from operations since its inception. During the three months ended March 31, 2026 and 2025, the Company incurred net losses of $1.2 million and $21.2 million, respectively. During the three months ended March 31, 2026 and 2025, the Company had negative cash flows from operations of $14.5 million and $22.8 million, respectively. As of March 31, 2026, the Company had an accumulated deficit of $317.8 million. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support the Company&#x2019;s cost structure. As of March 31, 2026, the Company had cash and cash equivalents of $14.1 million. The Company&#x2019;s management expects that the existing cash and cash equivalents will not be sufficient to fund the Company&#x2019;s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Management expects to finance the Company&#x2019;s future cash needs through equity or debt financings, collaborations or a combination of these approaches, and given the imminent need for additional funding to continue to fund operations in the near-term, the Company is actively seeking additional capital to extend the cash runway. However, due to several factors, including those outside management&#x2019;s control, there can be no assurance that the Company will be able to complete additional financings. The Company&#x2019;s ability to raise additional funds may be adversely impacted by negative global economic conditions and any disruptions to and volatility in the credit and financial markets in the United States and worldwide or other factors. There can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms favorable or acceptable to the Company. The Company routinely evaluates cost reduction measures to proactively manage cash burn, but if the Company is unable to obtain adequate financing when needed or on terms favorable or acceptable to it, the Company may be forced to take broader actions such as to delay, reduce the scope of or eliminate one or more of its research and development programs. The Company concluded the likelihood that its plan to successfully obtain sufficient funding or adequately delay or reduce expenditures, while reasonably possible, is less than probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The accompanying unaudited interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. These unaudited interim condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the condensed consolidated financial statements include, but are not limited to, the determination of the accrued research and development expenses, the measurement of stock-based compensation expense and the valuation of warrant liability. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total amount shown in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;14,144&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;28,692&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;417&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;417&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total cash, cash equivalents and restricted cash&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,561&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29,109&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Cash and cash equivalents consist of cash held in operating accounts and investments in money market funds. Restricted cash relates to the letter of credit secured in conjunction with the operating lease (Note 8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Company&#x2019;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America. Cash balances are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced any losses on its cash, cash equivalents and marketable securities&#x2019; balances and periodically evaluates the creditworthiness of its financial institutions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Company is subject to risks common to companies in the development stage, including, but not limited to, development and regulatory approval of new product candidates, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product plans. To achieve profitable operations, the Company must successfully develop and obtain requisite regulatory approvals for, manufacture, and market its product candidates. There can be no assurance that any such product candidate can be developed and approved or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product will be successfully marketed. These factors could have a material adverse effect on the Company&#x2019;s future financial results.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Products developed by the Company require approval from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#x2019;s future products will receive the necessary clearances. If the Company were denied such clearances or such clearances were delayed, it could have a materially adverse impact on the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;In November 2024, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date (&#x201c;ASU 2025-01&#x201d;). The amendments do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In September 2025, the FASB issued ASU No. 2025-06, Intangibles - Goodwill and Other - Internal - Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (&#x201c;ASU 2025-06&#x201d;). The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages. This ASU requires entities to begin capitalizing software costs when management authorizes and commits to funding the software project, and it is probable that the project will be completed, and the software will be used for its intended purpose. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In December 2025, the FASB issued ASU No. 2025-10, Accounting for Government Grants Received by Business Entities (Topic 832). This ASU provides recognition, measurement, presentation, and disclosure requirements for government grants, including guidance for grants related to an asset and grants related to income. ASU No. 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting: Narrow-Scope Improvements (Topic 270). This ASU improves clarity for interim financial reporting requirements under the existing guidance within ASC Topic 270, by creating a comprehensive list of interim disclosure requirements, clarifying scope and applicability, along with adding a principle to disclose all material events that have occurred since the most recently filed Annual Report on Form 10-K. ASU No. 2025-11 is effective for interim reporting for fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="cref_784925054" id="ixv-1478">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for financial reporting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The accompanying condensed financial statements are consolidated and include the accounts of Jasper Therapeutics, Inc. and its wholly-owned subsidiary, Jasper Tx Corp, which had no operations during the periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2025 included in the Company&#x2019;s Annual Report on the Form 10-K filed with the SEC on March 30, 2026. There were no changes to the Company&#x2019;s significant accounting policies as described in the Annual Report on Form 10-K. The information as of December 31, 2025, included in the condensed consolidated balance sheets was derived from the Company&#x2019;s audited financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company&#x2019;s consolidated financial statements. The results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026 or for any other interim period or for any other future year.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <jspr:GoingConcernPolicyTextBlock contextRef="cref_784925054" id="ixv-1489">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40, &lt;i&gt;Going Concern&lt;/i&gt;, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of the Company&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating effect of the Company&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. In performing this analysis, the Company excluded certain elements of its operating plan that cannot be considered probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The Company has incurred significant losses and negative cash flows from operations since its inception. During the three months ended March 31, 2026 and 2025, the Company incurred net losses of $1.2 million and $21.2 million, respectively. During the three months ended March 31, 2026 and 2025, the Company had negative cash flows from operations of $14.5 million and $22.8 million, respectively. As of March 31, 2026, the Company had an accumulated deficit of $317.8 million. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support the Company&#x2019;s cost structure. As of March 31, 2026, the Company had cash and cash equivalents of $14.1 million. The Company&#x2019;s management expects that the existing cash and cash equivalents will not be sufficient to fund the Company&#x2019;s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Management expects to finance the Company&#x2019;s future cash needs through equity or debt financings, collaborations or a combination of these approaches, and given the imminent need for additional funding to continue to fund operations in the near-term, the Company is actively seeking additional capital to extend the cash runway. However, due to several factors, including those outside management&#x2019;s control, there can be no assurance that the Company will be able to complete additional financings. The Company&#x2019;s ability to raise additional funds may be adversely impacted by negative global economic conditions and any disruptions to and volatility in the credit and financial markets in the United States and worldwide or other factors. There can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms favorable or acceptable to the Company. The Company routinely evaluates cost reduction measures to proactively manage cash burn, but if the Company is unable to obtain adequate financing when needed or on terms favorable or acceptable to it, the Company may be forced to take broader actions such as to delay, reduce the scope of or eliminate one or more of its research and development programs. The Company concluded the likelihood that its plan to successfully obtain sufficient funding or adequately delay or reduce expenditures, while reasonably possible, is less than probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The accompanying unaudited interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. These unaudited interim condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.&lt;/p&gt;</jspr:GoingConcernPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="cref_784925054"
      decimals="-5"
      id="ixv-8345"
      unitRef="uref_668202531">-1200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1378370445"
      decimals="-5"
      id="ixv-8346"
      unitRef="uref_668202531">-21200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_784925054"
      decimals="-5"
      id="ixv-8347"
      unitRef="uref_668202531">-14500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1378370445"
      decimals="-5"
      id="ixv-8348"
      unitRef="uref_668202531">-22800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_438560971"
      decimals="-5"
      id="ixv-8349"
      unitRef="uref_668202531">-317800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_438560971"
      decimals="-5"
      id="ixv-8350"
      unitRef="uref_668202531">14100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:UseOfEstimates contextRef="cref_784925054" id="ixv-1512">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the condensed consolidated financial statements include, but are not limited to, the determination of the accrued research and development expenses, the measurement of stock-based compensation expense and the valuation of warrant liability. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="cref_784925054" id="ixv-1526">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total amount shown in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;14,144&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;28,692&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;417&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;417&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total cash, cash equivalents and restricted cash&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,561&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29,109&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Cash and cash equivalents consist of cash held in operating accounts and investments in money market funds. Restricted cash relates to the letter of credit secured in conjunction with the operating lease (Note 8).&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="cref_784925054" id="ixv-1531">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total amount shown in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;14,144&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;28,692&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;417&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;417&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total cash, cash equivalents and restricted cash&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,561&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29,109&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8351"
      unitRef="uref_668202531">14144000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8352"
      unitRef="uref_668202531">28692000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8353"
      unitRef="uref_668202531">417000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8354"
      unitRef="uref_668202531">417000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8355"
      unitRef="uref_668202531">14561000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8356"
      unitRef="uref_668202531">29109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="cref_784925054" id="ixv-1585">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Company&#x2019;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America. Cash balances are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced any losses on its cash, cash equivalents and marketable securities&#x2019; balances and periodically evaluates the creditworthiness of its financial institutions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Company is subject to risks common to companies in the development stage, including, but not limited to, development and regulatory approval of new product candidates, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product plans. To achieve profitable operations, the Company must successfully develop and obtain requisite regulatory approvals for, manufacture, and market its product candidates. There can be no assurance that any such product candidate can be developed and approved or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product will be successfully marketed. These factors could have a material adverse effect on the Company&#x2019;s future financial results.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Products developed by the Company require approval from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#x2019;s future products will receive the necessary clearances. If the Company were denied such clearances or such clearances were delayed, it could have a materially adverse impact on the Company.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="cref_784925054" id="ixv-1596">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;In November 2024, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date (&#x201c;ASU 2025-01&#x201d;). The amendments do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In September 2025, the FASB issued ASU No. 2025-06, Intangibles - Goodwill and Other - Internal - Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (&#x201c;ASU 2025-06&#x201d;). The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages. This ASU requires entities to begin capitalizing software costs when management authorizes and commits to funding the software project, and it is probable that the project will be completed, and the software will be used for its intended purpose. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In December 2025, the FASB issued ASU No. 2025-10, Accounting for Government Grants Received by Business Entities (Topic 832). This ASU provides recognition, measurement, presentation, and disclosure requirements for government grants, including guidance for grants related to an asset and grants related to income. ASU No. 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting: Narrow-Scope Improvements (Topic 270). This ASU improves clarity for interim financial reporting requirements under the existing guidance within ASC Topic 270, by creating a comprehensive list of interim disclosure requirements, clarifying scope and applicability, along with adding a principle to disclose all material events that have occurred since the most recently filed Annual Report on Form 10-K. ASU No. 2025-11 is effective for interim reporting for fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="cref_784925054" id="ixv-1621">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 3. FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 &#x2013; Inputs are unadjusted, quoted prices     in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 &#x2013; Inputs are observable, unadjusted quoted     prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities     in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially     the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 &#x2013; Unobservable inputs that are significant     to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value and is a Level 1 financial instrument under the fair value hierarchy.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. The Company had no financial instruments classified at Level 2 as of March 31, 2026 and December 31, 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques and at least one significant model assumption or input is unobservable. As of March 31, 2026 and December 31, 2025, the Company&#x2019;s Level 3 liabilities consisted of the warrant liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;There were no transfers within the hierarchy during the three months ended March 31, 2026 and 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Financial assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;13,144&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_111159347"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1894122814"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;13,144&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total fair value of assets&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,144&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1072361442"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_804810147"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,144&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Financial liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrant liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1196049397"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1867564296"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,524&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,524&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total fair value of financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1620055900"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1092525917"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,524&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,524&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Financial assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;27,692&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1276276239"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_707032855"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;27,692&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total fair value of assets&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,692&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1289593603"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1353737602"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,692&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Financial liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrant liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_166082834"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1176672139"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total fair value of financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1449616030"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_978200156"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;During the three months ended March 31, 2026, the changes in the Company&#x2019;s warrant liability were as follows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Warrant&lt;br/&gt; Liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 88%; font-weight: bold"&gt;Fair Value as of December 31, 2025&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;16,164&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Change in the fair value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,640&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Fair Value as of March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,524&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Company uses the Black-Scholes pricing model to determine the fair value of its warrant liability using Level 3 inputs. Inputs used to determine estimated fair value of the warrant liability include the fair value of the underlying stock at the valuation date, the term of the warrants, and the expected volatility of the underlying stock. The significant unobservable input used in the fair value measurement of the warrant liability is the expected volatility of the warrants. The estimates of fair value are uncertain and&#160;changes in&#160;any of the estimated inputs used as of the date of this report could have resulted in significant adjustments to the fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The key inputs into valuation models used to estimate the fair value of the warrant liability as of March 31,2026 and December 31, 2025 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%"&gt;Common stock price&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;.88&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;1.83&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.98&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4.22&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;115.68&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;113.30&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.86&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.66&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="cref_784925054" id="ixv-1673">&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Financial assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;13,144&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_111159347"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1894122814"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;13,144&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total fair value of assets&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,144&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1072361442"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_804810147"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,144&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Financial liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrant liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1196049397"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1867564296"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,524&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,524&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total fair value of financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1620055900"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1092525917"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,524&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,524&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Financial assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;27,692&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1276276239"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_707032855"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;27,692&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total fair value of assets&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,692&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1289593603"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1353737602"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,692&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Financial liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrant liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_166082834"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1176672139"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total fair value of financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1449616030"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_978200156"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_10449924"
      decimals="-3"
      id="ixv-8357"
      unitRef="uref_668202531">13144000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_505402133"
      decimals="-3"
      id="ixv-8358"
      unitRef="uref_668202531">13144000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_414108446"
      decimals="-3"
      id="ixv-8359"
      unitRef="uref_668202531">13144000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1966633800"
      decimals="-3"
      id="ixv-8360"
      unitRef="uref_668202531">13144000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_15337254"
      decimals="-3"
      id="ixv-8361"
      unitRef="uref_668202531">6524000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_13823206"
      decimals="-3"
      id="ixv-8362"
      unitRef="uref_668202531">6524000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1361797107"
      decimals="-3"
      id="ixv-8363"
      unitRef="uref_668202531">6524000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1966633800"
      decimals="-3"
      id="ixv-8364"
      unitRef="uref_668202531">6524000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1849531206"
      decimals="-3"
      id="ixv-8365"
      unitRef="uref_668202531">27692000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1288544829"
      decimals="-3"
      id="ixv-8366"
      unitRef="uref_668202531">27692000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1483965117"
      decimals="-3"
      id="ixv-8367"
      unitRef="uref_668202531">27692000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1785879477"
      decimals="-3"
      id="ixv-8368"
      unitRef="uref_668202531">27692000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_739502903"
      decimals="-3"
      id="ixv-8369"
      unitRef="uref_668202531">16164000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_243881147"
      decimals="-3"
      id="ixv-8370"
      unitRef="uref_668202531">16164000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_894353261"
      decimals="-3"
      id="ixv-8371"
      unitRef="uref_668202531">16164000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1785879477"
      decimals="-3"
      id="ixv-8372"
      unitRef="uref_668202531">16164000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="cref_784925054" id="ixv-1980">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;During the three months ended March 31, 2026, the changes in the Company&#x2019;s warrant liability were as follows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Warrant&lt;br/&gt; Liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 88%; font-weight: bold"&gt;Fair Value as of December 31, 2025&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;16,164&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Change in the fair value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,640&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Fair Value as of March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,524&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1378325364"
      decimals="-3"
      id="ixv-8373"
      unitRef="uref_668202531">16164000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="cref_611083158"
      decimals="-3"
      id="ixv-8374"
      unitRef="uref_668202531">-9640000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_566781871"
      decimals="-3"
      id="ixv-8375"
      unitRef="uref_668202531">6524000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="cref_784925054" id="ixv-2019">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The key inputs into valuation models used to estimate the fair value of the warrant liability as of March 31,2026 and December 31, 2025 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%"&gt;Common stock price&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;.88&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;1.83&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.98&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4.22&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;115.68&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;113.30&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.86&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.66&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1826855759"
      decimals="2"
      id="ixv-8376"
      unitRef="uref_1055712422">0.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_634664125"
      decimals="2"
      id="ixv-8377"
      unitRef="uref_1055712422">1.83</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1240913286"
      decimals="2"
      id="ixv-8378"
      unitRef="uref_1055712422">3.98</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_940893104"
      decimals="2"
      id="ixv-8379"
      unitRef="uref_1055712422">4.22</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_823902052"
      decimals="2"
      id="ixv-8380"
      unitRef="uref_1055712422">115.68</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1403457930"
      decimals="2"
      id="ixv-8381"
      unitRef="uref_1055712422">113.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1331265187"
      decimals="2"
      id="ixv-8382"
      unitRef="uref_1055712422">3.86</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_2051178283"
      decimals="2"
      id="ixv-8383"
      unitRef="uref_1055712422">3.66</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <srt:CondensedFinancialStatementsTextBlock contextRef="cref_784925054" id="ixv-2081">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 4. CONDENSED CONSOLIDATED BALANCE SHEET COMPONENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Prepaid expenses and other current assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table summarizes the details of prepaid expenses and other current assets as of the dates set forth below (in thousands):&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Research and development prepaid expenses&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;4,847&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;4,320&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;653&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;866&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Prepaid travel expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;243&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;103&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other prepaid expenses and current assets&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;405&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;664&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,148&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,953&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Property and equipment, net&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table summarizes the details of property and equipment, net as of the dates set forth below (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Leasehold improvements&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,711&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,711&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Lab equipment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,513&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,513&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Office furniture &amp;amp; fixtures&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;522&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;522&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Computer equipment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Property and equipment, gross&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4,916&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4,916&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,835&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,814&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Property and equipment, net&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;81&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; Depreciation and amortization expense was $21,000 and $0.3 million for the three months ended March 31, 2026 and 2025, respectively. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Accrued expenses and other current liabilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table summarizes the details of accrued expenses and other current liabilities as of the dates set forth below (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Research and development accrued expenses&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;3,422&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;3,775&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Accrued employee and related compensation expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,889&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,589&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Accrued legal and professional expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;321&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;261&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;168&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,800&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,745&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</srt:CondensedFinancialStatementsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="cref_784925054" id="ixv-2091">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table summarizes the details of prepaid expenses and other current assets as of the dates set forth below (in thousands):&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Research and development prepaid expenses&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;4,847&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;4,320&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;653&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;866&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Prepaid travel expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;243&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;103&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other prepaid expenses and current assets&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;405&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;664&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,148&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,953&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <jspr:ResearchAndDevelopmentPrepaidExpenses
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8384"
      unitRef="uref_668202531">4847000</jspr:ResearchAndDevelopmentPrepaidExpenses>
    <jspr:ResearchAndDevelopmentPrepaidExpenses
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8385"
      unitRef="uref_668202531">4320000</jspr:ResearchAndDevelopmentPrepaidExpenses>
    <us-gaap:PrepaidInsurance
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8386"
      unitRef="uref_668202531">653000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8387"
      unitRef="uref_668202531">866000</us-gaap:PrepaidInsurance>
    <jspr:PrepaidTravelExpenses
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8388"
      unitRef="uref_668202531">243000</jspr:PrepaidTravelExpenses>
    <jspr:PrepaidTravelExpenses
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8389"
      unitRef="uref_668202531">103000</jspr:PrepaidTravelExpenses>
    <us-gaap:OtherAssetsCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8390"
      unitRef="uref_668202531">405000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8391"
      unitRef="uref_668202531">664000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8392"
      unitRef="uref_668202531">6148000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8393"
      unitRef="uref_668202531">5953000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="cref_784925054" id="ixv-2167">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table summarizes the details of property and equipment, net as of the dates set forth below (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Leasehold improvements&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,711&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,711&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Lab equipment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,513&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,513&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Office furniture &amp;amp; fixtures&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;522&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;522&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Computer equipment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Property and equipment, gross&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4,916&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4,916&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,835&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,814&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Property and equipment, net&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;81&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_982217023"
      decimals="-3"
      id="ixv-8394"
      unitRef="uref_668202531">2711000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_445054501"
      decimals="-3"
      id="ixv-8395"
      unitRef="uref_668202531">2711000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_176880314"
      decimals="-3"
      id="ixv-8396"
      unitRef="uref_668202531">1513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1742280107"
      decimals="-3"
      id="ixv-8397"
      unitRef="uref_668202531">1513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1979065684"
      decimals="-3"
      id="ixv-8398"
      unitRef="uref_668202531">522000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_671786867"
      decimals="-3"
      id="ixv-8399"
      unitRef="uref_668202531">522000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1539753648"
      decimals="-3"
      id="ixv-8400"
      unitRef="uref_668202531">170000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_753159246"
      decimals="-3"
      id="ixv-8401"
      unitRef="uref_668202531">170000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8402"
      unitRef="uref_668202531">4916000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8403"
      unitRef="uref_668202531">4916000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8404"
      unitRef="uref_668202531">4835000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8405"
      unitRef="uref_668202531">4814000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8406"
      unitRef="uref_668202531">81000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8407"
      unitRef="uref_668202531">102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="cref_784925054"
      decimals="0"
      id="ixv-8408"
      unitRef="uref_668202531">21000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="cref_1378370445"
      decimals="-5"
      id="ixv-8409"
      unitRef="uref_668202531">300000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="cref_784925054" id="ixv-2272">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table summarizes the details of accrued expenses and other current liabilities as of the dates set forth below (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Research and development accrued expenses&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;3,422&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;3,775&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Accrued employee and related compensation expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,889&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,589&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Accrued legal and professional expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;321&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;261&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;168&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,800&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,745&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <jspr:ResearchAndDevelopmentAccruedExpensesCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8410"
      unitRef="uref_668202531">3422000</jspr:ResearchAndDevelopmentAccruedExpensesCurrent>
    <jspr:ResearchAndDevelopmentAccruedExpensesCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8411"
      unitRef="uref_668202531">3775000</jspr:ResearchAndDevelopmentAccruedExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8412"
      unitRef="uref_668202531">1889000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8413"
      unitRef="uref_668202531">1589000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8414"
      unitRef="uref_668202531">321000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8415"
      unitRef="uref_668202531">261000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8416"
      unitRef="uref_668202531">168000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8417"
      unitRef="uref_668202531">120000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8418"
      unitRef="uref_668202531">5800000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_268000114"
      decimals="-3"
      id="ixv-8419"
      unitRef="uref_668202531">5745000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <jspr:CirmGrantDisclosureTextBlock contextRef="cref_784925054" id="ixv-2346">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 5. CIRM GRANT&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; In November 2020, California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) awarded the Company $2.3 million in support of the research project related to a monoclonal antibody that depletes blood stem cells and enables chemotherapy-free transplants. The Company has received an aggregate of $2.3 million from CIRM through March 31, 2026. &#160;&#160;There are no further amounts available for future distribution to the Company under the grant. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; Under the terms of the grant, both CIRM and the Company agreed to co-fund the research project and the amount of the Company&#x2019;s co-funding requirement was predetermined as a part of the award. Under the terms of the CIRM grant, the Company is obligated to pay royalties and licensing fees based on 0.1% of net sales of CIRM-funded inventions per $1.0 million of CIRM grant. As an alternative to revenue sharing, the Company has the option to convert the award to a loan. In the event the Company exercises its right to convert the award to a loan, it would be obligated to repay the loan within ten business days of making such election. Repayment amounts vary dependent on when the award is converted to a loan, ranging from 60% of the award granted to amounts received plus interest at the rate of the three-month LIBOR rate plus 25% per annum. Since the Company may be required to repay some or all of the amounts awarded by CIRM, the Company accounted for this award as a liability. Given the uncertainty in amounts due upon repayment, the Company has recorded amounts received without any discount or interest recorded, and upon determination of amounts that would become due, the Company will adjust accordingly. In the absence of explicit U.S. GAAP guidance on contributions received by business entities from government entities, the Company has applied to the CIRM grant the recognition and measurement guidance in ASC Topic 958-605 Not-for-Profit Entities: Revenue Recognition&#x2014;Contributions by analogy. As of each of March 31, 2026 and December 31, 2025, the amount of CIRM grant received of $2.3 million is included in other non-current liabilities in the condensed consolidated balance sheets. &lt;/p&gt;</jspr:CirmGrantDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="cref_1842275578"
      decimals="-5"
      id="ixv-8420"
      unitRef="uref_668202531">2300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jspr:ReceivedAggregateFromCIRM
      contextRef="cref_784925054"
      decimals="-5"
      id="ixv-8421"
      unitRef="uref_668202531">2300000</jspr:ReceivedAggregateFromCIRM>
    <jspr:PercentageOfLicensingFees
      contextRef="cref_784925054"
      decimals="3"
      id="ixv-8422"
      unitRef="uref_1055712422">0.001</jspr:PercentageOfLicensingFees>
    <jspr:NetSales
      contextRef="cref_1284574516"
      decimals="-5"
      id="ixv-8423"
      unitRef="uref_668202531">1000000</jspr:NetSales>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="cref_784925054"
      decimals="2"
      id="ixv-8424"
      unitRef="uref_1055712422">0.60</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:InvestmentInterestRate
      contextRef="cref_438560971"
      decimals="2"
      id="ixv-8425"
      unitRef="uref_1055712422">0.25</us-gaap:InvestmentInterestRate>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_438560971"
      decimals="-5"
      id="ixv-8426"
      unitRef="uref_668202531">2300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_268000114"
      decimals="-5"
      id="ixv-8427"
      unitRef="uref_668202531">2300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="cref_784925054" id="ixv-2354">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 6. SIGNIFICANT AGREEMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Stanford License Agreements&lt;/i&gt;&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In March 2021, the Company entered into an exclusive license agreement with Stanford (the &#x201c;2021 Stanford License Agreement&#x201d;). In July 2023, the Company entered into an amendment to the 2021 Stanford License Agreement to modify certain milestones set forth thereunder. The Company received a worldwide, exclusive license, with a right to sublicense, for briquilimab in the field of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated. Stanford transferred to the Company certain know-how and patents related to briquilimab (together, the &#x201c;Licensed Technology&#x201d;). Under the terms of this agreement, the Company is required to use commercially reasonable efforts to develop, manufacture and sell licensed product and to develop markets for a licensed product. In addition, the Company is required to use commercially reasonable efforts to meet the milestones as specified in the agreement over the six years from execution of the 2021 Stanford License Agreement and must notify Stanford in writing as each milestone is met.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The Company is obligated to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and second year, $35,000 for each third and fourth year and $50,000 at each anniversary thereafter ending upon the first commercial sale. The Company is also obligated to pay late-stage clinical development milestone payments and first commercial sales milestone payments of up to $9.0 million in total. The Company will also pay low single-digit royalties on net sales of licensed products, if approved. As of March 31, 2026, the Company recorded $50,000 in accrued expenses and other current liabilities in the condensed consolidated balance sheets related to annual license maintenance fees, with corresponding recognition of such amount as research and development expense in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026. The Company recognized $35,000 in annual license maintenance fees as research and development expense in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2025.&#160;&#160; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The 2021 Stanford License Agreement expires on a country-by-country basis on the last-to-expire valid claim of a licensed patent in such country. The Company may terminate the agreement by giving Stanford written notice at least 12 months in advance of the effective date of termination. The Company may also terminate the agreement solely with respect to any particular patent application or patent by giving Stanford written notice at least 60 days in advance of the effective date of termination. Stanford may terminate the agreement after 90 days from a written notice by Stanford, specifying a problem, including a delinquency on any report required pursuant to the agreement or any payment, missing a milestone or a material breach, unless the Company remediates the problem in that 90-day period.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; In December 2024, the Company entered into a co-exclusive license agreement with Stanford (the &#x201c;2024 Stanford License Agreement&#x201d;). The Company received a co-exclusive license in the United States, with a right to sublicense, for a certain patent to be used in the field of the treatment and prevention of human diseases, including the use of anti-CD117 antibodies (other than JSP191) for the purpose of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated (the &#x201c;Co-Exclusive Licensed Field of Use&#x201d;) and an exclusive license in the United States for the use of the same patent in the field provided in the 2021 Stanford License Agreement (the &#x201c;Exclusive Licensed Field of Use&#x201d;). Stanford will have at most one other commercial license for the licensed patent in the Co-Exclusive Licensed Field of Use. Under the terms of this agreement, the Company is required to use commercially reasonable efforts to develop, manufacture and sell a licensed product and to develop markets for a licensed product. In addition, the Company is required to use commercially reasonable efforts to meet the milestones as specified in the agreement over approximately 4.5 years from the execution of the agreement and must notify Stanford in writing when, and if, each milestone is met. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The Company paid a license issue fee of $75,000, following the execution of the agreement, in January 2025. The Company is also obligated to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement, as follows: $25,000 for each of the first through third years, $50,000 for each of the fourth through sixth years and $65,000 at each anniversary thereafter. The Company is also obligated to pay clinical development milestone payments of up to $1.3 million and sales milestone payments of up to $7.0 million in total. The Company will pay low single-digit royalties on net sales of licensed products, if approved. The Company will pay Stanford a portion of sublicensee consideration if a sublicense is granted. As of March 31, 2026 and December 31, 2025, there was $0 and $25,000, respectively, of accounts payable recorded in the condensed consolidated balance sheets related to the annual license maintenance fee.  &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Company may terminate the agreement by giving Stanford written notice at least 30 days in advance of the effective date of termination. Stanford may terminate the agreement by giving the Company 90 days written notice for a problem, including a delinquency on any report required pursuant to the agreement, missing a milestone or a material breach, and by giving the Company 30 days written notice for a payment default, unless the Company remediates the problem in that 90-day or 30-day period.&#160;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <jspr:MilestonePaymentsObligationToBePaidFirstAndSecondYear
      contextRef="cref_862585213"
      decimals="-3"
      id="ixv-8428"
      unitRef="uref_668202531">25000000</jspr:MilestonePaymentsObligationToBePaidFirstAndSecondYear>
    <jspr:MilestonePaymentsObligationToBePaidThirdAndFourthYear
      contextRef="cref_862585213"
      decimals="-3"
      id="ixv-8429"
      unitRef="uref_668202531">35000000</jspr:MilestonePaymentsObligationToBePaidThirdAndFourthYear>
    <jspr:MilestonePaymentsObligationToBePaidThereafter
      contextRef="cref_862585213"
      decimals="-3"
      id="ixv-8430"
      unitRef="uref_668202531">50000000</jspr:MilestonePaymentsObligationToBePaidThereafter>
    <jspr:SalesMilestonePayments
      contextRef="cref_145174291"
      decimals="-5"
      id="ixv-8431"
      unitRef="uref_668202531">9000000</jspr:SalesMilestonePayments>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="cref_862585213"
      decimals="-3"
      id="ixv-8432"
      unitRef="uref_668202531">50000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:CostMaintenance
      contextRef="cref_145174291"
      decimals="-3"
      id="ixv-8433"
      unitRef="uref_668202531">35000000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="cref_549257824"
      decimals="-3"
      id="ixv-8434"
      unitRef="uref_668202531">35000000</us-gaap:CostMaintenance>
    <jspr:ApproximatelyAgreement contextRef="cref_1282057323" id="ixv-8435">P4Y6M</jspr:ApproximatelyAgreement>
    <jspr:LicenseMaintenanceFee
      contextRef="cref_1282057323"
      decimals="-3"
      id="ixv-8436"
      unitRef="uref_668202531">75000000</jspr:LicenseMaintenanceFee>
    <jspr:MilestonePaymentsObligationToBePaidFirstThroughThirdYear
      contextRef="cref_1140767225"
      decimals="-3"
      id="ixv-8437"
      unitRef="uref_668202531">25000000</jspr:MilestonePaymentsObligationToBePaidFirstThroughThirdYear>
    <jspr:MilestonePaymentsObligationToBePaidFourthThroughSixthYear
      contextRef="cref_1140767225"
      decimals="-3"
      id="ixv-8438"
      unitRef="uref_668202531">50000000</jspr:MilestonePaymentsObligationToBePaidFourthThroughSixthYear>
    <jspr:MilestonePaymentsObligationToBePaidThereafter
      contextRef="cref_1140767225"
      decimals="-3"
      id="ixv-8439"
      unitRef="uref_668202531">65000000</jspr:MilestonePaymentsObligationToBePaidThereafter>
    <jspr:SalesMilestonePayments
      contextRef="cref_1282057323"
      decimals="-5"
      id="ixv-8440"
      unitRef="uref_668202531">1300000</jspr:SalesMilestonePayments>
    <jspr:ClinicalDevelopmentMilestonePayments
      contextRef="cref_1282057323"
      decimals="-5"
      id="ixv-8441"
      unitRef="uref_668202531">7000000</jspr:ClinicalDevelopmentMilestonePayments>
    <us-gaap:CostMaintenance
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8442"
      unitRef="uref_668202531">0</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="cref_1417501004"
      decimals="-3"
      id="ixv-8443"
      unitRef="uref_668202531">25000000</us-gaap:CostMaintenance>
    <jspr:WarrantsTextBlock contextRef="cref_784925054" id="ixv-2383">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 7. WARRANTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; In September 2025, in connection and together with the issuance of 11,670,707 shares of the Company&#x2019;s voting common stock through the underwritten offering (the &#x201c;September 2025 Offering&#x201d;), the Company issued pre-funded warrants to purchase 675,000 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;) and common stock warrants to purchase 12,345,707&#160;shares of common stock (the &#x201c;Common Warrants&#x201d;). See Note 9 for additional details about the September 2025 Offering. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The exercise price of each Pre-Funded Warrant is $0.0001 per share. The Pre-Funded Warrants are exercisable at the option of each holder in whole or in part at any time after their original issuance and have no expiration date. The Pre-Funded Warrants may be exercised by means of cash or the cashless settlement of the net number of shares of common stock determined according to a formula set forth in the Pre-Funded Warrants. However, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99% or 19.99%) of the number of issued and outstanding shares of common stock following such exercise. However, any holder of a Pre-Funded Warrant may increase or decrease such percentage to any other percentage not in excess of 19.99%, provided that the holder shall provide at least 61 days&#x2019; prior written notice to the Company prior to the date such increase shall be effective. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Pursuant to the terms of the Pre-Funded Warrant, upon the consummation of a Fundamental Transaction, as defined in the Pre-Funded Warrants, the holders of the Pre-Funded Warrants are entitled to receive, upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or other property that such holders would have received had they exercised the Pre-Funded Warrants immediately prior to such Fundamental Transaction, without regard to any limitations on exercise contained in the Pre-Funded Warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The Company concluded that the Pre-Funded Warrants met the equity indexation criteria and the Pre-Funded Warrants are therefore accounted for in stockholders&#x2019; equity. The Company recorded $0.3&#160;million to additional paid-in capital upon issuance of the Pre-Funded Warrants. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; As of March 31, 2026,&#160;&lt;span style="-sec-ix-hidden:fc_554114115"&gt;none&lt;/span&gt;&#160;of the Pre-Funded Warrants have been exercised. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Common Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The exercise price of each Common Warrant is $2.92 per share. Each Common Warrant is exercisable commencing on the six month anniversary of the date of issuance and thereafter for a period of four years. The Common Warrants may be exercised by means of cash or the cashless settlement of the net number of shares of common stock determined according to a formula set forth in the Common Warrants. However, a holder will not be entitled to exercise any portion of any Common Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99% or 19.99%) of the number of issued and outstanding shares of common stock following such exercise. However, any holder of a Common Warrant may increase or decrease such percentage to any other percentage not in excess of 19.99%, provided that the holder shall provide at least 61 days&#x2019; prior written notice to the Company prior to the date such increase shall be effective.&#160; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Pursuant to the terms of the Common Warrant, upon the consummation of a Fundamental Transaction, as defined in the Common Warrants, the holders of the Common Warrants are entitled to receive, upon exercise of the Common Warrant, the kind and amount of securities, cash or other property that such holders would have received had they exercised the Common Warrants immediately prior to such Fundamental Transaction, without regard to any limitations on exercise contained in the Common Warrants or the holder may require the Company or the successor entity to repurchase the unexercised portion of the Common Warrant for its Black Scholes Value, as defined in the Common Warrant; provided, however, if the holder shall only be entitled to receive from the Company or any successor entity the same type or form of consideration (and in the same proportion) at the Black Scholes Value of the unexercised portion of the Common Warrant, that is being offered and paid to the holders of common stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, shares or any combination thereof, or whether the holders of common stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of common stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of common stock will be deemed to have received common stock of the successor entity (which successor entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The Company concluded that the Common Warrants did not meet the equity indexation criteria due to the certain inputs to estimate the number of shares issuable in a Fundamental Transaction and the Common Warrants are therefore accounted for as liabilities. The Company recorded $24.7&#160;million to warrant liability upon issuance of the Common Warrants. The Company estimated fair value of the Common Warrants at the issuance date using the Black-Scholes valuation model and will remeasure the liability at each reporting date. The Company recorded a change in fair value of warrant liability of $9.6&#160;million in its condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2026. Refer to Note 3 for assumptions used to estimate the Common Warrants fair value. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;As of March 31, 2026,&#160;none&#160;of the Common Warrants have been exercised.&lt;/p&gt;</jspr:WarrantsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_26166482"
      decimals="0"
      id="ixv-8444"
      unitRef="uref_469718384">11670707</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_859966735"
      decimals="0"
      id="ixv-8445"
      unitRef="uref_469718384">675000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1893484374"
      decimals="0"
      id="ixv-8446"
      unitRef="uref_469718384">12345707</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_937223270"
      decimals="4"
      id="ixv-8447"
      unitRef="uref_1987543344">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <jspr:PreFundedWarrantPercentage
      contextRef="cref_784925054"
      decimals="4"
      id="ixv-8448"
      unitRef="uref_1055712422">0.0499</jspr:PreFundedWarrantPercentage>
    <jspr:PercentageOfElectionHolderWarrants
      contextRef="cref_1187790031"
      decimals="4"
      id="ixv-8449"
      unitRef="uref_1055712422">0.0999</jspr:PercentageOfElectionHolderWarrants>
    <jspr:PercentageOfElectionHolderWarrants
      contextRef="cref_400739651"
      decimals="4"
      id="ixv-8450"
      unitRef="uref_1055712422">0.1999</jspr:PercentageOfElectionHolderWarrants>
    <jspr:PercentagePreFundedWarrants
      contextRef="cref_784925054"
      decimals="4"
      id="ixv-8451"
      unitRef="uref_1055712422">0.1999</jspr:PercentagePreFundedWarrants>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_937223270"
      decimals="-5"
      id="ixv-8452"
      unitRef="uref_668202531">300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_143115946"
      decimals="2"
      id="ixv-8453"
      unitRef="uref_1987543344">2.92</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <jspr:PreFundedWarrantPercentage
      contextRef="cref_739243793"
      decimals="4"
      id="ixv-8454"
      unitRef="uref_1055712422">0.0499</jspr:PreFundedWarrantPercentage>
    <jspr:PercentageOfElectionHolderWarrants
      contextRef="cref_739243793"
      decimals="4"
      id="ixv-8455"
      unitRef="uref_1055712422">0.0999</jspr:PercentageOfElectionHolderWarrants>
    <jspr:PercentageOfElectionHolderWarrants
      contextRef="cref_784925054"
      decimals="4"
      id="ixv-8456"
      unitRef="uref_1055712422">0.1999</jspr:PercentageOfElectionHolderWarrants>
    <jspr:PercentageOfCommonWarrants
      contextRef="cref_784925054"
      decimals="4"
      id="ixv-8457"
      unitRef="uref_1055712422">0.1999</jspr:PercentageOfCommonWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="cref_143115946"
      decimals="-5"
      id="ixv-8458"
      unitRef="uref_668202531">24700000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_739243793"
      decimals="-5"
      id="ixv-8459"
      unitRef="uref_668202531">9600000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="cref_784925054" id="ixv-2428">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 8. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; As of March 31, 2026, the Company leased approximately&#160;25,900&#160;square feet of laboratory and office space in Redwood City, California, under an operating lease that expires in August 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; In conjunction with signing the lease, the Company secured a letter of credit in favor of the lessor in the amount of $0.4 million. The funds related to this letter of credit are presented as restricted cash on the Company&#x2019;s condensed consolidated balance sheets. The lease agreement includes an escalation clause for increased base rent and a renewal provision allowing the Company to extend this lease for an additional 60 months at the prevailing rental rate, which the Company is not reasonably certain to exercise. In addition to base rent, the Company pays its share of operating expenses and taxes. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; In March 2025, the Company extended its existing short-term lease for 12,500 square feet of laboratory and office space in Redwood City, California, through August 2026. As a result, the Company recorded a right-of-use asset and lease liability of $1.1 million in March 2025. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; In December 2025, in connection with the cessation of the Company&#x2019;s vivarium operations and consolidation of personnel office space, the Company ceased use of a portion of its leased headquarters space. As a result, the right-of-use asset associated with that lease was impaired by $0.4 million. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Company also pays variable costs related to its share of operating expenses and taxes. These variable costs are recorded as lease expense as incurred and presented as operating expenses in the condensed consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The components of lease costs, which were included in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss, are as follows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="font-weight: bold"&gt;Lease cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Operating lease cost&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;203&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;232&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Short-term lease cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1783648313"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;169&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Variable lease cost&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: 9.05pt"&gt;Total lease cost&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;381&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;519&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Supplemental information related to the Company&#x2019;s operating leases is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities (in thousands)&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;496&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;356&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Weighted average remaining lease term (years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;0.39&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1.4&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Weighted average discount rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;8.00&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;8.00&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table summarizes a maturity analysis of the Company&#x2019;s operating lease liabilities showing the aggregate lease payments as of March 31, 2026 (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Year Ending December 31,&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;2026 (remainder of the year)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;764&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Total undiscounted lease payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;764&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Total discounted lease payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;757&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less current portion of lease liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(757&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Noncurrent portion of lease liability&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_357656926"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;License Agreements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; In March 2021, the Company entered into the 2021 Stanford License Agreement (Note 6), which was amended in July 2023, pursuant to which the Company is required to pay annual license maintenance fees, clinical development and commercial sales milestone payments of up to an aggregate of $9.0 million, and low single-digit royalties on net sales of licensed products. All products were in development as of March 31, 2026, and no royalties were due as of such date. The Company recognized $50,000 and $35,000 in annual license maintenance fees as research and development expense in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026 and 2025, respectively. As of each of March 31, 2026 and December 31, 2025, no milestones were probable to be achieved and payable. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; In December 2024, the Company entered into the 2024 Stanford License Agreement (Note 6), pursuant to which the Company is required to pay a license issue and annual license maintenance fees, clinical development and commercial sales milestone payments of up to an aggregate of $8.3 million and low single-digit royalties on net sales of licensed products. All products were in development as of March 31, 2026, and no royalties were due as of such date. As of March 31, 2026, no milestones were probable to be achieved and payable. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Company, from time to time, may be party to litigation arising in the ordinary course of business. On September 19, 2025, a shareholder class action complaint captioned&#160;&lt;i&gt;Grant v. Jasper Therapeutics, Inc., et al.&lt;/i&gt;&#160;(Case No. 25-cv-08010) was filed in the United States District Court for the Northern District of California against the Company and certain of the Company&#x2019;s current and former officers. The complaint alleges that certain material misstatements or omissions related to the ongoing clinical trials of briquilimab were made in violation of federal securities laws. The plaintiffs are seeking unspecified monetary&#160;damages&#160;and an award of costs and expenses, including reasonable attorneys&#x2019; fees, expert fees and other costs. On December 3, 2025, a stipulated order was entered appointing co-lead plaintiffs and approving their selection of co-lead counsel, and on December 16, 2025, a stipulated order was entered setting a schedule for the filing and responses to an amended complaint. Per the terms of the December 16, 2025 stipulated order, an amended complaint captioned &lt;i&gt;Allard, et al. v. Jasper Therapeutics, Inc., et al.&lt;/i&gt; (Case No. 25-cv-08010) was filed, and defendants&#x2019; motion to dismiss was filed on April 20, 2026.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In addition, on November 5, 2025, a shareholder derivative complaint captioned &lt;i&gt;Bardauskas v. Martell, et al&lt;/i&gt;. (Case No. 25-cv-09561) was filed in the United States District Court for the Northern District of California, and on December 22, 2025, another shareholder derivative complaint was filed in the same court and captioned &lt;i&gt;Walsh v. Martell, et al.&lt;/i&gt; (Case No. 25-cv-10899).&#160;The derivative complaints name as defendants certain of the Company&#x2019;s current and former officers and directors, and allege claims related to the allegations raised in the shareholder class action complaint. On January 21, 2026, a stipulated order was entered, among other things, consolidating and staying the derivative actions.&#160;The Company believes the claims raised in these lawsuits are without merit, and intends to defend these matters vigorously.&#160;However, there can be no assurance that the Company will prevail.&#160;The Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore, no amount of loss has been accrued in the Company&#x2019;s condensed consolidated financial statements as of and for the three months ended March 31, 2026. Regardless of outcome, litigation can have an adverse impact on the Company due to costs involved, diversion of management resources, negative publicity, reputational harm, and other factors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Company believes that it is not currently a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations&#160; or cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Guarantees and Indemnifications &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of each of March 31, 2026 and December 31, 2025, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="cref_438560971"
      decimals="0"
      id="ixv-8460"
      unitRef="uref_1104703976">25900</us-gaap:AreaOfLand>
    <us-gaap:LinesOfCreditCurrent
      contextRef="cref_438560971"
      decimals="-5"
      id="ixv-8461"
      unitRef="uref_668202531">400000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="cref_438560971" id="ixv-8462">P60M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfLand
      contextRef="cref_1406915345"
      decimals="0"
      id="ixv-8463"
      unitRef="uref_1104703976">12500</us-gaap:AreaOfLand>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="cref_2133957400"
      decimals="-5"
      id="ixv-8464"
      unitRef="uref_668202531">1100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="cref_1417501004"
      decimals="-5"
      id="ixv-8465"
      unitRef="uref_668202531">400000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:LeaseCostTableTextBlock contextRef="cref_784925054" id="ixv-2448">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The components of lease costs, which were included in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss, are as follows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="font-weight: bold"&gt;Lease cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Operating lease cost&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;203&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;232&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Short-term lease cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1783648313"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;169&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Variable lease cost&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: 9.05pt"&gt;Total lease cost&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;381&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;519&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Supplemental information related to the Company&#x2019;s operating leases is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities (in thousands)&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;496&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;356&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Weighted average remaining lease term (years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;0.39&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1.4&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Weighted average discount rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;8.00&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;8.00&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8466"
      unitRef="uref_668202531">203000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8467"
      unitRef="uref_668202531">232000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8468"
      unitRef="uref_668202531">169000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8469"
      unitRef="uref_668202531">178000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8470"
      unitRef="uref_668202531">118000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8471"
      unitRef="uref_668202531">381000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8472"
      unitRef="uref_668202531">519000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8473"
      unitRef="uref_668202531">496000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8474"
      unitRef="uref_668202531">356000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="cref_438560971" id="ixv-8475">P0Y4M20D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="cref_1406915345" id="ixv-8476">P1Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="cref_438560971"
      decimals="4"
      id="ixv-8477"
      unitRef="uref_1055712422">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="cref_1406915345"
      decimals="4"
      id="ixv-8478"
      unitRef="uref_1055712422">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="cref_784925054" id="ixv-2582">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table summarizes a maturity analysis of the Company&#x2019;s operating lease liabilities showing the aggregate lease payments as of March 31, 2026 (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Year Ending December 31,&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;2026 (remainder of the year)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;764&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Total undiscounted lease payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;764&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Total discounted lease payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;757&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less current portion of lease liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(757&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Noncurrent portion of lease liability&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_357656926"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8479"
      unitRef="uref_668202531">764000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8480"
      unitRef="uref_668202531">764000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8481"
      unitRef="uref_668202531">7000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8482"
      unitRef="uref_668202531">757000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_438560971"
      decimals="-3"
      id="ixv-8483"
      unitRef="uref_668202531">757000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:PaymentsForRoyalties
      contextRef="cref_107187006"
      decimals="-5"
      id="ixv-8484"
      unitRef="uref_668202531">9000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForFees
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8485"
      unitRef="uref_668202531">50000000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8486"
      unitRef="uref_668202531">35000000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForRoyalties
      contextRef="cref_1989808306"
      decimals="-5"
      id="ixv-8487"
      unitRef="uref_668202531">8300000</us-gaap:PaymentsForRoyalties>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="cref_784925054" id="ixv-2672">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 9. COMMON STOCK&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The Company is authorized to issue 490,000,000&#160;shares of voting common stock, 2,000,000&#160;shares of non-voting&#160;common stock, and 10,000,000&#160;shares of undesignated preferred stock. There were&#160;27,996,819 shares of voting common stock, &lt;span style="-sec-ix-hidden:fc_1765267982"&gt;&lt;span style="-sec-ix-hidden:fc_1111002203"&gt;no&lt;/span&gt;&lt;/span&gt; shares of non-voting common stock&#160;and &lt;span style="-sec-ix-hidden:fc_2072766674"&gt;&lt;span style="-sec-ix-hidden:fc_549550349"&gt;no&lt;/span&gt;&lt;/span&gt; shares of preferred stock issued and outstanding as of March 31, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; Holders of the voting common stock and the non-voting&#160;common stock have similar rights, except that non-voting stockholders are not entitled to vote, including for the election of directors. Holders of voting common stock do not have conversion rights, while holders of non-voting&#160;common stock have the right to convert each share of non-voting&#160;common stock held by such holder into one share of voting common stock at such holder&#x2019;s election by providing written notice to the Company, provided that as a result of such conversion, such holder, together with its affiliates, would not beneficially own in excess of 9.9% of the Company&#x2019;s voting common stock following such conversion. There were &lt;span style="-sec-ix-hidden:fc_2048509785"&gt;&lt;span style="-sec-ix-hidden:fc_1054403778"&gt;no&lt;/span&gt;&lt;/span&gt; outstanding shares of non-voting common stock as of March 31, 2026 and December 31, 2025. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;As of March 31, 2026 and December 31, 2025, the Company had common stock reserved for future issuance as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Outstanding and issued common stock options&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,671,358&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,246,206&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Outstanding and issued restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;170,100&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;198,900&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Outstanding and issued performance-based restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1844764249"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;20,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;Shares issuable upon exercise of Public Warrants (1)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;499,986&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;499,986&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Shares issuable upon exercise of Common Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;12,345,707&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;12,345,707&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;Shares issuable upon exercise of Pre-Funded Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;675,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;675,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Shares available for grant under Equity Incentive Plans&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;418,817&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;843,360&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Shares available for grant under Employee Stock Purchase Plan&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;920,827&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;920,827&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shares available for grant under 2022 Inducement Equity Incentive Plan&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;180,960&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;132,769&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total shares of common stock reserved&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,882,755&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,882,755&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 0in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The                                             Company has 4,999,863 outstanding warrants to purchase an aggregate of&#160;499,986&#160;shares                                             of its common stock (the &#x201c;Public Warrants&#x201d;). A holder may purchase&#160;one&#160;share                                             of the Company&#x2019;s common stock for every&#160;ten&#160;Public Warrants at an exercise                                             price of $115.00&#160;per share. The Public Warrants are publicly traded and exercisable                                             during the exercise period, which commenced on October 24, 2021 and ends on September 24,                                             2026, for cash or, in certain circumstances, on a cashless basis. The Public Warrants were                                             reclassified to equity in January 2023.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Shelf Registration Statement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; On March 19, 2025, the Company filed a new shelf registration statement on Form S-3 (the &#x201c;S-3&#x201d;) with the SEC, which was declared effective on March 26, 2025. As of March 31, 2026, the Company can sell from time to time up to $263.5 million of common stock, preferred stock, debt securities, warrants, rights, units and depositary shares comprised of any combination of these securities, for the Company&#x2019;s own account in one or more offerings under the S-3. The terms of any offering under the S-3 will be established at the time of such offering and will be described in a prospectus supplement to the S-3 filed with the SEC prior to the completion of any such offering. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;ATM Offerings&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; On March 19, 2025, the Company entered into an Open Market Sale Agreement&lt;sup&gt;SM&lt;/sup&gt;&#160;with Jefferies LLC (&#x201c;Jefferies&#x201d;), pursuant to which the Company may offer and sell through or to Jefferies, as sales agent or principal, shares of common stock from time to time (the &#x201c;ATM Offering&#x201d;). On March 26, 2025, the Company filed with the SEC a prospectus under the S-3 in connection with the ATM Offering (the &#x201c;ATM Prospectus&#x201d;), pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to $100.0 million. As of March 31, 2026, the Company issued and sold an aggregate of 1,231,447 shares of common stock for net proceeds of approximately $6.5 million pursuant to the ATM Prospectus. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; As of March 31, 2026, $93.5 million remained available under the ATM Prospectus. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Underwritten Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; On September 18, 2025, the Company entered into an underwriting agreement with TD Securities (USA) LLC as the representative of the several underwriters, relating to an underwritten public offering under the S-3 of an aggregate of 11,670,707 shares of common stock, Pre-Funded Warrants to purchase 675,000 shares of common stock and Common Warrants to purchase 12,345,707 shares of common stock. The Company received net proceeds of $27.5&#160;million. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; As of March 31, 2026, $170.0 million remained available and unallocated under the S-3. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_601785078"
      decimals="0"
      id="ixv-8488"
      unitRef="uref_469718384">490000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_736074492"
      decimals="0"
      id="ixv-8489"
      unitRef="uref_469718384">2000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_438560971"
      decimals="0"
      id="ixv-8490"
      unitRef="uref_469718384">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_438560971"
      decimals="0"
      id="ixv-8491"
      unitRef="uref_469718384">27996819</us-gaap:CommonStockSharesIssued>
    <jspr:NumberOfSharePurchase
      contextRef="cref_438560971"
      decimals="0"
      id="ixv-8492"
      unitRef="uref_469718384">1</jspr:NumberOfSharePurchase>
    <jspr:VotingCommonStockPercent
      contextRef="cref_438560971"
      decimals="3"
      id="ixv-8493"
      unitRef="uref_1055712422">0.099</jspr:VotingCommonStockPercent>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="cref_784925054" id="ixv-2686">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;As of March 31, 2026 and December 31, 2025, the Company had common stock reserved for future issuance as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Outstanding and issued common stock options&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,671,358&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,246,206&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Outstanding and issued restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;170,100&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;198,900&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Outstanding and issued performance-based restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1844764249"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;20,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;Shares issuable upon exercise of Public Warrants (1)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;499,986&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;499,986&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Shares issuable upon exercise of Common Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;12,345,707&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;12,345,707&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;Shares issuable upon exercise of Pre-Funded Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;675,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;675,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Shares available for grant under Equity Incentive Plans&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;418,817&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;843,360&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Shares available for grant under Employee Stock Purchase Plan&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;920,827&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;920,827&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shares available for grant under 2022 Inducement Equity Incentive Plan&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;180,960&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;132,769&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total shares of common stock reserved&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,882,755&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,882,755&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 0in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The                                             Company has 4,999,863 outstanding warrants to purchase an aggregate of&#160;499,986&#160;shares                                             of its common stock (the &#x201c;Public Warrants&#x201d;). A holder may purchase&#160;one&#160;share                                             of the Company&#x2019;s common stock for every&#160;ten&#160;Public Warrants at an exercise                                             price of $115.00&#160;per share. The Public Warrants are publicly traded and exercisable                                             during the exercise period, which commenced on October 24, 2021 and ends on September 24,                                             2026, for cash or, in certain circumstances, on a cashless basis. The Public Warrants were                                             reclassified to equity in January 2023.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_841215262"
      decimals="0"
      id="ixv-8494"
      unitRef="uref_469718384">2671358</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1455265214"
      decimals="0"
      id="ixv-8495"
      unitRef="uref_469718384">2246206</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1634329083"
      decimals="0"
      id="ixv-8496"
      unitRef="uref_469718384">170100</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_166765776"
      decimals="0"
      id="ixv-8497"
      unitRef="uref_469718384">198900</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1329622523"
      decimals="0"
      id="ixv-8498"
      unitRef="uref_469718384">20000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1365582304"
      decimals="0"
      id="fc_1365582304"
      unitRef="uref_469718384">499986</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1665866085"
      decimals="0"
      id="fc_1665866085"
      unitRef="uref_469718384">499986</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_695848034"
      decimals="0"
      id="ixv-8501"
      unitRef="uref_469718384">12345707</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_749757817"
      decimals="0"
      id="ixv-8502"
      unitRef="uref_469718384">12345707</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_653971143"
      decimals="0"
      id="ixv-8503"
      unitRef="uref_469718384">675000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_467908750"
      decimals="0"
      id="ixv-8504"
      unitRef="uref_469718384">675000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_835672883"
      decimals="0"
      id="ixv-8505"
      unitRef="uref_469718384">418817</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1068906306"
      decimals="0"
      id="ixv-8506"
      unitRef="uref_469718384">843360</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_671366674"
      decimals="0"
      id="ixv-8507"
      unitRef="uref_469718384">920827</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1623292660"
      decimals="0"
      id="ixv-8508"
      unitRef="uref_469718384">920827</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1516512986"
      decimals="0"
      id="ixv-8509"
      unitRef="uref_469718384">180960</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1088620590"
      decimals="0"
      id="ixv-8510"
      unitRef="uref_469718384">132769</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_438560971"
      decimals="0"
      id="ixv-8511"
      unitRef="uref_469718384">17882755</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_268000114"
      decimals="0"
      id="ixv-8512"
      unitRef="uref_469718384">17882755</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1422418476"
      decimals="0"
      id="ixv-8514"
      unitRef="uref_469718384">4999863</us-gaap:ClassOfWarrantOrRightOutstanding>
    <jspr:PurchaseAnAggregateShares
      contextRef="cref_238056073"
      decimals="0"
      id="ixv-8515"
      unitRef="uref_469718384">499986</jspr:PurchaseAnAggregateShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_415871009"
      decimals="2"
      id="fc_415871009"
      unitRef="uref_1987543344">115</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="cref_438560971"
      decimals="-5"
      id="ixv-8517"
      unitRef="uref_668202531">263500000</us-gaap:EquitySecuritiesFvNi>
    <jspr:AggregateOfferingPrice
      contextRef="cref_648885515"
      decimals="-5"
      id="ixv-8518"
      unitRef="uref_668202531">100000000</jspr:AggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="cref_1187790031"
      decimals="0"
      id="ixv-8519"
      unitRef="uref_469718384">1231447</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_784925054"
      decimals="-5"
      id="fc_931614726"
      unitRef="uref_668202531">6500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <jspr:UnderwrittenOfferingRemainedAvailable
      contextRef="cref_784925054"
      decimals="-5"
      id="ixv-8521"
      unitRef="uref_668202531">93500000</jspr:UnderwrittenOfferingRemainedAvailable>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_2042008173"
      decimals="-3"
      id="fc_1996495367"
      unitRef="uref_668202531">11670707000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <jspr:PreFundedWarrantsToPurchase
      contextRef="cref_2042008173"
      decimals="0"
      id="ixv-8523"
      unitRef="uref_469718384">675000</jspr:PreFundedWarrantsToPurchase>
    <jspr:CommonWarrantsToPurchaseShares
      contextRef="cref_2042008173"
      decimals="0"
      id="ixv-8524"
      unitRef="uref_469718384">12345707</jspr:CommonWarrantsToPurchaseShares>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="cref_2042008173"
      decimals="-5"
      id="fc_2042008173"
      unitRef="uref_668202531">27500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <jspr:AvailableOfferingAmount
      contextRef="cref_343598538"
      decimals="-5"
      id="ixv-8526"
      unitRef="uref_668202531">170000000</jspr:AvailableOfferingAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="cref_784925054" id="ixv-2852">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 10. STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; As of March 31, 2026, 2,750,719 shares were reserved for issuance under the 2024 Equity Incentive Plan (the &#x201c;2024 Plan&#x201d;), of which 418,817 shares were available for future grant and 2,331,902 shares were subject to outstanding options and restricted stock units (&#x201c;RSUs&#x201d;), including 30,894 shares subject to performance-based awards. As of March 31, 2026, options to purchase 140,516 shares of common stock remained outstanding and unexercised, and continue to be governed by the 2019 Equity Incentive Plan (the &#x201c;2019 EIP&#x201d;). As of March 31, 2026, 1,000,000 shares were reserved under the 2024 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), of which 920,827 shares were available for future issuance and 79,173 shares had been issued. As of March 31, 2026, 550,000 shares were reserved for issuance under the 2022 Inducement Equity Incentive Plan (the &#x201c;2022 Inducement Plan&#x201d;), of which 180,960 shares were available for future grant and 369,040 shares were subject to outstanding stock options. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Stock Option Activity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table summarizes the stock option activities, including performance-based stock options, under the 2024 Plan, the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), the 2022 Inducement Plan and the 2019 EIP for the three months ended March 31, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise     Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average&lt;br/&gt; Remaining&lt;br/&gt;     Contractual&lt;br/&gt; Life&#160;(Years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic Value &lt;br/&gt;     (in thousands)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 52%"&gt;Balance, December 31, 2025&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,246,206&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;13.72&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;4.81&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_838649266"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Options granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,262,300&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1.65&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options cancelled/forfeited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(837,148&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.08&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Balance, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,671,358&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;10.10&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.43&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1603413953"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,671,358&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;10.10&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.43&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1454690266"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Exercisable, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,018,023&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;18.93&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.33&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1900409824"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. &lt;span style="-sec-ix-hidden:fc_577259707"&gt;&lt;span style="-sec-ix-hidden:fc_729631792"&gt;No&lt;/span&gt;&lt;/span&gt; options were exercised during the three months ended March 31, 2026 and 2025. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The total fair value of options that vested during the three months ended March 31, 2026 and 2025 was $0.9 million and $2.7 million, respectively. The weighted-average grant date fair value of options granted during the three months ended March 31, 2026 and 2025 was $1.33 and $4.92 per share, respectively. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; Unamortized stock-based compensation expense as of March 31, 2026 was $5.6 million, which is expected to be recognized over a weighted-average period of 3.0 years. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Performance-Based Stock Options&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; There was &lt;span style="-sec-ix-hidden:fc_597754003"&gt;no&lt;/span&gt; performance-based stock option activity under the 2024 Plan or the 2021 Plan during the three months ended March 31, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&#160;Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;     Contractual&lt;br/&gt; Life&#160;(Years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value     &#160;(in thousands)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 52%; padding-bottom: 1.5pt"&gt;Balance, December 31, 2025&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;30,894&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;7.33&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;4.43&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1799126299"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Balance, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,894&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.33&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.18&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_723560973"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,894&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.33&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.18&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1792648283"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Exercisable, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,894&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.33&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.18&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1994038587"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Restricted Stock Units (RSUs)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table provides a summary of RSU activity under the 2024 Plan during the three months ended March 31, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Share&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Grant Date     &lt;br/&gt; Fair Value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Unvested restricted stock units at December 31, 2025&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;198,900&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,800&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Unvested restricted stock units at March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;170,100&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Performance Restricted Stock Units (PSUs) &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; &#160;In June 2024, the Company granted PSUs for 20,000 shares that would vest in full if the closing price of the Company&#x2019;s common stock on the Nasdaq Capital Market reached or exceeded $35.00 per share (subject to adjustment for recapitalizations, stock splits and similar transactions) for thirty consecutive calendar days within two years from the grant date. If the vesting condition was not met within two years from the grant date, the PSUs would be forfeited. The Company concluded that issued PSUs were equity-based awards and include a market based vesting condition. The Company used a Monte Carlo simulation model to estimate the fair value of the PSUs with the following assumptions: common stock fair value of $23.95, which was the closing market price of the Company&#x2019;s common stock at the grant date, volatility of 133.00%, risk free rate of 4.87%, and vesting term of 2.0 years. Total estimated fair value of $0.4 million was recognized as stock-based compensation expense over 0.4 years, the derived requisite service period from the grant date. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; In January 2026, the employee holding the PSUs was terminated and the award was forfeited. &lt;span style="-sec-ix-hidden:fc_1423726112"&gt;No&lt;/span&gt; stock-based compensation expense was reversed upon forfeiture, as the award included only a market-based vesting condition and the derived requisite service period had been completed.  &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Employee Stock Purchase Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The Company did not issue any shares of common stock under the ESPP during the three months ended March 31, 2026 and 2025, and recognized less than $0.1 million and $0.1 million compensation expense related to the ESPP during the three months ended March 31, 2026 and 2025, respectively. There was $0.2 million unamortized stock-based compensation for shares issuable under the ESPP as of March 31, 2026, which is expected to be recognized over a weighted-average period of 1.7 years. The Company recorded $0.1 million in accrued expenses and other current liabilities related to contributions withheld as of March 31, 2026.&#160; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table presents stock-based compensation expenses related to options, PSUs and RSUs granted to employees and non-employees, employee stock purchase plan awards and restricted common stock shares issued to founders (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;General and administrative&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;202&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;1,240&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;221&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;571&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;423&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,811&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The Company recognized $0.1&#160;million and zero stock-based compensation expense related to performance-based options, PSUs and RSUs during the three months ended March 31, 2026 and 2025, respectively. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Valuation of Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 70%; text-align: left"&gt;Expected term (in years)&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;6.08&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;6.01 &#x2013; 6.08&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;99.87% &#x2013; 100.05&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;97.37% &#x2013; 97.93&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.85% &#160;&#x2013; 3.88&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.93% &#x2013; 4.35&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1964576807"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_402018995"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1643317952"
      decimals="0"
      id="ixv-8527"
      unitRef="uref_469718384">2750719</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="cref_1643317952"
      decimals="0"
      id="ixv-8528"
      unitRef="uref_469718384">418817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1643317952"
      decimals="0"
      id="ixv-8529"
      unitRef="uref_469718384">2331902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="cref_1643317952"
      decimals="0"
      id="ixv-8530"
      unitRef="uref_469718384">30894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1436491688"
      decimals="0"
      id="ixv-8531"
      unitRef="uref_469718384">140516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_436942179"
      decimals="0"
      id="ixv-8532"
      unitRef="uref_469718384">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="cref_436942179"
      decimals="0"
      id="ixv-8533"
      unitRef="uref_469718384">920827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="cref_517605843"
      decimals="0"
      id="fc_517605843"
      unitRef="uref_469718384">79173</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="cref_1757947245"
      decimals="0"
      id="ixv-8535"
      unitRef="uref_469718384">550000</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="cref_1757947245"
      decimals="0"
      id="ixv-8536"
      unitRef="uref_469718384">180960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_436942179"
      decimals="0"
      id="ixv-8537"
      unitRef="uref_469718384">369040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="cref_784925054" id="ixv-2862">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table summarizes the stock option activities, including performance-based stock options, under the 2024 Plan, the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), the 2022 Inducement Plan and the 2019 EIP for the three months ended March 31, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise     Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average&lt;br/&gt; Remaining&lt;br/&gt;     Contractual&lt;br/&gt; Life&#160;(Years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic Value &lt;br/&gt;     (in thousands)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 52%"&gt;Balance, December 31, 2025&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,246,206&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;13.72&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;4.81&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_838649266"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Options granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,262,300&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1.65&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options cancelled/forfeited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(837,148&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.08&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Balance, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,671,358&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;10.10&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.43&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1603413953"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,671,358&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;10.10&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.43&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1454690266"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Exercisable, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,018,023&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;18.93&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.33&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1900409824"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; There was &lt;span style="-sec-ix-hidden:fc_597754003"&gt;no&lt;/span&gt; performance-based stock option activity under the 2024 Plan or the 2021 Plan during the three months ended March 31, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&#160;Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;     Contractual&lt;br/&gt; Life&#160;(Years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value     &#160;(in thousands)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 52%; padding-bottom: 1.5pt"&gt;Balance, December 31, 2025&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;30,894&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;7.33&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;4.43&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1799126299"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Balance, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,894&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.33&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.18&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_723560973"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,894&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.33&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.18&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1792648283"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt"&gt;Exercisable, March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,894&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.33&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.18&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1994038587"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1840882305"
      decimals="0"
      id="ixv-8538"
      unitRef="uref_469718384">2246206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1840882305"
      decimals="2"
      id="ixv-8539"
      unitRef="uref_1987543344">13.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_1367888496" id="ixv-8540">P4Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_1511983395"
      decimals="0"
      id="ixv-8541"
      unitRef="uref_469718384">1262300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="cref_1511983395"
      decimals="2"
      id="fc_982109083"
      unitRef="uref_1987543344">1.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="cref_1511983395"
      decimals="0"
      id="ixv-8543"
      unitRef="uref_469718384">837148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="cref_1511983395"
      decimals="2"
      id="ixv-8544"
      unitRef="uref_1987543344">7.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1086398820"
      decimals="0"
      id="ixv-8545"
      unitRef="uref_469718384">2671358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1086398820"
      decimals="2"
      id="ixv-8546"
      unitRef="uref_1987543344">10.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_1511983395" id="ixv-8547">P7Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="cref_1086398820"
      decimals="0"
      id="ixv-8548"
      unitRef="uref_469718384">2671358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="cref_1086398820"
      decimals="2"
      id="ixv-8549"
      unitRef="uref_1987543344">10.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="cref_1511983395" id="ixv-8550">P7Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="cref_1086398820"
      decimals="0"
      id="ixv-8551"
      unitRef="uref_469718384">1018023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1086398820"
      decimals="2"
      id="fc_1086398820"
      unitRef="uref_1987543344">18.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_1511983395" id="ixv-8553">P4Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="cref_784925054"
      decimals="-5"
      id="ixv-8554"
      unitRef="uref_668202531">900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="cref_1378370445"
      decimals="-5"
      id="ixv-8555"
      unitRef="uref_668202531">2700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="cref_784925054"
      decimals="2"
      id="ixv-8556"
      unitRef="uref_1987543344">1.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="cref_1378370445"
      decimals="2"
      id="ixv-8557"
      unitRef="uref_1987543344">4.92</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="cref_438560971"
      decimals="-5"
      id="ixv-8558"
      unitRef="uref_668202531">5600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="cref_784925054" id="ixv-8559">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1206044327"
      decimals="0"
      id="ixv-8560"
      unitRef="uref_469718384">30894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1206044327"
      decimals="2"
      id="ixv-8561"
      unitRef="uref_1987543344">7.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_853288868" id="ixv-8562">P4Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_477447857"
      decimals="0"
      id="ixv-8563"
      unitRef="uref_469718384">30894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_477447857"
      decimals="2"
      id="ixv-8564"
      unitRef="uref_1987543344">7.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_1680691002" id="ixv-8565">P4Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="cref_477447857"
      decimals="0"
      id="ixv-8566"
      unitRef="uref_469718384">30894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="cref_477447857"
      decimals="2"
      id="ixv-8567"
      unitRef="uref_1987543344">7.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="cref_1680691002" id="ixv-8568">P4Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="cref_477447857"
      decimals="0"
      id="ixv-8569"
      unitRef="uref_469718384">30894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_477447857"
      decimals="2"
      id="ixv-8570"
      unitRef="uref_1987543344">7.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_1680691002" id="ixv-8571">P4Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="cref_784925054" id="ixv-3131">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table provides a summary of RSU activity under the 2024 Plan during the three months ended March 31, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Share&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Grant Date     &lt;br/&gt; Fair Value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Unvested restricted stock units at December 31, 2025&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;198,900&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,800&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Unvested restricted stock units at March 31, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;170,100&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="cref_384482861"
      decimals="0"
      id="ixv-8572"
      unitRef="uref_469718384">198900</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_384482861"
      decimals="2"
      id="ixv-8573"
      unitRef="uref_1987543344">6</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="cref_1227972248"
      decimals="0"
      id="ixv-8574"
      unitRef="uref_469718384">28800</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="cref_1227972248"
      decimals="2"
      id="ixv-8575"
      unitRef="uref_1987543344">6</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="cref_2127221751"
      decimals="0"
      id="ixv-8576"
      unitRef="uref_469718384">170100</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_2127221751"
      decimals="2"
      id="ixv-8577"
      unitRef="uref_1987543344">6</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="cref_714368909"
      decimals="0"
      id="ixv-8578"
      unitRef="uref_469718384">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="cref_714368909"
      decimals="2"
      id="ixv-8579"
      unitRef="uref_1987543344">35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="cref_1835780786"
      decimals="2"
      id="ixv-8580"
      unitRef="uref_1987543344">23.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_714368909"
      decimals="4"
      id="ixv-8581"
      unitRef="uref_1055712422">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_714368909"
      decimals="4"
      id="ixv-8582"
      unitRef="uref_1055712422">0.0487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_2065545269" id="ixv-8583">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <jspr:TotalEstimatedFairValue
      contextRef="cref_784925054"
      decimals="-5"
      id="ixv-8584"
      unitRef="uref_668202531">400000</jspr:TotalEstimatedFairValue>
    <jspr:RecognizedCompensationExpensePeriod contextRef="cref_784925054" id="ixv-8585">P0Y4M24D</jspr:RecognizedCompensationExpensePeriod>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_155106258"
      decimals="-5"
      id="ixv-8586"
      unitRef="uref_668202531">100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_664802157"
      decimals="-5"
      id="ixv-8587"
      unitRef="uref_668202531">100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="cref_784622662"
      decimals="-5"
      id="ixv-8588"
      unitRef="uref_668202531">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="cref_1154412494" id="ixv-8589">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_784622662"
      decimals="-5"
      id="ixv-8590"
      unitRef="uref_668202531">100000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="cref_784925054" id="ixv-3207">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table presents stock-based compensation expenses related to options, PSUs and RSUs granted to employees and non-employees, employee stock purchase plan awards and restricted common stock shares issued to founders (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;General and administrative&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;202&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;1,240&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;221&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;571&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;423&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,811&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1364903650"
      decimals="-3"
      id="ixv-8591"
      unitRef="uref_668202531">202000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_2045662903"
      decimals="-3"
      id="ixv-8592"
      unitRef="uref_668202531">1240000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1852720650"
      decimals="-3"
      id="ixv-8593"
      unitRef="uref_668202531">221000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1083033443"
      decimals="-3"
      id="ixv-8594"
      unitRef="uref_668202531">571000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_155304082"
      decimals="-3"
      id="ixv-8595"
      unitRef="uref_668202531">423000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1571420461"
      decimals="-3"
      id="ixv-8596"
      unitRef="uref_668202531">1811000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1680691002"
      decimals="-5"
      id="ixv-8597"
      unitRef="uref_668202531">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_279398949"
      decimals="0"
      id="ixv-8598"
      unitRef="uref_668202531">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="cref_784925054" id="ixv-3263">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 70%; text-align: left"&gt;Expected term (in years)&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;6.08&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;6.01 &#x2013; 6.08&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;99.87% &#x2013; 100.05&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;97.37% &#x2013; 97.93&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.85% &#160;&#x2013; 3.88&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.93% &#x2013; 4.35&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1964576807"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_402018995"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_502686246" id="ixv-8599">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_1143859271" id="ixv-8600">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_1055712422" id="ixv-8601">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_2040753095"
      decimals="4"
      id="ixv-8602"
      unitRef="uref_1055712422">0.9987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1518267216"
      decimals="4"
      id="ixv-8603"
      unitRef="uref_1055712422">1.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1143859271"
      decimals="4"
      id="ixv-8604"
      unitRef="uref_1055712422">0.9737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1055712422"
      decimals="4"
      id="ixv-8605"
      unitRef="uref_1055712422">0.9793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_2040753095"
      decimals="4"
      id="ixv-8606"
      unitRef="uref_1055712422">0.0385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1518267216"
      decimals="4"
      id="ixv-8607"
      unitRef="uref_1055712422">0.0388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1143859271"
      decimals="4"
      id="ixv-8608"
      unitRef="uref_1055712422">0.0393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1055712422"
      decimals="4"
      id="ixv-8609"
      unitRef="uref_1055712422">0.0435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:EarningsPerShareTextBlock contextRef="cref_784925054" id="ixv-3331">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 11. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Numerator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Net loss attributable to common stockholders&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(1,174&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(21,241&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;Denominator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Weighted average common shares and pre-funded warrant shares outstanding&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;28,671,819&lt;/td&gt; &lt;td style="text-align: left"&gt;(a)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;15,022,122&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Weighted average shares used to compute basic and diluted net loss per share&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,671,819&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,022,122&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net loss per share attributable to common stockholders &#x2013; basic and diluted&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.04&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1.41&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 0in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left"&gt;(a)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Includes 675,000 weighted-average shares underlying pre-funded warrants outstanding during the period, as such warrants are exercisable at any time for nominal consideration ($0.0001 per share).&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Outstanding and issued common stock options&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,671,358&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,186,226&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Outstanding and issued restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;170,100&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1768916711"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Shares issuable upon exercise of Public Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;499,986&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;499,986&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;Shares issuable upon exercise of Common Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;12,345,707&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1479140823"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unvested performance-based restricted stock units&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1505739634"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;15,687,151&lt;/td&gt; &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,706,212&lt;/td&gt; &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="cref_784925054" id="ixv-3335">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Numerator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Net loss attributable to common stockholders&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(1,174&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(21,241&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;Denominator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Weighted average common shares and pre-funded warrant shares outstanding&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;28,671,819&lt;/td&gt; &lt;td style="text-align: left"&gt;(a)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;15,022,122&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Weighted average shares used to compute basic and diluted net loss per share&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,671,819&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,022,122&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net loss per share attributable to common stockholders &#x2013; basic and diluted&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.04&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1.41&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 0in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left"&gt;(a)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Includes 675,000 weighted-average shares underlying pre-funded warrants outstanding during the period, as such warrants are exercisable at any time for nominal consideration ($0.0001 per share).&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8610"
      unitRef="uref_668202531">-1174000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8611"
      unitRef="uref_668202531">-21241000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="cref_784925054"
      decimals="0"
      id="fc_1840909275"
      unitRef="uref_469718384">28671819</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="cref_1378370445"
      decimals="0"
      id="ixv-8613"
      unitRef="uref_469718384">15022122</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_784925054"
      decimals="0"
      id="ixv-8614"
      unitRef="uref_469718384">28671819</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_784925054"
      decimals="0"
      id="ixv-8615"
      unitRef="uref_469718384">28671819</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1378370445"
      decimals="0"
      id="ixv-8616"
      unitRef="uref_469718384">15022122</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1378370445"
      decimals="0"
      id="ixv-8617"
      unitRef="uref_469718384">15022122</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_784925054"
      decimals="2"
      id="ixv-8618"
      unitRef="uref_1987543344">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_784925054"
      decimals="2"
      id="ixv-8619"
      unitRef="uref_1987543344">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1378370445"
      decimals="2"
      id="ixv-8620"
      unitRef="uref_1987543344">-1.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1378370445"
      decimals="2"
      id="ixv-8621"
      unitRef="uref_1987543344">-1.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="cref_784925054"
      decimals="0"
      id="ixv-8623"
      unitRef="uref_469718384">675000</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_438560971"
      decimals="4"
      id="ixv-8624"
      unitRef="uref_1987543344">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="cref_784925054" id="ixv-3420">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Outstanding and issued common stock options&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,671,358&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2,186,226&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Outstanding and issued restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;170,100&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1768916711"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Shares issuable upon exercise of Public Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;499,986&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;499,986&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;Shares issuable upon exercise of Common Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;12,345,707&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1479140823"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unvested performance-based restricted stock units&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1505739634"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;15,687,151&lt;/td&gt; &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,706,212&lt;/td&gt; &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_887924682"
      decimals="0"
      id="ixv-8625"
      unitRef="uref_469718384">2671358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_442461320"
      decimals="0"
      id="ixv-8626"
      unitRef="uref_469718384">2186226</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_565409357"
      decimals="0"
      id="ixv-8627"
      unitRef="uref_469718384">170100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_34643640"
      decimals="0"
      id="ixv-8628"
      unitRef="uref_469718384">499986</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1107233758"
      decimals="0"
      id="ixv-8629"
      unitRef="uref_469718384">499986</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1720545267"
      decimals="0"
      id="ixv-8630"
      unitRef="uref_469718384">12345707</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1722756702"
      decimals="0"
      id="ixv-8631"
      unitRef="uref_469718384">20000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_784925054"
      decimals="0"
      id="ixv-8632"
      unitRef="uref_469718384">15687151</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1378370445"
      decimals="0"
      id="ixv-8633"
      unitRef="uref_469718384">2706212</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="cref_784925054" id="ixv-3502">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 12. RELATED PARTIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; In the first quarter of 2024, a senior executive of the Company joined the board of directors of an information technology service provider that the Company has utilized to support a broad array of the Company&#x2019;s systems infrastructure as well as for general information technology support services. For the three months ended March 31, 2026 and 2025, the Company incurred $0.3 million and $0.2&#160;million, respectively, for various information technology support services performed by this service provider. There was $0.1 million of accounts payable recognized in the condensed consolidated balance sheets as of each of March 31, 2026 and December 31, 2025. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InterestCostsIncurred
      contextRef="cref_784925054"
      decimals="-5"
      id="ixv-8634"
      unitRef="uref_668202531">300000</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred
      contextRef="cref_1378370445"
      decimals="-5"
      id="ixv-8635"
      unitRef="uref_668202531">200000</us-gaap:InterestCostsIncurred>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="cref_438560971"
      decimals="-5"
      id="ixv-8636"
      unitRef="uref_668202531">100000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="cref_268000114"
      decimals="-5"
      id="ixv-8637"
      unitRef="uref_668202531">100000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="cref_784925054" id="ixv-3514">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 13. SEGMENT INFORMATION&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; The Company has determined it operates as a &lt;span style="-sec-ix-hidden:fc_1666881356"&gt;&lt;span style="-sec-ix-hidden:fc_975557945"&gt;single&lt;/span&gt;&lt;/span&gt; operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma. The Company&#x2019;s chief operating decision maker, its &lt;span style="-sec-ix-hidden:fc_743175501"&gt;Chief Executive Officer&lt;/span&gt; (the &#x201c;CEO&#x201d;), manages the Company&#x2019;s operations on a consolidated basis. The CEO assesses the segment&#x2019;s performance and allocates resources based on review of various development, manufacturing and clinical programs expenses, along with the segment&#x2019;s personnel and general and overhead costs. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In addition to the significant expense categories included within net loss presented in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise total operating expenses (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Personnel-related costs&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;4,038&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;8,431&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;General and overhead costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3,291&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3,611&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Program costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Briquilimab platform&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;266&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,957&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-left: 9pt"&gt;CMO&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;882&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;2,138&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-left: 9pt"&gt;CSU&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;2,378&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;2,746&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-left: 9pt"&gt;Asthma&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;(327&lt;/td&gt; &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,393&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-left: 9pt"&gt;CIndU&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;424&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;885&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-left: 9pt"&gt;SCID&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1357899928"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;523&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;MDS/AML&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1112529675"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Total program costs&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,623&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,760&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Total operating expense&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,952&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,802&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other income, net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,778&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;561&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net loss&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,174&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(21,241&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;All long-lived assets are located in the United States.&#160;&#160;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription contextRef="cref_784925054" id="ixv-3522"> The Company&#x2019;s chief operating decision maker, its Chief Executive Officer (the &#x201c;CEO&#x201d;), manages the Company&#x2019;s operations on a consolidated basis. The CEO assesses the segment&#x2019;s performance and allocates resources based on review of various development, manufacturing and clinical programs expenses, along with the segment&#x2019;s personnel and general and overhead costs.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="cref_784925054" id="ixv-3525">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In addition to the significant expense categories included within net loss presented in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise total operating expenses (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Personnel-related costs&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;4,038&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;8,431&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;General and overhead costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3,291&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3,611&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Program costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Briquilimab platform&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;266&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,957&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-left: 9pt"&gt;CMO&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;882&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;2,138&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-left: 9pt"&gt;CSU&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;2,378&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;2,746&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-left: 9pt"&gt;Asthma&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;(327&lt;/td&gt; &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,393&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-left: 9pt"&gt;CIndU&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;424&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;885&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-left: 9pt"&gt;SCID&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1357899928"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;523&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;MDS/AML&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1112529675"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Total program costs&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,623&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,760&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Total operating expense&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,952&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,802&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other income, net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,778&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;561&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net loss&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,174&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(21,241&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <jspr:PersonnelCosts
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8638"
      unitRef="uref_668202531">4038000</jspr:PersonnelCosts>
    <jspr:PersonnelCosts
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8639"
      unitRef="uref_668202531">8431000</jspr:PersonnelCosts>
    <jspr:FacilitiesAndOverheadCosts
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8640"
      unitRef="uref_668202531">3291000</jspr:FacilitiesAndOverheadCosts>
    <jspr:FacilitiesAndOverheadCosts
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8641"
      unitRef="uref_668202531">3611000</jspr:FacilitiesAndOverheadCosts>
    <us-gaap:CostOfRevenue
      contextRef="cref_1773614604"
      decimals="-3"
      id="ixv-8642"
      unitRef="uref_668202531">266000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_585224753"
      decimals="-3"
      id="ixv-8643"
      unitRef="uref_668202531">1957000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_920960091"
      decimals="-3"
      id="ixv-8644"
      unitRef="uref_668202531">882000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_199674710"
      decimals="-3"
      id="ixv-8645"
      unitRef="uref_668202531">2138000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_768267355"
      decimals="-3"
      id="ixv-8646"
      unitRef="uref_668202531">2378000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_158858565"
      decimals="-3"
      id="ixv-8647"
      unitRef="uref_668202531">2746000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_2109719354"
      decimals="-3"
      id="ixv-8648"
      unitRef="uref_668202531">-327000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_217583461"
      decimals="-3"
      id="ixv-8649"
      unitRef="uref_668202531">1393000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_1533989264"
      decimals="-3"
      id="ixv-8650"
      unitRef="uref_668202531">424000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_1187366974"
      decimals="-3"
      id="ixv-8651"
      unitRef="uref_668202531">885000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_543821224"
      decimals="-3"
      id="ixv-8652"
      unitRef="uref_668202531">523000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_358966682"
      decimals="-3"
      id="ixv-8653"
      unitRef="uref_668202531">118000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8654"
      unitRef="uref_668202531">3623000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8655"
      unitRef="uref_668202531">9760000</us-gaap:CostOfRevenue>
    <us-gaap:OperatingExpenses
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8656"
      unitRef="uref_668202531">10952000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8657"
      unitRef="uref_668202531">21802000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8658"
      unitRef="uref_668202531">9778000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8659"
      unitRef="uref_668202531">561000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="cref_784925054"
      decimals="-3"
      id="ixv-8660"
      unitRef="uref_668202531">-1174000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1378370445"
      decimals="-3"
      id="ixv-8661"
      unitRef="uref_668202531">-21241000</us-gaap:NetIncomeLoss>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="cref_784925054" id="ixv-3699">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 14. RESTRUCTURING&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; Starting in July 2025, the Company implemented a corporate reorganization and other cost reduction measures to extend its cash runway. These actions included a workforce reduction, refinement of the Company&#x2019;s operating plan to focus on briquilimab clinical development programs in chronic urticaria, halting enrollment in its Phase 1b asthma study, discontinuation of other clinical and preclinical programs and cessation of vivarium operations. In 2025, the Company incurred restructuring charges related to workforce reduction of approximately $2.3 million, primarily related to severance payments, and recognized impairment charges of $1.1 million related to the abandonment of certain fixed assets and a right-of-use asset associated with vivarium operations. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt; As of March 31, 2026 and December 31, 2025, the Company had $0.3 million and $0.4 million, respectively, of accrued severance costs related to the termination of one employee in connection with the restructuring, which are included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. The related severance payments are expected to be made over a period of approximately 12 months, through January 2027.&#160;&#160; &lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCosts
      contextRef="cref_1417501004"
      decimals="-5"
      id="ixv-8662"
      unitRef="uref_668202531">2300000</us-gaap:RestructuringCosts>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="cref_1417501004"
      decimals="-5"
      id="ixv-8663"
      unitRef="uref_668202531">1100000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:SeveranceCosts1
      contextRef="cref_486425029"
      decimals="-5"
      id="ixv-8664"
      unitRef="uref_668202531">300000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="cref_668202531"
      decimals="-5"
      id="ixv-8665"
      unitRef="uref_668202531">400000</us-gaap:SeveranceCosts1>
    <jspr:SeveranceCostsPeriod contextRef="cref_784925054" id="ixv-8666">P12M</jspr:SeveranceCostsPeriod>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="cref_784925054" id="ixv-8667">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="cref_784925054" id="ixv-8668">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="cref_784925054" id="ixv-8669">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="cref_784925054" id="ixv-8670">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#fc_1365582304"
          xlink:label="fc_1365582304"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1665866085"
          xlink:label="fc_1665866085"
          xlink:type="locator"/>
        <link:footnote id="fref_296657012" xlink:label="fref_296657012" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The                                             Company has 4,999,863 outstanding warrants to purchase an aggregate of&#160;499,986&#160;shares                                             of its common stock (the &#x201c;Public Warrants&#x201d;). A holder may purchase&#160;one&#160;share                                             of the Company&#x2019;s common stock for every&#160;ten&#160;Public Warrants at an exercise                                             price of $115.00&#160;per share. The Public Warrants are publicly traded and exercisable                                             during the exercise period, which commenced on October 24, 2021 and ends on September 24,                                             2026, for cash or, in certain circumstances, on a cashless basis. The Public Warrants were                                             reclassified to equity in January 2023.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1365582304"
          xlink:to="fref_296657012"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1665866085"
          xlink:to="fref_296657012"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1840909275"
          xlink:label="fc_1840909275"
          xlink:type="locator"/>
        <link:footnote id="fref_1477796849" xlink:label="fref_1477796849" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes 675,000 weighted-average shares underlying pre-funded warrants outstanding during the period, as such warrants are exercisable at any time for nominal consideration ($0.0001 per share).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1840909275"
          xlink:to="fref_1477796849"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
